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Thesis abstract 
 
Objectives - The research objective was to determine the feasibility of performing 
an appropriately-powered study investigating the use of methylphenidate for 
sarcoidosis-associated fatigue.  
Methods - The Fatigue and Sarcoidosis – Treatment with Methylphendiate (FaST-
MP) feasibility study was undertaken to compare methylphenidate with an identical 
placebo in a double-blind, randomised, parallel-arm study. Participants had the 
opportunity to discuss their perspectives on the study in post-trial focus groups.  
Alongside FaST-MP, further work was undertaken to determine future study design. 
Activity monitors were piloted to determine the preferred device in patients with 
sarcoidosis. Quality of life measures were compared using data from a cohort of 
patients with sarcoidosis to understand the relationship between clinical outcomes.  
Findings – Participant recruitment to the FaST-MP study was lower than expected 
(22 participants) but retention was high (100%) and the medication appeared well-
tolerated and safe. No statistical difference in change in fatigue scores was seen 
between the methylphenidate and placebo arms, although both groups showed 
improvement from baseline fatigue scores. Participants reported a positive 
experience of the trial from focus group discussion but raised concerns relating to 
the fatigue outcomes used and the frequency with which fatigue was measured.  
Comparison of quality of life questionnaires identified differences between two 
commonly used measures which may influence questionnaire choice in future 
studies investigating sarcoidosis-associated fatigue. 
Conclusion - Designing a full phase III study to investigate the clinical efficacy of 
methylphenidate for sarcoidosis-associated fatigue appears feasible, although 
future study design must consider how to best reflect “usual care”, as well as the 
optimal outcome measures within such a study.   
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1.1 Overview of Sarcoidosis 
Sarcoidosis is a multi-system disease characterised by non-caseating granulomas 
which affects all ethnic groups and ages. Disease presentation is highly variable as 
any organ system can be affected, although pulmonary manifestations are most 
common. Non-specific and constitutional symptoms, including fatigue, frequently 
occur. The disease can present acutely and may spontaneously resolve but for 
some patients follows a chronic disease course requiring treatment. In these cases, 
management is typically with corticosteroids or other immunosuppressant 
medications. For the majority of patients, the condition does not significantly affect 
survival but may have an impact upon quality of life; for this reason, management 
of symptoms is of great importance in patients with sarcoidosis. 
 
1.2 History of sarcoidosis 
Sarcoidosis was first described by Jonathan Hutchinson, a London surgeon (1, 2). In 
1877 Hutchinson described the case of a coal-wharf worker with symmetrical, non-
tender, purple skin plaques affecting his hands and legs (3). Hutchinson later 
described the disease as a “form of skin disease which has  - hitherto escaped 
special recognition” (4). Caesar Boeck, a Norwegian dermatologist, described 24 
cases of “benign miliary lupoids,” labelling the condition “sarkoid” due to the 
macroscopic resemblance to sarcoma but with a benign disease course. Some of 
the cases had involvement of other systems, including the lungs, lymph nodes, 
spleen, conjunctiva and bones (5). The common acute presentation of sarcoidosis 
was first described by Sven Lӧfgren, a Swedish clinician. He described the link 
between erythema nodosum and bilateral hilar lymphadenopathy, as well as the 
excellent prognosis of this presentation of the disease (6).  
Differentiation between sarcoidosis and tuberculosis was difficult. In 1941, Morten 
Kveim described a reaction to intradermal inoculation of lymphoid tissue (taken 
from sarcoidosis patients) which did not occur in subjects without the disease but 
occurred in 12 out of 13 patients with sarcoidosis (7). This test remained in clinical 
use for over 50 years (8, 9). The test had a less than 1% false positive rate in non-
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sarcoidosis cases (10, 11), as opposed to stimulating agents, including 
mycobacteria, beryllium and silica, which produce a reaction in almost all patients 
(12). The Kveim test is no longer used for the diagnosis of sarcoidosis, with modern 
diagnosis made using clinical, imaging and histological samples. 
 
1.3 Epidemiology 
There is significant variability in incidence by ethnic group and geographical region;  
the highest incidence is seen in African American and Northern European 
populations (13, 14). Table 1 shows the varying incidence of sarcoidosis across the 
globe, presenting the results from a literature search of the Medline electronic 
database the using the search terms “sarcoid” OR “sarcoidosis” OR sarcoidosis 
[MeSH Terms] OR Sarcoid* (truncation) AND incidence. Cases of sarcoidosis appear 
to be presenting at a later age. Work from the 1980s suggested a peak incidence in 
those aged 20 to 34 (15); more recent evidence from a similar population in 
Northern Europe revealed a mean age of 51.2 years at diagnosis (14), with similar 
changes seen between 1974 and 2012 in Japan (16). 
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Table 1 - Incidence of Sarcoidosis worldwide, ordered by continent 
Study 
Year(s) of data 
Country 
Annual 
incidence Rate  
(per 100,000 
population) 
Mean age 
at 
diagnosis 
(years) 
Male 
Sex 
Ethnicity Comments 
Europe 
Parkes et al (17) 
1962-1976 
1977-1983 
UK (Isle of Man) 
3.5 (3.3–3.8) (72-
76) 
14.7 (9.6-18.0) 
(77-83) 
Not stated 46.4% 
(1972-76) 
45.4% 
(1976-83) 
Not stated Cases diagnosed by 
kveim test after 1977. 
Active case finding; 
reminder to GPs and 
radiologists given in 
1977 about the 
condition. 
Hillerdal et al 
(15) 
1966-1980 
Sweden (Uppsala) 
19.0 (14.7-23.2) Men – 34 
Women – 
45 (Median 
ages) 
42.4% Not stated Identified cases in 
three ways: (1) CXR at 
health screening every 
(>50% cases), (2) 
Chance finding (e.g. 
incidental finding on 
CXR), (3) Presentation 
with symptoms 
Poukkula et al 
(18) 
1970-1981 
Finland 
15.0 Not stated 47.5% Not stated Cases identified by 3-
yearly CXR screening 
and followed-up in 
hospital 
Byg et al (19) 
1980-1994 
Denmark 
7.2 41.4 
(Median 
ages – Men 
38, Women 
45) 
50.9% Not stated Peak incidence in men 
aged 30-34 years 
14.8/100,000); two 
similar peaks were 
seen in female cases 
between 25-29 and 65-
69 years of age (10.5 
and 11.0/100,000 
respectively) 
Karakatsani et al 
(20) 
1981-2003 
Greece 
1.07 Not stated Not 
stated 
Not stated All cases registered 
across multiple 
centres, covering 
approximately 60% of 
Greek population 
Gribbin et al (21) 
1991-2003 
UK 
5.0 Not stated 47.3% Not stated Longitudinal data from 
primary care records 
Thomeer et al 
(22) 
1992-1999 
Belgium 
0.26 Not stated Not 
stated 
Not stated  
Tinelli et al (23) 
2000-1/2005 
Italy 
Not stated 52.4 +/- 
14.5 (Range 
11 – 87) 
45.1% Not stated Italian ILD registry; 
incidence not reported 
Deubelbeiss et al 
(24)  
2002-2005 
Switzerland 
7.0 45.0 
+/- 15.0 
Not 
stated 
Not stated Diagnosis taken from 
federal statistics 
Arkema et al (14) 
2003-2013 
Sweden 
10.4-14.8 51.2 
+/-16.0 
53.4% Not stated  Register-based; ICD-8, -
9 or -10 codes for 
sarcoidosis 
Kowalska et al 
(25) 
2006-2010 
Poland 
 
5.1-7.3 42.4-46.2 
years 
Not 
stated 
Not stated Retrospective data 
from the National 
Health Fund using ICD-
10 codes 
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Study 
Year(s) of data 
Country 
Annual 
incidence Rate  
(per 100,000 
population) 
Mean Age 
at 
diagnosis 
(years) 
Male 
Sex 
Ethnicity Comments 
USA 
Gorham et al (26) 
1975-2001 
USA (US Navy) 
Overall: 7.1 
Black: 24.9 
White: 3.5 
(All were 
hospitalised 
cases) 
Not stated Not 
stated 
Not stated: both 
white and black 
ethnicities 
included in cohort 
US naval records for 
old and new cases; 
incident cases 
identified using 
database of inpatient 
data records 
Ungprasert et al 
(27) 
1976-2013 
USA (Minnesota) 
10.0 44.2 +/-1 
13.8 
48% Caucasian – 92% 
African-American 
– 4% 
Asian – 1.5% 
Native American 
– 0.5% 
Other – 2% 
Physician diagnosis 
supported by 
histopathology and 
radiographic features 
with compatible 
clinical presentation. 
Dumas et al (28) 
1989-2011 
USA (nationwide) 
Black 43.0 
White 11.0 
48.0 
(range 28-
63yrs) 
0% 95.9% White; 
1.8% Black; 
2.3% other 
Data from Nurses’ 
Health Study II – 
prospective study of 
116,430 US female 
nurses  
Rybicki et al (29) 
1990-1994 
USA (Detroit) 
Black: 35.5 
White: 10.9 
38.6 years 35.3% 39.6% Caucasian 
60.4% African-
American 
Records from Health 
Maintenance 
Organisation data, 
using ICD-9 code 
Cozier et al (13) 
1995-2007 
USA (nationwide) 
71.0 38.0 
(Median) 
0% 100% African-
American women 
Data from Black 
Women’s Health Study 
– prospective study of 
59,000 participants 
Other 
Haraldsdottir et 
al (30) 
1981-2003 
Iceland 
3.84 
(2.8 during 1981-
1992, 
5.0 during 1993-
2000) 
50.8 
(women) 
47.5  
(men) 
48.1% Not stated All cases histologically 
proven 
Kim (31) 
1992-1999 
South Korea 
0.13 Not stated 35.4% Not stated Peak decade of onset 
was 30-39 (33% of 
cases). All cases 
biopsy-proven, from 58 
hospitals. Clinical 
manifestations similar 
to “western pattern” 
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1.4 Pathogenesis and aetiology 
The pathological hallmark of sarcoidosis is the presence of non-caseating 
epithelioid granulomas, leading to distortion of tissue architecture which may result 
in organ dysfunction (32). The granulomas form due to an inability to destroy and 
eliminate an antigen (33), which is internalised by macrophages and processed into 
peptides presented to CD4 T-cells (32). These interactions initiate granuloma 
formation and promote local proliferation of a clonal population of T cells, further 
stimulated by the trapping of antigens by serum amyloid A (SAA) and other 
proteins, establishing the nidus of the granuloma (33). A graphical overview of 
granuloma formation is shown in Figure 1. Further release of immune-mediators, 
including tumour necrosis factor (TNF), leads to continued proliferation due to 
amplified CD4 type 1 helper T cells (TH1) response. In tissue surrounding the central 
core of the granuloma an increase in TH17 cells is seen (34), which secrete potent 
pro-inflammatory cytokines including interferon gamma. The ability to clear the 
antigen may determine the subsequent disease course; the TH1 response may be 
effective at gaining immune control of the initial insult but the accumulation of SAA 
and other proteins as an antigen trap can sequester further circulating antigens and 
cause an ongoing inflammatory response (35). 
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Figure 1 - Granuloma formation in sarcoidosis 
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Whilst the pathogenesis of the disease may be uniform, the driving aetiology for 
the development of sarcoidosis remains obscure. Data from epidemiological 
research supports an infective agent as a possible trigger, with clusters linked by 
time or geographical location (36, 37). Potential identified triggers include; 
Mycobacterial Catalase G (mKatG) (38, 39), catalases from Proprionibacterium (KAT, 
particularly from P acnes) (39-41), inorganic dusts and metals (including aluminium, 
zirconium, titanium and beryllium) (42-44), and exposure to biomaterials such as 
wood pollen and organic dusts (45, 46). 
Genetic factors also play a role. Clustering within families is seen, with elevated risk 
observed in first- and second-degree relatives, particularly siblings who have a 
relative risk 4.7 for developing the disease (47). Registry-based twin studies show 
an 80-fold increased risk of developing sarcoidosis in monozygotic twins; in 
dizygotic twins the relative risk is 7 (48), not dissimilar from the risk in non-twin 
siblings observed in other studies (47). 
Genetic loci associated with sarcoidosis include; BNTL2 (49-51), ANXA11 (52) and 
multiple areas of the HLA region on chromosome 6 (53), including HLA-B, HLA-
DPB1, HLA-DRB1 and HLA-DQB1 (54). The polymorphisms HLA-DRB1*01, DRB1*03 
and DRB1*14 have been associated with Lӧfgren’s syndrome; DRB1*07, DRB*14 
and DRB1*15 are associated with non-resolving disease whereas DRB1*01 and 
DRB1*03 protect against persistent disease (55). Recently, additional non-HLA loci 
with a prominent role in the IL12/23 signalling pathway have been identified (54). 
IL12 is a T-cell stimulating factor that leads to differentiation of native T-cells into 
TH1 cells (56) whilst IL23 induces differentiation to TH17 cells (57). 
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1.5 Clinical manifestations of sarcoidosis 
The frequency of different patterns of organ involvement appears to vary between 
countries. Table 2 shows the results of a literature search of the Medline electronic 
database for studies describing the presentations of sarcoidosis and the oragsn 
affected. The most frequent organ affected is the lungs, occurring in 95% of cases 
of sarcoidosis, most commonly consisting of hilar lymphadenopathy (58). The 
association of bilateral hilar lymphadenopathy with erythema nodosum (EN) or 
bilateral ankle arthritis (Löfgrens syndrome) has been recognised as an acute and 
typically benign manifestation of sarcoidosis (59, 60). Longitudinal follow-up of 
these cases has reinforced the picture of these acute manifestations largely being 
benign; in one study only 11 of 133 patients (8%) had active disease within 2 years 
and only eight patients (6%) developed a recurrence of sarcoidosis(61). Beyond this 
well recognised syndrome, as a multi-system disease sarcoidosis can affect any 
organ or system within the body.  
Recently, a cluster analysis of 2,163 Caucasian patients with sarcoidosis identified 
five specific patterns of organ involvement (62). These patterns were 1) abdominal 
involvement (renal, spleen and hepatic involvement); 2) ocular-cardiac-cutaneous-
CNS involvement, also frequently showing cutaneous manifestations, salivary gland 
involvement and fatigue; 3) Musculoskeletal-cutaneous involvement, which were 
more likely to present acutely and more likely to suffer fevers, night sweats, weight 
loss or arthralgia; 4) Pulmonary-lymphonodal, where lung function was worse but 
skin and musculoskeletal involvement was less frequent; and 5) Extrapulmonary 
disease, which was similar to cluster 4 but associated with no impairment to lung 
function. The study (62) was the first to suggest specific patterns of organ 
involvement beyond the eponymous acute presentations and may enable better 
prognostication beyond existing staging systems. 
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Table 2 - Patterns of organ involvement across cohorts of sarcoidosis patients 
around the world 
Country of Study USA  
(58) 
Finlanda 
(63) 
Japana  
(63) 
Turkey 
(64) 
Europeb 
(62) 
Total patients 736 600 686 293 2163 
Mean Age (yrs) not reported 41.4 30.3 44.0 47.0 
Caucasians (%) 53.4 not reported 
not 
reported 
not 
reported 100 
Female (%) 63.6 58.8 54.8 67.5 59.6 
Organs Involved (%)       
- Lungs 95.0 93.8 76.4 95.2 75.5 
- Skin (excl.  erythema 
nodosum) 15.9 - - 16.0 16.1 
- Lymph node 15.2 23.3 20.0 - 77.0d 
- Eye 11.8 4.5 50.1 3.4 7.8 
- Liver 11.5 0.3 0.9 3.8c 4.9 
- Erythema nodosum 8.3 17.0 0.4 21.5 - 
- Spleen 6.7 4.2 0.0 4.1c 3.9 
- Neurological 4.6 - - - 3.4 
- Parotid/salivary 3.9 - - 1.4c - 
- Bone marrow 3.9 - - - - 
- Calcium 3.7 - - - - 
- ENT 3.0 - - - - 
- Cardiac 2.3 0.3 4.5 - 3.2 
- Renal 0.7 - - - 3.3 
- Bone/Joint 0.5 - - 28.7 9.6 
- Muscle 0.4 - - 4.8 7.5 
- Gastrointestinal - - - - 0.6 
- Genital - - - - 0.2 
- Other - 8.7 1.0 - - 
a Includes both familial and non-familial cases of sarcoidosis 
b Centres included Serbia. Germany, Italy, The Netherlands, Poland, UK, Czech Republic, Ireland, Iceland, 
France, Croatia, Hungary, Belgium,  
c Paper presents rates of organ enlargement but does not specify whether organ directly affected by 
sarcoidosis on radiology or biopsy. 
d Intrathoracic lymph nodes only; extrathoracic lymph nodes involved in 11.3% of cases 
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1.6 Diagnosis 
Chest X-ray (CXR) is the most common method of identifying pulmonary sarcoidosis 
and remains an important investigation. In the ACCESS study investigating 
presentations of sarcoidosis, 91.7% of patients had abnormalities on their CXR(58). 
The most widely used system for staging sarcoidosis by CXR is the Scadding criteria, 
a score initially proposed in the 1960s from a review of 136 cases (65) and amended 
in 1983 (66). The score is displayed in Table 3 below alongside the initial four 
groups as described by Scadding in 1961. 
 
Table 3 - Chest X-ray staging systems for sarcoidosis 
Stage Description – DeRemee (1983) (66) Description – Scadding (1961) (65) 
0 Normal chest radiograph Not mentioned 
I Lymph node enlargement (hilar, 
mediastinal) only 
Enlarged hilar lymph nodes only 
II Lymph node enlargement and 
parenchymal opacity 
Mottled shadowing in the lungs with 
enlarged hilar lymph nodes, either 
at present or known to have been 
present in the past 
III Parenchymal opacity, no evidence 
of fibrosis or lymph node 
enlargement 
Mottled shadowing in the lungs, 
without present or available past 
evidence of enlargement of hilar 
lymph nodes 
IV Lung fibrosis present Radiographic and clinical features 
suggesting fibrosis, usually in 
addition to mottled shadowing 
 
 
Further imaging, usually with computed tomography (CT), is recommended where 
the findings on CXR are atypical or subtle, or where complications such as 
pulmonary hypertension or bronchial stenosis are suspected (67, 68). CT imaging 
can guide where biopsies should be taken from, and disease extent as assessed by 
CT imaging correlating with the likelihood of a positive biopsy from the lung 
parenchyma (69). After diagnosis there is little benefit offered by CT scanning over 
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conventional CXR monitoring for follow-up of the disease unless complications 
occur (70). 
Magnetic resonance imaging (MRI) has no current role for the investigation of 
pulmonary sarcoidosis for a number of reasons, including low proton density of 
pulmonary tissue and movement during respiration resulting in artefacts (71). 
However, MRI has an important role when suspecting cardiac sarcoidosis due to its 
high sensitivity for identifying disease affecting the heart. For this reason it is 
recommended as the investigation of choice for patients with suspected cardiac 
sarcoidosis (72, 73).  
Positron emission tomography (PET) scanning, in combination with CT (PET-CT), 
allows cross-sectional imaging with overlay of metabolic activity to determine areas 
of activity in sarcoidosis (74), although it is reserved for atypical and complex cases, 
including for follow-up of response to treatment (75). It has a role for identifying 
cardiac sarcoidosis and is similar in accuracy to MRI, with the added benefit of 
being able to be performed where a non-MR compatible pacemaker is in situ (76).  
A firm diagnosis of sarcoidosis is usually made from biopsy specimens of affected 
organs, the exception being in patients presenting with acute presentations of 
sarcoidosis consistent with Lӧfgren’s syndrome (77). Biopsies are frequently taken 
from the lungs, given the frequency with which the organ is affected. In patients 
with parenchymal disease (stage II or III disease), transbronchial lung biopsies 
(TLBs) obtained during bronchoscopy offer good diagnostic yield (78-80).  
More recent developments in bronchoscopy have led to the widespread use of 
endobronchial ultrasound (EBUS), which enables safe transbronchial needle 
aspiration (TBNA) of enlarged lymph nodes or masses adjacent to airways. The 
GRANULOMA trial (81) compared TLBs with EBUS-TBNA sampling in stage I or II 
sarcoidosis, with the diagnostic yield of EBUS-TBNA significantly higher than TLBs 
(74% vs 48%). Although seemingly less effective than EBUS-TBNA at acquiring 
histological samples and confirming the diagnosis, traditional bronchoscopy and 
TBLB retains a place in the diagnosis pathway due to the inability to use EBUS in 
patients without mediastinal lymphadenopathy.  
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1.7 Treatment for Sarcoidosis 
Not all patients with sarcoidosis require treatment; pharmacological management 
is reserved for patients with organ dysfunction or to improve quality of life (82). 
Current UK guidelines recommend pharmacological treatment is not warranted for 
asymptomatic stage I disease, or for stage II or III disease when lung function is 
stable with only mild abnormalities (83).  
Present guidelines from the British Thoracic Society (BTS) recommend oral 
corticosteroids as the first-line agent when treatment is required. The BTS 
guidelines suggest that steroids are used for patients with progressive disease 
(radiologically or on lung function), or where disease is threatening other organs or 
leading to significant symptoms; in these cases a dose of 0.5mg/kg/day equivalent 
of prednisolone is recommended, with reduction of the dose over a period of 6-24 
months (83). The American Thoracic Society (ATS), the European Respiratory 
Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous 
Diseases (WASOG) also recommend oral corticosteroids as initial therapy where 
required for progressive symptomatic disease, suggesting an initial dose of 20-
40mg/day of prednisone or equivalent for at least 12 months (84). Evidence of 
benefit from corticosteroids is mixed; a meta-analysis found the only significant 
outcome improved by steroids was in CXR features, although the authors concluded 
that the data supports use of oral corticosteroids for patients with stage 2 or stage 
3 disease (85). 
The possible benefit must be balanced against the short and long-term side effects 
of corticosteroids, including increased risk of osteoporosis and subsequent fracture 
(86), weight gain (87), impaired quality of life and increased fatigue (88), and 
possibly even an increased risk of death (89).  
In patients where disease progresses despite steroids, when prolonged courses of 
steroids are required, or when steroids cannot be used or tolerated due to side 
effects it is recommended that other immunosuppressant medications are used, 
with methotrexate or azathioprine the preferred options (83, 84). An additional 
antimetabolite, leflunomide, is well tolerated and appeared as effective as 
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methotrexate (90, 91). At present leflunomide is reserved for those intolerant of 
azathioprine or methotrexate (83). 
Mycophenolate mofetil (MMF), an inhibitor of T- and B-cell replication through 
depletion of guanosine nucleotides (92), has been used to treat sarcoidosis with 
evidence of steroid sparing activity (93, 94). The use of MMF does not appear 
beneficial if azathioprine or methotrexate have failed to stabilise disease but can be 
used if they have not been tolerated; it is presently not mentioned in current 
guidelines as the trial evidence has only been released since the last updates (83). 
The antimalarials chloroquine and hydroxychloroquine are alternative second line 
therapy for sarcoidosis in some cases (83). The use of hydroxychloroquine alongside 
prednisolone has been shown to be effective for hypercalcaemia and hypercalciuria 
in sarcoidosis (95, 96); this is likely due to the reversal of abnormalities in vitamin 
D3 metabolism, inhibiting synthesis of 1,25-dihydroxyvitamin D3 by pulmonary 
alveolar macrophages responsible for hypercalcaemia via vitamin-D dependent 
pathways (97). 
Monoclonal antibodies are available for clinical use which block the actions of TNF-
alpha, a cytokine known to be involved in the granulomatous processes behind 
sarcoidosis (98, 99). Infliximab, adalimumab, golilimumab and etanercept have all 
been trialled in sarcoidosis.  
Infliximab has been shown to have some ability to reduce inflammation in 
sarcoidosis, demonstrated on PET scanning (100). It has been suggested that 
infliximab is most effective for extra-pulmonary sarcoidosis, especially in those with 
neurological, cardiac, skin or upper respiratory tract involvement (101). However, 
adverse events are common with infliximab. Infection is the most common adverse 
event (101-103), although reactions and antibody-formation against infliximab can 
also occur (101). The formation of anti-infliximab antibodies has been shown to 
correlate with poorer clinical responses (104). Adalimumab can be used where 
infliximab has failed, including where antibodies against infliximab have been 
produced, with trial evidence suggesting benefit in patients with ocular 
involvement as well a steroid-sparing effect (105). More recently, golilimumab, and 
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ustekinumab (a monoclonal antibody inhibiting IL12 and IL23) have been trialled in 
patients with ongoing steroid requirements; no differences were seen between 
golilimumab, ustekinumab and placebo after 16 weeks of therapy (106). 
Furthermore, despite the anti-sarcoidosis activity of TNF-blocking drugs, there are a 
number of reports of patients developing paradoxical sarcoidosis-like lesions during 
treatment with anti-TNF-alpha therapies for other conditions. A review of the 
literature identified 90 cases of such paradoxical reactions, most commonly 
occurring with etanercept (53 cases, 59%) but also with infliximab and adalimumab 
(107). The most recent UK interstitial lung disease guidelines recommend that these 
drugs are used with caution and only when there are no other alternatives (83). 
 
1.8 Prognosis and mortality 
The disease course of sarcoidosis is highly variable, although some prediction is 
possible based upon the disease stage. Up to 90% of cases with stage I disease, 
including those with the acute manifestation of Löfgren’s syndrome have 
spontaneous remission, remission in stage II disease occurs in up to 70% of cases, 
while less than 40% of cases in stage III will remit (15, 108). The recent 
identification of disease phenotypes, discussed in section 1.5, suggests that 
prognosis and need for treatment is dependent on more than simple CXR 
appearances. In the absence of cardiac or neurological involvement, rapid or 
extensive pulmonary fibrosis, or pulmonary hypertension, the disease course is 
frequently mild and prognosis is excellent (27). 
Mortality rates in cohorts with sarcoidosis have been claimed to be between 1 and 
5% (84). Variability in mortality is seen between patients referred to hospital 
settings and those within the general population. A systematic literature review 
published in 2002 estimated mortality attributable to sarcoidosis in “referral 
settings” (secondary care/hospital care) to be 4.8% from 2,838 cases within seven 
studies, approximately ten times the rate seen in sarcoidosis patients within wider 
population samples (0.5% of 812 cases across three studies) (89). The estimate of 
mortality in the review was described as “an imprecise measure” and is not a 
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standardised rate. The review also investigated possible factors predicting 
increased mortality; no relationship with ethnicity was seen but the author 
concluded that a lower threshold for administering corticosteroids is associated 
with an increased risk, independent of disease severity.  
 
1.9 Fatigue and Sarcoidosis 
Fatigue can be defined as “the awareness of a decreased capacity for physical 
and/or mental activity due to an imbalance in the availability, utilization, and/or 
restoration of resources needed to perform activity” (109). Whilst it is a subjective 
symptom it is experienced by everyone to varying degrees throughout the 
population, often as a temporary complaint due to psychosocial factors including 
work patterns, but also related to psychosocial problems or physical disease (110). 
Fatigue specifically related to underlying sarcoidosis, termed a “post-sarcoidosis 
chronic fatigue syndrome”, was described by DG James in 1993, who stated “up to 
5 per cent of patients, seemingly recovered from active sarcoidosis, develop a post-
sarcoidosis chronic fatigue syndrome” (111). The description included general 
myalgia, debilitating fatigue sleep-reversal and poor sleep quality, all occurring in 
the absence of physical signs. The presence of fatigue within this syndrome has a 
significant impact on both the physical and psychological burden of disease (Figure 
2), negatively affecting an individual’s quality of life and function. 
Fatigue is a chief complaint amongst patients with sarcoidosis. In a large cohort of 
sarcoidosis patients in the Netherlands (837 members of the Dutch Sarcoidosis 
Society and 68 outpatients), 80% of sarcoidosis patients reported significant fatigue 
using a validated fatigue measurement scale (112). A cross-sectional study of 121 
Dutch sarcoidosis patients and 126 American sarcoidosis patients revealed similar 
levels of fatigue. Using the same Fatigue Assessment Scale (FAS), 83.2% of the 
Dutch cohort and 74.6% of the American cohort reporting FAS scores >21, 
indicating significant fatigue, although more Dutch patients reported FAS scores of 
>35 (37.8% vs 19.0%, p=0.004), consistent with severe fatigue (113). A previous 
review reported frequencies of fatigue of between 33% to over 80% of patients 
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(114), reinforcing the importance of this symptom in sarcoidosis cohorts. It appears 
unrelated to disease severity and clinical parameters, with no clinical or 
physiological variables able to predict the presence or severity of fatigue (115). 
Sarcoidosis is not the only systemic disease associated with fatigue. Fatigue is also a 
problem in other chronic diseases including inflammatory bowel disease (116), 
rheumatoid arthritis and other rheumatic diseases (117), cancer (118), HIV (119), 
primary sclerosing cholangitis (120) and multiple sclerosis (121). Fatigue in 
sarcoidosis may be multifactorial in origin and a number of hypotheses for this 
fatigue have been put forward, including subclinical disease activity, post-
inflammatory effects on the central nervous system, treatment-related side-effects 
or disorders of sleep (122).  
Treatment of fatigue is difficult and often unresponsive to standard treatment 
regimens for sarcoidosis activity, making it a problematic symptom for the 
physician to treat. Multiple treatment options have been suggested by researchers 
which are discussed in greater detail in chapter 2. 
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Figure 2 - Interaction between physical and psychological symptoms within 
sarcoidosis 
 
Adapted from Gerke et al. 
Disease burden and variability in sarcoidosis. Ann Am Thorac Soc 2017;14(6):S421-S428 
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Proposed mechanisms for sarcoidosis-associated fatigue 
Systemic inflammation and cytokine release 
As sarcoidosis is a disease characterised by granulomatous inflammation that can 
occur within any system of the body, it has been suggested that the presence of 
ongoing inflammation is related to constitutional features, including fatigue (123). 
One small study reported the results of a cross-sectional assessment of 38 patients 
with sarcoidosis, showing that those with fatigue (n=25 using the energy and 
fatigue facet of the World Health Organization Quality of Life assessment 
instrument) had higher levels of C-reactive protein (CRP; 11.4±6.8mcg/ml vs 
3.2±6.8mcg/ml, p<0.0001) compared with non-fatigued sarcoidosis patients (123). 
Another study compared TNF-alpha and interleukin-1 beta (IL-1 beta) levels 
between 22 patients with sarcoidosis and 22 control subjects; those with 
sarcoidosis exhibited higher general fatigue scores measured by the 
multidimensional fatigue inventory (15.5+/-4.9 compared with 7.3+/-3.2, p<0.0001) 
and higher resting TNF-alpha levels (1.72pg/ml compared with 1.21pg/ml in 
controls, p=0.0008), with no difference in IL-1 beta levels between groups (124). 
Improvements observed in fatigue scores when targeting TNF-alpha with infliximab 
or adalimumab further suggests a possible role for this cytokine in the aetiology of 
sarcoidosis-associated fatigue (105, 125). It has been shown to have a role as a pro-
inflammatory cytokine in sarcoidosis, with evidence of increased production of TNF-
alpha and TNF-alpha receptor-1 and -2 by alveolar macrophages in ten patients 
with sarcoidosis (98, 126). 
These small studies of patients provide limited evidence to support the systemic 
inflammation theory but has led on to further work investigating the use of 18F-2-
fluoro-2-deoxy-D-glucose (18FDG) PET-CT. A review of 188 patients with sarcoidosis 
that underwent a PET scan revealed that 137 had evidence of inflammation, most 
commonly in the mediastinal lymph nodes (127). Further work suggests that 
inflammatory activity can persist in the absence of commonly measured serum 
markers of inflammation (128). Although this study did not investigate the presence 
of fatigue in these patients, another study of 12 patients with sarcoidosis received 
six cycles of infliximab with pre- and post-therapy PET scans. Nine of the patients in 
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this trial reported fatigue pre-intervention, although no validated measurement of 
fatigue pre- and post-intervention was undertaken. All patients reported subjective 
improvement in symptoms, including fatigue, post-treatment. All but one patient 
showed an improvement in their PET scan measures of inflammation, though one 
patient showed increased inflammatory changes post-treatment and yet reported 
improved fatigue (129). 
 
Small fibre neuropathy and autonomic dysfunction 
Involvement of the nervous system by sarcoidosis is rare; one recent meta-analysis 
of previous cohorts reported 5% of cases develop neurosarcoidosis (130). Direct 
involvement of the peripheral nerves is a rare cause of peripheral neuropathy. One 
case series of 3475 cases with peripheral neuropathy undergoing nerve biopsy 
revealed involvement by sarcoidosis in only 11 (0.31%) patients (131). Small fibre 
neuropathy appears to occur more frequently, with one cross-sectional study 
showing that 44% of patients with sarcoidosis suffered small fibre neuropathy, 
confirmed using intra-epidermal nerve fibre density (132). In these cases, the 
involvement of small peripheral fibres (myelinated Aδ or unmyelinated C fibres) 
leads to problems with pain, dysaesthesia, disturbed sense of temperature and 
possible autonomic involvement if the autonomic nervous system is affected; the 
mechanisms behind this are unclear (132). There is significant overlap between 
fatigue and symptoms of small fibre neuropathy. One series of 57 patients revealing 
that 49.1% of cases (28 patients) suffered constitutional symptoms including 
fatigue (133). Another study identified that small-fibre neuropathy symptoms were 
more likely to occur in patients with worsening fatigue; 94% of patients with 
continuous fatigue reported symptoms of small-fibre neuropathy (134).  
It has also been suggested that involvement of the autonomic nervous system, as 
occurs in small-fibre neuropathy, can lead to the development of chronic fatigue. 
The autonomic nervous system controls sympathetico-vagal balance through 
multiple pathways (135). Observations in chronic fatigue syndrome (CFS) have 
shown differences in autonomic function, measured by heart rate response during 
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tilt-table test, compared with healthy controls (136, 137). A pattern of sympathetic 
hyperactivity is observed in the setting of decreased parasympathetic activity (135). 
The same pattern of autonomic dysfunction, notably a shift of sympatho-vagal 
balance in favour of reduced parasympathetic activity and a relative sympathetic 
predominance, is seen in chronic sleep deprivation in healthy subjects (138, 139). 
Whilst a direct link between altered autonomic function and fatigue has not been 
drawn in patients with sarcoidosis, autonomic dysfunction has been identified in 
recent studies. One study investigated circadian blood pressure in 63 normotensive 
patients with sarcoidosis compared with 49 controls looking for alterations in blood 
pressure patterns suggestive of autonomic dysfunction; 80% of the sarcoidosis 
group had these alterations, compared with 50% of controls (p=0.002) (140). 
Another study investigating ECG changes consistent with autonomic dysfunction in 
31 sarcoidosis patients without cardiac involvement by the disease, compared with 
30 age-matched controls; the results revealed heart rate variability consistent with 
autonomic dysfunction, specifically increased sympathetic activation, in the 
patients with sarcoidosis (141). Both of these studies were small but the results 
suggest a possible role for autonomic dysfunction in the development of fatigue in 
patients with sarcoidosis. 
 
Depression 
Within cohorts of patients with sarcoidosis, increased depression and anxiety 
scores have been found to be associated with concomitant fatigue. One large study 
measured fatigue, anxiety and depression over an 18-month period in 443 patients 
with sarcoidosis in the Netherlands. The results showed that depressive symptoms 
and anxiety traits were both predictors for fatigue severity in multivariate 
regression analysis, although these symptoms were not found to fully overlap 
within the patient group (142). These findings have been replicated in other cross-
sectional studies of factors affecting quality of life in patients with sarcoidosis (143), 
with one study of 588 patients with sarcoidosis showing that depressive symptoms 
predicted fatigue more than personality types indicating distress (type “D”), and 
that both depressive symptoms and fatigue were predictors of poorer overall 
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quality of life (144). One study investigating the impact of fatigue on multiple 
outcomes in sarcoidosis showed that fatigue was associated with both depression 
and anxiety symptoms (145). Furthermore, when investigating how anxiety and 
depression alter with types of fatigue (mild, intermittent or continuous fatigue), 
anxiety and depressive symptoms were most strongly associated with continuous 
fatigue, possibly moderating the nature or severity of fatigue suffered by patients 
(142).  
The existing evidence only determines associations between depression and fatigue 
scores in a cohort of patients at a single time-point. This cannot determine whether 
the two symptoms are independent factors or whether there is interaction 
between them, and the direction and size of interaction between them. No studies 
have investigated pharmacological or psychological interventions for fatigue or 
depression in patients with sarcoidosis, therefore the change in depressive 
symptoms with improvement in fatigue, or vice versa, is unknown. 
 
Sleep Disturbance 
Poor subjective sleep quality in patients with sarcoidosis is associated with fatigue 
(146). Two mechanisms of sleep disturbance have been proposed as potential 
mechanisms for fatigue in patients with sarcoidosis; sleep-disordered breathing, 
including obstructive sleep apnoea (OSA) and periodic limb movement syndromes 
(PLMS), and abnormalities of circadian rhythm. 
Previous research has suggested that sleep disordered breathing, specifically OSA, 
is more common in patients with sarcoidosis than the general population. Table 4 
shows the results of a search of the Medline electronic data base, using the search 
terms “sarcoid” OR “sarcoidosis” OR sarcoidosis [MeSH Terms] OR Sarcoid* 
(truncation) AND “sleep” OR “apnoea” OR “apnea” OR “OSA” OR “ sleep-disordered 
breathing” OR Sleep Apnea, Obstructive [MeSH Terms]. Five studies (147-151) have 
investigated the prevalence of OSA in cohorts of patients with sarcoidosis using 
polysomnographs to diagnose OSA, one further study (152) recorded the 
prevalence of pre-diagnosed OSA in a large sarcoidosis cohort. The prevalence of 
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OSA seen amongst the five studies was between 8.6% and 66.6%, depending upon 
apnoea-hypopnoea index (AHI) criteria used. This is higher than the prevalence in 
the general population, where it is estimated to be between 3 and 17% (153). In 
one of the studies, electromyelography was performed to identify the presence of 
PLMS as well as OSA (151), with 7 (15%) of 46 patients having PLMS alone; PLMS 
was also present in 60% of the 20 patients who were found to have OSA on 
polysomnography. Although only including a small sample size, both of these 
results are significantly higher than the prevalence in the general population which 
has been estimated to be 7.6% (154). 
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Table 4 – Summary of studies investigating prevalence of OSA in patients with 
sarcoidosis 
Study Threshold for 
diagnosis of 
OSA 
No. 
sarcoidosis 
patients 
included 
No. 
sarcoidosis 
patients 
with OSA 
(%) 
No. 
control 
pop-
ulation 
No. 
controls 
with 
OSA (%) 
Notes 
Turner GA et al. 
(147) 
Sarc Vasc Diff 
Lung Dis 
1997;14(1):61-4 
AHI >5 on poly-
somnography 
83 14 (17%) 91 3 (3%) M>F, lupus pernio 
more frequent with 
sarcoidosis. 
Verbraecken et 
al.(151)  
Sarc Vasc Diff 
Lung Dis 2004; 
21(2):137-46 
AHI >5 on poly-
somnography 
46 20 (44%) None -- 12 of the OSA 
patients (44%) had 
periodic limb 
movement 
syndrome (PLM); 7 
patients (15%) had 
PLM but not OSA. 
Patterson KC et 
al. (148)  
Chest 
2013;143(6):15
62-8 
Mild – AHI 5-15 
Mod – AHI 15-30 
Severe – AHI >30 
62 Mild – 14 
(23%) 
Mod – 12 
(19%) 
Sev. – 20 
(32%) 
1,005 Mild – 
210 
(26%) 
Mod – 
247 
(25%) 
Sev. – 
462 
(46%) 
Retrospective 
review of previously 
performed 
polysomnographs 
with lung function; 
sarcoidosis found to 
be an independent 
predictor of 
sleepiness (Epworth 
score) 
Fleischer et al. 
(152)  
Respir Care 
2014; 
59(7):1086-
1094 
Cross-sectional 
study; diagnosis 
of OSA previously 
made prior to 
study, method of 
diagnosis and 
severity of OSA 
not reported 
1,197 104 (8.6%) None -- Cross-sectional 
study including all 
patients (i.e. prior 
diagnosis of 
sarcoidosis). 
Patients “without” 
OSA not screened 
within trial to 
confirm. 
Bingol et al. 
(150) 
Clin Respir J 
2015; 9(1):14-
21 
AHI >5 on poly-
somnography 
29 15 (51.7%) None -- Patients with risk 
factors for OSA 
(BMI >30, upper 
respiratory tract 
pathology) were 
excluded – “low risk 
population”. 
Higher rate in 
patients with 
parenchymal 
disease (n=10/15, 
66.6% - seven had 
AHI 5-15/h, three 
had AHI >30) than 
without (n=5/14, 
35.7% - all AHI 5-
15/h). 
Pihtili et al. 
(149)  
Sleep and 
Breathing 
2016;17(4):128
1-88 
AHI >5 on 
polysomnography 
15 10 (66.6%) None -- No division of 
results by severity 
within disease 
groups. 14/17 IPF 
patients and 10/18 
scleroderma 
patients had AHI 
>5/hr 
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The development of OSA has been postulated to be due to two possible 
mechanisms; firstly, the use of steroids which can lead to obesity and OSA, or 
secondly the direct involvement of the upper respiratory tract by sarcoidosis. Four 
case reports have been published describing granulomatous involvement of the 
larynx and upper airway which led to the development of OSA in these patients 
(155-158). These cases were diagnosed by direct inspection of the oropharynx and 
larynx or through cross-sectional radiology of the upper airways. All required 
treatment with corticosteroids, with or without an additional agent, with good 
resolution of symptoms. Caution should be used with corticosteroids in this 
situation as there is a risk of worsening OSA, thus reduction to the lowest effective 
dose of steroids should be undertaken rapidly (159). Direct laryngeal involvement 
by sarcoidosis is a rare occurrence, with a reported frequency of less than 1% 
amongst 2319 patients attending the Mayo clinic and diagnosed with sarcoidosis 
(160). 
An alternative cause for sleep disturbance in sarcoidosis may relate to disorders of 
circadian rhythm leading to abnormal sleep patterns. This may be related to the 
role of TNF-alpha as an inflammatory cytokine in sarcoidosis. The immune system 
function is impacted by central biological clocks, with immune cells and cytokine 
levels varying according to time of day and position within the sleep-wake cycle 
(161). TNF and its receptor has been shown in mouse studies to modulate circadian 
rhythm through actions on the suprachiasmatic nucleus (162). Abnormality of 
circadian rhythm in critically ill patients has been described, due to a number of 
causes including systemic inflammation and cytokine release (163). Whilst not 
investigated specifically in sarcoidosis, the known increase in TNF-alpha release and 
the improvement in fatigue with anti-TNF-alpha agents suggest a possible role for 
this in the development of fatigue, and the potential of TNF-alpha to influence 
circadian rhythm could therefore impact on the sleep-wake cycle. Furthermore, 
variations in TNF-alpha over the course of a 24-hour period are seen in other 
inflammatory conditions (164) and could provide a rationale for the variability of 
fatigue experienced in some patients with sarcoidosis (134). 
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Drug-induced symptoms 
The role of drugs in the development of sarcoidosis-associated fatigue is 
contentious, but the most commonly used medication for suppression of disease 
activity (glucocorticoid steroids) is associated with numerous problems that can 
lead to fatigue. One population-based assessment of adverse events affecting 6,517 
patients receiving glucocorticoids for various medical conditions demonstrated that 
increasing doses of glucocorticoids are associated with sleep disturbance, weight 
gain, elevated blood sugar and mood problems (165). All these factors showed 
strong dose-dependent association, with sleep disturbance showing association 
with increased dose even within the lowest dose range (0-7.5mg daily dose 
prednisolone). Prednisolone use has been associated with increased fatigue levels 
in a cross-sectional study of 1,197 members of the German Sarcoidosis Society 
(mean difference in FAS score 1.6, p<0.001), as was methotrexate (mean difference 
in FAS score 3.8, p=0.006) and the use of two or more medications for sarcoidosis 
(mean difference in FAS score 2.1, p=0.037), although these were not adjusted for 
disease severity and may reflect more severe disease (152). A prospective study of 
51 new cases of pulmonary sarcoidosis measured fatigue scores before and 
immediately after a six-month course of oral corticosteroids; of these, nine cases 
(17.6%) showed clinically important worsening in fatigue scores post-treatment, 
although it should be noted that patients had already discontinued steroids by the 
time of their post-treatment measurements, making it impossible to determine 
what happened to fatigue scores whilst receiving corticosteroids (88).  
 
Measuring Fatigue in Sarcoidosis 
The fatigue experienced by patients with sarcoidosis has been shown to vary 
between patients, with different natures of fatigue identified. In a survey of 434 
outpatients with sarcoidosis in Maastricht three distinct types of fatigue 
experienced by patients were discovered; mild fatigue, where the fatigue was not 
severe enough to render a complaint on daily life; intermittent fatigue, where the 
severity of fatigue varied throughout the day; and all-day fatigue, where sufferers 
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felt tired throughout the day (134). Furthermore, the presence of all-day fatigue 
correlate with higher levels of depressive symptoms and anxiety, impacting more 
on daily quality of life (142). Defining fatigue is therefore difficult and requires an 
appropriate choice of instrument. 
WASOG strongly recommends that all clinical trials involving patients with 
sarcoidosis should include measures of quality of life, including fatigue, as part of 
the outcomes assessed (166), reflecting both the frequency with which this 
symptom occurs and the impact that it has.  Accuracy in measuring fatigue is 
challenging due to a complex interaction of multiple factors, including biological 
processes, psychosocial difficulty and behavioural manifestations (109). Multiple 
questionnaires have been designed and validated for measuring fatigue but a 
preference for an endpoint that incorporates “validated, disease-specific objective 
instruments” is suggested by WASOG for measuring fatigue in sarcoidosis 
populations (166). 
A list of potential “objective instruments” that measure fatigue in sarcoidosis 
patients has been created by WASOG in their recommendations for endpoint in 
clinical trials involving patients with sarcoidosis (166). The possible questionnaires, 
including ones previously used as outcome measures for fatigue in studies involving 
patients with sarcoidosis, are described in detail below. It has been acknowledged 
that in view of the difficulties of characterising fatigue, as well as no single 
instrument being a perfect disease-specific measure, trials investigating change in 
fatigue should use several complementary questionnaires. This may include a 
specific questionnaire evaluating fatigue symptoms, such as FAS, alongside a 
general quality of life scale such as the Short-Form 36 (SF-36) instrument and 
measurement of confounders including depression (166). An extended summary of 
possible tools for monitoring fatigue, identified from previous observational or 
interventional studies investigating fatigue in patients with sarcoidosis, is shown 
below in table 5. 
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Table 5 – Summary of suggested fatigue-specific outcome measures previously 
studied in sarcoidosis cohorts or used in trials investigating sarcoidosis-associated 
fatigue 
Questionnaire Properties 
studied in  
sarcoidosis 
populations? 
Used in 
sarcoidosis 
intervention 
trial? 
Specific for 
fatigue? 
MCID 
specified 
Severity/ 
clinically 
relevant cut-
points 
identified? 
FAS ü ü ü ü ü 
FACIT-Fatigue X ü ü ü* X 
MFI-20 ü X ü ü* ü* 
FSS X ü ü ü* X 
CIS (Fatigue 
subscale) 
X ü ü X ü* 
*Established in conditions other than sarcoidosis 
 
Fatigue Assessment Scale (FAS) 
The FAS questionnaire is a widely-used tool for measuring fatigue in sarcoidosis 
which was originally developed to measure fatigue within a Dutch working 
population. It contains ten questions, five reflecting mental fatigue and five 
reflecting physical fatigue, with each question scored between 1 and 5, with 5 
corresponding to worst possible fatigue. Patients can score a maximum of 50 points 
and a minimum of 10 points, with a score of 22 or more indicating the presence of 
significant fatigue (112); a sub-group of “extreme fatigue” is denoted by scores of 
more than 34 points. The measurement of fatigue has been shown to be 
independent of depressive symptoms (167). 
The tool was subsequently tested within a cohort of 1,126 patients with sarcoidosis 
in the Netherlands, with 246 participants repeating the measurement after seven 
days, to validate its use for measuring fatigue in sarcoidosis (112). Content validity, 
construct validity and internal consistency were all good, and a test-retest reliability 
of 0.89 was found within the group repeating the measurement. Overall, the tool 
was found to be useful for measuring fatigue in patients with sarcoidosis, leading to 
its validation in sarcoidosis cohorts in other countries (168) and subsequent use in 
Chapter 1: Introduction and Background - Sarcoidosis and Fatigue 
  50 
exploring fatigue levels reported by patients with sarcoidosis in the USA (113), 
Poland (169) and the UK (170). Moreover, the minimal clinically important 
difference (MCID) for patients with sarcoidosis has been identified as a 4-point 
change; this was estimated through anchor-based and distribution-based methods, 
using data from 321 patients at Maastrict University Medical Centre (171). 
One potential problem of the FAS questionnaire is items 4 and 10 (“I have enough 
energy for everyday life” and “When I am doing something, I can concentrate quite 
well”), require negative scoring. This leads to confusion in participants completing 
the questionnaire, and has been suggested as a cause of reduced internal 
consistency. In one study of 107 patients with sarcoidosis attending an American 
outpatient pulmonary clinic, FAS scores were measured, with items 4 and 10 
subsequently removed to compare the internal consistency. Initial internal 
consistency of the FAS using Cronbach’s alpha was 0.740, indicating acceptable 
internal consistency, but this increased to 0.911 (excellent consistency) after 
removal of items 4 and 10 (172). Previous work within the sarcoidosis patient 
cohort in Norwich did not replicate this finding; internal consistency of the FAS 
from 66 patients within a previous study was 0.913 with all items included and 
0.921 with items 4 and 10 removed (unpublished data from previous trial (170)), 
showing excellent internal consistency as measured by Cronbach’s alpha. This 
discrepancy may be explained by the different settings where the questionnaires 
were completed. In the Norwich study, participants had the questionnaire 
explained to them by a member of the research team, including the reverse marked 
items. In the American study participants completed the questionnaire in an 
outpatient setting where they may not have received instruction. 
Despite this potential negative of the FAS, the body of evidence for using this 
questionnaire in patients with sarcoidosis, as well as a defined cut-off for significant 
fatigue and a defined MCID mean that the FAS has a number of benefits and has 
been used in previous trials where fatigue has been an outcome measure (173, 
174). 
 
Chapter 1: Introduction and Background - Sarcoidosis and Fatigue 
  51 
Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-Fatigue)  
The FACIT-Fatigue questionnaire was initially developed to measure fatigue in 
cancer patients using computerised adaptive testing to identify questions that 
provided the most information about patient-reported fatigue from a larger 
existing questionnaire. Two groups of respondents completed the questionnaire; 
1010 members of the general population and 1022 patients with various cancers, 
leading to the development of the final 13-item questionnaire (175). Each item is 
marked between 0 and 4 to give a maximum score of 52 points, with higher scores 
indicating worse fatigue. As with the FAS questionnaire, two items (“I have energy” 
and “I am able to do my usual activities”) are reverse scored.  
The tool has been used in patient groups with cancer, rheumatoid arthritis and 
systemic lupus erythematosus to determine the MCID, which has been estimated 
through multiple methods to be between 3 and 6 points, although this was 
validated in cohorts of patients with rheumatoid arthritis, cancer and systemic 
lupus erythematosus (176). No cut-off has been described for severity of fatigue 
with this scale. It has been used previously in two trials investigating possible 
treatments for sarcoidosis-associated fatigue, where changes in the FACIT-Fatigue 
score were similar to those seen in the FAS score but appeared to occur earlier in 
treatment (173, 174). 
 
Multidimensional Fatigue Inventory (MFI-20) 
The MFI is a 20-item questionnaire that was designed to be self-completed by 
patients. The questionnaire covers five dimensions; general, mental and physical 
fatigue as well as reduced motivation and reduced activity. Each of the items is 
scored out of five, giving a potential score range of 20-100 points. It was initially 
validated in cancer patients who had been treated with radiotherapy, as well as 
healthy populations (students, junior physicians and army recruits) in the 
Netherlands, and has good construct validity and internal consistency (177). 
Subsequent studies investigating the use of the MFI-20 estimated a MCID of 
between 11.5 and 13.3 points (176). Using data from cancer patients a cut-off score 
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of 53 points has been determined as the threshold for significant fatigue (178), 
although the validity of this cut-point in patients with sarcoidosis has not been 
performed.  
The MFI questionnaire has been studied in sarcoidosis populations. One study 
administered the questionnaire to 1197 patients in Germany, showing that the MFI-
20 showed similar percentages of patients reporting fatigue using the 53-point cut-
off compared with the FAS questionnaire. Sixty-eight percent of the population 
exceeded the MFI-20 fatigue cut-off compared with seventy percent exceeding the 
FAS fatigue cut-off. The total scores for the two questionnaires were also strongly 
correlated (r=0.86) (179), indicating that the MFI performs similarly to the FAS 
questionnaire in patients with sarcoidosis. 
 
Fatigue Severity Scale (FSS) 
The Fatigue Severity Scale was first used in 1989, initially in patients with multiple 
sclerosis (MS) and SLE, as well as healthy volunteers (180). It is a nine-item short 
questionnaire, with each item scored between 1 and 7 points and the overall score 
averaged to give a total score between 1 and 9. Alternatively the individual 
question scores can be added to give a score out of 63; a score of 36 or more 
indicates marked fatigue. When using the averaged value, the MCID has been 
estimated as 1 point from studies of patients with rheumatoid arthritis, lupus and 
multiple sclerosis (176), although no studies have investigated the properties of the 
scale in patients with sarcoidosis. In other conditions the FSS has been found to be 
internally consistent and correlated with visual analogue measures of fatigue (180). 
The FSS has only been used in one study including patients with sarcoidosis; this 
was an interventional trial investigating the effects of a structured exercise program 
on quality of life where change in fatigue was a secondary outcome (181).  
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Checklist Individual Strength (CIS) Fatigue subscale 
The CIS was initially developed in 1994 to measure fatigue in patients with chronic 
fatigue syndrome (182). The original questionnaire consisted of 20 items (CIS20R), 
though a subscale of 8 items relating to ‘subjective fatigue’ (CIS fatigue subscale; 
CIS8R) can be used separately to measure fatigue. CIS8R consists of 8 items, and 
has identified cut-offs for fatigue severity; 27-35 points for increased fatigue and 
>35 points for severe fatigue, although these cut-points have been identified from 
patients with rheumatoid arthritis, not sarcoidosis (183). No MCID is reported for 
this tool. The CIS8R has been shown to have good internal consistency (Cronbach’s 
alpha 0.92) and criterion validity (correlation co-efficient (r) of 0.61 compared with 
a fatigue visual analogue scale), although these values were from populations with 
rheumatoid arthritis (184). In sarcoidosis, only the fatigue subscale of the CIS 
(CIS8R) has been used previously (185). 
 
Impact of sarcoidosis-associated fatigue 
Impact upon health-related quality of life 
Quality of life is distinct from health-related quality of life (HRQoL), although 
distinguishing between the terms can be difficult. Quality of life is a concept which 
encompasses all aspects of life and is difficult to measure, requiring psychological, 
social and economic wellbeing to be considered alongside direct health-related 
effects of both disease and treatment. Regarding the term “Quality of Life” in 
medical literature, it may not have a defined meaning and is frequently substituted 
for HRQoL (186). By contrast, HRQoL is more narrowly-defined as it focuses on the 
health or disease status of an individual and how this influences quality of life, 
although this itself can be defined in multiple ways including the frequently used 
term “health state” (187).  
The presence of fatigue has been shown to have a negative impact on HRQoL (122). 
By comparison, traditional measures of disease severity including spirometric 
values (188) and chest X-ray staging are not associated with measures of health-
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related quality of life in patients with sarcoidosis (189). Multiple studies have 
measured fatigue and quality of life in patients with sarcoidosis. A search of the 
Medline electronic database, using the terms “sarcoid” OR “sarcoidosis” OR 
sarcoidosis [MeSH Terms] OR Sarcoid* (truncation) AND quality of life AND fatigue, 
identified a number of studies that have measured fatigue and quality of life in 
patients with sarcoidosis (Table 6). Common findings across the globe demonstrate 
that the presence of fatigue negatively affects quality of life in patients with 
sarcoidosis.  
A variety of quality of life measures have been used, as has a variety of fatigue 
scales. In each case a negative relationship between fatigue and quality of life has 
been found, with one exception where a single questionnaire was used to measure 
both fatigue and general quality of life (190). 
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Table 6 – Studies investigating links with quality of life in sarcoidosis 
Source Country No. 
Patients 
Fatigue 
Measure 
QoL 
measure 
Findings 
Michielsen et 
al (189) 
Croatia 145 FAS WHOQOL-
100 
Fatigue 
adversely 
affects all 
QoL domains 
Spruit et al 
(188) 
Belgium 22 CRDQ 
Fatigue 
Domain 
SF-36 Fatigue 
correlates 
with SF-36 
scores 
Elfferich et al 
(144) 
Netherlands 441 FAS WHOQOL-
BREF 
Fatigue and 
depressive 
symptoms 
predict QoL 
Korenromp 
et al (145) 
Netherlands 75 CIS (fatigue 
severity 
subscale) 
SF-36 Fatigued 
patients 
scored 
significantly 
lower in all 
domains of 
SF36 
Wirnsberger 
et al (190) 
Netherlands 71 WHOQOL-
100 (fatigue 
facet) 
WHOQOL-
100 
No 
correlation 
between 
fatigue facet 
and 
psychological 
health 
Jastrzebski et 
al (191) 
Not stated 111 FAS SF-36 Fatigue 
correlated 
with quality 
of life in SF-
36 
CIS = Checklist Individual Strength, CRDQ = Chronic Respiratory Disease Questionnaire, FAS 
= Fatigue Assessment Scale, SF-36 = Short Form 36, WHOQOL-100 = World Health 
Organisation Quality of Life Scale - 100, WHOQOL-BREF = World Health Organisation 
Quality of Life Scale – Brief 
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Impact of fatigue upon physical capacity 
Exercise limitation is a common problem in sarcoidosis, with multiple factors 
potentially responsible for exercise intolerance. These may include peripheral 
muscle weakness due to direct involvement of sarcoidosis, resulting from 
corticosteroid treatment, reduced pulmonary function and cardio-respiratory 
reserve, or general deconditioning (192). One study performed cardiopulmonary 
exercise testing of patients with thoracic sarcoidosis, revealing that these patients 
have reduced pulmonary gas exchange, even in some cases where transfer factor is 
normal (193).   
However, a direct relationship between fatigue and exercise capacity measured in a 
laboratory environment has not yet been proven. A study of 124 patients with 
sarcoidosis revealed that although 45% of patients had reduced exercise capacity 
measured by the six-minute walk test (6MWT), there was a non-significant 
difference in the number of patients with reduced 6MWT seen between fatigued 
and non-fatigued patients. More than half of the patients in this study reporting 
fatigue had no reduction in exercise capacity (194). Later analysis of the same 
cohort in a subsequent study showed a relationship with quality of life, as well as a 
relationship between fatigue score (measured by FAS) and quality of life, although 
it should be noted that only 19% of variability in the quality of life score (measured 
by the WHOQOL-BREF) was explained by the changes in FAS and 6MWT values 
(195). 
The 6MWT, as a self-paced test, measures the submaximal level of functional 
capacity (196). Other laboratory measures are incremental and measure maximal 
functional capacity. One example is the steep ramp test (SRT), a cycle-ergometer 
test with incremental load which gives results highly comparable with full cardio-
pulmonary exercise test (CPET) results. In an evaluation of 147 patients with 
sarcoidosis undergoing both 6MWT and SRT, neither the oxygen uptake during SRT, 
maximal work during SRT, distance covered during 6MWT, or percentage predicted 
6MWT distance showed significant correlation with FAS scores (r= -0.24, -0.27, -
0.27 and -0.25 respectively) (197). Even full CPET testing has not shown an 
association with fatigue; a study of 160 sarcoidosis cases revealed no association 
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between oxygen exchange at maximal exercise and fatigue scores (r = -0.060, 
p=0.474), although maximal work performed by subjects was not reported and so 
the link between fatigue and effort cannot be commented upon (193). Another 
study including 22 patients with sarcoidosis found no relationship between fatigue 
measured by the MFI-20 questionnaire and peak oxygen consumption (VO2max) 
calculated during an incremental CPET on a treadmill (124). These results reinforce 
the variable impact of fatigue upon physical capacity in laboratory settings. 
 
Impact of fatigue upon daily activity 
In contrast to laboratory measures of exercise capacity, such as the 6MWT and SRT, 
physical activity in free-living refers to the amount of exercise or activity performed 
by a person in their own environment. According to the International Classification 
of Functioning defined by the Wold Health Organization (WHO), activity (or 
exercise) capacity refers to “an individual’s ability to execute a task or action… 
indicating the highest probable level of functioning” whereas exercise performance 
“describes what an individual does in his or her current environment” (198). Whilst 
the former is typically assessed in a controlled environment using a standardised 
method, the latter is context specific and impacted by environmental and personal 
factors. 
Measuring physical performance in free-living conditions is more challenging than 
measuring physical capacity. Methods of accurately measuring energy expenditure, 
such as double-labelled water, are well validated but expensive (199). Furthermore, 
these methods measure energy expenditure in free-living conditions, rather than 
patterns of physical activity (200). Questionnaires are a simple method of recording 
physical activity in research participants but are open to recall bias and have been 
shown to be a poor method of assessing activity. In the case of the International 
Physical Activity Questionnaire – Short Form (IPAQ-SF), a widely used activity 
questionnaire, the questionnaire overestimated physical activity by an average of 
84 percent compared with objective measures of activity according to one 
systematic review (201). New accelerometer-based devices can measure 
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movements and track activity patterns. These devices have been shown to be able 
to reliably measure physical activity in free living conditions (202) and are used in 
large-scale population studies such as the National Health and Nutrition 
Examination Survey (NHANES) in the United States (203) and the UK Biobank study 
(204) as objective measures of physical activity. 
In sarcoidosis, two studies have investigated activity patterns in patients with 
fatigue. The first study, from Korenromp and colleagues, measured fatigue levels in 
75 patients with sarcoidosis as well as measuring daily activity over a seven day 
period using an ankle-worn tri-axial accelerometer (145). Levels of activity, 
measured by “accelerations” recorded by the device, were lower in the fatigued 
group compared with the non-fatigued group on both weekdays (75.14+/-24.09 
accelerations/day vs 82.06+/-27.69 accelerations/day, p=0.001) and weekend days 
(66.93+/-29.43 accelerations/day vs 79.81+/-31.99 accelerations/day, p<0.001). 
Unfortunately, no measure of physical capacity was undertaken so it was not 
possible to determine if a relationship existed between exercise performance and 
exercise capacity.  
A more recent study by Bahmer and colleagues investigated the association 
between activity levels measured by the sensewear armband (BodyMedia Inc, 
Pittsburgh PA, USA), a tri-axial accelerometer with in-built galvanometer and the 
ability to measure metabolic activity, and fatigue measurements (205). The study 
also included measurements of physical capacity (6MWT), generic and health-
related quality of life, and pulmonary function tests. The results showed only a 
weak association between fatigue scores, from the “reduced activity” and “physical 
activity” subscales of the MFI-20 questionnaire, and daily step-count calculated 
from the sensewear armband, with correlations co-efficients of -0.277 and -0.274 
respectively (p=0.037 and 0.039). The total MFI-20 score had weaker correlation 
with daily step count, and did not show a statistically significant association (r=-
0.259, p=0.052). In contrast, exercise capacity (6MWT) showed a stronger 
correlation with steps per day (r=0.499, p<0.001), remaining significant within a 
multiple regression model for predicting daily step count alongside St George’s 
respiratory questionnaire score and short form 12 (SF-12) physical health score (r2 = 
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0.34, p=0.002). In contrast to the earlier study by Korenromp et al (145), fatigue 
was not found to be a significant predictor of daily activity. This may be due to a 
number of factors. Firstly, step-count may not be the ideal measurement of 
physical activity as it does not consider the intensity of activity (e.g. metabolic 
activity), which may be reduced in fatigue. The authors also discuss further possible 
causes for the lack of association, notably the small number of participants, the 
large number of non-fatigued patients, and the lack of a disease-specific quality of 
life score such as the Kings’ Sarcoidosis Questionnaire.  
The conflicting results from the two studies, as well as the shortcomings in design 
and outcome measures, means that there is not yet evidence to prove or disprove a 
significant association between daily physical activity and sarcoidosis-associated 
fatigue. Furthermore, whether exercise in free-living is altered through purely 
physical limitations, or due to mental aspects of fatigue seen in sarcoidosis (170) 
impacting upon volition, is as yet unclear. 
 
1.10 Rationale and Overview of this Thesis 
Fatigue is a frequent manifestation of sarcoidosis that can be debilitating for 
patients and difficult to treat for the physician. Limited options are available if 
fatigue persists despite standard treatment, or where fatigue is the only symptom 
and systemic therapies are not recommended or patients do not wish to receive 
systemic treatments such as corticosteroids. The use of symptom-targeted 
therapies, including neurostimulants, offers a possible treatment option directly 
targeting the symptom of fatigue. The use of such agents requires evaluation, both 
in terms of efficacy and safety, but questions about the ideal trial design to answer 
these clinical questions exist. The aim of this thesis is to determine if it is possible to 
perform a randomised-controlled trial powered to confirm a clinical effect for 
neurostimulants in sarcoidosis-associated fatigue. 
The first chapter within this thesis presents a systematic review of the existing 
evidence for all possible treatments of fatigue in patients with sarcoidosis, including 
both pharmacological and non-pharmacological treatments (chapter 2). 
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The next chapter presents a crossover study comparing two widely used 
accelerometer-based activity monitors, which helps to determine the preferred 
device for patients in future trials, as well as comparing participants’ activity levels 
with recorded fatigue scores (chapter 3). 
In chapter 4 and chapter 5, the feasibility study “Fatigue and Sarcoidosis – 
Treatment with Methylphenidate (FaST-MP)” investigates how best to design a full 
phase-III study of neurostimulant medication for sarcoidosis-associated fatigue. It 
aims to determine the number of participants within a single centre who would be 
eligible for such a study, as well as the number who agree to participate. The study 
design allows longer follow-up of patients receiving methylphenidate than has 
previously been performed; this allows estimation of the persistence of treatment 
effect between placebo and medication arms. Following this, chapter 6 reports the 
outcomes of focus group discussions with participants from the FaST-MP, 
describing the experience of participants within the FaST-MP study and what might 
be done in a future trial which might improve the experience for participants. 
Chapter 7 reports the results of a questionnaire study comparing commonly used 
questionnaires in patients with sarcoidosis, including how measures of severity, 
treatment, and patient-reported fatigue and depression symptoms affect quality of 
life scores. The results from this will further support decisions regarding future trial 
design through helping to determine the preferred questionnaires for patient-
reported outcomes and quality of life. 
The overall results from the studies within this project are discussed in chapter 8, 
including the potential design of a subsequent phase III study investigating the 
clinical efficacy of neurostimulants for the treatment of sarcoidosis-associated 
fatigue. These discussions include the challenges posed to any future study, 
identified from those encountered within the FaST-MP study.  
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2.1 Introduction 
In the first chapter of this thesis the potential causes for developing marked fatigue 
in patients with sarcoidosis were discussed. Sarcoidosis-associated fatigue may be 
multifactorial and related to co-existent reversible conditions such as obstructive 
sleep apnoea; it is important that these conditions are excluded or managed in the 
first instance. Once these conditions have been excluded or treated, consideration 
can be given to management strategies aimed at directly treating the symptoms of 
fatigue. A systematic review of the literature was undertaken to evaluate the 
evidence for management strategies that have a potential role in the management 
of sarcoidosis-associated fatigue; the results are presented within this chapter. 
 
Background 
Both pharmacological and non-pharmacological interventions have been suggested 
for the treatment of fatigue in patients with sarcoidosis. Corticosteroids are the 
most commonly prescribed medication for treatment of sarcoidosis, although they 
have the potential to cause side effects which include fatigue. However, few studies 
have investigated fatigue during and after receiving corticosteroids. Treatment of 
the underlying inflammatory cascade hypothesised to drive symptoms of fatigue 
has been trialled. Blockade of the action of TNF-alpha, which is released by alveolar 
macrophages and is involved in the initial pathogenesis of sarcoidosis (206), has 
been investigated as a treatment for refractory sarcoidosis. Amongst trials 
investigating these agents, measurements of fatigue pre- and post-treatment have 
been taken. A novel therapy, ARA 290 (207), a small peptide modelled on 
erythropoietin and which possesses anti-inflammatory activity, has also been 
investigated for its potential effects on symptoms of small-fibre neuropathy. These 
symptoms include cognitive failure and fatigue (208).  
Direct, symptomatic treatment of fatigue has been trialled using neurostimulant 
therapy in other conditions where fatigue is a common and debilitating symptom. 
Methylphenidate and dexmethylphenidate, the d-isomer of methylphenidate and 
approximately twice as potent as a result, are central nervous system stimulants of 
Chapter 2: Management of sarcoidosis-associated fatigue – a systematic review of evidence for 
treatment 
  63 
the piperidine and phenethylamine classes which act by inhibiting noradrenergic 
and dopaminergic transport within certain areas of the brain (209). 
Methylphenidate is widely prescribed for its use in attention-deficit hyperactivity 
disorder (ADHD) (210), both in children and adults, but has been also trialled as 
treatment for fatigue in other situations (including chemotherapy (211), post-
radiotherapy (212), HIV (213), and Parkinson’s disease (214)) with some benefit. 
Another neurostimulant, Modafinil, and its enantiomer armodafinil, are used for 
promoting wakefulness in narcolepsy. They have a complex profile of 
neurochemical actions, not all of which are fully understood, with the overall effect 
being different to those of amphetamines (215). 
Finally, physical activity programmes have been shown to have wide-reaching 
benefits. The most widely-known example of this is the effect of pulmonary 
rehabilitation in chronic obstructive pulmonary disease (COPD), which includes 
improving dyspnoea scores, health-related quality of life, anxiety and depression 
(216). The use of pulmonary rehabilitation in patients with interstitial lung diseases 
is recommended by international guidelines (83, 217); the magnitude of benefit in 
these patients is similar to that seen in COPD patients (218). There have been 
recent trials investigating the use of physical activity and rehabilitation programmes 
in patients with sarcoidosis; among the outcome measures these trials investigated 
the impact of physical activity programmes on fatigue. 
This systematic review aimed to examine the existing evidence for possible 
interventions which may affect fatigue in patients with sarcoidosis who are 
experiencing clinically significant fatigue. This includes assessment of the quality of 
the evidence, including current shortcomings, and to present the results as a 
narrative review of the available data.  
 
2.2 Methods 
Publication Search 
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This systematic review was registered with PROSPERO (registration number 
CRD42015030079) and was performed in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA) statement (219). The full 
protocol of the methodology for the review can be accessed online through the 
PROSPERO database using the registration number. The electronic databases 
Medline (using PubMed) and Web of Science were searched using the following 
search strategy: “sarcoid” OR “sarcoidosis” OR sarcoidosis [MeSH Terms] OR 
Sarcoid* (truncation) AND “fatigue” OR “chronic fatigue” OR “chronic fatigue 
syndrome” OR fatigue [MeSH Terms] OR fatigue syndrome, chronic [MeSH Terms] 
AND “treatment” OR “management” OR “clinical trial”. 
Bibliographies of appropriate papers were reviewed for relevant additional sources. 
The title and abstract of all these papers were reviewed for relevance, with 
irrelevant studies excluded. Remaining papers were acquired and reviewed in full. 
The initial search included trials published up to December 2015. An updated 
search was performed in May 2018 to identify any new studies published.  
 
Selection Criteria 
Studies were considered suitable for inclusion if they evaluated the effect of an 
intervention (either pharmacological or non-pharmacological) on fatigue in patients 
with sarcoidosis. All trial designs (case series, case-control, cross-over and parallel-
arm randomised controlled trials) were included in the qualitative synthesis; only 
case reports were excluded, meaning trials where no comparator group or 
comparator intervention were included. This ensured the broadest collection of 
evidence. The studies must have 1) evaluated sarcoidosis patients exclusively or 
presented results of the patients with sarcoidosis separately to those of other 
conditions if multiple disease cohorts were included in the same study, 2) evaluated 
the efficacy of the intervention on a measured score of fatigue, 3) reported 
quantitative results for changes in fatigue score between pre- and post-intervention 
results and 4) be in English and presented in full-text form. 
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Data Collection 
Data extraction was performed independently by two assessors. Dr Chris Atkins and 
Professor Andrew Wilson extracted information using a pre-determined checklist. 
In addition, the Cochrane Collaboration’s tool for assessing risk of bias (220) was 
also used to assess the methodological quality of each trial, enabling identification 
of possible sources of bias at a study level. From each paper the following data was 
collected: Main author’s last name, year of publication, study design, number of 
participants, severity of sarcoidosis in participants by CXR staging (Scadding score, if 
given), intervention (including dose regime and duration of intervention), 
measurement score of fatigue used, change in fatigue outcome, number of 
participants reaching minimum clinically important difference on outcome score (if 
given), number of participants completing the intervention and adverse events 
reported within the trial. The summary measure of interest was mean 
improvement of fatigue score. Due to the small number of studies available for 
inclusion, and the heterogeneity of interventions and study designs, a meta-analysis 
of data was not possible. A narrative review of the data is presented for all the 
available data. 
 
2.3 Results 
Search results and characteristics of eligible trials 
The initial search was undertaken in November 2015 and published in 2016 (221). 
Through the planned search strategy, 150 records were identified from Medline 
and 126 records from Web of Science. Two further papers of interest were 
identified through review of the bibliographies of the identified papers. A total of 
154 papers were identified from the initial search after duplicates were removed. 
An updated search in May 2018 identified 200 records from Medline and 158 
records from Web of Science; this included a total of 50 extra papers of interest 
(204 in total) compared with the initial search once duplicates were removed. Titles 
and abstracts were reviewed for relevance. Studies were excluded if they did not 
include patients with sarcoidosis, were not evaluating a potential intervention to 
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treat fatigue or were case reports; review articles were also excluded but reviewed 
for other relevant papers of interest. From the screened papers, 67 studies were 
identified, of which thirteen met full the criteria for inclusion. The flow diagram 
(PRISMA 2009) of screened articles is shown in Figure 3. Only six randomised 
controlled trials (either parallel arm or cross-over) were identified, one of which 
randomised between two doses of the same drug without a comparator 
intervention or placebo. Of the remaining articles, six were observational studies 
and one was a retrospective review of cases.  
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Records identified through 
database searching 
Pubmed - n = 200 
Web of Science – n = 158 
Additional records identified 
through other sources 
n = 2 
Records after duplicates removed 
n = 204 
Records excluded 
(irrelevant articles) 
n = 137 
Full-text articles excluded 
n = 54 
- Not evaluating an 
intervention = 24 
- Case report only = 21  
- Fatigue score not an 
outcome measure = 3 
- Study protocol only = 2 
- Not full paper (letter) = 1 
- Baseline measurements 
at unspecified time after 
intervention started = 1 
- Did not report pre- and 
post-intervention fatigue 
= 1 
- Did not report 
quantitative change in 
fatigue scores = 1 
Studies included in 
qualitative synthesis 
n = 13 
Full-text articles assessed 
for eligibility 
n = 67 
Records screened 
n = 204 
Figure 3 – Flow diagram of study identification and exclusion 
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Six papers evaluated formal physical activity programs (five supervised exercise 
programmes, one inspiratory muscles training programme), two evaluated systemic 
treatment with tumour necrosis factor alpha (TNF-alpha) inhibitors (infliximab and 
adalimumab), two evaluated symptom-targeted therapy with neurostimulants 
(dexmethylphenidate and armodafinil), one trial reviewed change in fatigue after 
receiving prednisolone, one trial investigated a novel molecule aimed at treating 
small-fibre neuropathy (ARA 290) and one trial investigated the use of repository 
corticotropin (RCI) in patients receiving long-term prednisolone. All but three trials 
chose the FAS as a measure of fatigue. Of the remaining studies, two used the FSS 
and one used the CIS Fatigue subscale. The properties of these questionnaires are 
discussed in Chapter 1, section 1.9.  
Across all the included studies, a total of 602 patients were included across all the 
trials, with 296 participants in one study (222). The details of each included studies 
are shown in Table 7 for pharmacological interventions and Table 8 for non-
pharmacological interventions, with the risk of bias within each study displayed in 
Tables 9 and 10 for pharmacological and non-pharmacological interventions 
respectively. Furthermore, in addition to the thirteen studies that met the inclusion 
criteria, three papers that did not meet the inclusion criteria but provided useful 
information are discussed. 
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Table 7 - Overview of trials including change in fatigue as an outcome measure (Pharmacological interventions) 
Author and Year Lower et al. 
2007 (173) 
Erckens et al. 
2011 (105) 
Heij et al. 
2012 (207) 
Van Rijswijk et al. 
2013 (185) 
Lower et al. 
2013 (174) 
Aggarwal et al. 
2016 (223) 
Baughman et al. 
2017 (224) 
Study Design Cross-over RCT Observational study RCT Retrospective case 
review 
Cross-over RCT Observational study Parallel Arm RCT 
Intervention Dex-
methylphenidate 
Adalimumab ARA 290 Infliximab Armodafinil Prednisolone Repository 
Corticotropin 
Injection (RCI)  
Dose Up to 10mg twice 
daily 
40mg S/C weekly 2mg IV weekly 5mg/kg IV at 
0,2,6,10,14 and 18 
weeks 
Up to 250mg twice 
daily 
0.75mg/kg for 1 
month then wean to 
zero over 6 months 
80 units twice 
weekly 
Comparator Placebo None Placebo None Placebo None RCI, 40 units twice 
weekly 
Duration 8 weeks per arm 12 months 4 weeks 18 weeks 8 weeks per arm 6 months 24 weeks 
No. participants 10 26 22 (10 placebo) 27‡ 15 51 18 (16 analysed) 
% Male  20% 36.6% 50% 60% 33.3% 54.9% 26.9% 
Age (mean ± SD) 52 (range 39-74) 51 ± 15 48.1 ± 2.7 48.9 ± 10.1 54 (range 35-62) Not stated 58.5 (range 35-68) 
Disease stage 
(0/I/II/III/IV) 
Not stated 16/4/4/2/0 Not stated 5/7/14/5/14 3/5/2/2/3 0/32/19/0/0 Not specified 
Measurement of 
fatigue 
FAS and FACIT-
Fatigue 
FAS FAS ‘Fatigue severity’ 
within CIS 
 
FAS and FACIT-
Fatigue 
FAS FAS 
INTERVENTION: 
Pre- and Post- 
fatigue scores  
(mean ± S.D. 
unless stated) 
FAS (range): 
Pre: 32.5 (9-44) 
Post: 27.5 (23-43) 
FACIT-F (range): 
Pre: 19.5 (13-48) 
Post: 29.5 (5-50) 
Pre: 31.1 ± 11.1 
Post: 28.9 ± 10.0 
Pre: 37.9 ± 2.6 
Post: 33.3 ± 2.8 
Pre: 49.4 ± 9.2 
Change: -5.3 ± 8.5 
FAS (range): 
Pre: 37 (14-43) 
Change: -4.5 (-20, 5) 
FACIT-F (range): 
Pre: 23 (10-47) 
Change: +9(-12,26) 
Pre (median): 
24 (range 19-30) 
 
Post (median): 
21 (range 17-27) 
  
Pre: 28 (range 15-
46) 
Week 7: 26 (range 
10-37) 
Week 24: 22 (range 
11-42) 
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†Group values at the end of the placebo phase not given, data only presented as average values across placebo phase. 
‡48 patients included in study but quality of life scores (including fatigue) only available in 27. 
FAS = Fatigue Assessment Scale; FACIT-Fatigue = Functional Assessment of Chronic Illness Therapy – Fatigue; MCID = Minimal Clinically Important Difference  
Author and Year Lower et al. 
2007 (173) 
Erckens et al. 
2011 (105) 
Heij et al. 
2012 (207) 
Van Rijswijk et al. 
2013 (185) 
Lower et al. 
2013 (174) 
Aggarwal et al. 
2016 (223) 
Baughman et al. 
2017 (224) 
COMPARATOR: 
Pre- and Post- 
fatigue scores  
(mean ± S.D. 
unless stated) 
Average scores in 
placebo arm†: 
FAS: 33.6±4.43 
FACIT-Fatigue: 
24.3± 5.41 
N/A Pre: 33.6 ± 2.3 
Post: 29.8 ± 3.3 
N/A FAS (range): 
Pre: 37 (14-43) 
Change: +3.5 (-9,14) 
FACIT-Fatigue 
(range): 
Pre: 23 (10-47) 
Change: -5 (-17,11) 
N/A Not analysed 
separately: results 
above included all 
patients receiving 
RCI regardless of 
dose 
Statistical 
difference vs. 
comparator 
FAS: p=0.0295 
FACIT-Fatigue: 
p=0.0040 
(between groups) 
P < 0.01 compared 
with baseline 
Non-significant 
between groups 
P=0.003 compared 
with baseline 
FAS: p=0.0295 
FACIT-Fatigue: 
p=0.0040 (between 
groups) 
P=0.004 compared 
with baseline 
Not performed 
Number of 
participants with 
clinically 
significant 
improvement 
Not stated Not clear; 
14/21 less fatigued 
but doesn’t state 
MCID used. 
Not stated  Not stated 64% treated with 
armodafinil 
improved FAS by 4 
points (MCID); only 
7% in placebo  
21 (63.6% of initially 
fatigued patients) 
Ten patients had 
met FAS MCID of 4 
points reduction or 
more); eight 
patients had met 
MCID at 24 weeks. 
Drop outs/ Side 
Effects 
No withdrawals 
4 patients required 
lower afternoon 
dose 
No withdrawals. 1 
severe injection site 
reaction 
No drop outs 3 patients 
discontinued within 
6 infusions: 
1) Allergic reaction 
2) Progression of 
dyspnoea 
3) Hepatitis (due to 
methotrexate) 
1 withdrawal due to 
severe anxiety 
Not stated One patient 
withdrew pre-
therapy; one 
patient withdrew 
because of toxicity. 
Seven patients 
received reduced 
dosage. 
Evidence of 
treatment effect in 
fatigue 
Yes Yes No Yes Yes Yes (new diagnoses 
only) 
Yes, although no 
placebo arm to 
compare against 
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Table 8 - Overview of trials including change in fatigue as an outcome measure (Physical exercise interventions) 
Author and Year Strookappe et al. 
2015 (225) 
Marcellis et al. 
2015 (226) 
Strookappe et al. 
2015 (227) 
Karadalli et al. 2016 
(228) 
Lingner et al. 2018 
(222) 
Naz et al. 2018 (181) 
Study Design Observational Study Observational Study Retrospective, 
Observational 
Parallel Arm RCT Observational study RCT 
Intervention Physical activity 
programme 
Physical activity 
programme 
Physical activity 
programme 
Inspiratory muscle 
training programme 
Physical activity 
programme 
Physical activity 
programme 
Dose 12-week physical 
activity programme  
13-week physical 
activity programme 
12-week physical 
activity programme  
30 minutes/day 3-week intense activity 
and rehab programme 
12-week physical 
activity programme 
Comparator None None 41 patients who chose 
not to participate in 
programme 
Sham training None Usual Care 
Duration 12 weeks 13 weeks 12 weeks 6 weeks 3 weeks 12 weeks 
No. participants 12 24 49 34 (30 analysed) 296 18 
% Male  91.7% 75% 57.1% 36.6% 53.0% 33.3% 
Age (mean ± SD) 53.2 ± 11.7 49.4 ± 10.5 47.6 ± 11.3 Intervention: 45.1 ± 8.1 
Control: 47.5 ± 12.9 
49.1 ± 9.7 Intervention: 59 (52-64) 
Control: 51 (45-57) 
Disease stage 
(0/I/II/III/IV) 
0/0/0/0/12 0-I = 29.2% 
II-III = 66.6% 
IV = 4.2% 
4/11/22/0/4 Stage I = 9 subjects 
(30%) 
Stage II = 21 Subjects 
(70%) 
0 = 1.5% 
I = 18.3% 
II = 58.0% 
III = 13.7% 
IV = 4.6% 
0/0/0/10/8 
Measurement of 
fatigue 
FAS FAS FAS FSS (Turkish version) FAS FSS (Turkish version) 
INTERVENTION: 
Pre- and Post- 
fatigue scores  
(mean ± S.D. 
unless stated) 
Pre: 28.5 ± 5.4 
Post: 27.7 ± 5.7 
(6 of the 12 patients 
had FAS >21 at 
baseline) 
Pre: 29.7 ± 7.7 
Post: 27.0 ± 7.3 (in 18 
patients completing 
course) 
Pre: 29.8 ± 8.1 
Post: 25.6 ± 7.5 
Pre: 39.2 ± 14.9 
Post: 31.4 ± 15.0 
Mean difference: -8.0 (-
14.4 to -2.0) 
Pre: 26.6 ± 7.7 
Mean difference post-
intervention: 
-4.09  
(95% C.I. -4.82, -3.36) 
Pre (median):  
40 (range 23-47) 
Median change in FSS:  
-7 points  
(range -10 to +2) 
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FAS = Fatigue Assessment Scale; FACIT-Fatigue = Functional Assessment of Chronic Illness Therapy – Fatigue; MCID = Minimal Clinically Important Difference; FSS = 
Fatigue Severity Scale 
  
Author and Year Strookappe et al. 
2015 (225) 
Marcellis et al. 
2015 (226) 
Strookappe et al. 
2015 (227) 
Karadalli et al. 2016 
(228) 
Lingner et al. 2018 
(222) 
Naz et al. 2018 (181) 
COMPARATOR: 
Pre- and Post- 
fatigue scores  
(mean ± S.D. 
unless stated) 
N/A N/A Pre: 30.3 ± 9.0 
Post: 28.6 ± 9.0 
Pre: 40.9 ± 15.8 
Post: 31.1 ± 15.9 
Mean difference: -9.6 (-
15.4 to -3.8) 
N/A Pre (median):  
45 (range 18-50) 
Median change in FSS:  
+1 points (range 0 to 
+4) 
Statistical 
difference vs. 
comparator 
Non-significant 
compared with baseline 
P = 0.003 compared 
with baseline 
Within group 
(intervention): p=0.009 
Within group (placebo): 
p=0.408 
Groups not directly 
compared 
P = 0.71 P<0.0001 compared 
with baseline 
P = 0.001 compared 
with baseline 
Number of 
participants with 
clinically 
significant 
improvement 
66% of patients with 
FAS >21 at baseline had 
improvement in FAS, 
not specified if MCID 
used 
6 (3%) improve FAS by 
4 points (MCID); 9 
(50%) improved FAS by 
10% 
74.4% of intervention 
group and 48.5% of 
comparator group 
reduced FAS by 4 points 
(MCID). 
Not stated Absolute reduction 
fatigue (%): 11.5% 
 
Absolute reduction in 
severe fatigue(%): 18% 
Not stated 
Drop outs/ Side 
Effects 
No withdrawals 6 patients withdrew; 
3 = problems other 
than sarcoid 
2 = health insurance 
problems 
1= No reason 
Not stated No adverse events 
occurred 
Not reported No withdrawals 
Evidence of 
treatment effect in 
fatigue 
Unclear Yes Yes No – both arms 
improved markedly 
over course of trial 
Yes Yes 
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Table 9 - Risks of bias within trials reporting fatigue as an outcome measure (Pharmacological interventions) 
Author and Year Lower et al. 
2007 (173) 
Erckens et al. 
2011 (105) 
Heij et al. 
2012 (207) 
Van Rijswijk et al. 
2013 (185) 
Lower et al. 
2013 (174) 
Aggarwal et al. 
2016 (223) 
Baughman et al. 
2017 (224) 
Sequence 
Generation 
LOW RISK 
Random sequence 
computer-
generated 
HIGH RISK 
No randomisation 
(NOT RCT) 
LOW RISK 
Computer 
generated 
randomisation 
code 
HIGH RISK 
No randomisation 
(NOT RCT) 
UNCLEAR 
No statement on 
randomisation 
procedure 
HIGH RISK 
No randomisation 
(NOT RCT) 
UNCLEAR RISK 
Participants 
randomised on 1:1 
ratio but method 
of randomisation 
not stated 
Allocation 
Concealment 
LOW RISK 
Pharmacy-
controlled 
allocation 
HIGH RISK 
No concealment, 
all patients receive 
drug 
LOW RISK 
Pharmacy-
controlled 
allocation 
HIGH RISK 
No concealment, 
all patients 
received drug 
UNCLEAR 
No statement on 
allocation 
procedure 
HIGH RISK 
No concealment, 
all patients receive 
drug 
UNCLEAR 
No statement on 
allocation 
procedure 
Blinding of 
participants, 
personnel and 
outcome 
assessors 
LOW RISK 
Double-blind with 
low risk of 
breaking blinding 
HIGH RISK 
No blinding 
LOW RISK 
Only allocating 
pharmacist 
unblinded 
HIGH RISK 
No blinding 
LOW RISK 
Double-blind with 
low risk of 
breaking blinding 
HIGH RISK 
No blinding 
LOW RISK 
Investigators 
blinded though 
participants not 
blinded 
Incomplete 
outcome data 
 
 
 
 
 
UNCLEAR 
No description of 
missing data 
points or handling 
of missing data 
UNCLEAR 
No description of 
missing data 
points or handling 
of missing data 
LOW RISK 
Missing data 
compensated for 
by taking forward 
last value 
UNCLEAR 
No description of 
missing data 
points or handling 
of missing data 
UNCLEAR 
No description of 
missing data 
points or handling 
of missing data 
UNCLEAR 
No description of 
missing data 
points or handling 
of missing data 
UNCLEAR 
No description of 
missing data 
points or handling 
of missing data 
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  Author and Year Lower et al. 
2007 (173) 
Erckens et al. 
2011 (105) 
Heij et al. 
2012 (207) 
Van Rijswijk et al. 
2013 (185) 
Lower et al. 
2013 (174) 
Aggarwal et al. 
2016 (223) 
Baughman et al. 
2017 (224) 
Selective 
outcome 
reporting 
LOW 
All outcomes 
reported 
UNCLEAR 
No protocol 
available 
UNCLEAR 
No protocol 
available 
UNCLEAR 
No protocol 
available 
LOW 
All outcomes 
reported 
UNCLEAR 
No protocol 
available 
UNCLEAR 
No protocol 
available 
Other sources of 
bias 
No other clear 
causes of bias 
identified; cross-
over ensures 
groups balanced, 
patients are own 
controls. 
Small sample. 
Study design (case 
series) limits 
conclusions – no 
comparator group 
to eliminate 
placebo effect. 
Baseline imbalance 
in FAS and health 
status score (SF36) 
between groups – 
significantly lower 
fatigue scores in 
placebo arm. Small 
sample. 
Retrospective 
review – data 
collected pre- and 
post-intervention 
but high risk of 
bias from 
retrospective 
nature 
No other clear 
causes of bias 
identified; cross-
over ensures 
groups balanced, 
patients are own 
controls. 
Small sample. 
Study design (case 
series) limits 
conclusions – no 
comparator group 
to eliminate 
placebo effect. 
RCT but no 
placebo arm so 
unable to exclude 
placebo effect on 
patient-reported 
outcomes 
including fatigue. 
Small sample size. 
Overall risk of 
bias 
LOW – Well 
designed cross-
over trial, though 
only small sample 
HIGH – Study 
design (case 
series) means no 
blinding, 
randomisation or 
comparator. 
LOW – Well 
designed RCT but 
not powered to 
look at change in 
fatigue. 
HIGH – Design 
(retrospective case 
series) has no 
blinding, 
randomisation or 
comparator. 
UNCLEAR – Issues 
with description of 
randomisation 
allocation and 
concealment mean 
study at risk of bias 
HIGH – Study 
design (case 
series) means no 
blinding, 
randomisation or 
comparator. 
UNCLEAR – Issues 
with lack of 
placebo arm and 
description of 
randomisation, 
allocation and 
concealment mean 
study at risk of 
bias. 
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Table 10 - Risks of bias within trials reporting fatigue as an outcome measure (Physical exercise interventions) 
Author and Year Strookappe et al. 
2015 (225) 
Marcellis et al. 
2015 (226) 
Strookappe et al. 
2015 (227) 
Karadalli et al. 2016 
(228) 
Lingner et al. 2018 
(222) 
Naz et al. 2018 (181) 
Sequence 
Generation 
HIGH RISK 
No randomisation 
(NOT RCT) 
HIGH RISK 
No randomisation 
(NOT RCT) 
HIGH RISK 
No randomisation 
(NOT RCT) 
LOW RISK 
Computer generated 
randomisation code 
HIGH RISK 
No randomisation 
(NOT RCT) 
UNCLEAR 
Sequence generation 
not stated; groups in 
sealed envelopes 
prepared by 
independent member 
Allocation 
Concealment 
HIGH RISK 
No concealment, all 
patients on 
programme 
HIGH RISK 
No concealment, all 
patients on 
programme 
HIGH RISK 
No concealment, all 
patients on 
programme 
LOW RISK 
Evaluation and 
treatment were 
performed by 
different therapists 
HIGH RISK 
No concealment, all 
patients on 
programme 
UNCLEAR 
No statement on 
whether intervention 
and evaluation 
performed by 
different therapists 
 
Blinding of 
participants, 
personnel and 
outcome 
assessors 
HIGH RISK 
No blinding 
HIGH RISK 
No blinding 
HIGH RISK 
No blinding, including 
of assessors of 
physical function. 
LOW RISK 
Subjects and 
investigators 
collecting data were 
blinded 
HIGH RISK 
No blinding 
UNCLEAR 
No statement on 
blinding of assessors 
to allocation 
Incomplete 
outcome data 
UNCLEAR 
No description of 
missing data points or 
handling of missing 
data 
UNCLEAR 
No description of 
missing data points or 
handling of missing 
data 
UNCLEAR 
No description of 
missing data points or 
handling of missing 
data 
UNCLEAR 
No description of 
missing data points or 
handling of missing 
data 
LOW 
Handling of missing 
data described 
UNCLEAR 
No description of 
missing data points or 
handling of missing 
data 
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Author and Year Strookappe et al. 
2015 (225) 
Marcellis et al. 
2015 (226) 
Strookappe et al. 
2015 (227) 
Karadalli et al. 2016 
(228) 
Lingner et al. 2018 
(222) 
Naz et al. 2018 (181) 
Selective 
outcome 
reporting 
UNCLEAR 
No protocol available 
UNCLEAR 
No protocol available 
UNCLEAR 
No protocol available 
UNCLEAR 
No protocol available 
LOW RISK 
Study protocol 
published before 
results published 
UNCLEAR 
No protocol available 
Other sources of 
bias 
Not an RCT. 
Participants enrolling 
on programme would 
self-select as 
motivated people, 
generalisability limited 
Not an RCT, also 
participants enrolling 
on programme would 
self-select as 
motivated people, 
generalisability limited 
Patients choosing the 
intervention would be 
a self-selecting cohort; 
controls not 
randomised but 
refused intervention 
Small sample. No 
other causes of bias 
identified. 
Not an RCT, no 
comparator group; 
also participants 
enrolling on 
programme would 
self-select as 
motivated people, 
generalisability limited 
Comparator group is 
usual care so not a 
true control group as 
no ‘sham 
intervention’; will not 
control for non-
exercise components 
of course (interaction 
with healthcare team, 
social aspects) 
Overall risk of 
bias 
HIGH - Study design 
(case series) means no 
blinding, 
randomisation or 
comparator. 
HIGH - Study design 
(case series) means no 
blinding, 
randomisation or 
comparator. 
HIGH – Self-selecting 
intervention group, 
high risk of bias given 
control group declined 
intervention 
LOW – Well designed 
RCT, though only small 
sample 
HIGH - Study design 
means no blinding, 
randomisation or 
comparator. 
UNCLEAR – Issues 
with lack of true 
control group; limited 
description of 
randomisation, 
allocation and blinding 
mean study at risk of 
bias. 
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Systemic therapy: anti-TNF-alpha treatment and anti-inflammatories 
Five trials evaluated interventions which have systemic or disease-modifying 
effects. Two investigated anti-TNF-alpha drugs (adalimumab and infliximab) (105, 
185), one investigated ARA 290 (207), one investigated prednisolone and one 
investigated RCI (224). Only one trial, investigating ARA 290 (207), was a double-
blinded, randomised, placebo-controlled trial; neither of the studies investigating 
anti-TNF-alpha therapies were of a randomised design, nor was the study 
investigating prednisolone. The study investigating RCI was single-blinded and had 
no placebo arm; the two arms of the trial were comparing two different doses of 
the drug. 
Erckens and colleagues followed 26 sarcoidosis patients with refractory uveitis who 
had been commenced on Adalimumab (40mg subcutaneously once weekly) over a 
12 months treatment period (105). All patients had previously received 
prednisolone and methotrexate. Fatigue was measured using the FAS, with 21 
patients (80.7%) having a baseline FAS score >21 points. After the 12-month 
treatment period, there was a mean reduction in FAS score of 2.2 points and an 
improvement in FAS score in 14 of the 21 patients with a baseline FAS score >21 
points; although it is not stated what constituted an improvement in the FAS and 
whether these patients met the MCID for the FAS score. The risk of bias is high with 
this trial design, as there is no comparator group to determine if this is a placebo-
effect or natural progression of the disease, however, there is a suggestion that 
fatigue is improved by anti-TNF-alpha therapy.  
In another study from the Netherlands, Van Rijswijk and colleagues (185) 
retrospectively reviewed 48 sarcoidosis cases who required treatment with 
Infliximab (5mg/kg intravenously at 0, 2, 6, 10, 14 and 18 weeks). All patients had 
previously received immunosuppression; 30 had received prednisolone and 
methotrexate, 12 received prednisolone only and 1 received methotrexate only. 
Data involving quality of life measures, including fatigue scores (within the CIS 
questionnaire), had been collected pre-treatment in the most recent 27 cases. The 
fatigue score improved by a mean of 5.3 points from a baseline of 49.4 points 
(p=0.003), although it is not clear if this is a clinically important improvement. 
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Furthermore, as this was a retrospective review, and without a comparator or 
placebo group, it is not possible to definitively attribute the change in fatigue scores 
to the intervention and does not conclude the benefits of TNF-inhibition in treating 
fatigue. 
One study performed in Chandigarh, India, followed 51 consecutive cases of stage I 
or II pulmonary sarcoidosis treated with oral prednisolone commenced on 
0.75mg/kg and reduced to zero over six months (223). Fatigue scores, measured by 
the FAS questionnaire, were measured before treatment and after treatment at six 
months; it was not clear if this was a pre-planned primary outcome. Of the 51 
patients, 33 had pre-treatment fatigue (64.7%), with seven of these reporting 
severe fatigue (FAS score >34). Post-treatment, 21 patients showed an 
improvement in FAS scores of 4 points or more; four patients showed a clinically 
important worsening of their FAS score. All patients who initially complained of 
severe fatigue met the MCID for improvement in FAS score. Five patients who 
initially scored <22 on the FAS showed an increase in FAS score of >4 points. In 
total, nine patients showed a clinically significant deterioration in FAS scores 
(17.6%). Median change overall across all cases was 3 points (pre-treatment 24, 
post-treatment 21, p=0.004). This study is the only one to review the changes in 
fatigue after receiving corticosteroids, although these were newly-diagnosed cases 
and as such does not provide information on the effect of corticosteroids on 
sarcoidosis-associated fatigue in chronic cases. Post-treatment measures also 
occurred after receiving therapy, so it is unclear how fatigue scores changed whilst 
receiving prednisolone. Additionally, this was an observational study and it is 
unclear whether the changes in fatigue are treatment-related or the natural disease 
course after initial presentation with sarcoidosis. 
A small multi-centre study by Baughman and colleagues investigated the use of RCI, 
a melanocortin peptide that is thought to be at least as effective as oral 
corticosteroids with reduced toxicity, for patients with advanced pulmonary 
sarcoidosis receiving prednisolone (224). This study enrolled only 18 patients, with 
16 patients completing the 24 weeks of therapy in the study (eight patients in the 
40 units twice weekly arm and eight patients in the 80 units twice weekly arm). 
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Participants were excluded if they had received anti-TNF therapy in the past 6 
months or were being treated for pulmonary hypertension. The primary outcome 
was the reduction in dose of prednisolone, with fatigue (measured by the FAS 
score) recorded at baseline, week 7 and end-of-trial (week 24) time points. No 
results for change in fatigue are given by group; only changes across the entire 
cohort (both 40 units and 80 units twice weekly doses) are given for FAS scores. The 
cohort had baseline mean FAS scores of 28 points (range 15-46 points) and a 
reduction to a mean FAS score of 22 points (range 11-42 points) at week 24, a 
statistically significant reduction (p=0.0067). Eight patients had a reduction in FAS 
of four points or more at the end of the study compared with baseline. It is unclear 
if this was a dose-dependent effect as this was not discussed in the results. These 
results may reflect a reduction in prednisolone, which is known to cause fatigue 
through treatment side-effects (152, 165), or improved control of disease activity 
with the new treatment. However, the study was not powered to show 
improvement in fatigue, and the range of fatigue scores at 24 weeks shows that 
some participants remained significantly fatigued, with FAS scores as high as 42 
points at the end of the study. Further work is required to compare the use of RCI 
with placebo and to ensure that improvements in FAS seen were not a placebo 
effect within this study. 
Heij and colleagues (207) undertook a small double-blind, randomised controlled 
trial investigating the safety and efficacy of ARA 290 for symptoms of small fibre 
neuropathy in sarcoidosis patients. Only 12 patients were included in the active 
treatment arm. Of these patients, four were receiving steroids and 1 received a 
systemic anti-inflammatory drug. Participants were excluded if they received an 
anti-TNF drug within six months of the trial. Fatigue was measured using the FAS 
score, though this was a secondary outcome. The baseline groups were imbalanced 
with regards to fatigue (mean FAS 37.9 in the ARA 290 group, 33.6 in the placebo 
group), but despite the higher levels of fatigue in the treatment arm at baseline 
there was an identical reduction in FAS scores over the four-week trial period in 
both arms. There was no evidence that ARA 290 improved fatigue scores, but the 
trial was not powered for this outcome and was very short. It did show 
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improvement in its primary outcome (the small fibre neuropathy screening list) as 
well as being well tolerated; if a larger and longer trial investigating the drug were 
to be performed, measuring change in fatigue would be important to ensure that a 
treatment effect was not missed in this trial. 
 
Neurostimulants 
Two randomised-controlled trials, both using a cross-over design, investigated the 
use of neurostimulants for treating fatigue in sarcoidosis. One trial investigated the 
use of armodafinil (174) and one trial investigated dexmethylphenidate (173). In 
each trial the change in fatigue was the primary outcome being measured. 
Lower and colleagues (173) treated ten patients with sarcoidosis-related fatigue 
with dexmethylphenidate and assessed its response by measuring fatigue using the 
FAS score. Participants received up to 10mg twice daily of dexmethylphenidate or 
matched placebo and were investigated weekly for eight weeks per arm (treatment 
and placebo). All patients were receiving at least one systemic agent for their 
sarcoidosis. Treatment effect in the intervention arm was seen after five weeks of 
therapy, with a mean reduction of five points in the FAS score after eight weeks of 
treatment. The number of patients meeting the MCID was not reported. The drug 
was well tolerated, with no withdrawals. The small scale of the trial means that the 
results should be interpreted with caution, but suggests clinical benefit. 
In a cross-over trial by Lower and colleagues (174), fifteen patients with stable 
sarcoidosis received up to 250mg of armodafinil daily, all of whom underwent 
polysomnography and multiple sleep latency testing pre- and post-intervention. All 
participants had received systemic treatment for sarcoidosis (prednisolone, 
methotrexate, leflunomide, hydroxychloroquine, azathioprine or anti-TNF therapy) 
and nine were receiving continuous positive airway pressure therapy. There was a 
mean reduction of 4.5 points in the FAS score (the primary outcome) and nine 
patients (64%) exhibited a reduction of four points or more. Participants receiving 
armodafinil did have a prolonged sleep onset latency compared with placebo which 
was statistically significant, although it is not clear if this was a clinically significant 
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difference as no participants discontinued the medication due to insomnia. The 
paper did not report randomisation or allocation procedures, although it was 
double-blind and appeared an appropriate design for the study’s aims. The small 
number of patients and short period of the trial suggest that further evidence is 
needed to confirm the efficacy of armodafinil in this setting. 
 
Non-pharmacological treatment strategies 
Six recent papers have investigated the effect of structured physical training 
programmes on fatigue in sarcoidosis and one study has looked at the effect of 
inspiratory muscle training on fatigue. Marcellis and colleagues (226) undertook an 
observational case-series study of twenty-four sarcoidosis patients in the 
Netherlands suffering with fatigue and/or impaired exercise tolerance. The 
intervention consisted of both upper- and lower-extremity peripheral muscle 
resistance training, with progressively increasing resistance through the training 
period, and endurance training, consisting of either treadmill or walking or cycling 
on an ergometer. Eighteen patients completed the entire training regime, with six 
not completing the programme. A statistically significant improvement was 
observed in FAS scores at the completion of the intervention: mean baseline and 
post-exercise FAS scores of 29.7 and 27.0 points respectively. Of the eighteen 
participants who completed the exercise programme, six patients (33.3%) had a 
reduction of four points in their FAS score; when using the alternative MCID of a 
10% reduction, nine patients (50%) met this criterion. This study had no comparator 
group, it did not state how many patients were approached or screened for 
inclusion, and patients entering the trial and completing the exercise programme 
are likely to have been motivated to undertake such an intervention. Although the 
results from this study suggest that the intervention is beneficial for sarcoidosis-
associated fatigue, it is unlikely to be beneficial in all patients. 
Strookappe and colleagues (227) investigated physical activity programmes in a 
similar cohort of Dutch sarcoidosis sufferers in a retrospective observational study. 
From an initial cohort of 147 sarcoidosis patients who had undergone physical 
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performance assessment, 49 patients undertook a 12-week supervised exercise 
programme. This was similar to that described by Marcellis and colleagues, with the 
peripheral muscles strengthening individualized for each patient. Twenty-one 
(42.9%) of the group were receiving steroids. A comparison was made with 41 
sarcoidosis patients who had chosen not to undertake the programme but 
undertook identical physical assessments. Following re-assessment at the end of 
the 12-week period there was a statistically significant within-group improvement 
in FAS scores in those who received physical therapy (29.8 pre, 25.6 post, p=0.009) 
whereas the comparator group had a non-significant reduction (pre 30.3, post 28.6, 
p=0.408). In the exercise programme group, 74.4% of patients had an improvement 
in their FAS score of four points or more, although 48.5% of the comparator group 
showed the same reduction despite not receiving any intervention. The within-
group results suggest that physical training may be beneficial for fatigue, though 
the results should be interpreted with caution. As with the other trials investigating 
exercise programmes on fatigue, participants within the trial would have self-
selected as a group keen to undertake the intervention. Even given this source of 
bias, patients who chose not to receive the intervention reported a clinically 
significant improvement in their fatigue. Finally, although the authors state that 
blinding was not possible in this trial, it would be possible to blind assessors to 
patient groups when assessing physical and psychological parameters pre- and 
post-intervention; whether this occurred was not stated in the paper. 
Strookappe and colleagues (225) also investigated the physical training in patients 
with end-stage sarcoidosis-related pulmonary fibrosis, alongside a cohort with 
idiopathic pulmonary fibrosis (IPF). Twelve patients with stage IV sarcoidosis 
participated in a 12-week exercise programme, similar to those described in the 
previous trials (226, 227). Patients were recruited from the same centre and during 
the same period as those included in another study by the same authors (227), 
though it is not specified whether these patients were also included in the results 
from the earlier study. Despite this, the study was included as it reported the 
results of a sub-group of patients with end-stage pulmonary sarcoidosis, which 
were not reported separately in the other paper. FAS score was measured pre- and 
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post-intervention. Baseline mean FAS score was 25.1 in the sarcoidosis group, with 
only six patients (50%) having clinically significant fatigue. Following the 
programme, four of the six patients reported improved fatigue, although the paper 
does not state whether participants that improved met the MCID for the FAS score. 
This study did not have a non-intervention group, and only a small number of 
participants with fatigue at baseline were included. The same source of biases 
existed as described with the other two studies investigating this intervention, 
making it difficult to be confident of the effect of physical training programs for 
sarcoidosis patients suffering fatigue. 
Another study including advanced sarcoidosis was performed in Turkey. Naz and 
colleagues included 18 patients with stage III or IV sarcoidosis, randomised to either 
a supervised 12-week exercise programme with twice-weekly session or usual care 
only (181). Participants were recruited from a hospital ILD clinic and the course was 
individually tailored based on the disease severity and level of symptoms. The 
primary outcome was change in 6-minute walk distance but fatigue was measured 
as a secondary end-point using the FSS. Average FSS scores were over 36 points 
indicating significant fatigue at baseline, with a significant change seen between the 
intervention and usual care groups at the end of the programme (median change -7 
points vs +1 points, p=0.001); this occurred despite baseline FSS score being five 
points higher (median score) in the intervention group compared with the usual 
care group. The study is limited by the small number of participants and the lack of 
sham intervention to control for increased contact with the health professionals 
and/or other patients in the intervention group, it also fails to mention blinding of 
outcome assessors to intervention group. The results are in line with previous 
evidence indicating benefit in multiple aspects of quality of life, including fatigue, in 
patients undergoing a structured and tailored exercise programme. 
The largest study to date investigating the potential benefits of a structured 
exercise/rehabilitation programme was performed by Lingner and colleagues (222). 
The study included 296 cases undergoing a 3-week intense rehabilitation 
programme, including endurance training, strength training, patient education and 
group sessions with a respiratory physiotherapist; additionally, optional 
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components could be undertaken including inspiratory muscle training, relaxation 
training, and counselling. Early outcome data collected immediately following 
completion of the rehabilitation programme showed a mean reduction in FAS score 
of -4.09, from a baseline mean score of 26.6 points. Additionally, the study 
recorded the number of patients reporting fatigue as a “main clinical symptom” 
pre- and post-treatment; 78.5% of patients reported fatigue as such, with 33.5% 
describing it as very severe. At the end of the study, 72.4% of patients still reported 
fatigue as a symptom and 22.3% rated it as very severe; no analysis was performed 
to explore whether this was a statistically significant drop, although a 10% absolute 
reduction in patients reporting fatigue as a present symptom appears to be a 
marginal clinical benefit. The results are in keeping with earlier papers suggesting 
benefit on fatigue scores from pulmonary rehabilitation but in a much larger 
number of patients. The lack of a comparator group limits the conclusions that can 
be drawn on the benefit on fatigue scores compared with not undertaking a 
structured rehabilitation programme. Mean change in FAS score suggests marked 
benefit but the number of patients still reporting fatigue as a symptom at the end 
of the programme suggests that it may only have a large benefit on fatigue for a 
modest number of patients. 
Finally, a study undertaken in Turkey measured change in fatigue as a secondary 
outcome in patients undergoing an inspiratory muscle training programme. 
Karadalli and colleagues performed a randomised-controlled trial in patients with 
stage I or II sarcoidosis, with a 6-week programme of moderate intensity inspiratory 
muscle training, with the primary objective of improving dyspnoea scores (228). 
Fatigue was measured using the FSS, a nine-item questionnaire with a maximum 
score of 63 points; no threshold for significant fatigue has been determined 
although the MCID is estimated at 20.2 points (229). Additionally, this score has not 
been validated in cohorts with sarcoidosis. Both the treatment and control group 
had similar FSS scores at baseline (39.2 +/- 14.9 vs 40.9 +/- 15.8). Both groups saw 
statistically significant improvements in FSS score (-8.0 (-14.4 to -2.0), p=0.01 in the 
treatment group; -9.6 (-15.4 to -3.8), p=0.002 in the control group), although 
neither reached the MCID for the FSS tool and no difference in treatment effect 
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was seen between the groups (p=0.71). The study was small, with only 15 patients 
in each arm, and no justification for the sample size was given so it is unclear 
whether it was powered for its outcomes. These results suggest that inspiratory 
muscle training, as opposed to a more general physical training programme, does 
not improve fatigue levels compared with a sham intervention. 
 
Excluded Studies of Interest 
Although the search strategy identified thirteen relevant studies, an additional four 
papers were identified that did not meet the inclusion criteria but provided relevant 
data regarding potential therapies for sarcoidosis-associated fatigue. Two studies 
investigating anti-TNF-alpha therapy in large cohorts were not included in the 
systematic review; the first had no measurement of pre-treatment fatigue scores 
and the second failed to describe a quantitative change in fatigue (125). One article 
describing methylphenidate use for sarcoidosis-associated fatigue was excluded 
because it was not a full article and did not describe a baseline fatigue score. 
Furthermore, one cross-sectional study has suggested that the anti-malarial 
hydroxychloroquine may have benefits on fatigue. 
One study investigating cognitive failure and sarcoidosis-associated fatigue in 343 
patients was excluded as baseline assessment of fatigue occurred after patients had 
already been established on treatment (208). The study was a six-month cross-
sectional assessment of patients who had already received various therapies, 
including TNF-inhibition in 42 patients. The results showed an improvement in FAS 
scores in the anti-TNF alpha therapy group over six months (baseline FAS 32.8+/-
7.31, six-month change -4.90+/-5.57) when compared with patients on no 
treatment (baseline FAS 28.6+/-7.94, six-month change 0.44+/-5.13), or on 
corticosteroids with or without antimetabolite (methotrexate) therapy (baseline 
FAS 28.2+/-7.81, six-month change +1.19+/-4.87). The patients in the anti-TNF-
alpha therapy group had higher fatigue scores on their initial questionnaires 
compared with the other groups, and after six months there was no difference in 
fatigue scores between patients receiving other forms of therapy. However, 
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without baseline characteristics in each group before commencing treatment it is 
not possible to directly compare the results of the groups or establish the effect of 
treatment on fatigue scores. 
A further study investigating TNF-inhibitor treatment in sarcoidosis patients 
(adalimumab or infliximab) recorded pre-treatment fatigue levels in 111 patients 
was excluded because no numerical data for change in fatigue measure (FAS) were 
included (125). All patients had received prednisolone and methotrexate before 
receiving TNF blockade and had evidence of ongoing disease activity despite 
treatment. Of the 111 patients included, 100 (90.1%) reported a FAS score >21 
(mean baseline FAS 33.0) and 59 reported severe fatigue (FAS score >34). After 12 
months of therapy 60 patients who were fatigued at baseline had improvement in 
their fatigue score; unfortunately, the definition of improvement and the scale of 
change in the FAS score required to be classified as a responder are not stated, 
therefore it is not possible to evaluate whether the intervention was clinically 
effective from these results. 
Methylphenidate was used in a series of five patients with severe sarcoidosis-
associated fatigue that was described in a letter from Wagner and colleagues (230). 
Five patients received 10mg twice daily of methylphenidate. There was no formal 
measure of baseline fatigue severity but the paper describes a statistically 
significant reduction on the “Symptoms of Fatigue” scale after one month. There 
were positive reports from four of the five patients, with two reporting that they 
felt their lives were “back to normal”. The five patients continued methylphenidate 
long-term; at two-years, all five of the patients remained on methylphenidate and 
reported continuing improvement in fatigue, although no formal fatigue scoring 
was performed. The authors concluded that further studies in larger groups of 
patients are required, though at the time of writing only the two small cross-over 
studies of armodafinil and dexmethylphenidate have been undertaken. 
Although no papers directly investigated the use of chloroquine or 
hydroxychloroquine for fatigue, a possible effect of the drug on fatigue scores was 
noted in a cross-sectional study comparing two cohorts of sarcoidosis patients 
(113). This paper was not included in this systematic review as it did not report 
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change in fatigue scores pre- and post-treatment, but the authors noted that 
patients receiving hydroxychloroquine (n=22) had lower fatigue scores than 
patients on other agents in the absence of any other differences in disease activity 
or severity. The lack of pre- and post-treatment fatigue scores, as well as the small 
number of patients receiving the agent, mean that conclusions about the 
effectiveness of hydroxychloroquine for treating fatigue cannot be directly drawn 
from these results. 
 
2.4 Discussion 
The evidence base for treating fatigue in sarcoidosis is limited. Although 13 trials 
were identified, all of which are presented here, all the studies were either small or 
were of poor-quality study design, leading to the possibility of inherent biases 
affecting the results. This makes it difficult to draw strong conclusions about the 
benefits of each therapy.  
In patients with clinically significant fatigue with evidence of disease activity despite 
appropriate use of first- and second-line immunosuppressants, anti-TNF-alpha 
therapy may be indicated. In the absence of active, organ-threatening disease the 
risks and potential side-effects of these drugs make them difficult to recommend 
for treating fatigue alone. The findings from the use of RCI suggest that patients on 
significant doses of corticosteroids may benefit from additional therapy to help 
reduce their corticosteroid dose; given the small number of participants in the RCI 
trial it is not yet possible to recommend this therapy, but the use of other steroid 
sparing therapies such as methotrexate may be indicated where fatigue is felt to be 
a side-effect of steroid therapy itself. Prednisolone use itself, for a six-month 
period, appeared beneficial for new diagnoses where fatigue was present alongside 
respiratory disease requiring treatment, though it is impossible to say if this was the 
natural history of fatigue in new cases of sarcoidosis due to a lack of control arm in 
the one study investigating steroids. 
Hydroxychloroquine is considered effective for treating cutaneous sarcoidosis 
(231), but its use in patients with sarcoidosis-associated fatigue who require 
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corticosteroid therapy has been suggested in a previous review (232). The possible 
effectiveness of treating fatigue with this agent is interesting, but evidence from 
trials investigating pre- and post-intervention fatigue scores is needed before 
stronger recommendation can be made for its use. The current evidence base for 
using these agents for sarcoidosis-associated fatigue is insufficient to draw any 
conclusion about its effect on sarcoidosis-associated fatigue.  
The management of fatigue in patients with quiescent disease is often a clinical 
challenge, especially given the potential side effects of disease-modifying 
medications. Neurostimulants such as modafinil or methylphenidate may be 
appropriate in these cases. The two trials investigating these interventions were 
well designed, but only included a small number of patients. Long-term use of these 
medications has been safe in other conditions (ADHD) but the trials investigating 
their use in sarcoidosis have been very short. Furthermore, both studies 
investigating neurostimulants were cross-over trials, a design which has been 
suggested as an inappropriate design for trials investigating the use of 
methylphenidate, although these recommendations relate to its use in trials 
involving patients with adult ADHD (233). The primary reason for this is the inability 
to maintain blinding when using an agent with detectable positive effects and 
characteristic adverse effects, such as neurostimulants, which can eliminate any 
controlling for placebo effect. In adult ADHD, this has been seen in the results of 
previous trials. A meta-analysis showed that stimulants had a larger effect size in 
these patients when studied in cross-over trials compared with parallel-arm trials 
(234). This finding may be related to the removal of between-patient variability 
seen in parallel-arm studies, but could also be related to the susceptibility to 
expectancy effects from difficulty maintaining blinding, a factor highlighted by a 
Cochrane review previously (235). Future parallel-arm studies investigating the 
effect of neurostimulants on sarcoidosis-associated fatigue are required to better 
understand their effect.  
Beyond pharmaceutical intervention, physical exercise programmes appear to lead 
to improvements in fatigue scores, but in the one trial that had a comparison group 
almost half of the controls demonstrated clinically significant improvements in 
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fatigue without any intervention. The largest study, ProKaSaRe, showed evidence of 
benefit through the use of FAS scores, although the absolute number of patients 
still reporting fatigue as a main or significant symptom only reduced by 
approximately 10 percentage points (absolute reduction), suggesting that a marked 
benefit may be felt by some but that a large number of patients still suffer with the 
symptom following completion of the programme. The patients who did enrol on 
the exercise programmes were likely to have been motivated to undertake this and 
therefore most likely to benefit. It should be noted that the evidence for 
improvement in patients with sarcoidosis-associated fatigue was only seen with 
structured general physical exercise programmes, not specific inspiratory muscle 
training. These findings are in line with current understanding on the positive 
impact of graded exercise in patients with CFS (236), although the evidence from 
CFS is from self-guided graded exercise with minimal input from physiotherapists, in 
contrast to the structured programmes utilised in studies here. For patients with 
physical limitation and fatigue who express an interest in undertaking physical 
therapy, a structured exercise programme may provide benefits. This may be 
undertaken alongside other pharmacological interventions, either for underlying 
disease activity or to directly treat the symptom of fatigue, as part of an agreed 
plan between physician and patient to manage sarcoidosis-associated fatigue. 
Consideration must be given to alternative strategies beyond rehabilitation 
programmes for patients where fatigue persists despite having undertaken such an 
intervention without benefit. 
There were limitations to the methodology of this review. The review included only 
English language papers. No foreign language articles were identified from the 
search strategy, due to the non-MeSH search terms being English only. Although 
efforts were made to contact authors regarding missing data or unclear elements of 
trial design some gaps remain in the data presented here. The main limitation when 
drawing conclusions from the data relates to bias within the studies included.  
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Future research considerations 
The main limitation of the evidence base for managing fatigue is the lack of trials of 
sufficient sample size or duration to make firm recommendations for managing 
patients with fatigue in clinical practice. Much of the data available are from 
observational studies or studies of less than 30 patients. Only one study included 
more than 100 patients but this was not a randomised or controlled study. Any 
future trials investigating therapies for treating sarcoidosis should include fatigue as 
an outcome measure given the frequency and significance of fatigue in sarcoidosis 
cohorts, consistent with suggestions by WASOG (166); this would allow a greater 
evidence base around the effect of treatment modalities on fatigue scores. 
In patients with quiescent disease, where fatigue is the primary symptom driving 
treatment decisions, more randomised placebo controlled clinical trials are 
required. The need to eliminate any placebo effect is important; in one of the trials 
included in this review (207) almost identical changes in fatigue from baseline were 
seen in both intervention and placebo arms. Designing these trials appropriately to 
inform clinical decision making is therefore the primary concern. The randomised 
trials that have already been performed have been very short; either four- or eight-
weeks duration. Clinical use of agents such as neurostimulants would likely be over 
many months and future trials should therefore assess change in fatigue scores and 
tolerability of medications over a much longer period of time than previously seen, 
and at least six months.  
 
2.5 Conclusions 
The neurostimulants methylphenidate and modafinil offer the potential to provide 
symptomatic relief to patients with sarcoidosis-associated fatigue. Given the 
limitation of existing evidence for neurostimulant agents, designing a study 
investigating the efficacy of these drugs is an important step in determining 
whether they should be used as part of the care for patients with sarcoidosis who 
experience significant fatigue. A number of considerations remain when 
considering how best to design a full study powered to investigate this; for this 
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reason, a feasibility study would be beneficial to determine how to best design a 
full phase III study.  
An additional question relates to the benefits of exercise on sarcoidosis-associated 
fatigue and the direction of effect; if increasing exercise can improve fatigue, will 
improving fatigue lead to an increase in daily activity? To understand this, any 
future trial investigating the effect of a pharmaceutical intervention on fatigue 
scores would benefit from a review of exercise and activity levels. If medication-
driven improvements in fatigue improve physical exercise levels, these 
improvements may further improve fatigue and may allow reduction or even 
discontinuation of medications after a sufficient time period. Measuring activity 
levels can be problematic; determining the preferred way of doing this would be 
beneficial for any future study. 
In the next chapter, the findings of a pilot study of wrist-worn activity monitors in 
patients with sarcoidosis are presented. This forms the first step towards 
performing a feasibility study of the neurostimulant methylphenidate. The 
importance of measuring exercise levels in any study monitoring change in fatigue 
has been discussed above. In order to enable accurate measurement of activity it is 
important that a device is used with is acceptable to patients so as to maximise the 
likelihood of the device being worn and capturing the most data possible. In order 
to ensure an appropriate device is used, a comparison study of two widely used 
accelerometer devices is presented, the results of which will be used to identify the 
preferred device for use in the subsequent feasibility study, “Fatigue and 
Sarcoidosis – Treatment with Methylphenidate” (FaST-MP).  
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3.1  Introduction 
In the previous chapter, the importance of exercise in fatigued patients was 
discussed, with multiple studies investigating structured exercise courses as an 
intervention to improve fatigue scores. The interaction between exercise and 
fatigue may be bi-directional, with improvement in fatigue levels potentially 
improving exercise levels. To determine this, the FaST-MP feasibility study was 
developed to include objective measures of daily activity, planning to use a wrist-
worn activity monitor to track changes in participants’ daily activity before, during 
and at the end of the study. Before this can be undertaken it is important to 
determine which device should be used within the trial. A short pilot study of two 
widely-used activity monitors was undertaken to determine a preferred device by 
participants in order to maximise the likelihood of obtaining valid activity data from 
participants in the FaST-MP study. 
 
Background 
The ability to quantify daily physical activity is important when evaluating 
interventions where levels of exercise during daily living can be used as an outcome 
measure. The presence of mental fatigue, such as that seen in patients with 
sarcoidosis (170), leads to declines in endurance performance and higher perceived 
exertion, suggesting that exercise performance is regulated by the central nervous 
system (237). The potential use of neurostimulants, such as methylphenidate, can 
improve exercise capability in healthy individuals (238). The use of methylphenidate 
for the treatment of sarcoidosis-associated fatigue therefore may improve physical 
activity levels; for this reason, the change in measured physical activity was a 
planned secondary outcome measure within the FaST-MP feasibility study. 
Measures of exercise capability in clinic-based tests (six-minute walk distance) have 
not been shown to change in patients who have received methylphenidate 
compared with placebo (239). Six-minute walk tests (6MWT) are likely to be sub-
maximal for patients without significant cardiovascular limitation (240). 
Furthermore, measuring physical activity in free living allows a global overview of 
both exercise capability and volition, the latter of which may be markedly affected 
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by mental fatigue; therefore, measurement of physical activity in free-living 
conditions could be an important outcome variable to measure in order to 
understand the effect that methylphenidate has on patients with sarcoidosis-
associated fatigue. 
Measuring physical activity in free-living conditions is widely undertaken using 
questionnaires. These ask participants to recall the amount of exercise that they 
have undertaken during a defined period. The use of these activity questionnaires is 
associated with recall bias. Other methods, including the use of accelerometry-
based activity monitors, offer the possibility of measuring activity objectively (241). 
Accelerometers have been shown to produce comparable results to double-labelled 
water, the gold-standard measurement of energy expenditure, and can provide 
information on activity patterns rather than total energy expenditure over a set 
period (199). Some accelerometers are also able to measure sedentary behaviours 
comparable to the gold-standard measure of inclinometers (242-244).  
Activity monitors can either be worn proximally on the hip or upper arm, or distally 
on the wrist or ankle. The wrist position is associated with a reduction in accuracy 
when classifying activity intensity compared with the hip position, potentially due 
to constraint of movement at the wrist when performing certain activities (245). 
However, wrist-worn devices benefit from being more acceptable to participants 
and may therefore lead to better compliance and improved wear time (246). For 
this reason, wrist-worn devices are often preferred for measurement of physical 
activity in free-living conditions, as is the case in the UK Biobank and the USA 
NHANES projects. There are a number of wrist-worn devices available, yet it is 
unclear how much impact the individual design has on the comfort of wearing the 
device, as well as the subsequent effect on wear time.  
It has been suggested that activity levels are reduced in patients with sarcoidosis, 
particularly when suffering from fatigue (145), and that improving physical activity 
can improve fatigue scores (226, 227). Although the link between sedentary 
behaviours (defined as sitting or lying with low energy-expenditure) and fatigue has 
not been investigated in patients with sarcoidosis, an inverse correlation between 
them has been seen in other conditions where fatigue is a prominent symptom, 
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such as fibromyalgia (247) and rheumatoid arthritis (248). Furthermore, it has 
previously been suggested that when considering choice of device for future studies 
within a patient group that a pilot study be performed to determine the ideal 
accelerometer device (249). As part of this thesis, within the Fatigue and 
Sarcoidosis – Treatment with Methylphenidate (FaST-MP) feasibility study 
presented in Chapter 4, measurements of physical activity in free-living conditions 
were planned.  In preparation for this, a pilot study of two commonly-used devices 
was undertaken to determine which device is preferred by patients with 
sarcoidosis, aiming to improve the likelihood of collecting valid data from 
participants within FaST-MP.  
 
Choice of accelerometers 
This study investigates the relative acceptability of two widely-used wrist-worn 
accelerometry-based activity monitors, the Actigraph GT3X-bt and the GENEActiv 
original, in patients with sarcoidosis. The GENEActiv device has been used 
previously in large studies investigating activity patterns, including the Whitehall II 
study (250) and Fenland cohort (202) in the UK, and the Pelotas cohort in Brazil 
(251).  
We have previously undertaken our own work using the GENEActiv original device 
in patients with idiopathic pulmonary fibrosis (IPF), a form of progressive fibrosing 
interstitial lung disease (252). The device was chosen to evaluate the association 
between time spent in sedentary behaviours with measures of pulmonary function, 
exercise capacity and quality of life. Thirty-nine patients wore the GENEActiv 
original device for seven days. Data was collected from participants recording their 
perception of the device through a questionnaire. This recorded each participant’s 
rating of the device’s comfort, their awareness of the device whilst wearing it, their 
objection to wearing the device and how much the device interfered with daily life; 
each of these outcomes was rated on a 100mm visual analogue scale, with lower 
scores indicating a better rating. In addition, we assessed the number of 
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participants recording “valid” data, defined as at least 16 hours of data from two 
weekdays and two weekend days.  
The results of the visual analogue scale questionnaire are shown in Figure 4; mean 
scores in each domain were low confirming that the devices were well perceived by 
participants. Thirty-five (89.7%) of the participants recorded valid data during their 
wear period, with two of the device failures occurring due to incorrect set-up prior 
to wearing. Only two participants did not wear the device for sufficient time to 
record valid data. 
 
Figure 4 - IPF patient perception of GENEActiv devices; visual analogue scale results 
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On the basis of these positive results, the GENEActiv device was chosen as one of 
the two devices to trial prior to use in the planned feasibility study for investigating 
the use of methylphenidate in sarcoidosis-associated fatigue. 
The Actigraph GT3X-bt was chosen as the comparator for the GENEActiv device. The 
GT3X-bt has been shown to be reliable in recording activity, and continues to be 
used widely as a method of measuring activity (253). These Actigraph and 
GENEActiv devices are different in design but both output raw data which can be 
analysed in an identical fashion (243, 254). Both have also been shown to be able to 
measure sedentary behaviours from postural data (242, 243), an important 
advantage over a number of competing devices. 
 
Study objectives 
The objective of this study is to determine which wrist-worn activity monitor is 
preferred by patients with sarcoidosis. The primary outcomes of interest are 
patient preferences relating to device comfort and wear time of the devices. The 
secondary outcomes of interest are patterns of activity and sedentary behaviours in 
these patients, and the correlation between these outputs and the fatigue 
questionnaire scores, although the study is not powered for these secondary 
outcomes.  
 
3.2 Methods 
Subjects 
The study was undertaken at the Norfolk and Norwich University Hospital, in the 
UK. Patients with a diagnosis of sarcoidosis were eligible for inclusion. The 
requirement for a diagnosis of sarcoidosis was either (1) a previous biopsy 
confirming non-caseating granulomas consistent with sarcoidosis, or (2) previous 
discussion by multi-disciplinary interstitial lung disease meeting panel with 
consensus diagnosis of sarcoidosis. All participants had to be aged 18 years old or 
over and able to provide written consent. Ethical approval for the study was gained 
Chapter 3: Determining a preferred measurement device for recording daily activity in patients with 
sarcoidosis – a pilot trial of two wrist-worn accelerometer devices 
   98
from the South West – Central Bristol Research Ethics Committee, reference 
number 15/SW/0363. The trial was registered on clinicaltrials.gov, reference 
NCT02626897. 
Seventeen patients were approached to take part in this study; twelve consented to 
participate. All participants wore both devices for seven days each in a cross-over 
manner. The order in which the devices were worn was allocated randomly based 
on a computer-generated code.  
 
Clinical Assessments 
Data regarding body mass index (BMI), forced expiratory volume in 1 second 
(FEV1), forced vital capacity (FVC) and FEV1/FVC ratio were taken from the most 
recent clinic attendance. Data was recorded on current immunosuppression use, 
organs affected by sarcoidosis (stratified into pulmonary and extra-pulmonary 
disease), and duration since diagnosis. All participants completed the FAS 
questionnaire, a ten-question fatigue score with a maximum score of 50, as a 
measure of present levels of fatigue. Higher scores indicate greater levels of fatigue, 
with the threshold for significant fatigue in the FAS score being 22 points or greater 
(112). 
 
Recording of device preference 
All participants were asked to complete a survey documenting their impression of 
each device immediately after completing the period of wear for each. The 
questionnaire consisted of four 100 mm visual analogue scales (VAS), previously 
piloted in an earlier study using wrist-worn accelerometers to measure activity over 
a seven-day period (252), with participants asked to mark on the 100 mm scale 
their response to each of the following questions; (1) How comfortable was the 
device to wear? (2) How aware of it were you? (3) Would you have any objection to 
wearing it again? and (4) To what extent did it interfere with daily life? The VAS was 
scored by measuring the distance along a line from the left-hand side that the mark 
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was made; a score of zero (0 mm) referred to no problems for each question and a 
score of 100 (100 mm) indicated severe or constant problems for each question. In 
addition to these four questions, participants were asked to complete a free-text 
box detailing any difficulties that were encountered with either device. 
Measurement of daily activity 
The two wrist-worn devices chosen for comparison were the GENEActiv original 
device (Activinsights, Cambridgeshire, UK) and the Actigraph GT3X-bt device 
(Actigraph, Pensacola, Florida, USA). The GENEActiv is a tri-axial, accelerometer-
based activity monitor with a dynamic range of +/-8g (where g is equal to the 
gravitational pull of the earth), measuring 43 x 40 x 13mm with a traditional plastic 
watch strap, and weighs 16 grams. The Actigraph GT3X-bt is also a tri-axial, 
accelerometry-based activity monitor with a dynamic range of +/-6g, measuring 46 
x 33 x 15mm with a Velcro-fixing strap, and weighs 19 grams. It has been widely 
used for both hip-worn and wrist-worn monitoring of activity. Because the primary 
outcome was determining in the acceptability and comfort of the devices, devices 
were worn separately over consecutive periods rather than simultaneously.  
Each device was worn for seven days by each participant on their non-dominant 
wrist. Devices were initialised to record data over the seven-day period and then 
returned via postal envelopes. They were set to record output from the 
accelerometer thirty times per second (i.e. sampling frequency 30Hz). Data was 
defined as ‘valid’ if the devices were worn for at least 10 hours per day for at least 
two weekdays and two weekend days; the number of patients meeting a higher 
threshold of 16 hours per day were also recorded in keeping with previous studies 
(255). Finally, the number of days with 24 hours of wear time within each recording 
period was noted. 
Activity data was analysed for both time spent in thresholds of activity (light, 
moderate and vigorous), as well as sedentary time. The mean accelerometer 
outputs by magnitude of wrist acceleration (Euclidean norm minus one-g, ENMO) 
per 24 hour period, during the least active 5 hours (L5) and most active 5 hours 
(M5) were calculated using the R-statistics package GGIR (256). Time spent in 
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moderate or vigorous physical activity (MVPA) was calculated using the threshold of 
100milli-g as has been used previously (251, 254) and is close to the specific device 
outputs signifying the threshold for moderate activity for both the GENEActiv 
(93.2milli-g) and Actigraph (100.6milli-g) devices, which have been established in 
previous data (257). MVPA was also calculated by ‘bout’ criteria as per WHO 
recommendations of activity occurring in bouts of at least ten minutes (258), using 
thresholds of more than 80% of any ten minute epoch spent above the 100milli-g 
threshold to be counted (MVPA10). Magnitude of difference in outputs between 
devices was calculated where minimum valid data was available from both devices 
for a participant. 
In addition to the output from GGIR, data from the preferred device (from the 
reported preference and total wear-time) was analysed for time spent in sedentary 
behaviours using the sedentary sphere custom spreadsheet (available elsewhere 
(242)) after raw data from the devices had been converted into .csv format in 15-
second epochs. Thresholds for activity vigour within this spreadsheet were taken 
from previous data by Esliger et al (259) and adjusted for the sampling frequency of 
the accelerometers, leading to differences in calculated time spent performing 
moderate or vigorous activity compared with the GGIR output.  
 
Statistical analysis 
All data analysis was undertaken by SPSS Statistics version 22 (IBM Corp, Illinois, 
USA). Comparison of device outputs and participant experience by each brand of 
accelerometer was undertaken. Visual analogue scores of device acceptance 
between devices were compared using the paired t-test. Wear time was calculated 
in minutes per day, averaged over the entire seven-day period, and compared using 
the paired t-test. The number of full 24-hour periods recorded during the seven-day 
window were also compared using this method. The number of devices which 
recorded any data and the number of devices recording valid data at both the lower 
and higher thresholds, defined in the previous section, were compared using the 
chi-squared test. Differences in activity measurements (ENMO, L5, M5, MVPA and 
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MVPA10) between the two accelerometer outputs were compared using the 
magnitude of difference between paired samples. Where a participant returned 
both devices with minimum valid data on both devices, no statistical test was 
applied due to the small number of samples. Spearman’s correlations between FAS 
scores and time spent in sedentary behaviours and each threshold of activity was 
calculated using data from the preferred device.  
 
3.3 Results 
Baseline demographic data for the participants are shown in Table 11. All 12 
participants had pulmonary sarcoidosis and five participants (41.7%) had extra-
pulmonary disease. Five participants were receiving immunosuppression at the 
time of inclusion. Nine participants (75%) scored more than 21 on the FAS score, 
indicating significant fatigue.  
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Table 11 - Participant characteristics at baseline 
Baseline Characteristic Value 
Mean (S.D.) unless otherwise specified 
Age – years (S.D.) 54.5 (13.0) 
Male gender (%) 7 (58.3) 
BMI – kg/m2 (%) 27.3 (4.7) 
Years since diagnosis (S.D.) 8.9 (8.7) 
Pulmonary disease (%) 12 (100) 
Extra-pulmonary disease (%) 
- Cardiac 
- Cutaneous 
- Ophthalmological 
5 (41.7) 
- 2 
- 2 
- 1 
On immunosuppression (%) 
- Prednisolone 
- Methotrexate 
- Azathioprine 
- Methylphenidate 
5 (41.7) 
- 4 
- 1 
- 1 
- 1 
FEV1 – % predicted (S.D.) 78.9 (23.2) 
FVC – % predicted (S.D.) 74.8 (40.5) 
Ratio (S.D.) 75.1 (16.6) 
Fatigue Assessment Scale (FAS) Score (S.D.) 
- FAS >21 (%) 
28.8 (9.3)  
- 9 (75) 
 
 
The GENEActiv device was preferred by ten (83.3%) of the participants in this study. 
The results from the VAS questionnaire regarding experience of the devices are 
shown in Figure 5. Statistically significant differences (p<0.05) were seen between 
the devices, with the GENEActiv device being more highly rated by participants 
across all domains of comfort, awareness of the device, objection to wearing the 
device and interference with daily activities. Comments against the Actigraph 
device included being ‘too bulky ‘(three participants) and the ‘Velcro strap was too 
uncomfortable’ (three participants). Despite this, all but one of these participants 
recorded at least minimum valid data.  Two participants preferred the Actigraph to 
the GENEActiv device; one person found the GENEActiv strap uncomfortable and 
another developed a skin reaction to the strap, although both of these participants 
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recorded sufficient data to be considered valid monitoring periods. Other 
comments against the GENEActiv referred to the lack of a watch-face on the device. 
 
 
 
 
Amongst the twelve patients who wore an accelerometer, 11 (91.7%) of the 
GENEActiv devices and 9 (75%) of the Actigraph devices recorded the minimum 
‘valid’ data (Table 12). Results for the number of devices returned with any data, 
the number of devices returned with valid data and the mean duration of daily 
* 
* 
* 
* * = p<0.05 
Figure 5 - Box-whisker plots of Visual Analogue Scale scores for experience of Actigraph 
and GENEActiv devices 
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wear time is shown in Table 12. Preference for the GENEActiv device was reflected 
in greater wear time compared with the Actigraph device (mean wear time 1354 
minutes per day vs 1079 minutes per day, p = 0.001). A higher number of GENEActiv 
devices recorded valid data over the wear period, both at the minimum threshold 
(91.7% vs 75%) and higher threshold (75% vs 58.3%). A greater number of complete 
24-hour wear periods were recorded within each 7-day period using the GENEActiv 
than the Actigraph device (5.1 vs. 3.7). 
 
 
Table 12 - Number of devices capturing data, including valid data, and total wear 
time by device 
 Actigraph GENEActiv p-value for difference 
No. devices returned with 
any data captured (%) 9 (75%) 11 (91.7%) 0.197 
Number of devices with 
minimum valid data* (%) 9 (75%) 11 (91.7%) 0.685 
Number of devices with 
higher valid data† (%) 7 (58.3%) 9 (75%) 0.504 
Number of full 24-hour 
periods recorded (S.D.) 3.7 (2.3) 5.1 (1.8) 0.150 
Wear time/day – min 
(S.D.) 1079 (215) 1354 (102) 0.001 
* More than 10 hours data for 2 weekdays and 2 weekend days 
† More than 16 hours data for 2 weekdays and 2 weekend days 
 
 
Despite the devices being worn over two separate periods, the average output from 
the devices across 24 hours (ENMO), during the least active 5 hours (L5) and most 
active 5 hours (M5) showed no significant differences between devices (Table 13). 
Time spent in MVPA, using both bout and non-bout criteria, was higher when 
measured by the GENEActiv devices compared with the actigraph devices. Although 
this was not statistically significant, the magnitude of difference between the two 
devices was large with over two hours more MVPA recorded by the GENEActiv 
device over the course of a week where participants had valid data for both 
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devices. In total, only three participants met World Health Organization (WHO) 
recommendations on time in MVPA per week according to ‘bout’ criteria (MVPA10). 
 
 
Table 13 - Device outputs during wear periods 
 
Actigraph GENEActiv 
Within-patient 
magnitude of 
difference* 
ENMO – milli-g (S.D.) 25.7 (6.3) 27.4 (7.7) 1.24 (6.8) 
L5 – milli-g (S.D.) 4.2 (2.7) 4.3 (2.2) 0.62 (1.8) 
M5 – milli-g (S.D.) 48.5 (15.0) 51.3 (17.2) 3.19 (9.9) 
MVPA (week) – min (S.D.) 556.9 (308.4) 668.1 (345.2) 148.2 (239.8) 
MVPA10 (week) - min (S.D.) 56.1 (62.0) 72.2 (74.8) 30.4 (38.2) 
*Where paired data available; 8 participants provided data from both devices 
ENMO – Euclidean Norm Minus One-g (mean accelerometer output over 24-hour period) 
L5 – Mean accelerometer output (in milli-g) during the least active 5 hour period per day, averaged across all 
valid days 
M5 - Mean accelerometer output (in milli-g) during the most active 5 hour period per day, averaged across all 
valid days 
MVPA – Moderate or Vigorous Physical Activity using 100milli-g cut-off; no bout criteria used 
MVPA10 – Moderate or Vigorous Physical Activity using 100milli-g cut-off; bout criteria of 80% of any 10 minute 
block spent above 100milli-g threshold used 
 
From the GENEActiv data, participants spent 427.3 minutes per day in sedentary 
behaviour; over half of their awake time. The mean time spent within each activity 
threshold per day were 245.4 minutes in light activity, 118.1 minutes in moderate 
activity and 7.1 minutes in vigorous activity, although the time in vigorous activity 
was skewed because of a high outlying value. With the outlying value removed the 
mean time spent performing vigorous activity fell to 3.1 minutes per day. 
Correlations between FAS scores and time spent within activity thresholds are 
shown in Figure 6. Moderately strong associations were seen between FAS scores 
and time in sedentary behaviours (r = 0.554, p=0.077), and time in light activity (r = 
-0.585, p=0.059). Weaker correlation was seen between moderate activity (r=-
0.506, p=0.112) and FAS scores. 
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3.4 Discussion 
This study sought to clarify the preferred device by patients with sarcoidosis. A clear 
preference was demonstrated for the GENEActiv device, with the difference in 
scores on the VAS being statistically significant across all domains. Comments 
received from participants suggested they disliked the size and the strap of the 
Actigraph. The design of the GENEActiv appeared more comfortable, although 
feedback suggested that participants would have liked a watch face to negate 
needing to wear both a watch and the accelerometer. Overall, the GENEActiv 
appeared much less intrusive, with participants noting reduced awareness of the 
device with less interference with normal activity. This should provide a better 
reflection of daily activity through increased wear-time (which was seen in our 
results) and less disruption of normal daily activities. The high levels of wear time 
achieved from these devices is in keeping with benefits seen elsewhere; large 
population studies investigating activity, including the UK Biobank and NHANES, 
have switched from hip-worn accelerometers to wrist-worn devices due to 
increased wear time (260). Our results show that significant differences in wear 
time exist even within devices worn at the same location and reinforce the 
importance of choosing a device which is acceptable to the participants who will be 
wearing them. 
Figure 6 - Correlation of Fatigue Assessment Scale score and time spent in activity 
thresholds from GENEActiv data 
r = 0.554 
p = 0.077 
r = -0.585 
p = 0.059 
r = -0.506 
p = 0.112 
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The preferred device in this study, the GENEActiv, had a mean daily non-wear time 
of only 86 minutes per day averaged over the entire wear period. The ideal 
minimum wear time per day is debated with a number of different 
recommendations for valid wear time of accelerometers proposed. Our minimum 
validity definition (10 hours per day for two weekday and two weekend days) was 
taken from previous recommendations (261). Other reviews and studies have 
suggested that 13 hours (262) or 16 hours (255) are preferable to achieve an 
accurate picture of daily activity. Part of the rationale for these definitions was 
based on how sleep would impact on measurements due to difficulty separating 
sleep from periods of low activity (263). Modern accelerometry-based activity 
monitors, such as those tested here, incorporate additional sensors into the device 
(temperature and light sensing) which can be analysed with accelerometer outputs 
to determine sleep periods (264). These complex sensor arrangements allow sleep 
time and non-wear time to be excluded from activity analysis, meaning these 
devices can be truly “fit and forget” for participants in these trials. This also gives 
the option of collecting data on sleep patterns in addition to activity levels.  
An exploratory analysis was performed to identify if there was a potential 
correlation between fatigue measured by FAS scores and time in activity thresholds. 
Previous studies looking at fatigue and sarcoidosis have used clinic-based measures 
of exercise capacity such as the six-minute walk test as predictors for fatigue, which 
have been shown to be poor at predicting fatigue scores (197, 265). Conversely, 
activity in free-living conditions was shown to be affected by fatigue in one study of 
patients with sarcoidosis (145). In the small number of participants monitored here, 
time spent in light activity showed moderate negative correlation with FAS scores. 
Additionally, time in sedentary behaviours, which has not previously been 
investigated, showed association with FAS scores. This suggests that changes in 
fatigue may be reflected in changes in activity and sedentary behaviours. 
Assessment of larger cohorts of patients with sarcoidosis will help to confirm these 
associations, as well as whether a relationship exists between fatigue and moderate 
or vigorous activity. Furthermore, investigation into whether increasing a patient’s 
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activity levels reduces their fatigue scores could be made using devices such as the 
ones used here. 
The strengths of this study include the wear-time required by each participant of 
the devices as well as the cross-over design which ensured that all subjects wore 
both devices for a period of time which would mirror the wear-time expected in 
future studies. This enables us to be confident that the GENEActiv would be more 
comfortable to wear, and therefore have greater wear time, when used in future 
studies to record activity patterns. The limitation of this study is the small number 
of participants. The number included was sufficient to determine a clear preference 
between the devices and therefore meet the primary objective, but this limits any 
conclusions beyond this. Determining the relationship between activity levels and 
patient-reported fatigue scores could not be accurately determined from the 
number of participants here, although this was not the purpose of the study. 
 
3.5 Conclusions 
The results of this study show a clear preference expressed by participants for the 
GENEActiv device. This stems from the improved comfort and reduced awareness 
of the GENEActiv compared with the Actigraph device. This in turn led to increased 
wear time and a greater amount of data being collected. As a clear preference was 
expressed for this device by participants, the GENEActiv device was therefore 
chosen for use in the FaST-MP study for measuring daily activity outcomes. The 
results may also influence device choice for future studies involving patients with 
sarcoidosis where outcomes of free-living activity levels are measured. Informed by 
the findings of this study, the next chapter of this thesis reports the full results of 
the FaST-MP study, including the activity outcomes measured using the GENEActiv 
devices piloted here. 
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Chapter 4: Fatigue and Sarcoidosis – Treatment with 
Methylphenidate (FaST-MP) feasibility study methods 
 
 
Methods for Fatigue and Sarcoidosis – Treatment with Methylphenidate (FaST-
MP) feasibility study published as: 
Feasibility study of a randomised controlled trial to investigate the treatment of 
sarcoidosis-associated fatigue with methylphenidate (FaST-MP): a study protocol 
BMJ Open 2017;7(12):e018532 
 
Clinical Trial Registry – Registered with clinicaltrials.gov 
Registry number - NCT02643732 
Research Ethics Committee (REC) Approval Gained 
REC reference – 16/EE/0087 
Medicines and Healthcare Products Regulatory Agency (MHRA) Clinical Trial 
Authorisation 
EudraCT Number – 2016-000342-60  
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4.1 Introduction 
Existing guidelines for managing sarcoidosis (83, 84) do not include advice on 
managing sarcoidosis-associated fatigue. In Chapter 2 the current lack of evidence 
for treatment options was described, although evidence for the use of 
neurostimulants, such as methylphenidate, was promising and required further 
exploration. Questions remain regarding how best to undertake a study of these 
agents; previous trials utilised a cross-over design, short study duration and 
measured primary outcomes using questionnaire-data. In the previous chapter a 
cross-over study of activity monitors determined the preferred device by patients 
with sarcoidosis. The results identified that the GENEActiv original wrist-worn 
device was preferred by patients, resulting in longer wear-times. This study was 
performed in preparation for a double-blind, parallel-arm feasibility study of 
methylphenidate for sarcoidosis-associated fatigue as one of the outcomes being 
tested is the practicality and reliability of using outputs from a wrist-worn activity 
monitor device as an outcome measure. The FaST-MP feasibility study is described 
in this chapter, determining the feasibility of recruiting and retaining participants as 
well as which outcome measures should be considered for any full phase III trial 
performed in the future. 
 
Background 
Methylphenidate (and its isomer dexmethylphenidate), which is used to treat 
attention deficit hyperactivity disorder (266), is a piperidine class stimulant which 
works by amplifying dopamine signals through inhibition of dopamine reuptake and 
enhancement of extracellular dopamine in the basal ganglia (267). The use of 
methylphenidate as a symptomatic treatment of sarcoidosis-associated fatigue has 
been suggested and trialled in a small study (173). However, that study only 
included ten participants, receiving medication for only eight weeks, and used a 
cross-over design which has been suggested to be inappropriate for trials 
investigating methylphenidate due to potential carry-over effects and difficulties 
with blinding within a cross-over study (233). 
Chapter 4: Fatigue and Sarcoidosis – Treatment with Methylphenidate (FaST-MP) feasibility study 
methods 
   111
The drug has been used to treat fatigue in other settings with good effect. In a 
placebo-controlled, double-blind trial in post-chemotherapy participants with 
fatigue, methylphenidate exhibited a clinically significant reduction in fatigue (211). 
Prior to the results from that trial, a Cochrane review of treatments for cancer-
related fatigue from five randomised controlled trials (RCTs) had shown an 
improvement in fatigue scores during methylphenidate treatment, leading the 
researchers to conclude “the current evidence supports the use of 
psychostimulants in cancer-related fatigue” (268). Another trial investigated 
methylphenidate for the treatment of fatigue in 109 HIV-positive patients over a 6-
week period. Methylphenidate improved fatigue on a visual analogue scale, with a 
26.2 point increase (maximum of 100) from baseline, and 41% of participants 
receiving the drug demonstrating a greater than 50% improvement in visual 
analogue scale score (213). In contrast, no difference between methylphenidate 
and placebo was seen in a cohort of 68 fatigued patients followed over a 12-week 
period who had received radiotherapy for brain tumours (212). 
  
Rationale for a feasibility study 
Prior to designing a definitive phase III study to determine the efficacy of 
methylphenidate for treating fatigue in sarcoidosis, issues around the feasibility of 
undertaking a sufficiently large trial need to be resolved. Completed trials have only 
used methylphenidate for 8-12 weeks, whether using it for sarcoidosis-associated 
fatigue or other causes of fatigue. Therefore, sustainability of effect, tolerability of 
medications over a longer period and retention of participants within the trial are 
unknown. Whilst medications such as methylphenidate may not be used on a 
continuous basis in the clinical setting, their use on a 6-12 month basis may not be 
unreasonable, hence the need to review the effect of the medication over a longer 
period. It is however unclear how many people would be willing to participate in a 
longer trial. It is also unclear how many potential participants would be suitable for 
enrolment using our present inclusion and exclusion criteria. For this reason, a 
feasibility trial is necessary before committing to a larger trial. Finally, whether a full 
phase III RCT is feasible is unclear; the potential difficulty in maintaining blinding for 
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both clinicians and patients due to clear clinical effect and characteristic adverse 
events may render a placebo-controlled study meaningless. 
In addition to determining the feasibility of a larger trial, questions remain about 
whether recording of physical activity measures is useful and feasible within such a 
trial. Patients with sarcoidosis have been shown to have lower activity levels when 
fatigue is present (145) whereas 6MWT values have been shown not to change 
even when fatigue is treated (173) and the MSWT has not previously been trialled 
for this. The FaST-MP trial evaluates exercise capacity and physical activity using the 
modified shuttle walk test (MSWT) for exercise capacity and accelerometer-
measured physical activity volume and intensity. Measuring exercise capacity in a 
laboratory setting is different to measuring daily physical activity levels in free living 
conditions. Factors other than physical capability can affect levels of activity, 
including social factors and volition. This trial will therefore evaluate the feasibility 
of using the GENEActiv original wrist-worn accelerometer, evaluated in the previous 
chapter, as an outcome measure in a clinical trial. 
 
Objectives 
The primary objective of this feasibility study was to determine the feasibility of 
conducting a large trial to investigate the clinical effectiveness of methylphenidate 
for the treatment of fatigue associated with sarcoidosis. Exploratory analysis of 
clinical outcomes is a secondary objective, although the study is not powered for 
these outcomes.  
 
4.2 Methods 
Trial design 
This was a double-blind, placebo-controlled single-centre, randomised trial with a 
primary objective of determining the feasibility of performing a subsequent phase 
III study powered for clinical efficacy. Exploratory analysis of the clinical effect of 
methylphenidate on fatigue scores and health-related quality of life in patients with 
Chapter 4: Fatigue and Sarcoidosis – Treatment with Methylphenidate (FaST-MP) feasibility study 
methods 
   113
sarcoidosis was undertaken using the data collected. The trial allowed up to thirty 
participants to be randomized in a 3:2 ratio to receive methylphenidate or placebo 
for up to 24 weeks. The asymmetrical allocation was chosen to increase the number 
of participants receiving methylphenidate, increasing the data collection on side 
effects and drug tolerability. 
 
At the end of the study three audio-recorded, moderated focus groups, with 
purposive sampling to select patients with different baseline characteristics and 
response to therapy were undertaken to refine the understanding of the results 
and inform the design of any future definitive study. This was an optional additional 
part of the study and participants were asked to give their consent to participate in 
these focus groups. Participants were still able participate in the clinical trial even if 
they did not wish to participate in the focus groups. 
 
Study setting 
The study was undertaken at the Norfolk and Norwich University Hospital (NNUH; 
Norwich, Norfolk), a regional tertiary centre for patients with interstitial lung 
diseases (ILD). All study visits and activities took place within the NNUH. Patients 
were recruited from the respiratory department of the NNUH. In addition, patients 
could be recruited from other hospitals in the East of England if they were (a) 
willing to travel to the NNUH for the planned study visits and (b) their primary 
physician at their treating hospital was agreeable for them to participate in the 
study.  
 
Participants 
Sample size 
A target sample size of 30 participants was judged to be reasonable at a single site 
responsible for the care of approximately 300 patients with sarcoidosis through the 
respiratory medicine department, although a minimum target of 20 participants 
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was specified to estimate feasibility outcomes (269). Subsequent review of 
enrolment after four months showed that recruitment had been slower than 
expected. The ability to recruit centres as Participant Identification Centres (PICs) 
was added in a major amendment in April 2017 to facilitate increased recruitment; 
two centres (Papworth Hospital, Cambridgeshire and Addenbrooke’s Hospital, 
Cambridge) were approved as PICs during the study. All research activities beyond 
participant identification occurred at NNUH exclusively. 
The change in FAS score from baseline gave an estimate of effect size; this informed 
sample size requirements for any future phase III study. The number and 
proportion of participants recruited and retained within the study enabled an 
estimate of the number of additional participants required to cover for withdrawals 
during a future study. An estimated minimum retention rate of 60% of participants 
over the longer 24-week study duration was considered the minimum number to 
suggest a future study would be feasible over this duration.  
 
Eligibility criteria 
Participants were considered eligible for enrolment in this trial if they fulfilled all 
the inclusion criteria and none of the exclusion criteria as defined below. 
Participant inclusion criteria 
1. A proven diagnosis of sarcoidosis – this was defined as either a biopsy-
proven disease (non-caseating granulomas from a tissue biopsy), or a 
diagnosis of sarcoidosis agreed by an interstitial lung disease 
multidisciplinary team (ILD MDT) meeting. 
2. Stable disease (treatment unchanged for 6 weeks, without anticipation of 
change in treatment during trial period) 
3. Able to give informed consent 
4. Participant-reported fatigue and FAS score greater than 21 units (defined 
cut off for significant fatigue (270)) 
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Participant exclusion criteria 
1. Evidence of co-existing obstructive sleep apnoea. Patients were screened 
with the “STOP-Bang” questionnaire; those with a score of greater than 4 
were required to undertake overnight oximetry. Participants were excluded 
if overnight oximetry revealed a desaturation index of more than 15 events 
per hour. Below this, participants were eligible for inclusion. 
2. Documented history of significant cardiac disease (including cardiac sarcoid) 
OR associated disease which would increase risk of underlying coronary 
artery disease (cerebrovascular disease, previous stroke or peripheral 
vascular disease). Definitively treated cardiac disease e.g. previous 
myocardial infarction treated with stents or coronary artery bypass grafting 
with no ongoing symptoms was permitted.  
3. Abnormal thyroid function (hyper or hypothyroidism) defined as abnormal 
screening thyroid function tests (Thyroid stimulating hormone (TSH) outside 
normal range of 0.35 – 3.50 mU/L or thyroxine (T4) outside normal range of 
8 – 21 pmol/L). 
4. History of seizures, excluding febrile convulsions whilst an infant. 
5. Abnormal electrocardiogram (ECG) with evidence of arrhythmia (except first 
degree heart block which has been stable for 3 months). 
6. Concomitant therapy with any of the following drugs: 
a. Tricyclic anti-depressants (amitriptyline, clomipramine, dosulepin, 
doxepin, imipramine, lofepramine, nortriptyline, trimipramine, 
mianserin, trazodone) 
b. Monoamine oxidase inhibitors (phenelzine, isocarboxazid, 
tranylcypromine, moclobemide, selegiline) 
c. Buprenorphine 
d. Tramadol 
e. Levodopa 
f. Clonidine 
g. Methylene blue 
h. Warfarin 
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i. Antipsychotics, both typical and atypical  
j. Decongestants (phenylephrine, ephedrine, pseudoephedrine and 
others).  
7. Glaucoma or raised intra-ocular pressure for any reason. 
8. Patients with established liver disease defined as Child-Pugh class B or C. 
9. Documented medical history of psychiatric disorders (excluding depression) 
10. History of drug-dependence or addiction at any time 
11. Female participant who was pregnant, lactating or planning pregnancy 
during the course of the trial 
12. Female patient of childbearing potential who was unable or unwilling to 
take two acceptable forms of contraception (see below) 
13. Any patient receiving an investigational drug or biological agent within 6 
weeks (or five times the half-life if this is longer) prior to study entry. 
 
Exclusion criteria on pregnancy 
Female patients of childbearing potential were required to use contraception due 
to the theoretical risk of teratogenicity, growth retardation and premature birth 
with methylphenidate use in pregnancy. Those unable or unwilling to take two of 
the following acceptable methods of contraception for the duration of their 
treatment were excluded from participating in this trial: 
1. Established use of oral, injected or implanted hormonal methods of 
contraception 
2. Intra-uterine device (coil) 
3. Barrier methods of contraception (condom or occlusive cap with spermicide 
– use of spermicide without a form of barrier contraception was not 
considered an acceptable form of contraception) 
4. Alternatively, absolute and continuous abstinence was acceptable. Periodic 
abstinence (calendar, ovulation, symptothermal, post-ovulation) or 
withdrawal were not considered acceptable methods of contraception 
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For the purposes of this trial the definition of a woman of childbearing potential 
was a sexually mature woman (i.e. has experienced menstruation) who has not 
been postmenopausal for 12 consecutive months (i.e. who has had menses at any 
time in the last 12 months without an alternative medical cause). 
 
Permitted treatments and concomitant care 
Patients were permitted to receive any treatment for their sarcoidosis. Potential 
treatments included prednisolone, methotrexate, azathioprine, mycophenolate, 
hydroxychloroquine or infliximab. These treatments were required to be at a stable 
dose (i.e. no plan to wean down or increase dose during the trial period) for at least 
6 weeks prior to screening for enrolment in the trial. All concomitant medication 
was recorded at baseline and changes to concomitant medication were recorded at 
each visit. 
Patients receiving selective serotonin reuptake inhibitors (SSRIs) were permitted to 
enter the trial. Previous trials have used methylphenidate to attempt to enhance 
the effectiveness of SSRIs, including doses of methylphenidate greater than the 
maximum daily dose prescribed within this study. The side-effect profile when using 
these drugs together appeared safe, with no significant differences in side-effects 
or drop outs compared with placebo in one trial of 142 elderly patients (271). 
 
Participant identification, recruitment and retention 
Participant identification 
Patients were identified by review of ILD MDT meeting minutes or summaries, 
screening patient registries, hospital medical records, a locally-held and maintained 
database of patients interested in research, or clinical details. This occurred at the 
NNUH. PIC sites were able to identify additional potential participants and inform the 
study team at the NNUH but were not required to screen their entire sarcoidosis 
patient population. 
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Patients at the NNUH who were identified through any of these methods as potential 
candidates had a retrospective case review to determine whether they met inclusion 
criteria 1 and 2. Patients who met inclusion criteria 1 and 2 who did not obviously 
meet any exclusion criteria at pre-screening were approached with the permission of 
their primary respiratory physician. Participants referred from PIC sites were 
contacted by phone to check eligibility, with additional data to confirm their 
diagnosis sought from their treating hospital.  The data was collected using an 
anonymised form. The data captured consisted of: Patient demographics (age, sex, 
race, BMI), most recent lung function, duration of disease, current treatment and 
duration of treatment, organs affected by sarcoidosis and medical history.  
 
Participant recruitment 
Recruitment strategies included any of the following:  
• Patients could be approached by their clinical care team directly when they 
attend the hospital outpatient clinic. They received an invitation letter on 
hospital headed paper which provided an overview of the study and the 
patient information sheet. The research team contacted the patient by phone 
3-7 days later if they had given their usual team permission to be contacted. 
• Alternatively, the clinical team could post an invitation letter, with or without 
a patient information sheet, with a reply form detailing a range of methods 
for the interested potential patients to contact the research team. This 
method was used to contact patients identified either through the ILD team 
(clinic or MDT), or patients who are on the research participant database held 
by the respiratory research group at the NNUH.  
• Where patients were due to attend clinic for a routine appointment in the 
near future, the clinical care team could mail an invitation letter on hospital 
headed paper, providing an overview of the study, and a patient information 
sheet, so that the patient received these documents at least 24 hours in 
advance of their routine clinic assessment visit. This enabled consent to be 
sought during their attendance at clinic.    
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• Posters advertising the trial were placed in the respiratory department at the 
NNUH, including contact details for patients interested in the trial. 
• Patients who were identified at PIC sites rather than the Norfolk and Norwich 
University Hospital were sent a PIS by the research team in Norwich after 
their details had been passed on by their primary physician from their 
hospital. Consent was taken at the Norfolk and Norwich University Hospital. 
Potential patients could be contacted by phone between 3 and 7 days after the 
mailing of the letter to ensure that they had received it.  
 
Participant consent 
Consent was obtained prior to any study related procedure. Following consent, 
screening bloods were taken and other eligibility criteria were assessed. Patients 
meeting all entry criteria (after review of screening tests) were only randomised prior 
to their baseline visit (visit 0) once all inclusion and exclusion criteria had been 
checked. A two-week period between consent (at the screening visit) and 
commencing medications (at visit 0) allowed a cooling-off period for participants; 
consent was checked at visit 0. At the same time as confirming consent, a declaration 
of understanding was signed by the participant to confirm willingness to receive the 
medications at the dose prescribed and not to give away or sell their medications. 
Following this, medication was dispensed by hospital pharmacy to the study team, 
who would give the study medication directly to the participant at their study visit. 
 
Participant retention 
Participants who discontinued protocol treatment, for any reason, were asked to 
remain in the trial for the purpose of follow up and data analysis. Although not 
obliged to give a reason for discontinuing their trial treatment, a reasonable effort 
was made to establish this, whilst remaining fully respectful of the participant’s 
rights. 
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Interventions 
Active treatment arm 
The intervention under investigation was methylphenidate hydrochloride 
(Tranquilyn), which was manufactured for this study in 10mg tablets with over-
encapsulation by a gel capsule. The drug supply was produced by Guys and St 
Thomas’ Pharmacy Manufacturing Unit. Participants commenced at 10mg of 
methylphenidate hydrochloride (one capsule) twice daily, increasing to 20mg (two 
capsules) twice daily after two weeks. Participants continued the medication for up 
to 24 weeks in total; participants on the higher dose (20mg twice daily) received an 
additional two weeks supply of the lower dose (10mg twice daily) for 2 weeks 
following completion of the trial to minimise the risk of any withdrawal symptoms. 
 
Comparator arm 
The comparator arm for this study was an identical placebo capsule; the placebo 
was manufactured at Guys and St Thomas’ Pharmacy Manufacturing Unit. 
Participants in the placebo arm commenced medications at one capsule twice daily, 
increasing to two capsules twice daily after two weeks if the medication had been 
tolerated. Participants receiving two capsules twice daily at the end of the 24-week 
treatment period were reduced to one capsule twice daily and then discontinued 
the trial medications at the end of this period.  
 
Dispensing schedule 
Participants received sufficient investigational medicinal product (IMP) for them to 
take their prescribed dose until their next study visit. This was dispensed at two-
weekly intervals for the first 6 weeks, then a six-week supply of IMP dispensed at 6, 
12 and 18-week visits. All medication was dispensed from the pharmacy at the 
NNUH. The IMP was dispensed in bottles of 28 capsules. Assuming a participant was 
uptitrated to the higher dose (20mg twice daily) after two weeks and maintained 
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this dose through the study, the participant received the following quantities of IMP 
at each visit: 
• 1 bottle (28 capsules) at visit 0 (0 weeks) 
• 2 bottles (56 capsules) at visits 1 and 2 (2 and 4 weeks) 
• 6 bottles (168 capsules) at visits 3, 4 and 5 (6, 12 and 18 weeks) 
• 1 bottle (28 capsules) at visit 6 (24 weeks)  
 
Treatment modifications, interruptions and discontinuation 
The dose was down-titrated in the event of side effects at the higher dose (20mg/2 
tablets twice daily). In the case of side effects, the dose was reduced to 10mg (1 
tablet) twice daily. In the event of any side effects whilst receiving 10mg (1 tablet) 
twice daily the treatment was discontinued. Once a patient had a dose reduction no 
re-escalation was permitted, even if the adverse event leading to the reduction 
resolved. 
At the completion of the trial (week 24) participants on 20mg twice daily reduced to 
10mg twice daily for two weeks to reduce the risk of withdrawal symptoms before 
discontinuing IMP completely. 
Side effects which may lead to down-titration of the drug were: 
1. Nervousness or restlessness 
2. Nausea, indigestion 
3. Nasal stuffiness 
4. Tachycardia (resting HR >100 which had not been observed at lower dose) 
5. Cough 
6. Arthralgia 
7. Anorexia 
8. Participant choice 
Participants discontinued the study drug immediately (regardless of dose) in the 
case of the following events: 
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1. Intolerance to study drug due to development of clinical side effects 
2. Generalised rash and pruritis 
3. Abnormality of follow-up ECG (arrhythmia, severe tachycardia (>120bpm) or 
conduction abnormality) 
4. Development of palpitations or chest pain 
5. Development of severe anxiety or euphoria, personality change or 
abnormal/bizarre behaviour, or other psychiatric disease 
6. Development of seizures or other neurological problems 
7. Development of severe hypertension (BP >180mmHg on two separate 
occasions or symptoms of malignant hypertension, notably severe 
headache, blurred vision or seizure) 
8. Failure to take the medication as directed or overdose of study medication 
9. Change in liver function tests (raised ALT >3x upper limit of normal) or 
deterioration in renal function (eGFR <30ml/minute/1.73m2) 
10. Inter-current illness that prevents further treatment 
11. Any change in the participant’s condition that in the clinician’s opinion 
justifies the discontinuation of treatment 
12. Withdrawal of consent for treatment by the participant 
Participants within the trial who required increases in their usual treatment for 
sarcoidosis were permitted to remain in the trial if both the patient’s primary 
physician and the trial physician were in agreement. Any changes to sarcoidosis 
treatment or evidence of increased disease activity were recorded. 
 
Assessments and outcomes 
Feasibility outcomes 
The primary outcomes were chosen specifically to determine the feasibility of a 
future phase III study investigating the clinical efficacy of neurostimulant 
medications for treatment of sarcoidosis-associated fatigue. Each primary outcome 
below is followed by the specific question which the outcome point aimed to 
answer. 
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1. Number of potential participants excluded (how many patients with 
sarcoidosis are eligible?) 
2. Reason for exclusion from the study (as above, as well as generalisability of 
the results – is the population included and continuing the trial 
representative?) 
3. Number of eligible participants agreeing to participate (willingness of 
patients to participate) 
4. Recruitment rate (how many centres would need to be involved?) 
5. Retention of participants and reason for withdrawal (how many additional 
participants would be needed to ensure statistical power is maintained 
allowing for drop-outs?) 
6. Number of participants suffering side-effects or requiring reduction of 
methylphenidate dose due to emergence of side effects, and the dose most 
frequently tolerated by participants (see assessment of safety below) 
7. Sustainability of effect (does a future trial need to be as long or is 8-12 
weeks acceptable?) 
8. Number of missed or unfilled assessments (can accurate data be collected to 
capture the information required?) 
9. Number of patients correctly using accelerometers (will patients remember 
to use the accelerometers for the required minimum four days out of the 
seven-day period?) 
10. Accuracy of predicting allocation to active or placebo arm at the end of the 
study by assessor and participant (is blinding broken through participants 
determining which group they have been allocated to during the study from 
clinical effects or side-effects?) 
11. Acceptability of number of study visits and assessments (does the study 
design deter participants?) 
12. Acceptability of randomization (does the risk of only receiving placebo deter 
participants?) 
13. Acceptability of receiving a controlled drug (is the choice of intervention 
acceptable to participants?) 
14. Compliance with medications (how many doses are missed?) 
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15. Mean change in fatigue score and standard deviation of change (for power 
calculations; more detail is contained in the secondary outcomes section) 
16. Patient perception of participating in this trial (through the use of focus 
groups) 
 
Secondary outcomes 
In addition to the primary outcome measures listed above, an exploratory analysis 
of clinical measures was undertaken, covering participant-reported fatigue scores, 
depression scores, health-related quality of life, healthcare utilisation, physical 
capacity and activity and sleep quality. The specific outcome measures used, 
including the rationale for their use, are described below: 
 
Questionnaires 
Questionnaires were administered at each participant’s visit, with data checking at 
the time to minimise the risk of missing values. The final set of questionnaires, 
performed 6-8 weeks following the completion of study medications, was 
completed by the participant at home whereby postal questionnaires were sent to 
the participant and returned via pre-paid envelope. 
1. Fatigue was assessed using two separate questionnaires; the FAS (112) and 
FACIT-Fatigue (272). The FAS is a ten-question instrument with a maximum 
score of 50 points and a known MCID of four points; higher scores indicated 
greater fatigue (270) (22). The FACIT-Fatigue is a generic fatigue scale with 
13 items. Lower scores indicate greater fatigue. The measurement 
properties of both these instruments is discussed in chapter 1, section 1.9.  
2. Disease specific health related quality of life was assessed using the King’s 
Sarcoidosis Questionnaire (KSQ) (273). This is the only validated disease-
specific health related quality of life tool for sarcoidosis, which was 
developed with cohorts of sarcoidosis patients in the UK. It calculates health 
status scores related to sarcoidosis activity and also includes a visual 
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analogue scale to report severity of cough. Results are reported for different 
sub-scales of disease-related symptoms (general health status, lung 
symptoms, eye symptoms, skin symptoms and medication-related 
problems) and an overall score (composite score) incorporating all sub-scale 
values. Lower scores for each subscale indicate greater problems. 
3. Anxiety and depression were assessed using the Hospital Anxiety and 
Depression Score (HADS) (274). This 14-item questionnaire includes 
subscales for anxiety and depressive symptoms (HADS-A and HADS-D), with 
each item scored out of three. Total scores are out of 21 for each subscale, 
with a score >10 points indicating the presence of significant anxiety or 
depressive symptoms. Previous data have suggested that depression scores 
have improved with changes in fatigue scores (173). 
4. Generic quality of life was assessed using EuroQoL-5D-5L (EQ5D) and SF-36 
questionnaires. The EQ5D is a 2-page self-administered questionnaire (275), 
and was used to generate health utility values from the reported health 
states within the questionnaire. The SF-36 questionnaire consists of 36 
items measuring various aspects of quality of life. It is one of the most 
frequently used patient-reported outcome measures across many different 
health conditions (276), and has been shown to correlate with fatigue scores 
in sarcoidosis patients (277); the results from the SF-36 were converted into 
short form 6-dimension (SF-6D) health states and then into health utility 
values. 
5. Health and social care resource utilisation were captured through a custom-
designed costs questionnaire. This included a baseline socioeconomic 
questionnaire and 3-monthly resource use questionnaires that captured 
details of medical contacts, carers and out of pocket patient expenses. This 
questionnaire was developed from tools within the Medical Research 
Council project “Database of instruments for resource-use management” 
(278). The tool was piloted within this study to determine whether it is 
appropriate for future use.  
6. Sleep quality was measured using the Pittsburgh Sleep Quality Index (PSQI), 
a validated questionnaire for evaluating sleep quality (279, 280), to 
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determine if sleep quality is impacted by taking methylphenidate. This 
outcome was added during an amendment to the study made in April 2017 
due to several participants reporting a subjective improvement in sleep 
quality whilst receiving medications. 
7. An exit questionnaire (contained in appendix 5), asking whether a 
participant would want to continue the study medication if this were an 
option, was administered at week 24 or at the point of withdrawing from 
the study – these findings were complementary to the focus groups and 
assist with the feasibility outcomes. 
Exercise and activity 
Both physical capability and activity levels during free-living conditions were 
measured during this study, each recorded at 0, 12 and 24 weeks. 
8. Measurement of physical capability was undertaken using the modified 
incremental shuttle walk test (MSWT) (281). This modification of the 
incremental shuttle walk test has been shown to strongly correlate with 
peak VO2 levels when compared with cardiopulmonary exercise testing in 
sarcoidosis patients (240). It allows those with minimal cardiopulmonary 
impairment to be adequately stressed. This provides benefit over a 6MWT; 
methylphenidate has not been shown to significantly improve 6MWT 
measurements (173). This may be because as a self-paced test it is a sub-
maximal exercise test – this has been shown to be the case in a study of ILD 
patients (including sarcoidosis) where peak oxygen uptake, CO2 uptake and 
ventilation were all lower during 6MWT than on cardiopulmonary exercise 
testing (282). Using the MSWT overcomes these limitations.  
The test was performed on a 10 metre track, with two cones spaced 0.5 
metres short of each end of the course, which the participant walked 
around to travel 10 metres per shuttle, in line with instructions for the test 
(240). Two assessors were present to confirm that the correct number of 
shuttles was reported and to provide support in the event of difficulties. 
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9. Measurement of physical activity was undertaken using wrist-worn 
GENEActiv Original (Activinsights, Cambridgeshire, UK); these are the 
devices piloted in the previous chapter.  
A device was worn for three 7-day periods; at the beginning of the study 
(prior to any medications), at 12 weeks +/- 2 weeks, and within 2 weeks of 
the end of the study (24 weeks).  
 
Safety assessment 
Documentation of any adverse event occurred at each visit. In addition, a clinical 
assessment was undertaken at each visit to seek and identify any adverse effect or 
concern about patient safety. Participant reported problems/side effects were 
recorded to collect safety data regarding extended use of methylphenidate in a 
sarcoidosis population. The following were recorded: 
1. Number and severity of adverse events recorded during the trial. 
2. Number of participants that developed ECG abnormalities during the 
trial. 
3. Number of participants that developed abnormalities on blood tests 
(liver function, kidney function) and required discontinuation of the trial. 
 
 
Participant timeline 
A participant going through the trial was seen or contacted at the following time-
points: 
1) Screening visit (Visit (-1)); two weeks before starting medication 
2) Baseline visit at week 0 (Visit (0)); 2-week drug supply dispensed 
3) Phone call at week 1 (check for adverse events) 
4) Visit 1 at 2 weeks; Safety measures and uptitration if appropriate, 2-week 
drug supply 
5) Phone call at week 3 (check for adverse events) 
6) Visit 2 at 4 weeks; Safety measures, 2-week drug supply 
Chapter 4: Fatigue and Sarcoidosis – Treatment with Methylphenidate (FaST-MP) feasibility study 
methods 
   128
7) Phone call at week 5 (check for adverse events) 
8) Visit 3 at 6 weeks; Safety and clinical measurements, 6-week drug supply 
9) Phone call at week 8 (check for adverse events) 
10) Phone call at week 10 (check for adverse events) 
11) Visit 4 at 12 weeks; Safety and clinical measures, including measurements 
of activity and exercise, 6-week drug supply. Participants randomised after 
02/02/2018 discontinue study medications after this visit. 
12) Phone call at week 14 (check for adverse events) 
13) Phone call at week 16 (check for adverse events) 
14) Visit 5 at 18 weeks; Safety and clinical measures, 6-week drug supply. 
Participants randomised between 01/12/2017 and 02/02/2018 discontinue 
study medications after this visit. 
15) Phone call at week 20 (check for adverse events) 
16) Phone call at week 22 (check for adverse events) 
17) Final study visit at 24 weeks; Clinical measurements, including 
measurements of activity and exercise. 
18) Questionnaires measured at 30 weeks (sent by post and returned via post) 
19) [OPTIONAL] Focus group discussion regarding trial participation 
experience (at least 6 weeks after finishing the study) 
In total, participants were required to attend eight visits across the 24-week trial 
period, plus one optional extra visit for the focus group discussions, and they also 
received nine phone calls from the study team. The Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) diagram overleaf (Table 14) 
summarises the study visits and the assessments made at each one, although the 
diagram does not show the planned phone calls participants received at week 1, 3, 
5, 8, 10, 14, 16, 20 and 22. 
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Table 14 – SPIRIT diagram of events occurring within the FaST-MP trial 
 Enrolment Allocation Post-allocation Close-out 
TIMEPOINT -2 weeks   0 weeks  
2 w
eeks  
(+/- 3 days) 
4 w
eeks  
(+/- 3 days)  
6 w
eeks 
(+/ - 3 days)  
12 w
eeks 
(+/ - 1 w
eek) 
18 w
eeks 
(+/ - 1 w
eek) 
24 w
eeks 
(+/ - 1 w
eek)  
+4-8 
weeks 
ENROLMENT:          
Eligibility screen X X        
Informed consent  X         
Allocation  X        
Declaration of understanding 
(prior to receiving IMP)  X        
INTERVENTIONS:          
Methylphenidate 
(X = uptitrate dose) 
(O = drug dispensed) 
 
O 
 
O 
X 
O 
 
O 
 
O 
 
O 
 
 
 
 
Placebo 
(X = uptitrate dose) 
(O = drug dispensed) 
 
O 
 
O 
X 
O 
 
O 
 
O 
 
O 
 
 
 
 
ASSESSMENTS:          
Safety bloods 
(FBC/LFT/U+Es) X  X X X X    
Safety questionnaire  X X X X X X   
Pregnancy test X X        
ECG X  X X X X  X  
Spirometry  X    X  X  
Modified Shuttle Walk Test  X    X  X  
Accelerometer (7 days) X     X  X  
QUESTIONNAIRES:          
- FAS X X X X X X X X X 
- FACIT-F  X X X X X X X X 
- HADS  X   X X X X X 
- Short Form-36  X   X X X X X 
- EQ5D  X   X X X X X 
- KSQ  X   X X X X X 
- Costs  X    X  X  
- PSQI  X    X  X X 
- Exit 
Questionnaire        X  
Focus group (post-trial)         X 
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The timeline shows the study visits for participants recruited prior to 01/12/2017. 
Due to a lower than anticipated recruitment rate, participants entering the study 
after 01/12/2017 received a reduced period of study medication. Participants 
randomised between 02/12/2017 and 12/01/2018 received study medications for 
18 weeks, and discontinued the study medication at visit 5. Participants randomised 
between 13/01/2018 and 02/03/2018 received study medications for 12 weeks and 
discontinued the study medication at visit 4. In both cases, participants still 
completed postal questionnaires six weeks after completing study medications. This 
amendment was made to increase recruitment time and maximise participation in 
the study. 
 
Assignment of intervention 
Allocation sequence generation 
The allocated treatment for a patient was generated via computer-written code. A 
randomisation sequence with a 3:2 ratio in favour of methylphenidate was 
generated. Allocation was determined based upon block randomisation using 
blocks of five with stratification by severity of fatigue (FAS 22-34 and FAS 35-50). No 
other factors were used to adjust randomisation given the single-centre nature, 
small number of participants included and primary objective of assessment of 
feasibility. The randomisation sequence was generated by a statistician within 
Norwich CTU. 
 
Randomisation method and concealment 
Allocation (randomisation) was performed by a process embedded in a web-based 
data management system. This was designed using REDCap, a secure web-
application for managing databases.  The randomisation code was saved in the study 
database for emergency unblinding purposes. When a patient was randomised, the 
database automatically generated and sent an e-mail to the NNUH trial pharmacy to 
allow medication dispensing. Within the pharmacy, labels identifying group were 
used, with the group identifier then removed before medication was dispensed. This 
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system enabled blinding of the research team and participants during randomisation 
and medication dispensing. 
 
Blinding 
This was a double-blind study. The placebo and active treatments appear identical 
and were dispensed in identical containers. All trial patients, care providers, outcome 
assessors and data analysts remained blind to treatment throughout the study. The 
trial pharmacists at the NNUH were aware of the treatment group due to unequal 
arm size; they did not disclose the group allocation to any of the trial team and 
medication labels did not reference the group to which the participant was allocated; 
this data was contained on a tear-off strip which was removed prior to dispensing to 
the study team. During study monitoring and auditing, pharmacy monitoring was 
performed by a member of staff from the clinical trials unit; this ensured no member 
of the clinical or trial team within the NNUH was unblinded throughout the study. 
 
Emergency unblinding 
In the event of any of the following events, it was permitted for unblinding of an 
individual’s allocated treatment to be performed: 
 To enable treatment of severe adverse event/s, or 
 In the event of an overdose 
Where possible, requests for emergency or unplanned unblinding of individuals were 
made via the trial manager and agreement of the Chief Investigator was then sought. 
However, in circumstances where there was insufficient time to make this request or 
for agreement to be sought, it was possible for the treating clinician to request that 
the participant’s allocation was unblinded. The chief investigator was then required 
to authorise this, which could then be done through the REDCap research database. 
In the event of unblinding, it was required that the details of the request and the 
individuals alerted to the allocation be recorded and reported to Norwich Clinical 
Trials Unit (NCTU) by the chief investigator, including the identity of all recipients of 
the unblinding information. 
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Data management 
Data was entered into the approved FaST-MP database by a member of the trial 
team. Participants were given a unique trial Participant Identification Number (PIN). 
Data was entered under this identification number onto the central database stored 
on the servers based at NCTU. The database was password protected and only 
accessible to members of the trial team, as well as external regulators if requested.  
The identification, screening and enrolment logs, linking participant identifiable 
data to the pseudoanonymised Participant Identification Number (PIN), were held 
locally by the trial site in the form of a written case report form held alongside 
clinical notes in a locked filing cabinet within the respiratory research department 
at the NNIJH. 
At the end of the study, following entry of the last data, the database was locked 
and underwent data verification; this entailed a review of 10% of the data points 
compared with the paper case report forms and questionnaires to ensure data 
accuracy. Following data verification, the data were unblinded for analysis. 
 
Data monitoring and trial oversight 
Trial steering committee 
An independent trial steering committee (TSC) was convened to be responsible for 
the oversight of the trial, including safeguarding the interests of trial participants. 
The TSC provided guidance to the chief investigator (CI) and the sponsor on all 
aspects of the trial through the independent chairperson. A terms of reference 
document was drafted to specify the membership, activities, and authority, which 
all members of the TSC were required to approve and sign. Meetings of the TSC 
occurred every six months whilst the trial was open, with a final meeting once the 
trial was closed and analysed. A total of four meetings were held. 
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Safety committee 
A safety committee (SC) monitored adverse events occurring within the trial. This 
was convened rather than a full Data Monitoring and Ethics Committee (DMEC) due 
to the small nature of the study. The SC met every six months (three meetings were 
held in total) and reviewed the adverse events that were reported by each 
participant. The SC were provided with the allocation group for each participant to 
aid their decision making; no member of the trial team was present during this part 
of the SC meeting to avoid unblinding. 
Following each SC meeting, which took place one month prior to each TSC meeting, 
a report was generated for the TSC stating their assessment of whether the trial 
should be allowed to continue. 
 
Safety Reporting 
Definitions 
Definitions of harm from the EU directive 2001/20/EC Article 2 were used for this 
trial. The definitions of adverse events are shown in table 15. All adverse events 
were assessed for the strength of causal relationship between the study medication 
and each event. The definitions used for assessment of these relationships are 
shown in table 16. 
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Table 15 - Definitions of harm, adapted from EU directive 2001/20/EC Article 2 
Definition Description 
Adverse Event (AE) Any untoward medical occurrence in a patient or clinical trial 
participant administered a medicinal product and which does not 
necessarily have a causal relationship with this product. 
Adverse Reaction (AR) Any untoward and unintended response within a participant to the 
investigational medicinal product related to any dose administered. 
Unexpected Adverse 
Reaction (UAR) 
An adverse reaction, the nature or severity of which is not consistent 
with the summary of product characteristics (SPC). 
Serious Adverse Event 
(SAE) or Serious 
Adverse Reaction (SAR) 
Any AE or AR that at any dose: 
• results in death  
• is life threatening 
• requires hospitalisation or prolongs existing hospitalisation 
• results in persistent or significant disability or incapacity 
• is a congenital anomaly or birth defect 
• or is another important medical condition 
Life threatening refers to an event in which the patient is at risk of 
death at the time of the event; it does not refer to an event that might 
hypothetically cause death if it was more severe. 
Hospitalisation is defined as a non-elective in-patient admission, 
regardless of length of stay, even if the hospitalisation is a 
precautionary measure for continued observation. 
Suspected Unexpected 
Serious Adverse 
Reaction (SUSAR) 
A serious adverse reaction, the nature and severity of which is not 
consistent with the information about the medicinal product in 
question set out in the Summary of Product Characteristics (SmPC). 
 
 
 
 
 
Table 16 - Causality definitions 
Relationship Description 
Unrelated There is no evidence of any causal relationship 
Unlikely to be related There is little evidence to suggest that there is a causal relationship or 
there is another reasonable explanation for the event  
Possibly related There is some evidence to suggest a causal relationship. However, the 
influence of other factors may have contributed to the event. 
Probably related There is evidence to suggest a causal relationship and the influence of 
other factors is unlikely 
Definitely related There is clear evidence to suggest a causal relationship and other 
possible contributing factors can be ruled out. 
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Capturing safety data 
Adverse events for each participant were captured from the date of the first dose 
of study medications until 30 days after the last treatment dose (as per the 
research study protocol). Events occurring between consent and the first 
administered dose were not recorded as AEs as the participant had not been 
exposed to treatment beyond normal care. 
For each participant an AE form was kept, recording each AE experienced during 
the study. Each event recorded a description of the medical problem, the severity 
of the event defined using the Common Terminology Criteria for Adverse Events 
(CTCAE) v4.0 grading, assessment of relationship to the study medication, action 
taken (none, medication temporarily stopped, medication permanently stopped) 
and outcomes. Events were recorded at each follow-up visit and phone call, or 
recorded when brought to the attention of the investigators if the participant 
contacted the study team between scheduled visits. 
 
Adverse event reporting 
All SAEs were reported to NCTU and the NNUH Research and Development office 
within 24 hours of the trial team becoming aware of the event. For each event 
occurring, a report was completed including an assessment of the relationship 
between study medication and the event to determine if the event was an SAE, SAR 
or SUSAR. Any participant suffering an SAE, SAR or SUSAR was followed up until 
clinical recovery was complete or the event had stabilised, with follow-up forms 
completed and returned to NCTU to provide further information as it became 
available.  
NCTU was delegated the duties of reporting SUSARs and other SARs. Any fatal or 
life-threatening SUSAR experienced during the study was required to be reported to 
regulatory authorities (MHRA) within seven days of NCTU becoming aware of the 
event; for all other SUSARs, events had to be reported within 15 days. 
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Expected adverse events with Methylphenidate 
The summary of product characteristics (SmPC) document for Methylphenidate 
Hydrochloride (Tranquilyn) 10mg tablets lists the potential adverse events that 
have been reported during clinical trials and post-market spontaneous reports for 
this medication and other methylphenidate hydrochloride formulations. The 
expected adverse drug reactions documented in the SmPC are summarised in Table 
17, including the estimated frequency of event occurrence. 
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Table 17 - Frequency estimates of adverse drug reactions for methylphenidate 
hydrochloride 
Frequency  Adverse event 
Very common 
(≥1 in 10) 
Insomnia, nervousness; Headache. 
Common (≥1 
in 100, <1 in 
10) 
Naso-pharyngitis; Anorexia, decreased appetite; Affect lability, aggression, 
agitation, anxiety, depression, irritability, abnormal behaviour; Dizziness, 
dyskinesia, psychomotor hyperactivity, somnolence; Arrhythmia, tachycardia, 
palpitations; Hypertension; Cough, pharngolarygeal pain; Abdominal pain, 
diarrhoea, nausea, stomach discomfort and vomiting (usually occur at start of 
treatment and are alleviated by concomitant food intake), dry mouth; Alopecia, 
pruritis, rash, urticaria; Arthralgia; Pyrexia; Changes in blood pressure and heart 
rate (usually an increase), weight decreased. 
Uncommon 
(≥1 in 1000, 
<1 in 100) 
Hypersensitivity reactions, anaphylactic reactions, auricular swelling, bullous 
conditions, exfoliative conditions, urticarias, pruritis, rashes and eruptions; 
Psychotic disorders, auditory, visual and tactile hallucinations, anger, suicidal 
ideation, mood alteration, mood swings, restlessness, tearfulness, tics, 
worsening of pre-existing tics, hypervigilance, sleep disorder; Sedation, tremor; 
Diplopia, blurred vision; Chest pain; Dyspnoea; Constipation; Hepatic enzyme 
elevations; Angioneurotic oedema, bullous conditions, exfoliative conditions; 
Myalgia, muscle twitching; Haematuria; Chest pain, fatigue; Cardiac murmur. 
Rare (≥1 in 
10,000, <1 in 
1000) 
Mania, disorientation, libido disorder; Difficulties in visual accommodation, 
mydriasis, visual disturbance; Angina pectoris; Hyperhidoriss, macular rash, 
erythema; Gynaecomastia. 
Very rare (≤1 
in 10,000) 
Anaemia, leucopenia, thrombocytopenia, thrombocytopenic purpura; Suicidal 
attempt, transient depressed mood, abnormal thinking, apathy, repetitive 
behaviours, over-focussing; Convulsions, choreo-athetoid movements, 
reversible ischaemic neurological deficit, neuroleptic malignant syndrome; 
Cardiac arrest, myocardial infarction; Cerebral arteritis and/or occlusion, 
peripheral coldness, Raynaud’s phenomenon; Abnormal liver function, including 
hepatic coma; Erythema multiforme, exfoliative dermatitis, fixed drug eruption; 
Muscle cramps; Sudden cardiac death; Blood alkaline phosphatase increased, 
Blood bilirubin increased, platelet count decrease, white blood cell decrease. 
Not known 
(cannot be 
estimated 
from the 
available data) 
Pancytopenia; Delusions, thought disturbances, confusional state, logorrhoea; 
Cerebrovascular disorders (including vasculitis, cerebral haemorrhages, 
cerebrovascular accidents, cerebral arteritis, cerebral occlusion), grand mal 
seizures, migraine; Supraventricular tachycardia, bradycardia, ventricular 
extrasystoles, Extrasystoles; Erectile dysfunction; Chest discomfort, 
hyperpyrexia. 
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Data Analysis 
Primary outcomes (feasibility) 
Primary data analysis assessed the feasibility outcomes described in primary 
outcomes. A screening log was maintained of all patients reviewed against the 
study eligibility criteria, including patient demographics and reason for exclusion. A 
second screening log was kept of eligible patients contacted for the study. The 
results of both logs were presented as a Consolidated Standards of Reporting Trials 
(CONSORT) flow-chart of patient flow into the study; baseline characteristics of 
these patients were presented to compare the characteristics of excluded patients, 
eligible patients who declined participation, and patients included in the study. For 
participants who received their allocated intervention, baseline characteristics were 
presented according to their treatment allocation. 
Recruitment rate was calculated by capturing the number of new participants 
entering the study each calendar month and presenting a cumulative total across 
the recruitment period. Retention rate was calculated through determining the 
number of participants who completed the full period of IMP. An AE log was 
maintained through the study; the number of AEs occurring in each arm was then 
determined at the end of the study and presented by severity and category group. 
A calculation of the number of unfilled assessments was performed as a percentage 
of the total number of assessments made; any questionnaire which featured a 
missing data point was marked as unfilled, thereby giving the most conservative 
estimate of assessment completion. At the end of the study, the participant and the 
assessor indicated which allocation group they believed the participant had been 
assigned; accuracy of this was calculated as a percentage of the total number of 
participants that correctly guessed their allocation.  
Safety data was summarised by frequency of system affected using CTCAE v4.0 
definitions. The total number of individual AEs, including severity grade, were also 
reported. 
Post-trial review of participant perception was assessed using exit questionnaires 
and focus groups after study completion. The exit questionnaire is included in 
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appendix 5; the total number of participants who would wish to continue the IMP 
(if given the option), and who found the study beneficial, was calculated as a 
percentage of the total number of participants. A series of qualitative assessments 
of participant perception was undertaken using three moderated and audio-
recorded focus groups; the full methods for this aspect of the study, and the 
results, are discussed in chapter 6.  
 
Medication adherence 
Adherence to study treatment was measured in the form of returned tablet counts, 
which was monitored as part of drug accountability at each visit. The number of 
capsules remaining was counted at each visit, as well as a calculation of the number 
of capsules expected to remain (for example, a participant receiving two capsules 
twice daily and seen exactly 14 days after the previous study visit, having been 
dispensed 56 capsules at that visit, would be expected to have zero capsules 
remaining). Adherence was determined at each visit.  To account for potential 
expected remaining capsules (for participants who were seen early in their potential 
visit window), the difference between number of returned capsules and expected 
remaining capsules was calculated first. This value was used to determine adherence 
to the prescribed treatment. The formula for this is described below:  
 !"ℎ$%$&'$	(%)= 1 − /01. %$34%&$"	'56748$7 − 9:6$'3$"	%$;5<&<&=	'56748$7>1358	&4;?$%	1@	'56748$7	"<76$&7$" A:100	 
 
As well as calculating the adherence to study medications as a percentage of doses 
taken, the number of participants considered adherent to their medication was 
calculated by determining the number of participants meeting 80% adherence, the 
threshold for sufficient adherence to treatment (283).  
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In addition, ECGs and observations (blood pressure and pulse) taken through the trial 
were reviewed post trial to observe any changes which may give an indication of 
adherence. 
 
Secondary outcomes (clinical efficacy) 
Estimation of clinical effect size was evaluated using the mean difference in fatigue 
scores (FAS and FACIT-Fatigue). In addition, mean differences in change of KSQ 
health status, anxiety and depression scores (HADS-A and HADS-D), health utility 
scores from EQ5D and SF36, patient reported health status from EQ-VAS, and sleep 
quality and efficiency (PSQI) were estimated. Analysis was performed using an 
intention-to-treat approach. For each measurement, the baseline score was 
measured during the baseline study visit (week 0); the only exception is the FAS 
score, which used the average value of their screening and baseline scores as this 
was felt more likely to reflect each participant’s average fatigue score over time. 
Activity data from the GENEActiv devices were analysed in two ways. Firstly, the 
raw data were analysed using the software GGIR within R-studio to determine the 
wear time and the amount of time spent in moderate or vigorous activity (MVPA). 
This was determined from previous work establishing the threshold values for 
MVPA using the GENEActiv device, identified as an ENMO value of 93.2milli-g 
determined from the device’s accelerometer (257). Values for were determined for 
total time spent above this threshold for MVPA, as well as values adjusted for 
World Health Organization recommendations on “bouts” of MVPA time; this was 
defined in this study as at least 80% of any ten-minute period with activity intensity 
above the threshold for moderate activity (284). Moderate and vigorous activity 
thresholds for the activity monitor data were determined from previous work (257). 
Secondly, the raw data were converted to 15-second epoch data in comma 
separated value format by GENEActiv software (Activinsights, UK) and entered into 
a custom spreadsheet (“Sedentary Sphere”; A Rowlands (242, 243)) which 
calculated the number of minutes per day spent in sedentary behaviours based 
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upon posture classification and accelerometer output to determine when low-
intensity activity in a sitting, reclined or lying position was likely to be occurring.  
Only “valid” data, defined as a wear period more than ten hours per day for at least 
four of the seven days as used in previous studies (285), was used in analysis. The 
number of participants who wore the device for 24-hour periods on four or more 
days of the wear period was also recorded. 
 
Statistical analysis 
Participant flow 
A two-stage CONSORT flow diagram was constructed to display the flow of patients 
through screening, enrolment and allocation. The first stage described the 
participant screening including the number of participants excluded, including 
reasons for exclusion or reasons for declining participation among patients who 
were otherwise eligible. The second stage described the enrolment, allocation and 
progression through the study, including patient withdrawal. 
 
Outcomes and statistical analysis 
An exploratory analysis of the clinical data captured during the study was 
undertaken on an intention to treat (ITT) basis, including all participants who 
received trial medication. Plots were constructed for each outcome, displaying the 
mean scores by allocation group at each visit and the change over time. Mean 
differences between allocation group were compared initially at each 6-week time 
point using a two-sample t-test (unadjusted analysis), with further analysis of the 
data using a general linear regression model to adjust the between-group mean 
difference for baseline values of the analysed outcome and level of baseline fatigue, 
the latter factor to balance for stratification of fatigue severity at baseline. In the 
case of the fatigue outcomes (FAS and FACIT-Fatigue instruments) which both have 
defined MCIDs, the number and proportion of participants meeting the MCID at 
each 6-week time point, compared with baseline values, was calculated. Data 
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analysis was undertaken using Stata statistical software version 14 (StataCorp, 
Texas, USA). 
 
Substantial amendment 
After four months of recruitment it became apparent that the recruitment rate was 
below that expected. In order to increase the recruitment period, two amendments 
were made. Firstly, the ability to recruit participants from PIC sites in the eastern 
region was added, with Royal Papworth Hospital and Addenbrooke’s hospital 
operating in this capacity. Secondly, in order to increase the recruitment phase (and 
maximise the time participants could enter the study without reducing the overall 
study duration), follow-up for participants recruited between December 2017 and 
March 2018 was truncated. Participants randomised between 01/12/2017 and 
01/02/2018 received study medication for 18 weeks, plus an additional two weeks 
if a down-titration period at the end of the study was required; participants 
randomised between 02/02/2018 and 02/03/2018 received study medication for 12 
weeks, plus an additional two weeks if down-titration was required. The last date of 
follow-up was fixed at 06/07/2018.  
As part of this substantial amendment, two additional outcome measures were 
added. The PSQI and Exit questionnaires were administered to patients entering the 
study after 23/05/2017 according to the questionnaire schedule in table 1; 
participants who had already commenced the study were administered the 
additional questionnaires if they consented to completing these additional 
measurements. 
 
Trial approvals 
The FaST-MP trial was registered with the clinicaltrials.gov database (registration 
number NCT02643732) on 31/12/2015. Research Ethics Committee (REC) approval 
was first gained on 21/06/2016 (East of England Cambridge Central Research Ethics 
Committee, REC reference 16/EE/0087). MHRA approval (EudraCT number 2016-
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000342-60) was initially gained on 26/08/2016. The study was registered with the 
NIHR clinical research network portfolio (central portfolio management system ID 
32754).  
The substantial amendment described earlier was approved by REC on 21/04/2017, 
also requiring Health Research Authority (HRA) approval at that time due to 
changes in the REC and local site-specific approval since the initial application. HRA 
approval was gained on 21/04/2017, with MHRA approval for the amendment on 
23/05/2017. 
 
4.3 Conclusions 
In this chapter, the methods for the FaST-MP study are described; these methods 
were published (286) after study opening to ensure greater transparency of the 
research process, helping identify where changes may have been made during the 
undertaking of the study and reduce bias in reporting outcomes. In the next 
chapter, the outcomes from the study are reported and discussed.  
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Chapter 5: Fatigue and Sarcoidosis – Treatment with 
Methylphenidate (FaST-MP) feasibility study results 
 
 
Clinical Trial Registry – Registered with clinicaltrials.gov 
Registry number - NCT02643732 
Research Ethics Committee (REC) Approval Gained 
REC reference – 16/EE/0087 
Medicines and Healthcare Products Regulatory Agency Clinical Trial Authorisation 
EudraCT Number – 2016-000342-60  
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5.1 Introduction 
The previous chapter described the methods for the FaST-MP study, including the 
substantial amendment which was submitted after the study opened. In this 
chapter, the results of the quantitative data collected within the study are 
described in detail, including for the primary outcomes surrounding the feasibility 
of an appropriately-sized phase III study investigating the clinical efficacy of 
methylphenidate for sarcoidosis-associated fatigue, the safety data recorded, and 
the exploratory clinical outcomes recorded in both the methylphenidate and 
placebo arms. 
 
5.2 Results 
Screening and enrolment 
A total of 385 patients with sarcoidosis were evaluated against the inclusion and 
exclusion criteria between 07/11/2016 and 02/03/2018. Of these, 329 were 
excluded prior to being approached. The remaining 56 patients were approached 
about participating in the study, of which 23 were included in the study and 
underwent randomisation – one randomised participant was randomised in error 
after being found to be ineligible due to breaching an exclusion criteria 
(hyperthyroidism) between randomisation and receiving their allocated 
intervention. The number of people who were excluded or declined to participate 
in the study, including reasons why, are shown in the CONSORT flow chart (Figure 
7). 
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Figure 7 - CONSORT flow-chart part 1: participant enrolment 
 
 
Of the 385 participants assessed for eligibility, six were referred from other centres 
and did not receive their usual care at the NNUH. In total, 379 patients were 
identified as having sarcoidosis and receiving follow-up by the respiratory medicine 
department at the NNUH.  
Within the 379 NNUH patients assessed, 169 (44.6%) had reported fatigue or 
related symptoms (tiredness, lack of energy) during previous clinical visits. The 
most common cause for exclusion amongst patients reporting fatigue was active 
disease requiring ongoing changes to treatment (“Not stable disease”), with cardiac 
disease being the most common alternative medical condition preventing inclusion 
Excluded     329 
¨   Not sufficiently fatigued 216 
¨   Not stable disease  38 
¨   Cardiac disease  32 
¨   Contraindicated medication 13 
¨   Alternative cause for fatigue 11 
¨   Seizures   6 
¨   Liver disease   3 
¨   Glaucoma   2 
¨   Thyroid disease  1 
¨   Unable to give informed consent
    1 
¨   Unconfirmed diagnosis 1 
¨   Pregnant   1 
¨   Prior reaction to stimulant 1 
¨   Psychiatric disease  1 
¨   Pulmonary hypertension 1 
¨   End stage renal failure 1 
Enrolment 
Declined    19 
¨   Side effect profile  4 
¨   Too many visits  4 
¨   Perceived fatigue not severe enough
    3 
¨   Moving away   3 
¨   Considering pregnancy 2 
¨   Did not give reason  2 
¨   Already received stimulant 1 
Unable to contact  14 
 
Assessed for eligibility (n= 385) 
- Under NNUH Care = 379 
- Referral from other centre = 6 
Approached (n= 56) 
Randomised (n= 23*) 
*One randomised patient was found to be ineligible (thyroid abnormality) after 
randomisation but before receiving allocated intervention 
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in the study (n = 32). Of the six patients referred from other centres, two were 
excluded from the study before randomisation; one had glaucoma and one had a 
history of seizures. A total of 52 eligible patients were identified from the NNUH 
patient population, representing 13.7% of the hospital’s population with pulmonary 
sarcoidosis. Of these 52 eligible patients from the NNUH sarcoidosis cohort, 33 
patients (63.5%) declined to take part or were unable to be contacted by the study 
team and 19 (36.5%) consented to participate. In total, only 5.0% of the NNUH 
sarcoidosis cohort were eligible and willing to participate.  
Over the 16 months that the study was open to recruitment, the average monthly 
recruitment rate was 1.4 participants per month (including recruitment from 
outside the NNUH), or 1.2 participants per month from the NNUH population alone. 
 
Comparison of characteristics between patient groups 
To determine if the participants included in the study were significantly different 
from other patients with sarcoidosis, clinical characteristics of these patients were 
compared with the clinical data of those who were not included in the study. All 
patients who were assessed for inclusion in the study were split into three groups; 
those who were not fatigued or did not describe fatigue as a significant problem 
(group 1), those who reported fatigue as a clinical problem but who met one or 
more of the exclusion criteria for the study (group 2), and those who reported 
fatigue as a problem but declined to participate in the study (group 3). The clinical 
characteristics for each group are shown in Table 18.  No statistical tests were 
applied between groups; apparent differences between groups considered 
potentially significant are highlighted in bold.
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Table 18 - Characteristics of non-fatigued, fatigued but ineligible, fatigued but declined participation and eligible randomised participants  
Abbreviations: BMI – Body Mass Index; FEV1 – Forced Expiratory Volume in 1 second; FVC – Forced Vital Capacity; DLCO – Diffusing capacity of the lungs for carbon monoxide (single-breath 
hold); KCO – Transfer co-efficient of carbon monoxide; CXR – Chest X-Ray; sACE – Serum Angiotensin Converting Enzyme 
*23 participants were randomised but one participant was discovered to be ineligible prior to receiving the intervention; their details are included in Group 2.  
 Group 1 – Non-fatigued Group 2 – Fatigued, Ineligible Group 3 – Fatigued, Eligible, 
Declined 
Group 4 – Fatigued, Eligible, 
Randomised 
Number (% total cohort) 216 (56.1) 114 (29.6) 33 (8.6) 22 (5.7)* 
Age 56.8 (14.6) 54.9 (13.5) 49.3 (12.5) 56.0 (9.2) 
Female sex (%) 91 (42.1) 50 (43.8) 20 (60.6) 9 (40.9) 
Caucasian (%) 210 (97.7) 113 (99.1) 30 (90.9) 22 (100) 
BMI 32.8 (8.1) 32.6 (7.9) 30.4 (7.7) 31.5 (5.8) 
FEV1 (% predicted) 91.5 (23.0) 84.2 (22.7) 92.6 (14.7) 92.7 (23.7) 
FVC (% predicted) 99.8 (20.6) 91.5 (21.0) 98.1 (16.2) 100.0 (21.9) 
DLCO (% predicted) 77.9 (22.4) 72.7 (19.3) 84.1 (9.3) 74.1 (20.0) 
KCO (% predicted) 90.6 (23.7) 90.3 (18.8) 97.5 (12.8) 101 (11.3) 
Disease duration (years) 9.1 (8.8) 7.4 (9.6) 4.7 (4.6) 7.8 (7.1) 
Pulmonary disease (%) 212 (98.1) 113 (99.1) 32 (100) 22 (100) 
Extrapulmonary disease 65 (30.1) 47 (41.2) 9 (27.3) 9 (40.9) 
Initial CXR stage 0/1/2/3/4 (%) 22/85/38/45/10 
(11/42.5/19/22.5/5) 
15/42/20/24/5 
(14.2/39.6/18.9/22.6/4.7) 
3/16/5/5/0 
(10.3/55.2/17.2/17.2/0) 
4/10/2/1/1 
(22.2/55.6/11.1/5.6/5.6) 
sACE (presentation) 67.6 (42.0) 84.7 (66.4) 61.4 (28.7) 50.4 (27.6) 
sACE (latest) 55.2 (31.2) 58.7 (40.8) 52.4 (20.1) 42.5 (19.3) 
Calcium (presentation) 2.43 (0.19) 2.49 (0.29) 2.45 (0.15) 2.43 (0.10) 
Calcium (latest) 2.41 (0.10) 2.42 (0.10) 2.39 (0.08) 2.43 (0.09) 
Receiving steroids (%) 
- Mean dose (mg) 
44 (20.4) 
- 7.4 (4.3) 
63 (55.2) 
- 15.4 (9.1) 
3 (9.1) 
- 15.7 (12.5) 
5 (22.7) 
- 10.3 (6.9) 
Receiving other 
immunosuppressant (%) 
15 (6.9) 19 (16.7) 5 (15.2) 3 (13.6) 
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Participant recruitment and retention 
Of the 23 participants recruited to the study, 19 were recruited from patients under 
the care of the NNUH, equating to 5.0% of the sarcoidosis patient population at the 
NNUH. Four participants recruited from other centres were randomised, although 
one patient was found to be ineligible after randomisation and did not receive the 
allocated intervention (placebo); this patient was not included in the analysis. The 
study was open for recruitment between the 7th November 2016 and 2nd March 
2018, a total of 16 months. Recruitment across the period varied significantly; the 
highest recruitment for a single month was five participants, which occurred in 
March 2017 and February 2018. The mean recruitment rate was 1.4 participants 
per month, ranging between 0 and 5 participants per month. 
Of the 23 participants randomised within the study, one was excluded after 
randomisation due to the patient being randomised in error (found to have 
hyperthyroidism requiring treatment after randomisation but prior to receiving 
study medications). The remaining 22 participants received their allocated 
intervention, and all completed their planned study visits. Due to the previously 
described substantial amendment, not all participants completed the same 
duration of follow-up. Participants 1-16 completed the full 24-week follow-up 
period, covering eight study visits, as well as returning data six-weeks after study 
completion. Participant 17 completed 18-weeks follow up (seven study visits plus 
post-trial questionnaires) and the remaining participants completed 12-weeks 
follow-up (six visits plus post-trial questionnaires). The flow-chart for participant 
progress through the study is shown in Figure 8.  
All patients who received their allocated intervention completed all scheduled 
visits. One participant discontinued trial medications due to cardiac-type chest pain 
at week 20 but completed their planned visits.  
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Figure 8 - CONSORT flow chart part 2: allocation, follow-up and analysis 
 
 
Baseline characteristics 
The baseline characteristics of the participants who received their allocated 
intervention in the study are shown in Table 19. Baseline characteristics were well 
balanced between groups, although a greater proportion of females were seen in 
the placebo group (57.1% vs 33.3% in the methylphenidate arm). A greater 
proportion of the placebo group were also receiving treatment for their disease at 
the time of randomisation (57.2% vs 26.7%). The baseline scores for each outcome 
measure are shown in Table 20. In keeping with the number of participants in the 
Analysed     (n= 15) 
Excluded from analysis   (n= 0) 
Completed 12-week visit   (n=15) 
   - Final visit truncated at 12 weeks  (n=10) 
Completed 18-week visit   (n=11) 
   - Final visit truncated at 18 weeks  (n=1) 
Completed 24-week visit   (n=10) 
Lost to follow-up    (n=0) 
Post-trial questionnaires returned  (n=13) 
 
Allocated to methylphenidate  (n=15) 
- Received allocated intervention  (n=15) 
Did not receive methylphenidate (n=0) 
Completed 12-week visit  (n=7) 
   - Final visit truncated at 12 weeks (n=1) 
Completed 18-week visit  (n=6) 
   - Final visit truncated at 18 weeks (n=0) 
Completed 24-week visit  (n=6) 
Lost to follow-up   (n=0) 
Post-trial questionnaires returned (n=7) 
 
Allocated to placebo   (n= 8) 
- Received allocated intervention  (n= 7) 
Did not receive placebo  
- Breached exclusion criteria  (n=1) 
Analysed     (n=7) 
Excluded from analysis 
   - Did not receive placebo   (n=1) 
Randomized (n=  23) 
Discontinued 
intervention (n=1) 
- Adverse event (n=1) 
Discontinued 
intervention (n=0) 
Allocation, follow-up 
and analysis 
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placebo group receiving immunosuppression, pulmonary function was worse in the 
placebo group than in the methylphenidate group; this was reflected in a lower 
lung-related disease-specific health status (KSQ-Lung) score (58.8 vs 43.7). Baseline 
physical activity levels varied significantly within groups but were lower (by total 
time in MVPA) in the placebo group than the methylphenidate group (87.4 
minutes/day vs 105.7 minutes/day). 
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Table 19 - Baseline characteristics by group 
Variable 
Methylphenidate 
(n = 15) 
Placebo 
(n=7) 
Age at randomisation (years) 55.5 (10.1) 55.4 (7.7) 
Gender (%) 
 Male 
 Female 
 
10 (66.7) 
5 (33.3) 
 
3 (42.9) 
4 (57.1) 
Smoking status (%) 
 Current 
 Ex 
 Never 
 
0 (0.0) 
4 (26.7) 
11 (73.3) 
 
0 (0.0) 
3 (42.9) 
4 (57.1) 
Smoking history (pack years) 17.5 (14.2) 6.7 (4.9) 
Alcohol intake (units/week) 5.3 (7.6) 4.7 (10.3) 
Body Mass Index (kg/m2) 30.3 (4.5) 33.8 (7.6) 
Weight (kg) 94.0 (16.8) 94.0 (21.3) 
Blood pressure, systolic (mmHg) 
Blood pressure, diastolic (mmHg) 
145.4 (16.3) 
88.7 (10.7) 
135.6 (24.7) 
85.9 (9.7) 
Pulse (beats per minute) 73.5 (16.4) 75.9 (9.8) 
Disease duration at randomisation 
(years) 
 >3 years 
 1-3 years 
 <1 year 
6.7 (7.1) 
9 (60.0) 
2 (13.3) 
4 (26.7) 
6.0 (7.8) 
4 (57.1) 
2 (28.6) 
1 (14.3) 
Pulmonary disease (%) 15 (100.0) 7 (100.0) 
Extrapulmonary disease (%) 9 (60.0) 3 (42.9) 
Ethnicity 
 Caucasian 
 
15 (100.0) 
 
7 (100.0) 
Current treatment for sarcoidosis 
 Prednisolone 
 Methotrexate 
 Azathioprine 
 4 (26.7) 
3 (20.0) 
1 (6.7) 
0 (0.0) 
 4 (57.2) 
1 (14.3) 
2 (28.6) 
1 (14.3) 
Values presented as means (standard deviations) or frequencies (%) 
Abbreviations: kg – kilograms; m – metres; mmHg – millimetres of mercury  
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Table 20 - Baseline scores in each outcome measure by group 
Outcome (baseline score) Methylphenidate Placebo 
FAS score1 
 FAS score 22-34 (%) 
 FAS score 35-50 (%) 
35.9 (7.7) 
7 (46.7) 
8 (53.3) 
35.9 (8.8) 
3 (42.9) 
4 (57.1) 
FACIT-Fatigue score1 19.9 (11.0) 20.0 (10.8) 
HADS-A2 
HADS-D2 
7.8 (3.3) 
7.9 (2.9) 
8.0 (4.9) 
6.6 (4.5) 
EQ5D Utility3 
EQ-VAS (mm)3 
SF-6D Utility3 
0.694 (0.271) 
62.5 (21.9) 
0.613 (0.094) 
0.679 (0.244) 
68.0 (12.9) 
0.559 (0.164) 
KSQ General Health Status4 
KSQ Lung4 
KSQ Medications4 
KSQ Skin4 
KSQ Eyes4 
KSQ Composite4 
48.8 (12.8) 
58.8(16.5) 
86.0 (20.3) 
86.0 (21.4) 
66.7 (21.5) 
54.2 (7.7) 
47.1 (11.8) 
43.7 (15.8) 
85.6 (23.2) 
87.5 (17.3) 
62.6 (22.5) 
50.0 (6.7) 
PSQI Score5 
Sleep efficiency (% of night asleep) 
8.9 (4.1) 
86.9 (27.7) 
13.5 (3.4) 
55.4 (15.9) 
FEV1 (percentage of predicted value) 
FVC (percentage of predicted value) 
99.5 (24.1) 
104.3 (21.7) 
79.1 (19.0) 
88.6 (18.4) 
MSWT (m) 522.7 (330.9) 438.6 (353.6) 
Sedentary time (minutes/day) 
MVPA (minutes/day) 
MVPA10 (minutes/day)6 
644.4 (152.8) 
105.7 (68.3) 
19.0 (25.4) 
602.5 (118.7) 
87.4 (43.9) 
4.6 (5.0) 
Values presented as means (standard deviations) or frequencies (%) 
Abbreviations: FAS – Fatigue Assessment Scale; FACIT – Functional Assessment of Chronic illness 
therapy; EQ5D – EuroQoL 5 Dimension, 5 level; EQ-VAS – EuroQoL Visual Analogue Scale; SF6D – 
Short form 6 dimension; KSQ – Kings Sarcoidosis Questionnaire; PSQI – Pittsburgh Sleep Quality 
Index; FEV1 – Forced Expiratory Volume in 1 second; FVC – Forced Vital Capacity; MSWT – Modified 
Shuttle Walk Test; MVPA – Moderate or Vigorous Physical Activity 
1Fatigue score values; Higher FAS scores indicate greater levels of fatigue, lower FACIT-Fatigue 
scores indicated greater levels of fatigue 
2Depression and anxiety scores; Higher scores indicate greater level of anxiety or depression 
symptoms 
3Health utility scores; Higher values indicate greater health utility (greater quality of life) 
4Disease specific quality of life; Lower values indicate greater problems with health related to 
sarcoidosis. Each subscale relates to an organ system potentially affected by sarcoidosis, the 
composite value considers all organ systems and general health status. 
5PSQI score indicates overall quality of sleep – lower values indicate better quality.  
6MVPA10 = Activity only counted if >80% of any 10 minute period above threshold for MVPA 
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Medication adherence 
Adherence to study medications was excellent throughout the study. Median 
adherence to prescribed medications across each group was never lower than 96%. 
Levels of adherence were similar between groups (Table 21), with all but one 
participant meeting at least 80% adherence with prescribed medications; this 
participant was included in the analysis. No changes in adherence levels were seen 
over the duration of the study to suggest adherence reduced at any point during 
the study. 
 
Table 21 - Adherence rates to study medication (% adherence) by allocation group 
for period (weeks) and overall adherence 
  Methylphenidate Placebo 
Week n Median % (IQR) ≥80% n Median % (IQR) ≥80% 
0-2 15 100 (95-100) 13 (87) 7 100 (100-100) 7 (100) 
2-4 15 100 (96-100) 15 (100) 7 100 (99-100) 7 (100) 
4-6 15 98 (93-100) 14 (93) 7 100 (97-100) 7 (100) 
6-12 15 99 (96-100) 13 (87) 7 100 (99-100) 6 (86) 
12-18 11 100 (98-100) 10 (91) 6 100 (99-100) 5 (83) 
18-24 10 96 (89-100) 8 (80) 6 97 (91-100) 6 (100) 
Overall 15 98 (90-100) 15 (100) 7 99 (97-100) 6 (86) 
 
Data completeness 
Data completeness was excellent throughout, with no single instrument having 
greater than 5% missing data. The missing data rate across all data points was only 
2.6%, indicating that participants could reliably complete the questionnaires 
despite many instruments being administered simultaneously at most study visits. 
The completion rate for other measures was also good, although there was a 
problem with loss of facilities to safely undertake the MSWT towards the end of the 
study; for this reason, six MSWT (10% of the total data points) were not 
undertaken. Only one other MSWT was not undertaken; this was due to a 
participant feeling unable to undertake the test due on the day. Only three data 
points were missing for the activity monitors; two missing data points were due to 
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the devices not being worn (zero data on device), the other was a non-returned 
device which was lost in the process of being returned. The full range of missing 
data points for the clinical outcomes are shown in Table 22.  
 
 
Table 22 - Completion rates for questionnaires and other outcomes performed 
during the study, including missing data rate 
Outcome Expected data points - n Missing Data points - n (%) 
FAS 165 2 (1.2) 
FACIT-Fatigue 165 2 (1.2) 
HADS 121 4 (3.3) 
KSQ 121 3 (2.5) 
EQ5D 121 3 (2.5) 
SF36 121 4 (3.3) 
Costs (Health economics) 60 2 (3.3) 
Safety1 104 5 (4.8) 
PSQI2 43 2 (4.7) 
Spirometry (FEV1 and FVC)3 60 3 (5.0) 
MSWT4 60 7 (11.7) 
Activity monitor data5 60 3 (5.0) 
Total 1142 30 (2.6) 
Acronyms: FAS – Fatigue Assessment Scale; FACIT-Fatigue – Functional Assessment of Chronic Illness 
Therapy – Fatigue; HADS – Hospital Anxiety and Depression Scale; KSQ – Kings Sarcoidosis 
Questionnaire; EQ5D – EuroQoL 5 Dimension 5 Level scale; SF36 – Short Form 36; PSQI – Pittsburgh 
Sleep Quality Index; FEV1 – Forced Expiratory Volume in 1 second; MSWT – Modified shuttle walk 
test 
1Safety questionnaire was administered up to week 12; participants completing a truncated time 
period who completed study medications at week 12 did not all receive safety questionnaires at their 
final visit (4 out of 5 missing data points). 
2PSQI only administered following major amendment approved in April 2017; expected data points 
refers to the number of visits where the questionnaire should have been administered after the study 
amendment was approved. 
3All missing spirometry values occurred in a single participant who was unable to perform the test 
without suffering syncope; spirometry was not performed for this participant 
4Six of the seven missing MSWT values occurred due to loss of facilities to undertake the test 
5Missing data points for activity watches refers to an unreturned device (1 missing data point) or 
device not worn during wear period (2 missing data points).  
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Medication safety and tolerability 
Medication down-titration and discontinuations 
Three participants (13.6%) required down-titration of their study medications and 
one participant (4.5%) required discontinuation of study medications. The three 
participants that required dose reduction decreased from 20mg (2 capsules) twice 
daily to 10mg (1 capsule) twice daily for reasons of significant anxiety (participant 3, 
week 6), increased and severe fatigue (participant 13, week 6) and dry mouth 
causing significant discomfort (participant 19, week 10). The participant who 
discontinued study medications suffered cardiac-type chest pain at week 22; this 
participant had previously reduced to 10mg twice daily due to significantly 
increased fatigue on the higher dose. Subsequent investigations did not identify a 
cardiac event as a cause for the pain, but the participant did not re-start 
medications. In addition, three participants did not increase their dose from 10mg 
to 20mg twice daily due to personal choice; in each case they felt that they had a 
good response to medications and did not wish to increase the dose further.  
All dose reductions and withdrawals occurred in the methylphenidate group; all 
seven participants in the placebo group tolerated 2 capsules twice daily through the 
entire study and no patients required discontinuation of medications. 
 
Adverse events 
Across the 22 participants, 96 adverse events were observed including one serious 
adverse event. All but one participant developed an AE during the course of the 
study; the only participant who did not suffer an AE was allocated methylphenidate 
and was adherent to the medication throughout the study. The commonest 
systems affected were the nervous system, respiratory system and gastrointestinal 
system. The number of participants developing at least one AE in each organ 
system is shown in Table 23; the total number of adverse events stratified by organ 
system and severity is shown in table 24. 
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No cardiac events occurred during the study and no participants developed ECG 
abnormalities during the trial.  
One SAE occurred during the study. This was an episode of syncope which appeared 
unrelated to the study medications; the participant was investigated for possible 
cardiac problems or arrhythmia but none were found and the participant was able 
to continue the study medications to the end of the study. 
 
 
 
 
 
Table 23 - Adverse event rates by treatment allocation; number of participants in 
each arm developing at least one AE within each individual organ system 
CTCAE System Class 
Methylphenidate 
Number of participants 
with ≥1 event (%) 
Placebo 
Number of participants 
with ≥1 event (%) 
Ear and labyrinth  2 (13.3) 0 
Eye  1 (6.7) 3 (42.9) 
Gastrointestinal  7 (46.7) 1 (14.3) 
General disorders  2 (13.3) 2 (28.6) 
Infections and infestations 1 (6.7) 1 (14.3) 
Investigations 2(13.3) 0 
Metabolism and nutrition  1 (6.7) 0 
Musculoskeletal  5 (33.3) 1 (14.3) 
Nervous system  10 (66.7) 3 (42.9) 
Psychiatric  5 (33.3) 3 (42.9) 
Respiratory 7 (46.7) 6 (85.7) 
Reproductive system and breast  1 (6.7) 0 
Skin and subcutaneous tissue  4 (26.7) 1 (14.3) 
Vascular disorders 2 (13.3) 0 
Any 14 (93.3) 7 (100.0) 
Abbreviations: CTCAE – Common Terminology Criteria for Adverse Events 
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Table 24 - Total number of adverse events occurring (including percentage of total within each treatment allocation) by organ system 
 Methylphenidate (n=15) Placebo (n=7) 
CTCAE Organ Class Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Ear and labyrinth  2 (2.7) 0 0 0 0 0 0 0 0 0 
Eye  1 (1.4) 0 0 0 0 3 (13.0) 0 0 0 0 
Gastrointestinal  13 (17.8) 2 (2.7) 0 0 0 1 (4.3) 0 0 0 0 
General disorders  2 (2.7) 2 (2.7) 0 0 0 1 (4.3) 1 (4.3) 0 0 0 
Infections and infestations 1 (1.4) 0 0 0 0 0 1 (4.3) 0 0 0 
Investigations 2 (2.7) 0 0 0 0 0 0 0 0 0 
Metabolism and nutrition  1 (1.4) 0 0 0 0 0 0 0 0 0 
Musculoskeletal  3 (4.1) 2 (2.7) 0 0 0 0 1 (4.3) 0 0 0 
Nervous system  14 (19.2) 1 (1.4) 1 (1.4) 0 0 3 (13.0) 0 0 0 0 
Psychiatric  2 (2.7) 3 (4.1) 0 0 0 2 (8.7) 2 (8.7) 0 0 0 
Respiratory 9 (12.3) 4 (5.5) 0 0 0 6 (26.1) 1 (4.3) 0 0 0 
Reproductive system and breast  2 (2.7) 0 0 0 0 0 0 0 0 0 
Skin and subcutaneous tissue  2 (2.7) 2 (2.7) 0 0 0 0 1 (4.3) 0 0 0 
Vascular disorders 1 (1.4) 1 (1.4) 0 0 0 0 0 0 0 0 
Any adverse event 55 (75.3) 17 (23.3) 1 (1.4) 0 0 16 (69.6) 7 (30.4) 0 0 0 
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Safety monitoring was undertaken throughout the study for all participants, 
consisting of measurements of blood pressure, pulse and weight at weeks 2, 4, 6, 
12 and 24.  Mean baseline systolic blood pressure was 10mmHg higher in the 
methylphenidate group than the placebo group (145.4mmHg vs 135.8mmHg) but 
there were no differences in mean diastolic blood pressure, pulse rate or weight at 
baseline between the two arms.  
Figure 9 shows the change in recorded weight at each visit compared with baseline 
weight. No change was seen in the placebo arm compared with baseline (mean 
change 0.3kg increase) whereas the methylphenidate group saw a mean reduction 
in weight by 2.9kg. Weight loss is a known side effect of methylphenidate and this 
difference is an expected effect of the treatment. 
No differences were seen in changes in systolic blood pressure, diastolic blood 
pressure or resting pulse rate (Figure 10) over the duration of the study in either 
arm; data was unavailable at week 30 as this time-point consisted of questionnaires 
returned via post only. 
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All participants provided weight recordings at week 0, 2, 4, 6, 12 and 24.  
Values for each visit after week 0 denote change from baseline value 
−2
0
−1
5
−1
0
−5
0
Ch
an
ge
 in
 F
AS
 sc
or
e
0 2 304 6 12 18 24
Week
Methylphenidate Placebo
Figure 9 - Change in weight (kg) across the duration of the study, stratified by 
treatment arm. Results are mean values with 95% confidence intervals 
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Acronyms: BP – Blood pressure; mmHg – millimetres of mercury 
All participants provided systolic BP, diastolic BP and pulse recordings 
at week 0, 2, 4, 6, 12 and 24.  
Values for each visit after week 0 denote change from baseline value 
A 
B 
C 
Figure 10 - Change in systolic BP (A), diastolic BP (B) and pulse rate (C) compared 
with baseline values across the duration of the study, stratified by treatment arm. 
Results are mean values with 95% confidence intervals 
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Participant-reported problems and side-effects were captured using five-point likert 
scales within a safety questionnaire. The results are shown are shown in Figure 11, 
displayed as median, interquartile range and total range of participant-reported 
values across the study, where participants were receiving medications.   
No differences were seen between the two arms of the study, either in cardiac or 
non-cardiac symptoms. In keeping with the sleep quality and efficiency results, 
methylphenidate did not lead to increased problems with sleep onset or sleep 
maintenance compared with the placebo arm. The score for cardiac symptoms 
(palpitations and chest pains) was slightly higher in the placebo arm compared with 
the methylphenidate arm (median score 0 vs 1 for both palpitations and chest 
pain).  
The results suggest that participants receiving methylphenidate did not develop 
symptomatic cardiac problems during the study. This is in keeping with the ECG 
data, with no participants developing new ECG abnormalities during the course of 
the study in either arm. 
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Safety questionnaire scores (likert scale, 1-5) reported by participants whilst receiving 
methylphenidate or placebo. 
Higher scores indicate greater problems. 
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Figure 11 - Box and whisker plots denoting reported problems in the safety 
questionnaire (likert scales) whilst receiving medications. Plots are split into cardiac-
related symptoms (A) and non-cardiac symptoms (B). The central box represents the 
interquartile range 
Chapter 5: Fatigue and Sarcoidosis – Treatment with Methylphenidate (FaST-MP) feasibility study 
results 
 163 
Activity monitor use 
There were 60 planned wear periods across the 22 participants who received study 
medications. The data regarding device return rates and data validity are shown in 
Table 25. Three data points (5.0% of all wear periods) were missing from the 
activity monitor data – two were due to the participant failing to wear the device at 
any point during the monitoring period and one was due to loss of device during 
the process of returning the monitor. The missing device was never recovered. Of 
the remaining data, two participants failed to wear the activity monitor for 
sufficient duration to calculate at one time period apiece; in total, five data points 
were missing to the extent that no activity data could be calculated for that period. 
Data validity was defined as any participant wearing the activity monitor for at least 
10 hours across four days. Fifty-four wear periods recorded sufficient data to be 
considered valid (90.0% of the total wear periods, 98.2% of devices that returned 
any data). Of the participants who returned valid data, the majority had worn their 
device for full 24-hour periods; between 86.7% and 95% of participants returning 
minimum valid data had worn the device for at least four full 24-hour periods. 
 
 
 
Table 25 - Activity monitor data relating to device return rates and data validity 
Period No. participants 
Devices 
returned (%) 
Any data 
returned (%) 
Minimum valid 
data1 (%) 
Wear for 24h 
periods2 
Week 0 22 22 (100.0) 20 (90.9) 20 (90.9) 19 (95.0) 
Week 12 22 21 (95.5) 20 (90.9) 19 (86.4) 17 (89.5) 
Week 24 16 16 (100.0) 15 (93.8) 15 (93.8) 13 (86.7) 
Total 60 59 (98.3) 55 (91.7) 54 (90.0) 49 (90.7) 
1Defined as at least 10 hours of wear time per 24 hours in at least two weekdays and two weekend 
days 
2The number of participants returning minimum valid data who wore the device for 24-hour periods 
on at least four days of the wear period 
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Secondary clinical outcomes 
Fatigue 
Baseline fatigue scores were well-balanced between arms. The baseline FAS score 
was 35.9 in both arms and the baseline FACIT-fatigue score was 19.9 in the 
methylphenidate arm and 20.0 in the placebo arm. Both groups showed a reduction 
in fatigue, scored by both the FAS and FACIT-Fatigue scores, although a greater 
mean improvement in both fatigue scores was seen in the placebo arm. 
Figure 12 shows the changes in both FAS and FACIT-Fatigue scores from baseline 
values plotted over time and stratified by allocation group. The mean change at 
each time point is greater than the MCID for each questionnaire in both groups, 
although the extent of change in both fatigue scores is greater in the placebo arm 
than in the methylphenidate arm. The size of effect appears similar throughout all 
visits, suggesting that the effect seen from the medications in each arm was 
sustained. Both groups showed increases in fatigue levels at 6 weeks post-
medication (week 30 time-point). The mean value for the placebo arm remained 
below the MCID for both questionnaires whereas the methylphenidate arm showed 
a return to near-baseline FAS scores, suggesting any effect seen whilst receiving the 
trial medication did not persist on discontinuing medications.  
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Week 30 time-point includes all data for participants returning data six-weeks after 
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FAS – Higher scores = worse fatigue; FACIT-Fatigue – Lower scores = worse fatigue 
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Figure 12 - Change in fatigue scores (FAS (A) and FACIT-Fatigue (B) questionnaires) 
from baseline values over time, stratified by allocation. Results are mean values 
with 95% confidence intervals 
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Tables 26 and 27 show the mean scores during study follow-up and the between-
group differences for the FAS and FACIT-Fatigue questionnaires respectively, both 
unadjusted and adjusted for baseline fatigue severity. The results of the unadjusted 
between-group analysis showed that the FAS score was lower in the placebo arm, 
1.92 to 6.20 points less than the methylphenidate arm, consistent with lower levels 
of fatigue in the placebo group. The FACIT-Fatigue scores showed a similar trend; 
participants in the placebo arm had a higher FACIT-Fatigue score, consistent with 
lower fatigue levels, compared with those allocated methylphenidate (between 
0.69 and 10.17 points higher in the placebo arm whilst receiving medications).  
Adjustment of the between-group differences for baseline values of each outcome 
led to some modification of the results. Participants allocated to methylphenidate 
had a higher FAS score than those receiving placebo, on average, whilst receiving 
the medication, varying between 1.7 and 6.2 points greater, consistent with higher 
fatigue levels in the methylphenidate arm; at six-weeks after discontinuing 
medications the placebo arm had an adjusted mean FAS score 7 points lower than 
the methylphenidate group (95% CI 1.3, 12.8 points), consistent with significantly 
lower fatigue post-trial. The FACIT-Fatigue scores in the methylphenidate arm were 
between 0.4 and 9.2 points lower than the placebo arm, also consistent with higher 
fatigue levels in participants allocated methylphenidate; at 24 weeks the between-
group difference was significant (9.2 points, 95% CI -17.8, -0.6 points).  
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Table 26 - Fatigue scores measured by Fatigue Assessment Scale (FAS) 
questionnaire during follow-up, including between-group differences 
 Methylphenidate Placebo Unadjusted difference1,2 Adjusted difference
1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 15 35.9 (7.7) 7 35.9 (8.8) 0.0 -7.7, 7.6 - - 
6 15 29.4 (11.5) 7 24.4 (9.2) 5.0 -5.4, 15.4 4.6 -2.9, 12.0 
12 15 29.1 (9.4) 7 27.1 (12.9) 1.9 -8.2, 12.0 1.7 -5.4, 8.7 
18 11 28.3 (9.3) 6 23.2 (7.0) 5.1 -4.2, 14.4 4.5 -3.1, 12.0 
24 10 28.2 (8.7) 6 22.0 (8.6) 6.2 -3.4, 15.8 6.2 -1.4, 13.7 
30 13 32.7 (9.5) 7 27.6 (12.1) 5.1 -5.2, 15.4 7.0 1.3, 12.8 
Higher values indicate greater reported fatigue symptoms. 
1Mean difference is equivalent to the methylphenidate group value minus the placebo group value. 
Positive values indicate the methylphenidate group value was higher than the placebo group, 
negative values indicate the methylphenidate group value was lower than the placebo group.  
2Between-group difference tested using two-sample t-test with equal variance 
3Between-group difference tested using linear regression analysis performed with adjustment for 
baseline fatigue severity and FAS score at visit 0 
 
 
 
 
 
Table 27 - Fatigue scores measured by Functional Assessment of Chronic Illness 
Therapy - Fatigue (FACIT-Fatigue) questionnaire during follow-up, including 
between-group differences 
 Methylphenidate Placebo Unadjusted difference1,2 Adjusted difference
1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 15 19.9 (11.0) 7 20 (10.8) -0.1 -10.5, 10.3 - - 
6 15 27.9 (15.3) 7 33.7 (13.2) -5.9 -19.9, 8.2 -5.5 -15.3, 4.2 
12 15 28.6 (13.1) 7 29.3 (17.6) -0.7 -14.6, 13.2 -0.4 -9.1, 8.2 
18 11 30.2 (13.3) 6 36.0 (12.6) -5.8 -19.9, 8.3 -4.5 -14.9, 5.9 
24 10 29.0 (10.7) 6 39.2 (11.8) -10.2 -22.5, 2.1 -9.2 -17.8, -0.6 
30 13 23.9 (11.8) 7 28.3 (18.1) -4.4 -18.8, 9.6 -6.9 -14.7, 1.0 
Lower values indicate greater reported fatigue symptoms. 
1Mean difference is equivalent to the methylphenidate group value minus the placebo group value. 
Positive values indicate the methylphenidate group value was higher than the placebo group, 
negative values indicate the methylphenidate group value was lower than the placebo group.  
2Between-group difference tested using two-sample t-test with equal variance 
3Between-group difference tested using linear regression analysis performed with adjustment for 
baseline fatigue severity and FACIT-Fatigue score at visit 0 
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Table 28 shows the number of participants in each arm reaching the MCID for the 
FAS (reduction of 4 points) and the FACIT-Fatigue (increase of 3 points) instruments. 
Similar proportions of participants in each arm met the MCID at each time point, 
although fewer participants who had received methylphenidate continued to meet 
the MCID for either FAS or FACIT-Fatigue 6 weeks after discontinuing medications 
(30 weeks). 
 
Table 28 - Number of participants, stratified by allocation arm, achieving the MCID 
for FAS and FACIT-Fatigue measurements of fatigue, compared with their baseline 
values for each instrument, at the end of each 6-week study period 
 Methylphenidate Placebo 
Week n FAS FACIT-Fatigue n FAS 
FACIT-
Fatigue 
6 weeks 15 10 (66.6) 10 (66.7) 7 7 (100.0) 6 (85.7) 
12 weeks 15 11 (73.3) 11 (73.3) 7 5 (71.4) 5 (71.4) 
18 weeks 11 8 (72.7) 10 (90.9) 7 6 (100.0) 5 (83.3) 
24 weeks 10 8 (80.0) 8 (80.0) 6 5 (83.3) 5 (83.3) 
30 weeks 13 6 (46.2) 7 (53.8) 7 5 (71.4) 5 (71.4) 
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Anxiety and Depression 
Baseline levels of anxiety symptoms were similar between groups. The mean 
baseline HADS-A score was 7.8 for participants allocated to methylphenidate and 
8.0 for those allocated to placebo. Depression symptom scores (HADS-D) were 
slightly higher in the methylphenidate arm than the placebo group (7.9 vs 6.6 
points). 
Figure 13 shows the HADS-A and HADS-D scores recorded by each arm plotted over 
the course of the study. The anxiety symptoms (HADS-A) reported by the 
participants allocated to the placebo arm reduced over the course of the study 
whereas the participants who received methylphenidate did not show much 
reduction from baseline on average. The progression of HADS-D scores did not 
differ between the methylphenidate and placebo arms, with only slight changes 
from baseline mean differences seen at each visit. 
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Number of participants per time-point: 
Methylphenidate: Week 0 – 15; Week 6 - 14, Week 12 - 15; Week 18 – 11; Week 24 – 10 
Placebo: Week 0 - 7, Week 6 - 6, Week 12 – 7; Week 18 – 6; Week 24 – 6 
Week 30 time-point includes all data for participants returning data six-weeks after 
completing medications (n=13 for methylphenidate arm, n=6 for placebo arm) 
Higher scores indicate greater problems 
A 
B 
Figure 13 - Change in anxiety (HADS-A) scores (A) and depression (HADS-D) scores (B) 
over time, stratified by allocation. Results are mean values with 95% confidence intervals 
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Both the HADS-A and HADS-D scores reduced over time in the placebo arm 
compared with the methylphenidate arm. Table 29 displays the data for HADS-A 
scores at each study visit, stratified by allocated treatment. The mean HADS-A score 
was between 2.5 and 4.4 points lower in the placebo arm than the 
methylphenidate arm, indicating a lower level of anxiety symptoms within the 
participants receiving placebo. This between-group difference was still present six 
weeks after completing trial medications (week 30). Adjustment for baseline HADS-
A values showed that the between-group difference became statistically significant, 
in favour of the placebo group, from week 12 and remained so for the duration of 
the study. 
 
 
 
Table 29 - Anxiety symptoms measured by the Hospital Anxiety and Depression 
Scale – Anxiety (HADS-A) score during follow-up, including between-group 
differences 
 Methylphenidate Placebo Unadjusted difference1,2 Adjusted difference
1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 15 7.8 (3.3) 7 8.0 (4.9) -0.2 -3.9, 3.5 - - 
6 14 7.1 (5.1) 6 4.0 (3.0) 3.1 -1.6, 7.9 1.9 -1.6, 5.3 
12 15 6.8 (3.9) 7 4.3 (4.3) 2.5 -1.2, 6.3 2.7 0.4, 5.0 
18 11 7.1 (3.6) 6 2.7 (2.7) 4.4 0.8, 8.1 4.3 1.8, 6.7 
24 10 5.6 (1.8) 6 2.2 (2.7) 3.4 1.0, 5.8 3.4 1.6, 5.3 
30 13 6.9 (3.7) 7 2.5 (2.5) 4.2 0.6, 7.8 3.6 0.6, 6.5 
Higher values indicate greater reported anxiety symptoms. 
1Mean difference is equivalent to the methylphenidate group value minus the placebo group value. 
Positive values indicate the methylphenidate group value was higher than the placebo group, 
negative values indicate the methylphenidate group value was lower than the placebo group.  
2Between-group difference tested using two-sample t-test with equal variance 
3Between-group difference tested using linear regression analysis performed with adjustment for 
baseline fatigue severity and HADS-A score at visit 0 
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The data for HADS-D scores across the study are displayed in Table 30. The 
between-group difference in HADS-D score varied between -0.7 and 3.2 points 
whilst receiving study medications, although there was a larger between-group 
difference in HADS-D scores compared with HADS-A scores at baseline (week 0). 
After six weeks without medications, the difference between HADS-D scores had 
widened, with the placebo group having a lower mean HADS-D score (4.2 points 
lower than the methylphenidate arm). After adjustment for severity of baseline 
fatigue there was little difference in the mean between-group differences, although 
the difference is significant in favour of the placebo arm at week 18; this difference 
does not remain significant at week 24, though the between group difference 
widens in favour of the placebo arm again after participants had discontinued 
medications for six weeks (week 30). The results did not show such an early and 
sustained improvement in HADS-D scores in favour of placebo as was seen with the 
HADS-A values, though. 
 
 
Table 30 - Depression symptoms measured by the Hospital Anxiety and Depression 
Scale – Depression (HADS-D) score during follow-up, including between-group 
differences 
 Methylphenidate Placebo Unadjusted difference1,2 Adjusted difference
1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 15 7.9 (3.0) 7 6.6 (4.5) 1.3 -2.0, 4.6 - - 
6 14 6.4 (5.2) 6 4.8 (3.6) 1.6 -3.4, 6.6 0.8 -3.4, 5.0 
12 15 6.9 (4.3) 7 7.6 (6.6) -0.7 -5.6, 4.2 -1.1 -5.5, 3.3 
18 11 6.9 (3.1) 6 3.8 (2.1) 3.1 -0.1, 6.2 3.2 0.5, 5.9 
24 10 6.4 (2.5) 6 3.2 (5.0) 3.2 -0.8, 7.2 2.7 -1.3, 6.7 
30 13 8.1 (3.8) 7 3.8 (4.6) 4.2 -0.1, 8.4 4.3 1.5, 7.1 
Higher values indicate greater reported symptoms of depression. 
1Mean difference is equivalent to the methylphenidate group value minus the placebo group value. 
Positive values indicate the methylphenidate group value was higher than the placebo group, 
negative values indicate the methylphenidate group value was lower than the placebo group.  
2Between-group difference tested using two-sample t-test with equal variance 
3Between-group difference tested using linear regression analysis performed with adjustment for 
baseline fatigue severity and HADS-D score at visit 0 
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Disease-specific health status 
Scores from each subscale of the KSQ described patient-reported disease-related 
symptoms and health status. Baseline scores were similar for all subscales except 
the lung subscale; the participants allocated to placebo had lower scores than the 
methylphenidate group (mean score 43.7 vs 58.8, unadjusted mean difference 15.1 
points), consistent with a greater burden of lung-related symptoms in the placebo 
group than the methylphenidate group. This was in keeping with the lower 
spirometry values observed in the placebo group at baseline. 
The changes in scores for each KSQ subscale and the composite value are shown in 
Figure 14. Similar changes are seen over time for the skin, medicine, eye and 
composite scores (graphs C, D, E and F) over the course of the study. Slight 
divergence is seen in the general health status scores (graph A) between the two 
arms of the study after week 6; participants allocated to placebo saw an increase in 
this score whilst receiving medications (to week 24). This improvement was not 
sustained six-weeks after discontinuing medications (week 30), where no difference 
between the groups was seen. In the lung subscale scores (graph B), the placebo 
group saw an improvement in their scores over the duration of the study despite 
starting with a lower score than the methylphenidate group. Although there was a 
slight reduction in their lung subscale scores after stopping medications in the 
placebo arm, similar scores were seen in both arms at the end of the study, despite 
the placebo arm beginning with a lower mean score.  
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Figure 14 - Change in disease-specific health status according to KSQ values; General 
health status (A), Lung (B), Skin (C), Medications (D), Eyes (E) and Composite (F) 
score (encompassing general health state, lung, skin, medications and eye scores). 
Results are mean values with 95% confidence intervals 
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The unadjusted and adjusted between-group differences for each KSQ subscale are 
shown in table 31 and 32. For the general health status, divergence is seen between 
the groups in favour of the placebo arm, with a significant difference in values seen 
between the groups at week 18 and increasing at week 24 when adjusted for 
baseline fatigue severity (mean difference -14.9 points, 95% CI -23.7, -6.2).  
 
In the lung subscale, although both groups showed improvements in mean scores 
over the course of the study, the values show a narrowing of the mean difference 
over the course of the study. The initial mean difference was 15.1 points 
(unadjusted) in favour of the methylphenidate arm, narrowing over the duration of 
the study, with the mean difference at 24 weeks being 6.3 points (unadjusted) in 
favour of the placebo arm. Adjustment for baseline values increased the between-
group difference in favour of the placebo group, coming close to but not achieving 
statistical significance compared with the methylphenidate arm.  
 
Improvements were also seen in the composite KSQ outcome, with the adjusted 
analysis showing a significant improvement in favour of the placebo arm at week 
12, which increased in magnitude over the remainder of the duration the 
participants were receiving medications; at week 24 the mean KSQ composite score 
was 12.4 points lower in the methylphenidate arm (95% CI -20.6, -4.2), suggesting 
worse disease-related symptoms and health status compared with the placebo arm. 
This between-group difference persisted, albeit to a lesser extent, at six weeks after 
discontinuing intervention. 
 
The improvements seen in the placebo group during the 24 weeks of study 
medication showed some evidence of persistence compared with their baseline 
values. Both the placebo and methylphenidate groups saw improvements in KSQ 
general health status and lung scores at the end of the study compared with their 
baseline values, although the size of improvement was larger in the placebo group 
for both (10.0 vs 5.1 points and 18.1 vs 5.2 points for the lung and general health 
state scores respectively). 
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Table 31 - Disease-related health status (general health status, lung and skin 
subscales) measured by the Kings Sarcoidosis Questionnaire (KSQ) during follow-up, 
including between-group differences 
  Methylphenidate Placebo Unadjusted difference1,2 
Adjusted 
difference1,3 
 Week n Mean (S.D.) n 
Mean 
(S.D.) Mean 95% C.I. Mean 95% C.I. 
Ge
ne
ra
l H
ea
lth
 St
at
e 0 15 48.8 (12.8) 7 47.1 (11.8) 1.7 -10.2, 13.6 - - 
6 14 58.5 (20.7) 7 59.4 (16.5) -0.9 -19.7, 17.9 -4.0 -13.9, 6.0 
12 15 55.8 (14.7) 7 64.0 (26.2) -8.3 -26.3, 9.8 -10.3 -21,7, 1.1 
18 11 58.9 (12.7) 6 68.6 (15.6) -9.8 -24.6, 5.1 -9.7 -19.1, -0.2 
24 10 59.0 (14.4) 6 71.2 (13.1) -12.3 -27.7, 3.2 -14.9 -23.7, -6.2 
30 13 53.9 (13.1) 7 57.1 (28.8) -3.2 -22.7, 16.2 -8.8 -20.6, 3.1 
Lu
ng
 
0 15 58.8 (16.5) 7 43.7 (15.8) 15.1 -0.4, 30.7 - - 
6 14 64.3 (19.8) 7 52.2 (9.1) 12.1 -4.5, 28.7 0.3 -11.7, 12.3 
12 15 58.4 (18.0) 7 53.7 (30.5) 4.7 -16.8, 26.2 -11.5 -26.7, 3.7 
18 11 59.4 (16.0) 6 67.6 (16.9) -8.2 -25.8, 9.5 -11.7 -26.0, 2.6 
24 10 64.5 (20.8) 6 70.8 (15.9) -6.3 -27.5, 15.0 -16.7 -33.7, 0.2 
30 13 64.0 (24.1) 7 61.8 (24.0) 2.3 -21.5, 26.0 -11.9 -31.6, 7.8 
Sk
in
 
0 15 86.0 (21.4) 7 87.5 (17.3) -1.6 -20.9, 17.8 - - 
6 14 90.8 (13.6) 7 96.0 (6.8) -5.3 -16.8, 6.3 -4.7 -14.9, 5.5 
12 15 85.8 (17.1) 7 85.7 (17.2) 0.2 -16.2, 16.5 0.5 -15.9, 16.9 
18 11 91.2 (16.8) 6 87.9 (19.7) 3.3 -16.0, 22.6 5.5 -9.8, 20.9 
24 10 94.6 (9.3) 6 100 (0.0) -5.4 -13.7, 2.9 -4.4 -12.4, 3.7 
30 13 90.3 (15.4) 7 81.8 (25.4) 8.5 -10.5, 27.6 7.8 -9.2, 24.7 
Higher values indicate greater health-related quality of life and lower burden of disease-related 
symptoms. 
1Mean difference is equivalent to the methylphenidate group value minus the placebo group value. 
Positive values indicate the methylphenidate group value was higher than the placebo group, 
negative values indicate the methylphenidate group value was lower than the placebo group.  
2Between-group difference tested using two-sample t-test with equal variance 
3Between-group difference tested using linear regression analysis performed with adjustment for 
baseline fatigue severity and KSQ subscale scores at visit 0 
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Table 32 - Disease-related health status (medication and eye subscales, composite 
score of all subscales) measured by the Kings Sarcoidosis Questionnaire (KSQ) during 
follow-up, including between-group differences 
  Methylphenidate Placebo Unadjusted difference1,2 
Adjusted 
difference1,3 
 Week n Mean (S.D.) n 
Mean 
(S.D.) Mean 95% C.I. Mean 95% C.I. 
M
ed
ica
tio
n 
0 15 86.0 (20.3) 7 85.6 (23.2) -0.4 -19.9, 20.7 - - 
6 14 89.0 (18.5) 7 88.3 (16.7) 0.7 -16.7, 18.1 0.3 -12.7, 13.2 
12 15 88.5 (18.0) 7 77.3 (38.9) 11.2 -13.7, 36.1 11.1 -10.4, 32.7 
18 11 94.8 (8.9) 6 89.0 (17.1) 5.8 -7.4, 19.1 7.4 -7.2, 22.0 
24 10 94.3 (9.2) 6 90.5 (10.5) 3.8 -6.9, 14.5 4.4 -6.3, 15.1 
30 13 81.4 (27.0) 7 78.3 (36.9) 3.1 -27.0, 33.3 -0.4 -26.8, 26.0 
Ey
e 
0 15 66.7 (21.5) 7 62.6 (22.5) 4.1 -16.8, 25.0 - - 
6 14 66.4 (18.2) 7 61.5 (28.0) 4.8 -20.5, 30.2 2.8 -12.9, 18.5 
12 15 67.0 (13.5) 7 62.1 (33.9) 4.9 -15.9, 25.7 3.0 -16.4, 22.4 
18 11 67.2 (14.0) 6 71.9 (18.6) -4.7 -21.7, 12.3 -6.3 -21.5, 8.9 
24 10 68.4 (17.5) 6 73.3 (21.9) -4.9 -26.1, 16.3 -6.3 -29.3, 16.7 
30 13 66.6 (14.7) 7 71.2 (23.3) -4.7 -22.5, 13.1 -6.9 -19.4, 5.6 
Co
m
po
sit
e  
0 15 54.2 (7.7) 7 50.0 (6.7) 4.2 -2.8, 11.3 - - 
6 14 59.7 (11.7) 7 55.9 (8.2) 3.8 -6.6, 14.2 -2.4 -6.9, 2.2 
12 15 55.8 (8.6) 7 61.0 (21.0) -5.2 -18.1, 7.7 -11.1 -20.0, -2.2 
18 11 57.4 (7.6) 6 64.1 (12.4) -6.6 -16.9, 3.6 -8.6 -15.1, -2.1 
24 10 59.5 (11.9) 6 66.3 (10.6) -6.8 -19.5, 6.0 -12.4 -20.6, -4.2 
30 13 56.4 (10.5) 7 59.3 (19.1) -2.8 -16.6, 10.9 -9.6 -18.0, -1.2 
Higher values indicate greater health-related quality of life and lower burden of disease-related 
symptoms. 
1Mean difference is equivalent to the methylphenidate group value minus the placebo group value. 
Positive values indicate the methylphenidate group value was higher than the placebo group, 
negative values indicate the methylphenidate group value was lower than the placebo group.  
2Between-group difference tested using two-sample t-test with equal variance 
3Between-group difference tested using linear regression analysis performed with adjustment for 
baseline fatigue severity and KSQ subscale scores at visit 0 
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Health utility values 
Health utility values were derived from the EQ5D and SF-36 data (converted to SF-
6D scores for this purpose) using existing UK population conversion sets. Scores 
from the visual analogue scale of patient-reported health status (contained within 
the EQ5D questionnaire) was also included for comparison. The mean values for 
each measure across the study duration are shown in Figure 15. The EQ5D and SF-
6D-derived utility values show differences at baseline; the mean utility values from 
the EQ5D questionnaires at baseline was higher in both the methylphenidate and 
placebo arms, by 0.081 and 0.120 respectively.  
The performance of both the EQ5D and SF-6D appears similar across the study 
period, with an earlier divergence in SF-6D-derived values seen between the two 
groups compared with the EQ5D-derived values. The EQ-VAS scores do not show 
any difference between the two groups, with the change over time in the EQ-VAS 
scores appearing almost identical in the two arms.  
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Figure 15 - Change in health utility scores (EQ-5D and SF-6D-derived values) 
and EQ-VAS score (mm). Results are mean values with 95% confidence 
intervals 
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The mean differences between the SF-6D and EQ5D utility values are shown in 
Tables 33 and 34. The participant-reported health status from EQ-VAS, scored 
between 0 and 100, are shown in table 35.  Minimal differences were seen in the 
EQ-VAS scores across the study; adjusting for fatigue severity at baseline did not 
alter the results. Both the EQ5D and SF-6D utility values showed divergence 
between the two groups across the course of the study, with the magnitude of 
change similar between the two measures in the unadjusted comparison. The SF-
6D-derived utility values also showed divergence between the mean difference of 
the two groups at an earlier time-point compared with the EQ5D-derived values, 
with the adjusted values for baseline SF-6D utility values showing statistically 
significant differences between the methylphenidate and placebo arms at 12 
weeks, compared with 18 weeks for EQ5D-derived utility scores; both scores 
showed higher utility values in the placebo arm. A greater magnitude of difference 
between groups was seen in the SF-6D scores compared with the EQ5D scores. 
Six weeks after discontinuing study medications, small improvements in health 
utility values remain compared to baseline in EQ5D-derived utility values in both 
the methylphenidate and placebo arms (0.032 and 0.064 respectively). The SF-6D-
derived values behaved slightly differently; the placebo group maintained an 
improvement over baseline utility scores (0.118) whereas participants in the 
methylphenidate arm reported a lower utility score at 30 weeks using SF-6D values 
compared with baseline values (-0.016 compared with baseline). The adjusted 
analysis for the SF-6D showed a between-group difference at week 30 that was 
statistically significant, in favour of placebo, whereas the EQ5D values showed no 
difference between groups in either the adjusted or unadjusted analysis. 
The results suggest that the two quality of life measures used behaved slightly 
differently within the study, both in calculated baseline health status values and the 
change in utility scores across the trial visits, and that these derived utility values 
are different to participant-reported quality of life from the EQ-VAS score. 
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Table 33 - Health utility scores derived from the EQ5D instrument during follow-up, 
including between-group differences 
 Methylphenidate Placebo Unadjusted difference1,2 Adjusted difference
1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 15 0.694  (0.271) 7 
0.679  
(0.244) 
0.015 -0.237, 
0.266 
- - 
6 14 0.727  (0.281) 7 
0.754  
(0.364) 
-0.027 -0.327, 
0.272 
-0.036 -0.177, 
0.104 
12 15 0.733  (0.249) 7 
0.725  
(0.378) 
0.008 -0.273, 
0.289 
-0.005 -0.121, 
0.111 
18 11 0.746  (0.262) 6 
0.906  
(0.066) 
-0.160 -0.395, 
0.075 
-0.102 -0.195,  
-0.008 
24 10 0.817  (0.133) 6 
0.947  
(0.061) 
-0.129 -0.254, -
0.004 
-0.139 -0.214,  
-0.065 
30 13 0.726  (0.262) 7 
0.743  
(0.351) 
-0.017 -0.308, 
0.273 
-0.052 -0.209, 
0.104 
 
Table 34 - Health utility scores derived from the SF-6D instrument during follow-up, 
including between-group differences 
 Methylphenidate Placebo Unadjusted difference1,2 Adjusted difference
1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 15 0.613  (0.094) 7 
0.559 
(0.164) 0.054 
-0.060, 
0.169 - - 
6 14 0.658  (0.160) 6 
0.662 
(0.154) -0.004 
-0.158, 
0.149 -0.048 
-0.178, 
0.081 
12 15 0.617  (0.120) 7 
0.657 
(0.204) -0.040 
-0.184, 
0.103 -0.097 
-0.173,  
-0.021 
18 11 0.629  (0.084) 6 
0.744 
(0.127) -0.115 
-0.224, -
0.007 -0.135 
-0.209,  
-0.060 
24 10 0.631  (0.085) 6 
0.764 
(0.153) -0.132 
-0.259, -
0.006 -0.161 
-0.266,  
-0.056 
30 13 0.597  (0.108) 7 
0.677 
(0.204) -0.080 
-0.229, 
0.070 -0.130 
-0.217,  
-0.043 
Higher values indicate greater health status (1.0 = best imaginable quality of life, 0.0 = worst 
imaginable quality of life; states worse than 0.0, indicating a quality of life worse than death, are 
possible in the EQ5D-derived values). 
1Mean difference is equivalent to the methylphenidate group value minus the placebo group value. 
Positive values indicate the methylphenidate group value was higher than the placebo group, 
negative values indicate the methylphenidate group value was lower than the placebo group.  
2Between-group difference tested using two-sample t-test with equal variance 
3Between-group difference tested using linear regression analysis performed with adjustment for 
baseline fatigue severity and utility instrument score at visit 0 
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Table 35 - Participant-reported quality of life taken from the EQ-VAS instrument 
(within EQ5D) during follow-up, including between-group differences 
 Methylphenidate Placebo Unadjusted difference1,2 Adjusted difference
1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 15 62.5 (21.9) 7 68.0 (12.9) -5.5 -24.3, 13.2 - - 
6 14 62.2 (21.4) 6 60.3 (22.5) 1.9 -19.1, 23.0 2.9 -16.8, 22.7 
12 15 62.1 (19.9) 7 66.0 (21.4) -3.9 -23.4, 15.5 -3.6 -20.9, 13.6 
18 11 71.0 (19.1) 6 73.7 (19.8) -2.7 -23.6, 18.3 -3.3 -19.7, 13.1 
24 10 65.5 (24.4) 6 72.5 (22.9) -7.0 -33.4, 19.4 -7.6 -32.4, 17.2 
30 13 64.3 (20.9) 7 57.6 (24.6) 7.2 -15.1, 29.5 4.5 -10.7, 19.6 
Higher values indicate greater perceived health (100 = best imaginable quality of life, 0 = worst 
imaginable quality of life). 
1Mean difference is equivalent to the methylphenidate group value minus the placebo group value. 
Positive values indicate the methylphenidate group value was higher than the placebo group, 
negative values indicate the methylphenidate group value was lower than the placebo group.  
2Between-group difference tested using two-sample t-test with equal variance 
3Between-group difference tested using linear regression analysis performed with adjustment for 
baseline fatigue severity and utility instrument score at visit 0 
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Sleep quality 
Sleep quality through the trial was scored using the PSQI questionnaire and an 
assessment of sleep quality. Figure 16 shows the changes in sleep quality and PSQI 
scores for each group across the duration of the study. The number of data-points 
at each time point are lower than other measures as not all participants completed 
the PSQI questionnaire; the addition of this instrument occurred following a 
substantial amendment in April 2017, by which time nine participants had entered 
the study, two of which had completed all study visits. 
 
  
 
  
Number of participants per time-point: 
Methylphenidate: Week 0 - 9; Week 12 – 10; Week 24 – 8 
Placebo: Week 12 – 4; Week 18 – 4; Week 24 – 6 
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Figure 16 - Change in PSQI score and sleep efficiency (percentage of night 
asleep). Results are mean values with 95% confidence intervals 
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Sleep quality was worse at baseline in participants allocated to placebo, with higher 
mean PSQI scores and lower sleep efficiency compared with the methylphenidate 
group. Sleep quality and efficiency showed very slight worsening of values in the 
methylphenidate group although a modest improvement in sleep quality was seen 
in the placebo group. Sleep efficiency showed a modest increase in the placebo 
group, which was maintained to week 24. Tables 36 and 37 show the mean scores 
at each visit for both PSQI scores and sleep efficiency, as well as between-group 
differences (both unadjusted values and adjusted for baseline scores). No 
significant differences were seen between groups for either PSQI or sleep 
efficiency, although when adjusted for baseline values the placebo group saw small 
improvements in sleep quality (both PSQI and sleep efficiency) as the study 
progressed, relative to the methylphenidate group. 
The results suggest that methylphenidate use did not have a marked negative 
impact in sleep quality for participants in the study, either compared to the placebo 
group performance or relative to baseline values of sleep quality and efficiency. 
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Table 36 - Subjective sleep quality, taken from the PSQI instrument during follow-
up, including between-group differences 
 Methylphenidate Placebo Unadjusted difference1,2 Adjusted difference
1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 9 8.9 (4.1) 4 13.5 (3.4) -4.6 -9.8, 0.6 - - 
12 10 8.4 (4.0) 4 10.5 (6.5) -2.1 -8.2, 4.0 4.4 -3.2, 11.9 
24 8 9.8 (2.5) 6 10.8 (5.8) -1.1 -6.1, 3.9 0.9 -23.3, 25.1 
Higher values indicate worse perceived sleep quality 
1Mean difference is equivalent to the methylphenidate group value minus the placebo group value. 
Positive values indicate the methylphenidate group value was higher than the placebo group, 
negative values indicate the methylphenidate group value was lower than the placebo group.  
2Between-group difference tested using two-sample t-test with equal variance 
3Between-group difference tested using linear regression analysis performed with adjustment for 
baseline fatigue severity and PSQI score at visit 0 
 
 
 
Table 37 - Sleep efficiency (percentage of the time in bed spent asleep) during 
follow-up, including between-group differences 
 Methylphenidate Placebo Unadjusted difference1,2 Adjusted difference
1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 9 86.9 (27.6) 4 55.4 (15.9) 31.5 -1.6, 64.5 - - 
12 10 81.4 (15.4) 4 67.0 (18.8) 14.4 -6.6, 35.5 -12.4 -40.3, 15.4 
24 8 76.5 (12.4) 6 65.6 (22.4) 11.0 -9.3, 31.3 1.6 -64.7, 68.0 
Higher values indicate better sleep efficiency (higher percentage of the time in bed spent asleep) 
1Mean difference is equivalent to the methylphenidate group value minus the placebo group value. 
Positive values indicate the methylphenidate group value was higher than the placebo group, 
negative values indicate the methylphenidate group value was lower than the placebo group.  
2Between-group difference tested using two-sample t-test with equal variance 
3Between-group difference tested using linear regression analysis performed with adjustment for 
baseline fatigue severity and sleep efficiency at visit 0 
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Spirometry and Exercise (MSWT) 
Figure 17 displays the progression of spirometry results for each group over the 
course of the study. No significant changes were seen for either FEV1 or FVC over 
the duration of the study in either group, although values for both the 
measurements were lower at baseline in the placebo group compared with the 
methylphenidate group. 
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Figure 17 - Change in Forced Expiratory Volume in 1 second (FEV1) and Forced 
Vital Capacity (FVC) values during the trial. Results are mean values with 95% 
confidence intervals 
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Tables 38 and 39 show the mean values in each group alongside between-group 
differences. Although the FEV1 and FVC values were markedly higher in the 
methylphenidate group than the placebo group, no significant difference existed 
between them in the adjusted analysis. 
 
 
Table 38 - Forced Expiratory Volume in 1 second (FEV1) during follow-up, including 
between-group differences. Values are percentages of predicted values 
 Methylphenidate Placebo Unadjusted difference1,2 Adjusted difference
1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 14 99.5 (24.1) 7 79.1 (19.0) 20.4 -1.5, 42.2 - - 
12 10 98.4 (14.6) 6 78.3 (20.7) 20.1 3.9, 36.4 8.2 -2.2, 18.6 
24 10 94.5 (19.6) 6 80.0 (20.8) 14.5 -7.7, 36.7 6.4 -6.6, 19.3 
1Mean difference is equivalent to the methylphenidate group value minus the placebo group value. 
Positive values indicate the methylphenidate group value was higher than the placebo group, 
negative values indicate the methylphenidate group value was lower than the placebo group.  
2Between-group difference tested using two-sample t-test with equal variance 
3Between-group difference tested using linear regression analysis performed with adjustment for 
baseline fatigue severity and FEV1 at visit 0 
 
 
Table 39 - Forced Expiratory Volume in 1 second (FEV1) during follow-up, including 
between-group differences. Values are percentages of predicted values 
 Methylphenidate Placebo Unadjusted difference1,2 Adjusted difference
1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 14 104.3 (21.7) 7 88.6 (18.4) 15.7 -4.3, 35.8 - - 
12 10 106.1 (13.0) 6 88.0 (20.8) 18.1 2.7, 33.5 8.2 -1.5, 18.0 
24 10 101.1 (15.5) 6 85.5 (20.9) 15.6 -3.9, 35.1 10.9 -1.4, 23.3 
1Mean difference is equivalent to the methylphenidate group value minus the placebo group value. 
Positive values indicate the methylphenidate group value was higher than the placebo group, 
negative values indicate the methylphenidate group value was lower than the placebo group.  
2Between-group difference tested using two-sample t-test with equal variance 
3Between-group difference tested using linear regression analysis performed with adjustment for 
baseline fatigue severity and FVC at visit 0 
  
Chapter 5: Fatigue and Sarcoidosis – Treatment with Methylphenidate (FaST-MP) feasibility study 
results 
 188 
The results from exercise capacity assessment across the study, performed using 
the MSWT. A number of participants were unable to perform all three 
measurements due to a loss of suitable facilities for performing the MSWT; in total, 
ten data-points were missing for this reason (16.7% of all MSWTs that should have 
been undertaken). Only eleven participants were able to provide MSWT 
measurements at week 24. As a result, only sixteen participants performed at least 
two MSWT values. 
Between group differences for MSWT distances at weeks 0, 12 and 24 are shown in 
Table 40. Although the methylphenidate group managed 100m further on average 
at baseline compared with the placebo group, this difference gradually increased 
according to the unadjusted analysis, with the mean between-group difference 
reaching 191.8m at week 24. When adjusted for baseline distance and severity the 
difference between groups remained in favour of the methylphenidate group, 
albeit by a reduced margin; the mean difference was 43.9m in favour of the 
methylphenidate group in the adjusted analysis. The change in mean scores is 
shown graphically in Figure 18. 
 
Table 40 - Modified Shuttle Walk (MSWT) distances (in metres) during follow-up, 
including between-group differences 
 Methylphenidate Placebo Unadjusted difference1,2 Adjusted difference
1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 10 597.0 (373.0) 6 496.7 (348.8) 
100.3 -303.4, 
504.1 
- - 
12 10 658.0 (397.7) 6 515.0 (252.4) 
143.0 -220.8, 
506.8 
56.4 -73.9, 186.6 
24 7 624.3 (430.3) 4 432.5 (235.4) 
191.8 -118.2, 
501.8 
43.9 -216.3, 304.1 
1Mean difference is equivalent to the methylphenidate group value minus the placebo group value. 
Positive values indicate the methylphenidate group value was higher than the placebo group, 
negative values indicate the methylphenidate group value was lower than the placebo group.  
2Between-group difference tested using two-sample t-test with equal variance 
3Between-group difference tested using linear regression analysis performed with adjustment for 
baseline fatigue severity and MSWT at visit 0 
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Number of participants per time-point: 
Methylphenidate: Week 0 - 10; Week 12 – 10; Week 24 – 7 
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Figure 18 - Change in MSWT distance during the trial. Results are mean values with 
95% confidence intervals for participants providing at least two values during the 
study 
Chapter 5: Fatigue and Sarcoidosis – Treatment with Methylphenidate (FaST-MP) feasibility study 
results 
 190 
Activity 
Daily time in MVPA at baseline was similar between groups, although the 
methylphenidate group spent a greater period of time in MVPA according to WHO-
criteria. Over the duration of the study the time spent per day in MVPA did not 
change in either group, although a small increase was seen in the daily time in 
MVPA according to WHO “bout” criteria in the placebo group compared with 
baseline. The placebo group spent less time than the methylphenidate group per 
day in sedentary behaviours (any activity involving sitting, reclined or lying flat) at 
baseline, but spent longer periods of time in sedentary behaviours in the later 
recording periods. By contrast, the methylphenidate group spent less time in 
sedentary behaviours as the study progressed. The change in activity levels during 
the study are shown in Figure 19. 
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Number of participants per time-point: 
Methylphenidate: Week 0 – 14; Week 12 – 15; Week 24 - 9 
Placebo: Week 0 – 6; Week 12 – 4; Week 24 – 6 
Bout criteria = >80% of any 10-minute period must be above threshold for 
Moderate and Vigorous Physical Activity (MVPA) 
Hysical  
Figure 19 - Changes in GENEActiv-recorded activity levels (MVPA), daily time in 
MVPA according to World Health Organisation recommendations on activity, 
and daily time in sedentary behaviours) during the study 
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The mean values for the activity outcomes, including between-group differences, 
are shown in tables 41, 42 and 43. The methylphenidate group spent longer periods 
performing at least moderate activity over the duration of the study, spending on 
average between 18.3 and 40.2 more minutes per day in MVPA than the placebo 
group; this was also true when using WHO-criteria to define valid time in MVPA, 
although both groups spent less time in MVPA using these criteria. The adjusted 
analysis reduced the mean-difference between the two groups. 
 
Despite the methylphenidate group spending slightly more time per day in MVPA 
than the placebo group, the baseline average duration of sedentary behaviours was 
also higher in the methylphenidate group than placebo. Over the duration of the 
study the methylphenidate group spent less time in sedentary behaviours than the 
placebo group (Table 44); after 12 weeks, participants allocated to the 
methylphenidate arm spent on average 134.4 minutes less time in sedentary 
behaviours per day than those in the placebo arm; this between-group difference 
increased when adjusted for baseline levels of sedentary behaviours, with the 
methylphenidate group spending a significantly shorter duration in sedentary 
activities per day at 12 weeks (-167.3 minutes, 95% CI -320.9, -13.8 minutes per 
day).  
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Table 41 - Daily time in MVPA (minutes); mean values for each group, with 
unadjusted between-group difference and adjusted for baseline fatigue severity 
 Methylphenidate Placebo Unadjusted difference1,2 Adjusted difference
1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 14 105.7 (68.3) 6 87.4 (43.9) 18.3 -45.7, 82.4 - - 
12 15 116.8 (76.6) 4 76.6 (47.7) 40.2 -45.6, 126.1 14.7 -29.1, 58.6 
24 9 108.1 (62.9) 6 86.4 (48.7) 21.7 -44.1, 87.6 24.6 -16.8, 65.9 
 
 
 
 
Table 42 - Daily time in MVPA (minutes) using WHO bout criteria; mean values for 
each group, with unadjusted between-group difference and adjusted for baseline 
fatigue severity 
 Methylphenidate Placebo Unadjusted difference1,2 Adjusted difference
1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 14 19.0 (25.4) 6 4.6 (5.0) 14.4 -7.8, 36.7 - - 
12 15 19.4 (32.8) 4 3.8 (3.4) 15.6 -19.8, 50.9 -0.2 -22.3, 21.9 
24 9 15.0 (20.3) 6 12.0 (15.4) 3.0 -18.2, 24.1 -6.7 -27.2, 13.8 
 
 
 
 
Table 43 - Daily time in sedentary behaviours (minute); mean values for each group, 
with unadjusted between-group difference and adjusted for baseline fatigue 
severity 
 Methylphenidate Placebo Unadjusted difference1,2 
Adjusted 
difference1,3 
Week n Mean (S.D.) n Mean (S.D.) Mean 95% C.I. Mean 95% C.I. 
0 14 665.0 (152.7) 6 602.5 (118.7) 
52.5 -95.3, 200.2 - - 
12 15 565.9 (156.6) 4 700.2 (123.2) 
-134.4 -313.9, 45.2 -167.3 -320.9,  
-13.8 
24 9 567.9 (96.7) 6 656.5 (126.1) 
-88.6 -212.7, 35.4 -139.2 -341.4, 
63.0 
1Mean difference is equivalent to the methylphenidate group value minus the placebo group value. 
Positive values indicate the methylphenidate group value was higher than the placebo group, 
negative values indicate the methylphenidate group value was lower than the placebo group.  
2Between-group difference tested using two-sample t-test with equal variance 
3Between-group difference tested using linear regression analysis performed with adjustment for 
baseline fatigue severity and daily time in sedentary behaviours 
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Exit questionnaire data 
Trial perception 
Participants reportedly favourably on their experience of the study. The results 
from the exit questionnaire, administered to 19 participants after approval was 
given for the substantial amendment in April 2017 (after 3 participants had already 
completed the study), show that participants found the study to be useful and 
would be willing to participate in similar studies in the future. A greater number of 
participants who had received methylphenidate wished to continue the study 
medications if the option to continue them had been available compared with 
those in the placebo arm (91.7% vs 71.4%). The results from the exit questionnaire 
suggest that the high number of visits was not too arduous for participants, 
although data was not collected from eligible patients who declined to participate. 
Table 44 shows the data from the exit questionnaire. 
 
Table 44 - Exit questionnaire responses by treatment allocation 
Exit Question Methylphenidate (n=12) Placebo (n=7) 
If you were given the choice to continue 
receiving the study medication, would you want 
to? 
11 (91.7) 5 (71.4) 
Did you find participation in the study useful? 12 (100) 7 (100) 
Given the chance again, would you still have 
taken part in this study? 12 (100) 7 (100) 
Would you recommend taking part in any future 
study investigating methylphenidate to other 
patients? 
12 (100) 7 (100) 
 
 
Impression of treatment allocation 
Both the participants and the investigator were required to predict the assigned 
allocation group at the final participant visit (week 24); the participants were not 
informed of the investigator’s thoughts. Overall, the participants were able to 
predict with greater accuracy their true allocation group; 18 participants (81.8%) 
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correctly predicted their allocation, compared with the investigator who correctly 
determined the allocated intervention for 16 participants (72.7% accuracy). The 
participants who received methylphenidate predicted their allocation with greater 
accuracy; 14 participants (93.3%) allocated to methylphenidate correctly 
determined their allocation whilst the investigator correctly predicted the 
allocation of 11 participants (73.3%). The results were reversed for the placebo 
group; the investigator correctly predicted the allocation for 5 of the 7 participants 
(71.4%) compared with 4 of the participants (57.1%) correctly determining their 
allocation to the placebo arm. The results suggest that blinding of the trial team, 
including the investigator, and participants, is feasible when using methylphenidate 
in a double-blind, parallel-arm study. 
 
5.3 Discussion 
This study, performed as a double-blind, parallel-arm, placebo-controlled trial, 
reported outcomes for 22 participants with sarcoidosis and associated fatigue who 
were randomised to receive either methylphenidate or placebo for up to 24 weeks, 
with the primary aim of determining the feasibility of performing future studies 
powered to determine the clinical efficacy of interventions for sarcoidosis-
associated fatigue. The results suggest that while performing such a trial is feasible, 
there are important findings that must be considered when designing and 
implementing any follow-up studies to FaST-MP.  
The exploratory efficacy outcomes suggested that no difference was seen between 
the methylphenidate and placebo arms, with between-group differences slightly 
favouring the placebo arm relating to improvements in fatigue, anxiety, disease-
related health status and quality of life. The study was not powered to detect 
clinical differences between groups, but the lack of any signal to suggest benefit for 
methylphenidate was surprising. The clinical results seen may relate to several 
factors, including the chosen inclusion criteria for study participants, changes made 
to the study design during review by the research ethics committee, choice of dose 
ranges for the intervention, and possible issues with the chosen fatigue outcomes 
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that may have failed to identify changes in the methylphenidate group. The results 
also reinforce the multifactorial nature of fatigue; the use of methylphenidate for 
patients with chronic fatigue related to sarcoidosis should only be considered as 
part of the management strategy when treating such patients in clinic. 
 
Trial interpretation 
Recruitment and retention – The final recruitment total, and the monthly 
recruitment rate, was lower than originally anticipated. Despite originally 
anticipating a recruitment rate of 2-3 participants per month, the overall 
recruitment rate was 1.3 participant per month, necessitating extension of the 
recruitment period. Although the study did not recruit the full number of 
participants that were able to be randomised, the 22 participants that did receive 
study medications represented 73.3% of the recruitment target (30 patients). The 
22 participants also represented 36.5% of potentially eligible patients who were 
approached during the study. It was initially anticipated that a greater proportion of 
eligible patients would wish to participate, given the lack of widely-used 
interventions for sarcoidosis-associated fatigue and the known impact upon quality 
of life when present (170). The reasons for declining participation varied, although 
several patients declined due to the practicalities of taking part, specifically the 
number of visits entailed and the distance to travel to each visit. These factors 
could be improved in a future study with design changes, potentially increasing the 
likelihood of eligible patients agreeing to participate. 
Although some aspects of trial design deterred patients from participating, those 
who entered the study reported a positive experience of taking part according to 
the exit questionnaire results. Participant retention was high, with all trial subjects 
completing the study and no drop-outs occurring. This may be a positive aspect of 
the amount of participant contact with the study team, and a lower number of 
study visits may increase the likelihood of participants withdrawing during the 
study. When considering any future study, efforts to reduce the number of hospital 
visits must be undertaken to maximise the likelihood of patients agreeing to 
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participate, but ongoing contact or ease of contacting the study team must also be 
considered to maintain high levels of participant retention. Using alternative means 
of contacting participants other than bringing them to study visits, such as phone 
calls or electronic means of communication, may be able to improve recruitment 
rates whilst maintaining high participant retention. 
Adherence – Throughout the study adherence to medications was excellent. All 
participants in the methylphenidate group and all but one of the placebo group met 
an adherence level of ≥80%, with median adherence levels of 99% in the 
methylphenidate group and 98% in the placebo group, suggesting that the use of 
short-acting medications requiring twice-daily dosing is feasible; this schedule also 
allows for more tailoring to individual needs compared with long-acting 
preparations. Participants also reliably returned unused study medications at the 
end of the study – there was no evidence of participants stockpiling or holding back 
medications during the study. This adherence may also relate to frequent contact 
with the study team, either in person or via telephone, as well as the small gel 
capsule size used to over-encapsulate the tablet (size 0) which enabled easy 
swallowing of the medication. 
Safety – Methylphenidate appeared well-tolerated and safe during this study, 
although this conclusion is limited by the small number of participants. No 
participants were withdrawn due to ECG changes, which were monitored 
throughout the study, and although one participant discontinued medications due 
to cardiac-type chest pain, subsequent investigations did not identify any cardiac 
problems. Reported adverse events were all in keeping with the known common 
side effects of methylphenidate, including anxiety or cough. Although nausea was 
common, this most frequently occurred when medications were taken without 
food; participants were subsequently advised to take their morning dose with 
breakfast, which led to resolution of symptoms in most cases. No changes in blood 
pressure or pulse rate were observed over the duration of the study, either relative 
to baseline values or compared with changes observed in the placebo arm, 
suggesting that methylphenidate is safe from this aspect. One observed effect in 
the methylphenidate arm was a modest reduction in weight from baseline, a known 
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side-effect of the drug but one which would need to be monitored in future studies. 
Only one serious adverse event occurred which was in the methylphenidate arm 
but was unrelated to the medication. Overall, the medication was well-tolerated by 
participants over the study period and no concerns relating to safety, or the ability 
to identify adverse events when they did occur, were identified. This finding gives 
reassurance that fewer patient visits are required in future studies investigating 
methylphenidate as less monitoring is likely to be required given the low rate of 
significant adverse events occurring here. 
Blinding – Neither participants nor investigator were able to correctly predict the 
allocation group for all participants, although prediction of allocation was able with 
a good degree of accuracy overall. More than three-quarters of participants (81.8%) 
were able to correctly predict their allocated group at the end of their time 
receiving study medications, with slightly lower accuracy achieved by the 
investigator (72.7%). Participants were more likely to be accurate in their prediction 
if they had been allocated to methylphenidate and the investigator was more likely 
to be accurate if the participant had been allocated to placebo. This suggests that, 
whilst blinding can be maintained to an extent, participants are able to distinguish if 
they are receiving methylphenidate, either due to the clinical efficacy or the side 
effects of the medication. The importance of this finding is that it reinforces that a 
cross-over design is inappropriate for investigating neurostimulants; participants 
can determine when they are receiving the medication with high levels of accuracy, 
therefore they are likely to be able to break blinding in the period of a cross-over 
study where the active medication is being given. The level of accuracy in predicting 
placebo allocation by participants was barely more than 50% in this study but 
would likely be much higher in a cross-over study where a period on 
methylphenidate would effectively break blinding for the placebo arm. Therefore, 
any future study requiring blinding would need to be parallel-arm not cross-over in 
design. 
Activity monitoring and exercise outcomes – The use of activity monitors as a 
potential outcome measure appears to be feasible based on the high return rates of 
devices. Only one device was lost during return to the study team out of 60 wear 
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periods (1.7% of all wear periods), although four participants (6.7%) did not return 
any data (zero wear time) and a further three participants did not wear the device 
for sufficient duration to record valid levels of data; in total, 54 wear periods (90.0% 
of all wear periods) yielded valid data for analysis. It is unclear how the 98.3% 
device return rate compares with other large-scale studies utilising activity 
monitors, such as NHANES or UK Biobank, but it is reassuring that using pre-paid 
postal methods to return the accelerometer devices was reliable and suggests that 
it is feasible to use these devices in any future study.  
In contrast to the feasibility of using the activity monitors, the use of the MSWT as a 
clinic-based measure of exercise capacity appeared less likely to be feasible for 
future trials; if it were to be used as an outcome measure then it would be 
important to clarify that potential sites have sufficient space to perform a MSWT. 
This finding is due to the difficulty in having reliable access to a safe and 
appropriate space to undertake the test. As the MSWT is a maximal effort test, 
requiring participants to increase their speed along the course to the point of 
running, a large amount of dedicated space is required to safely undertake the test. 
During the course of the FaST-MP study the facilities we were able to use for the 
MSWT were removed due to a change in the research department’s location. 
Despite searching for an alternative location, no appropriate facilities were 
identified within the Norfolk and Norwich University Hospital. As we could not 
expect other sites to have access to dedicated facilities for an MSWT in any future 
study, the need for outcomes like the MSWT should be considered; there was 
evidence to support increased maximal effort on exercise tests from the data 
collected here, albeit limited by the reduced amount of data collected, and so the 
use of a laboratory-based test, using a treadmill or ergometer, is likely to be more 
feasible than performing MSWTs at NHS sites. 
Clinical outcomes – This study was not powered to detect clinical differences 
between groups. An analysis of the clinical data collected was performed to explore 
how the outcome measures changed within the study, although it is important to 
interpret these findings with caution and use them to raise questions for future 
work to investigate further. 
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Both the methylphenidate and placebo groups showed reductions in fatigue scores 
from baseline, with most participants in both arms showing improvements in both 
FAS and FACIT-Fatigue in excess of the MCID for each instrument. Despite this, the 
magnitude of the improvement was larger in the placebo group than the 
methylphenidate group, albeit a non-significant difference from the 
methylphenidate arm. The placebo group also showed improvements in anxiety 
and depression scores (HADS-A and HADS-D) compared with those allocated to 
methylphenidate. There were also improvements seen in disease-related health 
status, with the participants randomised to placebo showing improvements in the 
lung and general health status sub-scores of the KSQ. The improvements in all these 
factors were reflected in the health utility scores derived from the EQ5D and SF-6D 
results, with mean improvements in health utility scores favouring the placebo arm 
over the methylphenidate arm. In all cases there appeared to be persistence of 
effect over the full study duration. The between-group differences are in contrast 
to previous data (173), although this is from a short cross-over study which may 
have been affected by the issues related to blinding, discussed above. 
Although the between-group differences rarely reached significance, and the study 
was never powered to detect clinical difference between study arms in any of the 
outcomes, the performance of the placebo arm was unexpected.  A number of 
potential elements were identified that may explain why participants allocated to 
methylphenidate performed no better than placebo: 
• The trial design was changed at the point of review by the research ethics 
committee; the initial design envisaged a similar first 12 weeks of the study, 
with close monitoring of participants for adverse events and to allow dose 
titration of the study medication. At week 12 participants would then be 
dispensed a 12-week supply of medication and not be reviewed between 
week 12 and 24 unless any issues arose, so that this second half of the study 
period was a closer mirror of usual clinical practice. In the process of gaining 
ethical approval, changes had to be made to introduce increased clinical 
contact, specifically the between-visit phone calls and the additional visit at 
week 18. These changes drastically increased the amount of clinical contact 
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for participants within the study and potentially led to increased “quality” of 
interaction with the research team, an acknowledged factor that can be 
“extremely influential in patient outcomes [and] may be more important 
than specific treatment,” conclusions which are based on work from studies 
investigating pain (287, 288). As a result, no “usual care” group existed 
within the trial, given that the frequency of contact that both groups had 
with the study team was far in excess of the usual extent of clinical contact 
in the outpatient clinic and may be considered an intervention itself. 
• The placebo group saw marked improvements in both anxiety scores, 
possibly as a direct result of the factor discussed above relating to a lack of a 
“usual care” arm. The methylphenidate group did not see such changes; in 
contrast to the placebo group, scores in the HADS-A questionnaire did not 
change over the duration of the study. Anxiety and depression are known to 
be moderators of fatigue scores in patients with sarcoidosis (122); the 
significant reduction in anxiety may have led to reductions in fatigue levels. 
Furthermore, a study published following the conclusion of the FaST-MP 
trial reinforced the impact of emotional distress and anxiety about physical 
concerns, identifying these factors as strongly influencing fatigue scores in a 
small cohort of patients with sarcoidosis in Poland (289). 
• The dose range was chosen based on previous research using 
dexmethylphenidate for sarcoidosis which used the equivalent dose range 
(173). However, higher doses can be used. Some participants within the 
methylphenidate reported only small benefits, yet tolerated the medication 
with only mild or transient adverse events, so having the option of using a 
higher daily dose (30mg twice daily) may have been beneficial for these 
participants. 
• The inclusion criteria were broad to enable participants with sarcoidosis and 
significant fatigue to participate. No cut-off was specified for the duration of 
disease at the point of entering the study; this was primarily done to ensure 
that patients who had endured significant delay in reaching a diagnosis of 
sarcoidosis were eligible if they suffered chronic symptoms. The 
consequence of this was that a number of participants had been diagnosed 
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with the disease for less than a year. For some patients, fatigue may 
improve over time, and so including only participants diagnosed for at least 
a year (17 of the 22 participants in the study (77.3%) met this criteria) may 
have ensured only patients with chronic, non-resolving fatigue were 
included. 
• The level of sedentary behaviour per day in the methylphenidate group 
decreased during the study, whereas it increased in the placebo group, with 
a large difference between the groups, most markedly at the 12-week stage. 
There was a large amount of variability seen in the reported durations of 
sedentary behaviour, and the number of data points is small, but the results 
could suggest that the methylphenidate group performed more activity than 
those allocated to placebo during the study. This increased activity may 
have meant performing more usual daily activities, and their increased 
fatigue levels resulted from them accomplishing more and becoming 
physically fatigued. The data collected here is unable to determine if this 
occurred, but future studies may be able to incorporate better methods of 
recording this such as an activity diary or a formalised activity record such as 
the National Institute of Health (NIH) activity record (290). 
• Only seven participants (31.8%) were randomised to placebo, below the 3:2 
methylphenidate:placebo ratio originally anticipated. This was due to one 
participant being randomised despite not being eligible, although this does 
not suggest failure of the randomisation sequence given the small number 
of participants randomised in total. This small number of participants 
allocated to placebo does make it difficult to draw accurate conclusions 
about the performance of this arm and increases the likelihood of spurious 
or misguiding results. 
• Whilst no clear evidence of a selection bias appeared to exist, with no 
difference in baseline characteristics either between groups or relative to 
the larger cohort of patients with sarcoidosis who did not enter the study, 
the presence of “demand characteristics” (the risk of participants changing 
their behaviour in line with the study aims) leading to bias cannot be 
excluded. The large amount of interaction between the investigator and the 
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participants may have led to influence on the participants’ perception of the 
study, such as all participants being aware that this research was forming a 
large portion of the investigator’s thesis, which possibly led to participants 
filling the “good participant” role and striving to meet the study hypothesis 
(291). Alternatively, the process of participating in the research itself, 
including completing multiple questionnaires throughout the study may 
alter their thinking and perception, an effect that has been considered part 
of the “Hawthorne effect” and has been suggested should be broadened to 
“research participation effect” (292), leading to the unexpected 
performance of the placebo arm. 
The FaST-MP study inclusion and exclusion criteria did not specify a minimum 
duration of disease, potentially leading to the inclusion of participants with a recent 
diagnosis who may have experience spontaneous resolution of disease (including 
symptoms of fatigue) during the trial. This issue was investigated through re-
analysis of the collected data from FaST-MP. Excluding participants with a disease 
duration of less than 1, 2 or 3 years did not significantly alter performance of the 
active and placebo arms, although the number of eligible participants decreases 
accordingly. For illustration, the FAS scores for participants with a disease duration 
of at least 1, 2 or 3 years are shown in Figure 20. Despite the lower number of 
participants as the pre-study disease duration increases, the change in FAS scores 
over time, and the relative performance of the placebo and methylphenidate arms, 
remain unchanged from the scores seen without a pre-specified minimum disease 
duration at study entry. 
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Figure 20 - Change in Fatigue Assessment Scale score (FAS) over duration of the 
study dependent upon duration of disease at study entry; (A) 1 year, (B) 2 years, 
(C) 3 years. Values are mean scores with 95% confidence intervals 
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These factors are hypotheses for the relative performance of the methylphenidate 
and placebo arms, although the lack of clinical effect should not be considered a 
barrier to future trials investigating treatment for sarcoidosis-associated fatigue 
with methylphenidate. Any future study would require careful consideration of the 
inclusion criteria, the definition of the control arm to consider whether it would be 
representative of usual care, the optimal range of doses and the choice of outcome 
measures for defining clinical effect. An in-depth discussion of these issues is 
presented in chapter 8. 
 
Strengths and limitations 
The FaST-MP study had a number of strengths. It met its primary objective of 
determining the feasibility of undertaking a full study powered to confirm or refute 
the clinical efficacy of methylphenidate for sarcoidosis-associated fatigue. It 
provided estimates of recruitment rates and, through thorough screening of the 
entire cohort of patients with sarcoidosis under the care of the respiratory 
medicine department at the NNUH, also provided estimates of the proportion of 
patients with sarcoidosis who would be eligible for participation in any future study. 
In the process of recruiting participants, barriers to participation were also 
identified that could be modified to improve recruitment rates in any follow-up 
study from this. As the first parallel-arm study investigating methylphenidate in 
sarcoidosis-associated fatigue, it also identified the difficulty in maintaining blinding 
when utilising a cross-over study design and the resulting risk of introducing bias.  
The study succeeded in identifying a number of issues with the study design that 
could be amended in future work, relating to the choice of inclusion criteria, 
randomisation sequence, duration of follow-up, choice of control arm or 
comparator, and choice of outcome measures. When considering outcome 
measures in a future study, the feasibility of using the activity monitors within this 
population was piloted successfully, suggesting they can be used in any future 
study. Finally, trial practices established with NCTU relating to risk assessment, 
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safety and quality management can be utilised as a basis for future studies 
expanding on the outcomes from FaST-MP. 
The study also had a number of limitations. Participants recruited after December 
1st had truncated follow-up, with the final five participants randomised in the study 
having follow-up truncated after 12 weeks receiving their allocated intervention. 
Only 16 participants had full data for the entire 24-week intervention period. This 
limits the assessment of outcomes after 12 weeks, including retention, adherence, 
tolerability of study medications, persistence of clinical effect, and exploratory 
analysis of clinical outcomes. This was also a single-centre study, which may make 
estimates of recruitment and retention optimistic when expanding across multiple 
sites as recruitment rates in single-centre studies are known to often be higher than 
across multi-centre trials (293). Finally, the clinical outcomes suggested no benefit 
from methylphenidate compared with placebo, which may relate to the lack of a 
true “usual care” arm in this study, stemming from the number of study visits and 
phone calls participants undertook. Therefore, the performance of 
methylphenidate relative to usual care alone remains unknown. 
 
Considerations for a future study 
Despite the lack of signal in support of methylphenidate use for sarcoidosis-
associated fatigue compared with placebo, many factors support the feasibility of 
future studies into the use of methylphenidate or other neurostimulants for 
sarcoidosis-associated fatigue. Recruitment, whilst lower than anticipated, is likely 
to be sufficient for a trial powered for clinical efficacy performed across multiple 
sites with much larger populations of patients with sarcoidosis under their care, 
even allowing for lower recruitment rates than observed here. The use of activity 
levels recorded by wrist-worn monitors as an outcome measure also appears to be 
feasible based on the number of participants wearing the device for valid periods of 
time and the reliability of returning devices.  
The included participants were able to have been diagnosed with sarcoidosis for 
any duration of time, although specifying a minimum duration of time since 
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diagnosis is likely to reduce the chance of spontaneous resolution of symptoms. Of 
the participants in this study, 17 (77.3%) had been diagnosed for at least one year, 
so specifying this as an inclusion criterion would still allow sufficient recruitment to 
occur whilst ensuring that the included population was less likely to see 
improvements in fatigue during the study which are unrelated to the intervention. 
Although there was minimal difference between the methylphenidate and placebo 
arms, the data suggested that improvements occur quickly and persist across the 
study. Designing a study longer than 12-weeks for determining clinical efficacy of 
methylphenidate may be unnecessary based on these results.  Of more importance 
is the choice of comparator. The exceptional performance of the placebo arm may 
have been due to the high level of clinical contact received by all participants. As a 
result, this study did not have a “usual care” arm. Ensuring the control arm is a true 
representation of usual care is more challenging. Reducing the number of follow-up 
visits may be beneficial, as well as feasible given that methylphenidate was well-
tolerated. For this reason, a follow-up period of more than 12-weeks may be 
beneficial as it would allow a longer period without regular contact with the study 
team once dose titration had been achieved; for example, an 18-week study would 
allow the first 6 weeks to be used for dose adjustment with regular contact and 
review, followed by 12 weeks on a steady dose without regular contact. This would 
allow a closer representation of follow-up in an outpatient clinic and provide a 
more accurate control arm, but would also require participants to be confident in 
being able to contact the study team if any issues were to occur and a robust 
pathway in place for dealing with issues as they arise.  
A final consideration reflects the reduced anxiety and perceived physical symptoms 
identified in the placebo group which may have led to the reduced fatigue scores 
seen within these participants. Whilst it is important to consider the small number 
of participants allocated to receive placebo, and the potential impact upon the 
results seen in this group, it is also important to consider how the improvements 
seen in fatigue may relate to the reduction in other symptoms. Avoiding the need 
to employ medication for management of chronic fatigue would be beneficial; given 
the improvements seen in the placebo group and the known influence of anxiety on 
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fatigue (289), including a psychological intervention prior to enrolment should be 
considered for any future trial. This addition could screen out patients who would 
benefit from such an intervention, leaving only participants more likely to benefit 
from a pharmacological intervention directly targeting fatigue, although it would 
increase the cost of any such trial. 
None of the issues raised would be insurmountable for designing and implementing 
a future study investigating the clinical efficacy of neurostimulants for the 
treatment of sarcoidosis-associated fatigue; the proposed design changes would 
ensure that only patients likely to require and benefit from methylphenidate would 
be included.  
 
5.4 Conclusions 
The results from the quantitative data collected during the FaST-MP study has 
demonstrated the feasibility of performing future trials investigating the clinical 
efficacy of neurostimulants for the treatment of sarcoidosis-associated fatigue, as 
well as identifying the issues that may influence the clinical outcomes in the 
placebo arm. Recruitment, retention, safety and adherence outcomes supported 
the feasibility of future trials. Outcomes in the placebo group raised concerns about 
what should form the control group as the placebo group within this study did not 
reflect what would be considered “usual care” in an outpatient setting. The lessons 
learnt can help to influence future trial design to account for these issues. 
In the next chapter the outcomes from the focus groups, undertaken as part of the 
FaST-MP study to investigate individual experiences of trial participation, are 
presented. The qualitative method allows a closer inspection of the impact of 
sarcoidosis-associated fatigue to individuals, as well as the improvement 
experienced during the study. Additionally, changes to trial design and methods are 
discussed with participants, utilising their experience of the FaST-MP trial to 
generate ideas that would improve future work arising from this feasibility study. 
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6.1 Introduction 
In chapter 4, the FaST-MP study provided important data regarding the feasibility of 
designing, implementing and undertaking a phase III study investigating 
interventions for sarcoidosis-associated fatigue. The results suggested that 
undertaking a randomised-controlled trial in patients with sarcoidosis-associated 
fatigue was feasible, although exploratory clinical outcomes suggested 
improvement in fatigue scores compared with the placebo arm . In this chapter, the 
results of focus group discussions with FaST-MP participants, undertaken alongside 
the study prior to unblinding of allocation, helps to bring into focus the positive and 
negative aspects of trial participation, particularly relating to receiving 
methylphenidate, as well as suggesting practical changes for any future study 
investigating the clinical efficacy of neurostimulants. 
 
Background 
Although relatively uncommon, the use of qualitative methods alongside 
randomised controlled trials offers many benefits, including developing and refining 
interventions or outcome measures, as well as exploring the outcomes from the 
study and the reasons for them (294). Previous trials have used a mixture of RCTs 
and qualitative methodology to aid a number of outcomes. This includes better 
understanding around how trials work in the real-world, drawing attention to 
outcomes that are important to participants, and understanding simple 
interventions where complexities beyond the intervention may exist (295). There 
are specific examples of how qualitative work has been highly beneficial in previous 
RCTs; in one case qualitative interviews explored issues and identified changes 
relating to recruitment, leading to significant improvements in recruitment (296). In 
another example, interpretation of previous negative results enabled further insight 
into the effect of intervention that was not identified from quantitative work (297). 
As part of the FaST-MP study, qualitative data collection was planned to enable 
participants within the study to have a direct impact on the design of any follow-on 
study investigating clinical efficacy. This would maximise the chances of optimal 
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recruitment and retention, as well as influence the selection of outcome measures 
to ensure that they are relevant to patients. This methodology ensures that 
participant experience and opinions directly influence future trial design. 
In addition to eliciting opinions about the trial design and methodology from those 
who had participated in the study, the qualitative methodology allowed the 
possibility to explore the effect of the intervention on participants within the study. 
Exploring the positive or negative aspects of the intervention itself, and the effect 
experienced by participants, gives meaning to the changes in fatigue score seen. It 
can illuminate examples of changes seen by individuals during the study period 
which may provide a different picture to that seen in the quantitative data. The 
complexity and multi-dimensional nature of fatigue makes a convergent mixed 
methods approach, combining the logical empiricism of quantitative methods and 
the constructivism of qualitative methods, an attractive way of exploring the impact 
of the study on participants. This methodology has been explored before and 
provides additional benefit over a solely quantitative approach (298). The 
quantitative outcomes were reported in the previous chapter; in this chapter the 
focus group outcomes, relating to the effect of fatigue, the impact of alleviating 
fatigue through intervention and suggested changes to related future studies, are 
reported.  
 
Objectives 
The focus groups were performed with the following objectives: 
1. Description of participant experience of receiving medications during the 
study, including the effect on their lives and changes from pre-trial 
experience of fatigue. As part of this objective, pre-trial fatigue was 
discussed by participants. 
2. Explore positive and negative aspects of participation within the FaST-MP 
study, including possible improvements or changes for any follow-on study 
from FaST-MP which may improve participant recruitment, retention or 
experience within that study. 
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6.2 Methods 
In order to explore participant perception of the FaST-MP study, three focus groups 
were organised to allow extended discussion with participants of the study. All 
participants of the FaST-MP study were offered the chance to attend one of the 
focus-groups; the participants within the focus groups represented a convenience 
sample of those who were able to attend any of the three focus group sessions.  
Focus groups were chosen as the preferred methodology for exploring participant 
experience of the FaST-MP study because the group discussion was felt to allow 
interaction between participants, inviting them to discuss their own experiences 
and reflect upon or consider other viewpoints. The focus group methodology was 
also felt to be more likely to generate new ideas relating to future clinical trials as 
the facilitated discussion allows participants to “piggyback” on each other’s ideas; 
this positive aspect of the focus group format makes it ideal for idea generation and 
project evaluation (299). Homogeneity in the composition of focus groups is 
considered important to encourage free-flowing dialogue between members of the 
group (300). All members of the focus groups were patients with sarcoidosis and 
had recently completed the FaST-MP study; this was felt to represent two shared 
experiences that would facilitate discussion between members of the group 
through a “common ground”, increasing the likelihood that focus group members 
would consider themselves equal. In this respect the group could be considered 
homogenous due to this shared experience despite heterogeneity in social 
background and demographics. In addition, the methodology represented the best 
opportunity of maximising the amount of data collected in an appropriate time 
scale. 
Three audio-recorded, moderated focus groups were planned for participants of 
the FaST-MP study who had completed their participation in the FaST-MP trial (i.e. 
had completed their week 30 assessments). Each focus-group was planned to have 
between four and six participants, dependent upon participant availability. Focus 
groups with less than four members were not permitted. All focus groups were 
undertaken at the same location (the Bob Champion Research and Education 
Building at the University of East Anglia, Norwich). A pre-specified topic guide was 
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used to facilitate discussion using open-ended questions (topic guide available 
within appendix 4). The two key topics included were participant experience of trial 
participation (both positive and negative) and suggested changes to the study 
which might improve the future recruitment or retention of participants to any 
follow-up study to FaST-MP. Each topic heading included a series of open-ended 
questions, some containing prompts to aid discussion if required. To avoid 
embarrassment or discussion of sensitive issues relating to impact of fatigue, 
questions pertaining to the impact of fatigue were not included in the topic guide 
and were not asked during the focus groups. Where participants began to discuss 
the impact of sarcoidosis-associated fatigue on their lives during the course of 
discussion within the focus groups, these conversations were allowed to continue 
and were permitted as long as participants were comfortable continuing the 
discussion. No additional questions exploring the impact of sarcoidosis-associated 
fatigue were asked by the moderator (Dr C Atkins) during these discussions. 
All participants within the focus group provided written informed consent as part of 
the consent process for the FaST-MP study; this was not a mandatory aspect of the 
FaST-MP study and only those providing written consent were approached about 
participation within the focus groups. 
Audio data collected from the focus-groups was transcribed, with transcription and 
participant identity within the transcripts checked and confirmed by the lead 
researcher, Dr Chris Atkins. The audio data was complemented by written notes 
collected by Dr Atkins, with a research assistant present during each focus group to 
assist with the running of the session. Analysis of the data was undertaken using a 
thematic analysis approach, according to recommendations by Braun and Clarke 
(301). This involved the following steps: 
1. Familiarisation with the data 
2. Generating initial codes 
3. Searching for themes 
4. Reviewing themes 
5. Defining and naming themes 
6. Report production 
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Dr Chris Atkins undertook data familiarisation, code generation and identification of 
initial themes. These initial themes were then modified through back-and-forth 
discussions between Dr Atkins and Dr Andrea Stockl, who was the supervisor for 
the qualitative aspect of this project. Coding of themes was assisted by NVIVO 11 
software.  
 
6.3 Results 
Fourteen participants from the FaST-MP study took part in the three focus groups 
that were undertaken, representing 63.6% of the total number of participants 
within the FaST-MP study. Each focus group took between 75 and 120 minutes in 
total. The age, gender and allocation to treatment or placebo arm within the FaST-
MP study are shown in Table 46 below. All the focus groups took place before 
unblinding the FaST-MP study, therefore none of the participants were aware of 
their treatment allocation at the time of the focus groups. 
 
Table 45 - Focus group participant demographics 
Focus 
group 
number 
FaST-MP 
Trial ID 
Number 
Age Gender Baseline 
Fatigue Score 
(FAS) 
Allocation arm in 
FaST-MP 
1 002 59 F 34 Methylphenidate 
003 71 M 23 Methylphenidate 
005 53 F 30 Placebo 
006 56 M 26 Methylphenidate 
2 001 69 F 26 Methylphenidate 
004 59 M 28 Placebo 
007 44 F 42 Placebo 
008 53 M 38 Methylphenidate 
009 52 M 22 Methylphenidate 
3 011 65 M 40 Placebo 
013 65 F 45 Methylphenidate 
014 67 F 35 Placebo 
016 34 M 44 Methylphenidate 
019 69 M 31 Methylphenidate 
 
Chapter 6: Participant perceptions of the FaST-MP study – outcomes from focus group discussions 
 215 
Three main themes arose from the focus group discussions. These can broadly be 
broken down into problems experienced through each patient’s sarcoidosis and 
associated fatigue prior to trial participation (“Before”), the experience of trial 
participation and the effect of medications experienced by participants (“During”), 
and factors that could be changed for any follow-on study (“After”). 
 
Before - Biographical disruption, premature aging and the invisible illness 
The concept of biographical disruption was first described by Michael Bury in 1982 
and relates to the disruption to an individual’s life in multiple ways, having 
significant impact upon the concept of self and future self. Bury described chronic 
illness as “that kind of experience where the structures of everyday life and the 
forms of knowledge which underpin them are disrupted” (302). Biographical 
disruption has never been explored in patients with sarcoidosis though it has been 
identified in other chronic diseases, including patients with chronic fatigue 
syndrome (303). Given the chronic nature of sarcoidosis and the interaction 
between symptoms and quality of life, it is unsurprising that this framework was 
found to have applications to the cohort of patients included here. For the patients 
with sarcoidosis here, there was significant variation in the level of disruption 
encountered, but those who suffered severe fatigue described a life-altering change 
in their own capabilities: 
“Once I had developed severe chronic fatigue it was like the end of my life, and I was 
so restricted in what I could do, and even going to the supermarket is a major chore 
for me”. (013, Focus group 3) 
The description of the impact as the end of a life reinforces the potential impact 
that fatigue can have on normal activities, and the ending of what is considered a 
normal life. The concept of “brain fog” as a major aspect of the fatigue was raised 
by two participants, with one discontinuing driving because of this aspect of her 
fatigue. Others described having a “day-to-day fight” with fatigue, dreading waking 
up in the morning because of their fear of facing the day and the tasks it entails. As 
noted in Bury’s work with rheumatoid arthritis patients, adaptations were 
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undertaken by participants to deal with their symptoms and their disability. For one 
participant, this meant a very prescribed set of activities to work within his 
capabilities: 
“If I’m going outside I’m going to do everything I need to do outside in one go, 
rather than backwards and forwards, backwards and forwards… I had to write 
down a list of what I needed to do today, what’s the best way to do it, and plan days 
out”. (016, Focus group 3) 
In this case, function was maintained through planning and the need to get things 
done. This participant had children at home which meant that he had to work 
around his limitations from fatigue, explaining that it he “didn’t get to stop” as a 
result of needing to be active for his children.  Other participants, whilst using 
similar techniques of pacing activities, coped by withdrawing from social situations 
when she felt particularly bad: 
 “My friends say, “Do you want to come out for a meal, Monday night?” I’ll say, 
“Can’t do it.” I can only pick one thing in a day to do, I can’t rush home, get ready, 
and go out and do something else. It just doesn’t work.” (014, Focus group 3) 
For some of the participants, the impact of fatigue and sarcoidosis on their normal 
function had led to a perception of being prematurely aged, restricted in function 
and quality of life compared with peers of similar age and lifestyle. Relating to the 
impact of fatigue on lifestyle, one participant mused about “how much [he] had 
missed out on in life” (009, Focus group 2). Frustration was expressed about life lost 
because of the symptom, including one participant who felt that he was suffering 
the effects of aging at an earlier age than he expected: 
“I know we all get old and slow down and fall apart and whatever, but it’s all 
happening too early in life. I have people around me the same age and they’re still 
living an active life and me, I’m not, even though… not as much as I should do.” 
(009, Focus group 2) 
Another participant considered whether it was her expectations of the aging 
process that were wrong and that she was blaming the sarcoidosis for symptoms 
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that were related to her age, although this may have been an attempt to 
“normalise” her symptoms; she had previously appeared shocked and irked when 
her son had suggested that 59 years of age represented “getting old”. Six of the 
participants expressed frustration relating to this feeling of premature aging. This 
concept, when considered alongside the changes that were made to lifestyle to 
maintain function, bear parallels to the concept of “selective optimisation with 
compensation” as part of a successful aging process (304). The restriction of 
activities mirrors the domain of selection, concentrating on high priority domains 
such as work and looking after other members of the family. The optimisation 
domain, moving towards tasks that “enrich and augment,” does not initially appear 
to be fulfilled here. However, the optimisation strategies appear to surround 
necessary tasks, relating to work or carer responsibility for younger members of the 
family, at the cost of other activities; for example, this meant falling asleep early in 
the evening for one participant and missing out on time with his partner. Finally, 
compensation is attempted with strategies that will maximise functioning for 
individuals. These strategies include pacing, structuring and limitation of tasks, as 
shown above, to maximise achievement within an individual’s capabilities. 
Participants had tried different treatments, remedies and managements for fatigue, 
without improvement. Even attempts at restoring energy through sleep failed to 
achieve the desired effect: 
“I know however tired I am I won’t go off [to sleep]. I have laid down before and 
thought, “Well I’ll try and have a sleep in the afternoon and see if that gets me 
feeling better tomorrow,” but that doesn’t because I don’t go to sleep. I can’t” (002, 
Focus group 1) 
The result of these actions appears to be a similar strategy to those manging the 
aging process later in life, but one which can never be fully achieved due to existing 
requirements on their time such as work or families. 
Returning to Bury’s concept of biographical disruption in chronic illness, this has 
been successfully applied to patients with many different chronic diseases, 
including those with potentially clear physical or functional impediment (e.g. 
rheumatoid arthritis (302) or stroke (305)) or with clearly understood implications 
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for third parties (e.g. cancer (306)). In contrast to these examples, in sarcoidosis the 
manifestations of the disease were not felt to be immediately obvious, including 
the symptom of fatigue. Participants raised examples of the condition being 
invisible to other people. Examples were cited of both medical professionals, such 
as primary care physicians having little familiarity with sarcoidosis and its potential 
manifestations due to the relative rarity of the disease, and lay people being 
unaware of the condition. In the case of the latter, the invisibility related to the lack 
of physical symptoms relating to the condition, with one participant describing his 
sarcoidosis as “one of those hidden diseases” (006, Focus group 1). Another 
participant felt that the invisibility was particularly difficult when dealing with work 
and employers: 
“If you try and explain it, especially at work, it’s really hard to explain, because you 
don’t look ill, but you are ill, and they don’t understand”. (005, Focus group 1) 
This participant worked in a customer-facing role at a high-street shop, continuing 
to work despite significant fatigue, but when her disease flared it was difficult to 
explain how it was affecting her to her employers. This invisibility, and resultant 
difficulty in others understanding the illness, leads to difficulty in patients feeling 
able to access the classic sick-role behaviour that was suggested by Bury’s 
biographical disruption. Instead, the lack of a visible or well-understood medical 
condition removed acknowledgement from others. A similar framework was 
identified by Sarah Nettleton in patients with medically unexplained symptoms, 
including fatigue, where “permission to be ill” was not granted due to a lack of 
diagnosis (307); in the case of patients with sarcoidosis and associated fatigue, the 
lack of visible and understandable illness appeared to cause comparable issues. 
Prior to commencing medications within the study, it was clear from discussions 
that the sarcoidosis-related chronic fatigue suffered by all the participants had 
significant impacts upon their life beyond just reduced function. The feeling of a life 
being “over”, or reflection on years of life not fully lived, paint a vivid picture of the 
negative impact that fatigue has upon quality of life.  
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During – Effect of Medications and moral ambivalence on their use 
The patients in this study had suffered the chronic effects of sarcoidosis; their 
descriptions of the impact of the fatigue related to the condition upon their lives 
appeared to comply with the framework of biographical disruption. Within the 
FaST-MP study, an opportunity was afforded to receive medications that could 
ameliorate or even fully reverse this symptom. When asked about their rationale 
for participating in the study, four participants discussed the altruistic aspects, 
wanting to “put something back in” or help others and another two participants 
spoke about the reassurance from receiving the additional tests performed during 
the study. However, one primary driver was the hope of receiving the active 
medication and the direct benefit that may come from this.  
For those who perceived benefit from the medications, the positive impact upon 
their life was remarkable. Participants who had spoken of lost life and poor function 
relative to their peers, discussed in the previous section, noticed marked 
improvements in their quality of life. For one patient who had severe fatigue, the 
effects of the medication had a significant benefit: 
“I felt like I was whole again. I still didn’t have the same normal energy levels like I 
had before I became sarcoid, but at least I could get on with my life and not feel like 
my life was diminished to the extent that I was no longer really functional.” (013, 
Focus group 3) 
This participant continued to run a business and was involved in dog breeding; 
having previously shown dogs at competitions her fatigue had left her unable to do 
this. During the course of the trial she felt was able to return to showing her dogs at 
competition again due to her improved energy levels.  
Such improvements in function were not uncommon, with nine of the participants 
in the focus groups reporting improvements. For one patient, commencing 
medications led to a marked improvement in her “brain fog”, describing the feeling 
as if “this cloud had lifted” (002, Focus group 1). Another reported improvement at 
work, improvements in willpower and drive, and accomplishing tasks that he had 
been planning for months but felt unable to do. These were a few specific 
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examples, but a general theme from these patients was the restoration of some 
semblance of a normal life, one participant stating that he “felt alive for the first 
time in years” (009, Focus group 2). 
As described quantitatively in the previous chapter, significant benefits were 
perceived by participants receiving the placebo. At the time of the focus groups 
none of the participants were unblinded, therefore the reasons for this 
improvement could not be explored. The magnitude of effect is illustrated by one 
participant who noticed significant life changes during the study despite not 
receiving the active medication: 
“Huge differences. We’ve been able to lead what I would say is a more normal life 
after not managing much at all, being able to keep up with my 11-year old, almost. 
Being able to have a social life, not fall asleep during the day, not fall asleep on the 
sofa every time I sat down.” 
“It makes life – for me it made life easier, it wasn’t that constant, “Oh God I can’t do 
this.” … For years – that’s the first time in a long time I wanted to get up each day 
and felt alive to get up each day and managed to enjoy going for a walk.” (Both 
007, Focus group 2) 
Other examples of improvements were given by participants who had received 
placebo; in one case a participant who had given up driving due to “brain fog” felt 
well enough to restart driving her car during the study despite not being allocated 
to the methylphenidate arm. 
Relating this re-gain of function and quality of life does not easily fit with previous 
concepts of chronic illness; participants did not notice any difficulty in returning to 
normal function and were grateful for the opportunity to experience this, even for 
the short duration of the study. This in itself presented a potential problem as 
ongoing treatment was not available at the end of the study. As one participant 
rationalised: 
“A lot of us have done this knowing it’s not available but we’re all, in the back of our 
heads, have got that it’s one step closer to it potentially being available. Where 
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we’re not going to have to jump through hoops and do all this to get hold of it”. 
(016, Focus group 3) 
For this participant, even knowing that the duration of medications was finite was 
acceptable in the bigger picture of making this treatment more widely available, 
returning to the theme of altruism as a reason for participation knowing that any 
improvement during the study was likely to be transient. 
Despite the dramatic improvements there were some concerns over the ongoing 
use of methylphenidate that were discussed within the second focus group. One 
participant within the group considered how the use of medications to feel better 
within this group could lead to potential drug-seeking behaviour. During the study 
he had noticed benefits to his normal fatigue levels but had also noticed that the 
effect was not the same over time: 
“That’s what my worry was, I felt my body got used to it.” He went on to say, “It’s 
almost as though you got used to the smaller dose and then start to take the higher 
dose, bang, I got that hit again.” (008, Focus group 2) 
The use of language associated with illicit drugs was echoed by other participants, 
in other focus groups as well, referring to getting a “hit” or a “buzz”, as well as 
“coming down again” as the medication wore off. This moral ambivalence of using 
the medication was difficult to resolve and there was a clear concern that long-term 
use of the medication might result in individuals “chasing” a hit and leading to 
medication abuse and addiction. The main rationale for this concern related back to 
the marked positive effects that these individuals had felt. The same participant 
who had initially raised these concerns expressed it as such: 
“The only problem with that is four of us sat around the table and said we felt great. 
I think it would just become – who doesn’t want to feel great all the time?” (008, 
Focus group 2) 
Whilst this is a valid concern, it is interesting to note that the participants all agreed 
that they felt great – even though their level of function and energy had “just been 
normal, how it should be really” (009, Focus group 2). Simultaneously, whilst 
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medications had restored them to what was considered a normal quality of life for 
their age, it appeared they had previously created a “new” normality to enable 
them to live with their fatigue. This concept of patients creating a “new normal” as 
a form of coping strategy has been described before in other conditions including 
traumatic brain injury (308), inflammatory bowel disease (309) and cancer (310). 
The impact of returning to pre-morbid levels of function in other conditions, or in 
sarcoidosis, has not been explored. For some of the participants here, returning 
from their created “new normal” to the level of function they would expect to be 
able to do when well (“true normal”) led to difficulties adjusting, mistaking their 
“true normal” level of function for a synthetic or artificial “high”. This in turn had 
led to this ambivalence on using medications to improve function so markedly.  
Despite these concerns, participants were keen to continue with the medication. 
Those participating in focus group 2 wanted to ensure that the medications were 
controlled and used at as low a dose as possible, but this negative aspect of 
receiving methylphenidate or related medications was not raised in either of the 
other two focus groups. No other significant issues were raised relating to adverse 
or negative effects of methylphenidate. The overwhelming outcome from those 
who received benefit was that the medications enabled a return to normal life and 
a significant improvement in quality of life as a result. 
 
After – Feedback on study design and outcome measures 
Beyond the potential negative connotations and moral ambivalence of receiving 
stimulant medications for sarcoidosis-associated fatigue, specific negative aspects 
of the FaST-MP study design were raised by participants. One major problem 
related to a key aspect of the study, notably the questionnaires used for clinical 
outcome measures. For some of the participants, frustration was expressed at the 
number of questionnaires and the overlap between them. Although part of this was 
frustration at the time it took, in some cases the symptoms of fatigue led to actual 
difficulty in completing the questionnaire pack, one participant recalled thinking 
“Gosh, how am I going to get through this [questionnaire pack]?” (013, Focus group 
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3) once she had discontinued the medications. Five of the participants felt that too 
many questionnaires were included, although two participants were happy with the 
number of questionnaires used if it meant that the study was not compromised for 
outcomes.  
Whilst the number of questionnaires was considered a problem, a bigger issue was 
raised concerning the sensitivity of the questionnaires for collecting data which 
reflects improvements for the patients. The questionnaires were described as “not 
relevant,” or “too vague” to adequately pick up the impact of fatigue on daily life; 
this lack of relevance was echoed by others, especially relating to the variability of 
fatigue day-to-day and the difficulty in giving an answer reflecting the severity of 
fatigue over a period of several weeks: 
“I think the answers were very vague as well, especially the multiple-choice ones 
where it’s ‘sometimes’ or ‘often’. Well, and then it’s over the last two weeks. Well, 
actually, I’ve had some good days and I’ve had some bad days but I can’t write, 
“Well, actually, some of it was this, but some of it was this,” or, like you said, it’s 
often or sometimes.” (016, Focus group 3) 
An initial concern when designing the trial was that questionnaires were being 
administered too frequently, as often as every two weeks during the first six weeks 
of the study, but the feedback from focus group participants was that the visit 
schedule was not too onerous and yet the ability to track fatigue levels and the 
effect of medications was still hindered by not being able to measure fatigue levels 
frequently enough to obtain the resolution of data to adequately show change in 
fatigue. Clearly seeing or contacting a patient on a daily basis to score their fatigue 
levels is likely to be impractical and, for the participants, potentially tiresome, 
although a self-report diary may enable collection of this data. Participant 16, who 
had identified the vagueness in our method of measuring and tracking fatigue, 
offered a suggestion: 
“I think, almost, like a daily diary. Not like a full questionnaire every day, but even if 
it’s just notes for us. Some way of logging, “Today was a rubbish day, it took me 
almost two hours to get out of bed and I went back to bed because I was just too 
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tired,” and other days, “I got up, actually, I was really good until lunch time.” (016, 
Focus group 3) 
Whilst this form of data would allow greater insight into the impact of fatigue, it 
may present difficulties in quantitative analysis to detect change over time or 
change between groups unless self-rating scales were included to score daily 
fatigue levels. The use of technology was suggested, using a smartphone-type 
device as a way of administering a simple likert or visual analogue scale question on 
a daily basis relating to fatigue, with the option to add additional data as a diary 
entry if needed. This was considered interesting by the members of focus group 3, 
where this discussion had occurred, and offered a solution to what was considered 
a significant problem with the chosen outcome measures. 
Another outcome measure being evaluated in the FaST-MP study was the use of 
activity monitors, worn for three seven-day periods during the study. The output 
from the devices, as shown in the previous chapter, suggested that it was possible 
to reliably obtain valid data from them. The GENEActiv activity monitor had 
previously been piloted and preferred to a competing device, as described in 
chapter 3, but the experience of using them within the FaST-MP study split opinion. 
Three participants found no problem in using the devices and spoke about the 
devices positively, putting it on and forgetting about it. However, four participants 
spoke negatively about the GENEActiv device, describing it as “too big”, 
“inappropriate for work”, “uncomfortable”, or generally finding the rubber strap 
uncomfortable. Mention was also made of the lack of watch face (also mentioned 
in the feedback on the devices from the pilot study reported in chapter 3) and 
unpleasant appearance; suggestions were made for the use of commercial devices, 
notably Fitbits, which one of the participants wore normally, or apple watches. 
These had the benefit of being more functional and more pleasant in appearance. 
Finally, criticism was also aimed at the facilities used for the modified shuttle walk 
tests. These occurred in the clinical trials unit within the Norfolk and Norwich 
University Hospital, itself a repurposed formed ward area. Whilst there was space 
for the necessary track, in practice it was surrounded by potential obstacles and 
could be crossed by members of staff within the unit accessing storage areas. 
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Incidents had occurred where collisions or interrupted tests had resulted from 
other staff members walking onto the track by accident. A number of participants 
raised this during discussions: 
“…when you do that [walking test], that needs a more defined area. Doing it in the 
corner of a corridor with filing cabinets, desks, chairs…” (006, Focus group 1) 
“It wasn’t very good when I knocked that person walking was it?” (003, Focus group 
1) 
“I had a nurse come in at the last, she stopped me and I was in the peak wasn’t I? 
The peak of my physical fitness and she came across.” (002, Focus group 1) 
“[It’s] just embarrassing when you’re walking down the corridor and someone 
comes around the corner.” (008, Focus group 2) 
The majority of complaints came from members of focus group 1, which relates to 
problems with staff awareness early in the trial. This appeared to become less 
frequent as the trial progressed and staff in the unit were more aware of the test 
being conducted. Participants expressed frustration at these incidents occurring, 
reflecting the importance of obtaining the best possible result in their walking test 
for them and the failure to do this when they were interrupted, or embarrassment 
at running into a member of hospital staff. For some it was a humorous event which 
they laughed at when recollecting the event, but it was universally agreed that the 
location was not ideal for a modified shuttle walk test. One participant in focus 
group 3 went on to suggest a static test, considering a treadmill-based test to be 
preferable given the lack of space for a shuttle walk test to occur whilst 
simultaneously allowing for incremental effort through faster speeds or increased 
inclines. This was also raised by another participant in another focus group who had 
noted that his exercise performance on the flat was good and may not reflect his 
true limitation: 
“I mean, I done quite well with the walking test on the flat, but I think steps [stairs] 
or something of that nature would give a bigger indication of how I struggle in my 
day to day.” (008, Focus group 2) 
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An ergometer, be it treadmill or cycle-based, would have overcome these 
shortcomings and was suggested by one focus group member as an alternative, and 
was considered preferable to the MSWT used in the FaST-MP study. 
 
6.4 Discussion 
This chapter reports an analysis of how participants within the FaST-MP study 
found involvement in the trial, both positive and negative, as well as the problems 
they faced before receiving the trial intervention relating to the impact of fatigue 
on their daily lives. The findings identified here overlap with previous data from 
chronically fatigued patients with rheumatoid arthritis (RA), another chronic 
condition. The patients with RA described an unpredictable or variable fatigue, a 
significant effect on everyday life, and the emergence of self-management 
strategies to minimise the impact of fatigue to the individual (311). In the patients 
with sarcoidosis included here, daily variability in fatigue was mentioned relating to 
difficulties in measuring the symptom in a relevant way within the study. The 
impact of fatigue upon day-to-day life prior to the study was clearly illustrated by 
examples, with self-management and pacing techniques employed by some 
participants to enable essential daily activities to occur. The characteristics of the 
fatigue described appears to be similar to those described in other conditions. The 
resulting impact of this sarcoidosis-associated fatigue leads to disruption of an 
individual’s life, in keeping with Michael Bury’s thematic framework of biographical 
disruption which was described above (302). This is the first time that patients with 
sarcoidosis have been investigated in this way, and the results are in keeping with 
results from other chronic diseases.  
It was notable that the presence of fatigue and reduced energy levels led to some 
of the participants feeling prematurely old, and the coping strategies employed by 
them to maintain function is in line with those employed as part of “healthy aging,” 
maintaining function with a focus on critical tasks such as work or caring for family 
members (304). The insight from this could be used to enable patients who wish to 
manage fatigue, rather than seek pharmacological treatment with agents such as 
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methylphenidate, to follow pacing techniques which require restriction of activities 
to optimise others. This is particularly important when considering the somewhat 
unexpected quantitative results from the FaST-MP study relating to the relative 
efficacy of methylphenidate compared with placebo; despite appearing safe and 
well tolerated, exploring other options before considering neurostimulant therapy 
appears particularly relevant as significant improvements in fatigue, with 
discernible improvements cited in examples from participants included in the focus 
groups, were seen in focus group participants who had been allocated to the 
placebo arm within the FaST-MP study. 
It was unexpected, therefore, to see the ambiguity in discussions from some 
participants relating to taking the medications and returning to a “normal” life, for 
many an incredible and previously unreachable achievement. The inability to split 
apart the notion of a prescribed medication to return to normal function from that 
of an illicit substance used to chase an artificial high was an unexpected finding, 
indicating a reticence on the part of some participants to expose themselves to the 
possibility of addiction. This reinforces the importance of treatment strategies 
involving symptomatic treatment of fatigue with neurostimulants to be undertaken 
with strict oversight and monitoring by secondary care, ideally with experience of 
using these agents. Joint goal setting by patients and clinicians, as well as selection 
of patients to reduce the risk of abuse, is also important. These points were 
considered very important by one participant to prevent him, and others, becoming 
dependent upon a medication and self-medicating with ever-higher doses. 
During discussion of the potential changes that could be made to any related future 
studies a number of positive suggestions were made. The importance of ensuring 
an appropriate facility for conducting all outcome measures, specifically exercise-
based ones such as the modified shuttle walk test, was reinforced through 
discussions with participants. Suggestions included: 
• Future measures of exercise capacity should be considered in light of the 
expected localities where trial activities would expect to be taken place.  
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• The use of static equipment such as exercise bikes or treadmills may provide 
a reasonable alternative as many hospitals have access to a physiology 
laboratory for cardiopulmonary exercise testing, which could be utilised for 
this purpose.  
The other major changes suggested related to the questionnaires and the activity 
monitors. Problems with both of them, notably the inability of the questionnaires 
to measure daily fluctuations in fatigue and the discomfort of wearing the activity 
monitors, led to the suggestion of a unified solution in the form of smart phones or 
smart watches – these devices would have a number of advantages: 
• They are able to track activity levels as part of in-built health data collection 
• They would be able to administer a simple questionnaire on a daily basis 
(e.g. rating fatigue level between 0-100), tracking daily fatigue levels.  
• Different types of wrist straps are available for most smart watches, which 
would provide participants with the option to choose a strap that would be 
most comfortable for them. 
Using the example of the apple watch, specific developer tools are available for 
health research; development of a program (‘app’) to collect both activity and 
fatigue data was considered an interesting solution by some participants and could 
be considered as a way of collecting the necessary resolution of data for any future 
study.  
There were limitations to these focus groups. Three focus groups were convened, 
allowing 14 of the 22 FaST-MP participants to discuss their views. However, new 
ideas and discussions were still being raised in the third focus group, suggesting 
that saturation was not reached within the three groups. There was also limited 
scope to explore in depth the impact of fatigue on daily living which, though not the 
primary rationale for undertaking focus group discussions, would have provided 
interesting data in a disease group that has not previously been investigated using 
these methods. Focus groups were not the ideal forum for discussing this in depth 
and contributed to the decision not to explore the impact of fatigue on individual 
patients prior to study entry. Future work would require semi-structured interviews 
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with individuals to validate the findings relating to impact of fatigue on these 
patients. Finally, the focus groups occurred whilst FaST-MP was ongoing; as a result, 
participants were still blinded to their allocation at the time of the focus groups, so 
no insight could be gained into why participants believed such a significant benefit 
was possible on the placebo medication, or their reaction to finding out their 
allocation. Given the aims of the focus groups it was felt appropriate to explore 
these issues before unblinding, reducing the length of time between completion of 
the main study and participation in the focus groups and hopefully aiding recall of 
any issues that occurred during the study. Despite these limitations, the data 
collected here provided clear examples of benefit from neurostimulant therapy to 
individual patients, as well as identifying weaknesses of the FaST-MP’s trial design 
and suggested potential changes for any follow-up study. 
 
6.5 Conclusions 
This chapter has given insight into the problems faced by patients with sarcoidosis-
associated fatigue, the potential benefits of neurostimulant therapy to an individual 
through some illuminative examples of return to function and improvement to 
quality of life, as well as potential suggestions for alterations to any successor to the 
FaST-MP study. Measuring quality of life in any future study investigating treatment 
for sarcoidosis-associated fatigue is clearly an important outcome. In the next 
chapter, two methods of measuring health-related quality of life are compared to 
identify the preferred instrument for any future study. 
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7.1 Introduction 
The results of the Fatigue and Sarcoidosis – Treatment with Methylphenidate (FaST-
MP) feasibility study have shown that it is feasible to perform trials into the use of 
neurostimulants for treating sarcoidosis-associated fatigue. Whilst recruitment to 
the study was acceptable, and retention of participants through the study was 
excellent, negative issues were flagged by participants during focus group sessions 
relating to the outcome measures used. In the focus group discussions, a number of 
participants suggested that it would be beneficial to reduce the number of 
questionnaires in any future study, and to ensure any future questionnaires were 
able to reflect changes in how participants felt whilst receiving medications.  
One outcome from the exploratory analysis of the questionnaire data collected in 
FaST-MP was the difference seen between the two health utility scores at baseline, 
derived from the EQ5D and SF-6D questionnaires. In order to better understand this 
an additional project was undertaken, administering both the EQ5D and SF-6D 
(through the longer SF-36) simultaneously, alongside other instruments relating to 
fatigue, anxiety, depression and disease status. Some of these factors were seen to 
vary over the course of the study between the methylphenidate and placebo arms, 
therefore the influence of these upon the EQ5D and SF36 utility values is of 
interest.  
Determining which of the EQ5D and SF-6D instruments are preferable for 
measuring health utility in patients with sarcoidosis is important for any future 
health utility analysis, as well as minimising questionnaire burden for participants in 
future trials. This study was undertaken to understand what causes the relative 
difference in performance of the EQ5D and SF-6D questionnaires by collecting and 
analysing cross-sectional data from a cohort of patients with sarcoidosis.  
 
Background 
Quality of life is an important consideration in sarcoidosis, either through the direct 
effects of granulomatous inflammation from the disease (312), constitutional 
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symptoms including fatigue (122, 313), or side effects of treatment which can cause 
symptoms of its own (314). These factors are discussed in depth within chapter one 
of this thesis. 
Health-related quality of life (HRQoL) is distinct from quality of life, although 
distinguishing between the terms can be difficult. Quality of life is a concept which 
encompasses all aspects of life and is difficult to measure, requiring psychological, 
social and economic wellbeing to be considered alongside direct health-related 
effects of both disease and treatment. The term “Quality of Life” in medical 
literature does not have a defined meaning and is frequently substituted for HRQoL 
(186). By contrast, HRQoL is more narrowly-defined, as it focuses on the health or 
disease status of an individual and how this influences quality of life. HRQoL itself 
can be defined in multiple ways, including the frequently used term “health state” 
(187).  
To facilitate comparisons of interventions, “quality-adjusted life years” (QALYs) are 
typically used to measure the impact of treatment on length and/or quality of life. 
The National Institute for Health and Care Excellence (NICE) requires the use of 
QALYs when appraising health technologies (315). In order to generate QALYs, 
weighting of preferences for health states is required. This is termed health utility, 
with more desirable health states having a greater weight. Utility is scored between 
0 and 1; 0 indicates death and 1 indicates full health, with negative health states 
indicating a health state considered worse than death also permitted (316). QALYs 
are calculated from both HRQoL and survival; an individual in a health state 
associated with a utility value of 1.0 living for five years would generate five QALYs, 
as would an individual living in a health state of 0.5 for ten years, although this does 
not consider discounting of future QALYs which reduces the number of future 
QALYs as survival increases. NICE currently recommends a discount of future QALYs 
at a rate of 3.5% per year but can vary this amount (317). QALYs consider both 
survival and changes in health states, combining both these markers into a single 
universal index which enables comparison across different areas of healthcare. The 
number of QALYs lost or gained across a population during an intervention forms 
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the basis of cost-utility analysis (316), which can influence decision-making on 
resource allocation.  
In order to calculate QALYs it is necessary to calculate HRQoL and health utility. 
Patients can be asked to rate their own health-related quality of life using measures 
such as the EQ-VAS on a scale of 0-100. Although there are drawbacks to this 
method, specifically the end-of-scale bias leading to respondents being less likely to 
use the extreme ends of the scale, it is a simple way of measuring health status and 
it directly records an individual’s perception of their own HRQoL (316, 318). It is 
also not a true measure of health utility as it does not require the subject to 
consider sacrificing time or health, or indeed express a preference for their current 
health compared with other possible health states. Alternatively, questionnaires 
can be used to indirectly measure health state values.  These instruments, which 
include the EuroQoL-5D-5L (EQ5D) or the Short Form 6-dimension (SF-6D, which is 
derived from SF-36 values (319)), have multiple dimensions relating to health; the 
responses across all the dimensions within the instrument can be converted into a 
health state. Previous work in healthy populations allows these health states to be 
converted to a utility value, with different methods used for determining 
preference of health states. The two main approaches are the standard gamble (SG) 
and time trade off (TTO). The SG approach, which invites patients to consider 
gaining perfect health (health utility value = 1) compared to their current health, at 
a risk of suffering the worst possible outcome (health utility value = 0). The SG 
approach was used to calculate a value set for the SF-6D instrument (319). This 
method is liable to loss aversion and probability weighting biases leading to higher 
utility vales being reported than with the TTO method (320). By comparison, the 
TTO approach invites patients to consider how much of their remaining life-
expectancy they would trade for living in perfect health compared with their 
current state. The TTO method was used to create a value set for UK populations 
from the EQ5D instrument (321). It is considered more likely to have balanced 
upward and downward biases, thus better reflecting preference for health states 
than the SG method (320). Either method can be used to determine health utility 
values. 
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In sarcoidosis there are no studies comparing generic HRQoL measures, nor has 
there been any investigating the association between disease-specific measures of 
health-related quality of life and generic HRQoL measures. There is also limited 
research investigating the impact of fatigue and depression symptoms on HRQoL; 
only one previous study has investigated this but using the EuroQoL-5D-3L rather 
than the 5L (the previous iteration of the EQ5D questionnaire which had 
shortcomings due to the use of only 3 levels per dimension), with no other generic 
or disease-specific measurements taken at the same time (313). Comparisons of 
health status/HRQoL have been made in other chronic conditions, such as 
rheumatoid arthritis. The health utility scores calculated from the SF-6D, EQ5D and 
EQ-VAS questionnaires in these patients showed marked differences in agreement 
between the measurements, as well as a markedly different relationship with 
clinical parameters and the various utility instruments (322). These differences are 
also of importance when considering health-economic analysis using these utility 
instruments, as the choice of instrument would have a large impact on the outcome 
of any cost-utility analysis. 
It is unclear if this difference in utility instrument performance occurs in patients 
with sarcoidosis given the differences between it and rheumatoid arthritis. In the 
latter, significant disease activity leads to joint deformity and marked physical 
disability. By contrast, although progressive and irreversible pulmonary fibrosis 
does occur in patients with sarcoidosis, the majority will not suffer this outcome. It 
is more common for patients with sarcoidosis to have ongoing constitutional or 
non-specific symptoms with potential adverse impact upon quality of life. These 
constitutional symptoms include fatigue, which has been the focus of this thesis.  
As described previously, fatigue is a multi-dimensional symptom with both physical 
and mental effects. It is unclear whether the severity of this symptom maps onto 
any of the five dimensions of the EQ5D; if none of the dimensions are responsive to 
changes in fatigue level then the instrument would not demonstrate any change in 
health state, and therefore utility value, despite improvements in fatigue. The SF-
6D contains the dimension “vitality”, which reflects energy and fatigue levels (319). 
It is possible that this score would be more responsive to changes in sarcoidosis-
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associated fatigue, but this has yet to be proven. Demonstrating whether there is a 
difference between these instruments in response to fatigue is important; the 
EQ5D instrument is preferred by the NICE for performing economic evaluations, 
although NICE state that other instruments can be used when “EQ5D data are not 
available or are inappropriate for the condition or effects of treatment” (323). 
Given the concerns regarding the dimensions of the EQ5D, it may be that this tool is 
inappropriate for reflecting change in sarcoidosis-associated fatigue and that SF-6D 
should be utilised instead.  
Having a better understanding of how the EQ5D and SF-6D perform relative to 
other instruments measuring clinical problems within sarcoidosis, particularly 
fatigue levels, will help to better understand how any future cost-utility analysis 
within the follow-on study from FaST-MP might be affected by the questionnaires 
included. This knowledge will also help to determine which tools should be included 
in any future study investigating sarcoidosis-associated fatigue. This study uses 
cross-sectional data from a large cohort of patients with sarcoidosis alongside the 
longitudinal health utility data from FaST-MP to answer these questions. 
 
Objectives 
To understand the difference in performance between the EQ5D and SF-6D 
questionnaires through comparing the calculated utility scores from both 
instruments, and determining the relationship between them and a disease-specific 
health status measurement (KSQ), fatigue measurement (FAS) and anxiety or 
depression symptoms (HADS-A). 
Primary Outcome: 
(1) Compare the health utility scores of the EQ5D and SF-6D within a cohort of 
patients with sarcoidosis and determine the relationship and level of 
agreement between the two utility values. 
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Secondary Outcomes: 
(1) Investigate association between health utility scores and disease-specific 
quality of life scores (KSQ), fatigue (FAS), depression (HADS), and clinical 
predictor variables (Age, gender, extra-pulmonary disease, use of 
immunosuppression). 
(2) Determine significant predictive clinical factors (disease-specific quality of 
life scores (KSQ), fatigue (FAS), depression (HADS), and clinical predictor 
variables) for health utility determined by EQ5D and SF-6D using linear 
regression modelling. 
 
7.2 Methods 
Study design 
This is a cross-sectional questionnaire study, which involved administering five 
questionnaires to patients with sarcoidosis. Data were collected from patients with 
sarcoidosis under active follow-up at the NNUH, without evidence of another major 
cardio-respiratory co-morbidity. Patients were contacted via post, with the 
permission of their treating consultant physician, with a return envelope included 
with the questionnaire pack and participant information sheet. Alternatively, 
patients with sarcoidosis who were attending clinic could be given the 
questionnaire pack whilst attending their clinic appointment and offered the option 
of completing the questionnaires whilst at the hospital or taking the questionnaire 
pack away to complete at home and return via post. All questionnaire packs were 
fully anonymous to attempt to increase the number of patients returning 
questionnaires. 
The data from these patients was analysed along with baseline questionnaire and 
demographic data from participants in the FaST-MP study. All questionnaires within 
this study were also administered at the baseline visit for the FaST-MP study, 
allowing the ability to include pre-treatment data for these sarcoidosis patients to 
be analysed alongside data from patients returning questionnaires. A target sample 
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size of 80 patients was pre-specified based upon an achievable sample from 
patients under the care of the Norfolk and Norwich University Hospital, based upon 
an eligible cohort of 271 patients (using data from table 18 in chapter 5), and a 
return rate of 30%, based upon return rates for cohort studies considered feasible 
(324). It also ensures a minimum of ten data points per variable within the 
regression analysis.  
All subjects were aged 18 or over and able to give informed consent. Ethical 
approval was gained from the London – Chelsea Research Ethics Committee, REC 
reference 17/LO/1872, prior to the study commencing. 
 
Study population 
For participants recruited for this study the following inclusion and exclusion 
criteria were used: 
Inclusion Criteria: 
1. Male or Female aged over 18 
2. Diagnosed with sarcoidosis and is under follow-up by hospital, or has 
been previously, for the condition. 
3. Has mental capacity to complete the questionnaires 
4. Agreement from primary physician to contact the patient 
Exclusion Criteria: 
1. Presence of another significant cardio-respiratory disease, major organ 
disease (except where related to sarcoidosis) or chronic inflammatory 
condition 
2. Unable to give informed consent 
There was no restriction on current medications, with data on oral steroid usage, 
steroid dose, and use of other immunosuppressant drugs collected as part of the 
demographic data. 
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Study assessments 
Participants within the study were asked to complete five questionnaires in 
addition to providing data regarding their age, sex, year of diagnosis with 
sarcoidosis, use of oral corticosteroids (including dose), use of other 
immunosuppressant medications, and extent of disease (pulmonary disease only, 
pulmonary and extrapulmonary disease, or extrapulmonary disease only). 
Participants were then asked to complete the following questionnaires in the 
following order: 
(1) Fatigue Assessment Scale (FAS) 
(2) Hospital Anxiety and Depression Score (HADS) 
(3) Kings’ Sarcoidosis Questionnaire (KSQ) 
(4) EuroQoL-5 dimension-5 level (EQ5D) questionnaire 
(5) Short Form 36 (SF-36), used to derive Short Form 6-dimension (SF-6D) 
values 
The details and properties of each questionnaire are discussed previously within the 
methods section for FaST-MP in chapter 4. The questionnaires were chosen to 
capture data on fatigue levels, disease-related health status, and anxiety and 
depression symptoms. These factors were considered important based upon the 
clinical outcomes in the FaST-MP study (chapter 4), and that these factors were 
likely to influence health utility scores derived from the EQ5D and SF-6D 
questionnaires. All questionnaires can be completed without input from a 
healthcare professional or research team member. 
 
Utility instruments 
Respondents completed the SF-6D and EQ5D questionnaires; results from the EQ5D 
were directly used to determine health utility values whereas SF36 data had to be 
converted to six-dimension SF-6D values first. The details of these two instruments 
has been described previously in chapter 4, section 4.2. The EQ5D consists of five 
dimensions, each with five potential answers, giving 3,125 potential responses 
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(“health states”). Health utility values less than 0.0, reflecting a health state 
considered worse than death, are possible from the EQ5D data set. SF-6D is an 
instrument which can enable translation of SF-36 scores to a health utility score. SF-
6D consists of six dimensions (physical functioning, bodily pain, physical role 
functioning, social role functioning, mental health and vitality), each dimension 
having between four and six levels. Higher scores within each domain (scored out of 
6) indicate worsening function within the dimension. Over 18,000 health states can 
be described from the SF-6D. Data from each of the instruments can be used to 
derive health utility values, using existing value sets derived from UK populations; 
the EQ5D utility values have been previously calculated using the time trade-off 
method (321) and SF-6D values previously determined using a standard gamble 
method (319).  
 
Statistical Analysis  
All data were transcribed onto a Microsoft excel spreadsheet on a password-
protected computer. Values for the FAS and HADS scores were calculated according 
to the questionnaire instructions. FAS scores out of 50 were stratified into 
respondents reporting a score >21 (clinically significant fatigue) and >34 (severe 
fatigue). HADS scores were calculated by tallying the scores within the anxiety sub-
score (HADS-A) and depression sub-score (HADS-D); data was then stratified to 
report the number of respondents with HADS-A and -D scores <8 (normal), 8-10 
(borderline) or >10 (anxiety or depression present).  
Values from the KSQ were converted to overall sarcoidosis-related health scores 
within the domains of general health (KSQ-GHS), lungs (KSQ-Lung), medications 
(KSQ-Med), skin (KSQ-Skin), eyes (KSQ-Eye) and a composite value of each domain 
(KSQ-GLMSE). In each case, lower scores indicate greater problems relating to 
sarcoidosis impacting upon the domain. These values were calculated using a 
custom excel spreadsheet, available from the copyright holder of the questionnaire 
(273).  
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Analysis of descriptive statistics (mean and standard deviations or frequencies and 
percentages) were planned for respondent demographics and questionnaire 
answers. Number and percentage within each stratum for the FAS and HADS scores 
were also calculated.  
Data from the SF36 questionnaire was converted to SF-6D scores within a custom 
spreadsheet which calculated health utility values. Responses from the EQ5D and 
SF-6D were converted to health utility values using excel existing datasets for UK 
population health utility values. Each patient response for the two questionnaires 
was converted to a calculated health utility value. The median responses from each 
dimension of the EQ5D and SF6D questionnaires was calculated; bivariate 
correlation (spearman’s rho given the ordinal nature of the data) was used to 
calculate the correlation coefficient between each dimension. Utility values from 
the EQ5D and SF-6D were compared against two global measures of health status 
contained within two of the questionnaires; the SF36 contains a five-point scale 
rating health (which is not involved in the calculation of utility scores) that asks 
respondents to rate their overall health; the KSQ contains a six-point scale rating 
health asking respondents to score their overall quality of life related to their 
sarcoidosis. Mean scores for each utility was calculated for each level of the scale.  
Distribution of EQ5D and SF-6D health utility scores was checked visually using 
histograms. Agreement between these two measures was then determined using a 
Bland-Altman plot. Bivariate correlation, examined by spearman’s rank co-efficient 
(rho), was performed between health status (EQ5D and SF-6D) and both 
demographics (age, disease duration) and questionnaire scores (HADS-A, HADS-D, 
FAS and KSQ values). Correlation strength was interpreted according to previous 
recommendations (325); rho values of 0.3-0.5 were weak, 0.5-0.7 were moderate 
and >0.7 were strong. Linear regression models were then calculated for each utility 
instrument to determine which factors were important predictors of health utility 
values, with predictor variables removed stepwise from the model if their 
significance was <0.2 at any step until all remaining variables were significant at the 
0.05 level; the R2 statistic was calculated to determine model fit. Only the KSQ 
composite value (KSQ-GLMSE) was included from the KSQ outputs due to the high 
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level of interaction between this and other KSQ outputs. This enabled a review of 
the factors which could be used to predict utility scores for EQ5D and SF-6D, 
therefore determining which factors the utility scores were responsive to. 
Following data entry, a review of missing entries was undertaking; few incomplete 
questionnaires were submitted, therefore missing data was handled via listwise 
deletion for any analysis involving the instrument with the missing data point. The 
exception to this method was the HADS-A and -D scores which had value 
substitution using the average value of the remaining subset answers (-A or -D), as 
long as >50% of the questions were answered (326).  
All statistical analysis was performed using SPSS Statistics version 25 (IBM Corp, 
Illinois, USA). 
 
7.3 Results 
Participants 
One hundred and forty-five questionnaires were sent out to patients, representing 
the patients who met the criteria for inclusion in the study and had been reviewed 
in the respiratory clinic during the past 12 months. Of these questionnaires, sixty-
eight respondents returned their completed questionnaire pack, a return rate of 
46.9%. Additionally, baseline questionnaire data from the twenty-two participants 
in the FaST-MP study was included, giving a total of 90 datasets from patients with 
sarcoidosis. The questionnaire completion rate was high, with the SF-36 having the 
highest number of non-valid returned questionnaires (5/90, 5.5%); 100% of 
respondents correctly completed the EQ5D. Only one patient each returned invalid 
data for the FAS and KSQ instruments, although the data completed within the KSQ 
was still sufficient to provide results for four of the six domains investigated here. 
The remaining data after list-wise removal was sufficient to perform exploratory 
regression analysis on the predictor variables for EQ5D and SF-6D utility values. 
The demographics for the respondents are shown in table 46. Average scores from 
respondents for each questionnaire are shown in table 47. A high number of 
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respondents reported significant fatigue symptoms from their FAS questionnaire, 
with 65.2% of respondents recording a FAS score of >21, and over a third of those 
reporting marked fatigue having a FAS score of >34, consistent with severe fatigue.  
 
Table 46 - Respondent Demographics 
Demographic Respondents 
Female sex – n (%) 39 (43.3%) 
Age, years – mean (S.D.) 
Stratification by age – n (%) 
  <21 
 21-40 
 41-60 
 61-80 
 >80 
 Data missing 
57.0 (11.3) 
 
0 (0.0%) 
9 (10.0%) 
43 (47.8%) 
36 (40.0%) 
1 (1.1%) 
1 (1.1%) 
 
Disease duration, years – mean (S.D.) 7.4 (8.4) 
Pulmonary disease – n (%) 90 (100.0%) 
Extra-pulmonary disease – n (%) 52 (57.8%) 
Currently receiving steroids – n (%) 36 (40.0%) 
Receiving other immunosuppressant – n (%) 15 (16.6%) 
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Table 47 - Respondent questionnaire results 
Questionnaire Result (mean, S.D. unless stated) 
FAS 26.5 (10.5) 
Fatigue 
Severity 
No fatigue (score 0-21) 31 (34.8) 
Fatigue (score 22-34) 39 (43.8) 
Severe fatigue (score 35-
50) 19 (21.4) 
HADS – Anxiety  Mean Value 7.2 (4.8) 
Anxiety 
symptoms 
severity 
No anxiety symptoms  
(score 0-7) 50 (56.2) 
Borderline (score 8-10) 16 (18.0) 
Anxiety symptoms present 
(score 11-14) 23 (25.8) 
HADS – Depression Mean Value 5.5 (4.1) 
Depression 
symptoms 
severity 
No depression symptoms 
present (score 0-7) 63 (70.8) 
Borderline (score 8-10) 14 (15.7) 
Depression symptoms 
present (score 11-14) 12 (13.5) 
KSQ domains 
– General Health Status 
– Lung 
– Medicine 
– Skin 
– Eye 
– Overall (composite) health status 
 
58.7 (17.7) 
61.6 (20.6) 
81.2 (23.1) 
85.6 (22.5) 
71.1 (22.8) 
57.8 (11.5) 
SF-6D dimensions (median, range) 
– Physical functioning 
– Role limitations 
– Social functioning  
– Pain  
– Mental health  
– Vitality  
 
3 (1 – 6) 
2 (1 – 4) 
2 (1 – 5) 
3 (1 – 6) 
2 (1 – 5) 
3 (2 – 5) 
EQ5D dimensions (median, range) 
– Mobility 
– Self-care 
– Usual activities 
– Pain and discomfort 
– Anxiety and depression 
 
1 (1 – 4) 
1 (1 – 4) 
2 (1 – 5) 
2 (1 – 5) 
2 (1 – 5) 
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Comparison between EQ5D and SF6D dimension results 
Moderate to strong correlation was seen between most of the dimensions of the 
EQ5D and SF-6D. The strongest coefficient values were seen between SF-6D pain 
and EQ5D pain dimensions (r = 0.749, p<0.001), SF-6D mental health and EQ5D 
anxiety dimensions (r = 0.730, p<0.001) and SF-6D physical functioning and EQ5D 
usual activities (r = 0.722, p<0.001). The remaining correlations are shown in Table 
48. 
 
 
 
 
 
 
Table 48 - Correlations between reported patient-reported levels in SF-6D and EQ5D 
dimensions 
 EQ5D Dimensions 
SF-6D 
dimensions 
Mobility Self-care Usual 
activities 
Pain and 
discomfort 
Anxiety and 
depression 
Physical 
functioning 0.620** 0.621** 0.722** 0.577** 0.387** 
Role 
limitations 0.518** 0.324** 0.560** 0.443** 0.480** 
Social 
functioning 0.545** 0.483** 0.651** 0.560** 0.609** 
Pain 0.606** 0.273* 0.510** 0.749** 0.447** 
Mental 
health 0.235* 0.251* 0.345** 0.329** 0.730** 
Vitality 0.491** 0.401** 0.637** 0.458** 0.444** 
* = significant at p=0.05 level ** = significant at p=0.01 level 
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The SF-6D dimension “physical functioning” correlated best with the EQ5D 
dimensions of “usual activity” and “self-care”. “Role limitations” (SF-6D) did not 
correlate with one single EQ5D dimension, showing moderate correlation with 
“Mobility” and “Usual activities” but weak correlation with “self-care”. “Social 
functioning” and “usual activities” showed strong correlation, as did the “mental 
health” and “Anxiety and depression” dimensions. The “pain” dimension of SF-6D 
and the “pain and discomfort” dimension from EQ5D showed the strongest 
correlation coefficient of any two dimensions, whilst “vitality” within SF-6D best 
correlated with “usual activities” in EQ5D. 
 
Utility scores across global measures of health 
The performance of each of the individual questionnaires (SF-6D and EQ5D) 
appeared similar across both general health (SF36) and sarcoidosis-related quality 
of life (KSQ). Each questionnaire showed good discrimination across levels of 
health, although differences were seen in performance between each individual 
questionnaire. The number of respondents returning each level of self-reported 
health and sarcoidosis-related quality of life are shown in the first row of tables 49 
and 50. The EQ5D values were higher across all levels of sarcoidosis-related quality 
of life and general health compared to the SF-6D values, except in participants 
reporting very severe problems where the mean EQ5D score was lower than the SF-
36 (Tables 49 and 50).  
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Table 49 - Utility scores across KSQ-derived self-reported health 
 No 
problem 
Minimal 
problem 
Mild 
problem 
Moderate 
problem 
Severe 
problem 
Very 
severe 
problem 
No.  respondents 
reporting this 
level 
19 19 11 27 11 3 
EQ5D Utility 0.928 0.864 0.833 0.714 0.524 0.351 
SF-6D Utility 0.832 0.725 0.689 0.598 0.522 0.501 
 
 
 
 
Table 50 - Utility scores across SF36-derived self-reported health 
 
 Excellent Very good Good Fair Poor 
No.  respondents 
reporting this 
level 
3 19 23 26 19 
EQ5D Utility 0.966 0.902 0.896 0.713 0.532 
SF-6D Utility 0.765 0.799 0.745 0.619 0.511  
 
 
 
Distribution of health utility scores 
Mean/median scores for the SF-6D and EQ5D scores were 0.671/0.639 and 
0.770/0.828 respectively. Two respondents (2.2%) reported an EQ5D utility score of 
less than zero. All respondents provided data to determine an EQ5D utility score; 
five patients (5.6%) did not provide sufficient data to calculate an SF-6D utility 
score. SF-6D values showed a near normal distribution; EQ-5D derived utility values 
showed a left (negative) skew. Distribution of utility scores across each of the 
health measures are shown in Figure 21. 
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Agreement of health utility scores 
Agreement between the health utility values derived from EQ5D and SF-6D 
responses was poor. At poorer health states, the EQ5D utility results are 
significantly lower than the SF-6D utility scores, whereas at higher health states the 
EQ5D result is higher than the SF-6D values. Although the average difference 
between the utilities derived from the two instruments was 0.098, the range in 
differences between the two values was -0.609 to +0.325. The Bland-Altman plot 
(Figure 22) graphically illustrates this difference between the results from the two 
questionnaires, indicating that the bias between the two health utility values was 
not stable across the range of scores seen. 
 
 
Figure 21 - Distribution of SF-6D and EQ5D utility values 
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Figure 22 - Bland-Altman plot comparing EQ5D and SF-6D utility scores 
 
 
 
 
Correlations between health utility scores and other clinical markers 
Correlations between demographic values and questionnaire results were 
examined; no dimensions from the SF-6D or EQ5D were included as they would not 
be independent of the calculated health utility value from the respective 
instruments. Strong correlation with the health utility scores was seen between 
general health status, lung and composite domains of the KSQ, anxiety and 
depression symptoms (HADS-A and HADS-D) and reported fatigue levels (FAS). 
Moderate correlation was seen with the remaining domains of the KSQ. The 
demographic data included (age and disease duration) did not show any significant 
correlation with health utility values (Table 51). 
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Table 51 - Bivariate correlation with health utility scores 
 EQ5D SF-6D 
Demographics 
Age 0.055 0.131 
Disease Duration -0.063 -0.085 
Disease Activity 
KSQ-GHS 0.808** 0.866** 
KSQ-Lung 0.583** 0.711** 
KSQ-Med 0.381** 0.216** 
KSQ-Skin 0.288** 0.361** 
KSQ-Eye 0.513** 0.542** 
KSQ-Composite 0.741** 0.820** 
Anxiety and Depression 
HADS-A -0.574** -0.642** 
HADS-D -0.677** -0.792** 
Fatigue 
FAS -0.787** -0.824** 
Values are spearman’s rho values 
*Significant at 0.05 level 
** Significant at 0.01 level 
 
Regression modelling 
The results of the linear regression analysis are shown in table 52 (EQ5D) and 53 
(SF-6D). Due to high inter-correlated nature of multiple variables in Table 51, and 
the relatively low number of respondents to the number of variables, only four 
variables were included in the regression model; FAS, HADS-A, HADS-D, and the 
KSQ-Composite score. Significant predictor variables only are displayed in the table. 
Both the FAS questionnaire and HADS-A questionnaire scores were significant 
predictors for both SF-6D and EQ5D-derived utility values. For the SF-6D utility 
scores the KSQ-Composite score was also found to be a significant predictor, 
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indicating perceived physical symptoms and general health status also influenced 
SF-6D utility scores.  
 
Table 52 - Regression co-efficients of multiple factors on EQ5D-derived health utility 
values 
 B 95% CI p Standardised co-efficient 
FAS -0.011 -0.016, -0.007 <0.001 -0.507 
HADS-A -0.015 -0.024, -0.006 0.002 -0.292 
(constant) 1.180 1.081, 1.279 <0.001 - 
 
 
Table 53 - Regression co-efficients of multiple factors on SF-6D-derived health utility 
values 
 B 95% CI p Standardised co-
efficient 
FAS -0.005 -0.007, -0.003 <0.001 0.392 
HADS-A -0.008 -0.011, -0.004 <0.001 -0.248 
KSQ-Composite 0.005 0.003, 0.007 <0.001 0.387 
(constant) 0.588 0.425, 0.751 <0.001 - 
 
The following predictor equations were derived using the linear regression results: 
• EQ5D Utility = 1.180 - 0.011 x FAS – 0.015 x HADS-A, adjusted R2 = 0.492 
• SF-6D Utility = 0.005 x KSQ-Composite - 0.005 x FAS – 0.008 x HADS-A + 
0.588, adjusted R2 = 0.793 
Of the significant predictor variables for each HRQoL score’s derived utility values, 
the FAS score had the strongest effect on EQ5D-derived utility values (standardised 
coefficient -0.507), whilst the KSQ-Composite scores and FAS scores had similar 
effects upon SF-6D-derived utility values (standardised coefficients 0.392 and -
0.387 respectively). Overall, the model for SF-6D utility values predicted 79.3% of 
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variance seen, whereas the EQ5D model only explained 49.2% of variability in the 
derived utility scores. 
 
7.4 Discussion 
Relative performance of the EQ5D and SF-6D 
Comparing the individual dimensions of the EQ5D and SF-6D shows that there are 
dimensions that behave similarly and are therefore likely to measure the same 
aspects of health status. Some show strong correlation coefficient values between 
single dimensions in each instrument, such as “pain” in SF-6D and “pain and 
discomfort” in EQ5D, or “mental health” in SF-6D and “anxiety and depression” in 
EQ5D. These dimensions are very similar, and it is unsurprising that they show good 
correlation. Some dimensions of the SF-6D have no single equivalent in EQ5D, so 
moderate correlation at best was seen with multiple EQ5D dimensions. This was 
particularly noticeable with the “role limitation” and “vitality” dimensions in the SF-
6D, where the dimension encompasses both physical and mental condition, 
although the vitality dimension showed moderate correlation with usual activities. 
Given that the vitality domain reflects energy and fatigue level, the correlation 
between scores within these two dimensions supports the suggestion that fatigue 
and activity levels in free living are related (327), although the correlation 
coefficient between these dimensions was moderately strong (rho = 0.637). Overall, 
the lack of a specific dimension in EQ5D equivalent to the vitality dimension in SF-
6D suggests that SF-6D health states and derived utility values are more likely to be 
responsive to changes in fatigue levels within an individual. 
The spread of utility scores derived from the EQ5D suggests that there is a ceiling 
effect with the utility values from this instrument, something which has been 
suggested from previous studies (328). This may mean that the instrument is less 
able to discriminate between people in fair health when compared with the SF-6D. 
The results showed that a significant number of respondents had a utility score of 
1.0 with a skewed distribution towards higher values. This occurred despite the 
patient cohort within this study being more likely to be suffering chronic disease or 
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extrapulmonary disease compared with non-respondents. The reason for this 
ceiling effect may be due to the dimensions included in EQ5D not being responsive 
to chronic symptoms from sarcoidosis due to constitutional symptoms such as 
fatigue or small fibre neuropathy. The increased number of dimensions within SF-
6D (six) compared with EQ5D (five), and therefore the higher number of potential 
health states available (18,000 and 3,125 respectively), may explain why the SF-6D 
appeared better able to respond to variations between patients which was seen in 
this study. The greater number of health states gives greater resolution and greater 
ability to differentiate health states within patients, particularly in milder disease 
where the EQ5D appeared to have a ceiling effect.  
The observed distribution of health utility values from the SF-6D utility values was 
markedly different to those calculated from the EQ5D results, with the score 
behaving differently at the extremes compared with the SF-6D. Whilst SF-6D and 
EQ5D values all individually showed good discrimination across self-reported health 
states related to general health and sarcoidosis-related health (Tables 49 and 50), 
there was poor agreement between EQ5D and SF-6D utility values. Differences in 
utility scores over 0.5 are seen between the two instruments, a large difference 
considering the scale of possible health utility values permitted by the instruments. 
The size of the difference between the two instruments was seen to vary in size 
depending on the health state of the patient (shown in the Bland-Altman plot, 
Figure 22). This finding has been identified previously in other conditions, including 
rheumatoid arthritis (322) and chronic pain (329). This may be related to the 
extended range of the EQ5D, where it is possible to give responses that equate to a 
health state perceived as worse than death. However, it should be noted that the 
EQ5D score showed a skew towards higher values rather than lower ones, and only 
two respondents reported EQ5D scores corresponding to a utility value of less than 
zero.  
An alternative explanation is that the health utility score calculations for EQ5D and 
SF-6D were performed in different ways; the SF-6D values were calculated using the 
SG method whilst the EQ5D values were determined using a TTO method. The 
biases present in each method are different, leading to variances in utility values 
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calculated by the two methods. The SG method is thought to suffer upward bias, 
giving a higher utility value for a given health state compared with the TTO method 
(320). Unfortunately, no UK-derived utility value sets using the TTO method are 
available for the SF-6D questionnaire to allow direct comparison with the EQ5D 
value sets, although the SF-6D-derived health status values observed here were 
lower than those derived from the EQ5D questionnaire results, suggesting that the 
known biases between the SG and TTO methods of deriving health utility are not 
responsible for the difference seen. This makes it more likely that the disparities are 
due to how the dimensions within the EQ5D and SF-6D instruments respond to 
differences in clinical factors, including fatigue. 
 
Predicting utility values from other measures 
Regression models were able to predict SF-6D values with a good degree of fit; the 
adjusted R2 value of a model containing the KSQ-composite, HADS-A and FAS scores 
was 0.793, suggesting that almost 80% of variability in the calculated utility score 
from SF-6D was explained by the model. By contrast, the model for the EQ5D was 
able to predict less than half of the variability seen in the utility scores from the 
predictor variables captured in this study.  
Fatigue has previously been shown to correlate with lower EQ-VAS scores (313) but 
had not been compared with utility values derived from the questionnaire. This 
study has allowed the opportunity to do this. Fatigue, as measured by the FAS 
score, was found to be a significant predictor for both SF-6D and EQ5D values. It 
was hypothesised before the study began that this may not be the case due to the 
difference in the dimensions contained within the EQ5D and SF-6D instruments. SF-
6D features the dimension “vitality”, which is derived from a question pertaining to 
energy levels and activity. Despite this, the EQ5D was still responsive to levels of 
fatigue reported by respondents. Both scores were also responsive to changes in 
anxiety (HADS-A) scores. The SF-6D utility scores were also impacted by changes in 
the composite KSQ score, reflecting the overall score from the KSQ incorporating 
multiple disease-related issues including general health status. This would have 
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been the measure most likely to reflect physical symptoms and suggests that the 
SF-6D utility score may be more likely to reflect changes in disease severity.  
The results from the cross-sectional data suggest that the SF-36 questionnaire from 
which SF-6D health states are derived should be considered an appropriate and 
responsive instrument for measuring health utility in patients with sarcoidosis. 
Alternatively, the shorter SF-12 questionnaire could also be used as the SF-6D 
health states can also be derived from this tool and is a third of the length of the SF-
36 questionnaire. The SF-6D utility score appears to be responsive to changes in 
disease-related health status, anxiety symptoms and fatigue severity, all of which 
are important variables in any study investigating patients with sarcoidosis, 
whereas variation in the EQ5D utility score was only explained by two of these 
three important factors.  
 
Strengths and limitations 
This study included a well-defined sarcoidosis cohort from a hospital outpatient 
roster, ensuring that patients with a secure diagnosis of the condition were 
included. There was also a good return rate for a postal questionnaire, with almost 
half of the patients contacted returning the questionnaire pack. This cohort of 
patients contained a range of disease severities, with a tendency towards wider 
disease involvement given the number of patients reporting extra-pulmonary 
disease and the use of immunosuppressant medications. This cohort also included a 
large number of non-fatigued patients, allowing a wider understanding of how 
these questionnaires perform across levels of fatigue, not just in patients with 
significant fatigue as was the case in the FaST-MP study (chapter 5). Directly 
comparing the EQ5D and SF-6D questionnaires in patients with sarcoidosis has 
enabled differences in the performance of the two measures to be identified.  
This study had a number of limitations. It contained patients recruited from a single 
centre only, although this was chosen deliberately to ensure a well-defined cohort 
was included. This meant that the cohort was small compared with other cohort 
studies in other chronic diseases, which have included over a thousand participants 
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(322). The included patients tended towards more severe disease and older age, 
although this may be related to the demographic in the Norfolk area. The data was 
also from a single time-point only. Performing repeated measurements would have 
allowed an exploration of the changes between fatigue scores and calculated utility 
values over time. This would have allowed insight into how the change in one 
response would relate to the other. Finally, the data collected was anonymous, a 
decision taken to try and maximise the response rate from patients. This did mean 
that the data could not be linked back to individual clinical parameters, such as 
pulmonary function and radiological staging. 
 
7.5 Conclusions 
The HRQoL instruments measured in this study varied in their performance; to 
explain this it is important to consider that  HRQoL is a multi-dimensional construct 
which is affected by a multitude of factors, including disease-related factors and 
symptoms (223), personality type (330), and mood (331). Within patients with 
sarcoidosis, HRQoL can be impaired by problems with mobility, working capacity, 
cognitive aspects, sleep, social interaction, depression and issues with usual 
activities (332). Not all patients will have impairment in HRQoL due to all of these 
aspects; the optimum instrument to measure HRQoL should be responsive to all of 
these factors. In this study SF-6D appeared responsive to more factors than EQ5D 
and so should be considered preferable to EQ5D for measuring HRQoL, and 
calculating health utility, in patients with sarcoidosis. 
With this chapter, additional data has been presented for the performance of the 
various questionnaires. The outcomes support the use of SF-6D over the EQ5D in 
trials enrolling patients with sarcoidosis, given that the measure appears to be 
responsive to a greater number of important factors in patients with sarcoidosis, 
notably fatigue, anxiety and disease-related quality of life. Alongside data gathered 
from the FaST-MP study (chapter 5) and feedback from participants during focus 
group discussions (chapter 6), the results from this study help to inform the choice 
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of outcome measures for any future study investigating treatment for sarcoidosis-
associated fatigue.  
In the next chapter, the results from all the studies undertaken in this thesis are 
discussed, leading to a proposed design for a future study to determine the clinical 
efficacy of neurostimulant agents for sarcoidosis-associated fatigue. 
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8.1 Introduction 
The work presented in this thesis has demonstrated the limited current evidence 
for interventions targeting sarcoidosis-associated fatigue, and undertaken research 
to determine how to design and perform a full randomised-controlled trial to 
determine the clinical efficacy of methylphenidate for treating sarcoidosis-
associated fatigue. This chapter concludes the thesis by considering what was 
discovered throughout this project, and reflecting on how the lessons learnt could 
influence future work in this area. 
 
8.2 Fatigue as a feature of sarcoidosis 
Prior to the undertaking of this thesis, fatigue had been identified as a common 
symptom affecting patients with sarcoidosis (122), including work already 
undertaken by the author in a cohort of patients with sarcoidosis who were under 
the care of the Norfolk and Norwich University Hospital (170); that research, 
performed as a cross-sectional study of patients attending the respiratory clinic 
with a diagnosis of sarcoidosis, identified that 50.7% of cases reported significant 
fatigue when scored using the FAS questionnaire, and that these participants were 
more likely to report symptoms of mental fatigue. The research themes addressed 
within this thesis directly stemmed from that earlier work, and whilst it was not a 
primary objective of this thesis to replicate and confirm these earlier findings, it is 
reassuring to see that the findings presented in this thesis support these previous 
results.  
Two of the projects undertaken within the thesis collected data that enabled 
estimation of fatigue rates within the cohort of patients at the Norfolk and Norwich 
University Hospital. In the screening log for the FaST-MP study, 43.9% of 
participants were identified as reporting fatigue; this was lower than the earlier 
study but included all participants under the care of the respiratory clinic, including 
those who had mild disease (stage I) or incidentally discovered disease, and may be 
less likely to suffer significant fatigue. Alternatively, the lower rate may represent 
an under-reporting of fatigue within clinical notes. By contrast, the rate of fatigue 
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reported in chapter 7 (A comparison of measurements of health-related quality of 
life in patients with sarcoidosis) was higher than previously identified, with 65.2% 
(58/90) of respondents reporting a FAS score of >21, consistent with significant 
fatigue. However, the data for 22 of these participants came from the FaST-MP 
study; with this data removed, the reported fatigue rate in the remaining group was 
52.9% (36/68 respondents), almost identical to earlier work. Fatigue therefore 
remains a high burden and one with a significant negative impact upon quality of 
life for patients suffering this symptom. 
Beyond reported quality of life, fatigue itself appears to reduce levels of physical 
activity undertaken. In Chapter 3 (Determining a preferred measurement device for 
recording daily activity in patients with sarcoidosis) the data collected from 
participants undertaking a cross-over study of two wrist-worn activity monitors was 
analysed to compare fatigue levels (measured using the FAS questionnaire) with 
recorded levels of activity and sedentary behaviours. Despite the small numbers 
undertaking the study, the data did support at least moderate correlation between 
daily time spent performing sedentary activities and fatigue scores, with increasing 
fatigue leading to increased sedentary time. As patients become increasingly 
sedentary this in itself may increase fatigue, propagating a cycle which leads to ever 
worse activity, fatigue and quality of life.  
When considered alongside the negative impacts seen in patients suffering 
significant fatigue, the results reinforce the importance of treatment of this 
debilitating symptom. The rationale for introducing treatment in patients with 
sarcoidosis is moving towards one of treating for two reasons; risk of long-term 
damage to organ function or risk of unacceptable impairment to quality of life (82), 
with the latter fitting with the impact of fatigue on patients’ lives. The current 
evidence base for any form of treatment for sarcoidosis-associated fatigue is weak. 
This was the rationale for undertaking the work presented here, aiming to move a 
step towards undertaking appropriately designed studies that may help to 
determine the optimum management strategies for patients with sarcoidosis-
associated fatigue, including the role of methylphenidate for symptom 
management. 
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8.3 Methylphenidate as a therapeutic option for sarcoidosis-associated fatigue 
Previous data supporting methylphenidate use 
The evidence base for possible interventions for sarcoidosis-associated fatigue was 
discussed in chapter 2, with limited evidence available for any single approach to 
managing this difficult symptom. Neurostimulants, such as methylphenidate, were 
a promising therapeutic option where sarcoidosis activity was not deemed 
sufficient to require systematic therapies such as corticosteroids or, in severe 
disease, anti-TNF-alpha agents; these drugs often risk significant side-effects of 
their own. There was an unmet need in the respiratory clinic for effective 
management strategies for sarcoidosis-associated fatigue, including the use of 
neurostimulants, but the evidence base for their use was limited. 
A single previous trial had investigated the use of methylphenidate for patients with 
sarcoidosis-associated fatigue; Lower and colleagues used dexmethylphenidate, the 
d-isomer of methylphenidate, for symptomatic relief of sarcoidosis-associated 
fatigue (173). This work took place on the back of earlier work investigating the 
effectiveness of dexmethylphenidate for cancer-associated fatigue post-
chemotherapy, which had suggested benefit compared with placebo over an eight-
week period (211). In the trial by Lower and colleagues, the clinical outcomes 
suggested a benefit compared with identical placebo, with a mean drop of five 
points in the FAS score over an eight-week treatment period. The study was small, 
including only ten participants, and measured outcomes over a short period of time 
(8 weeks). This sample size was insufficient to prove the clinical efficacy of 
methylphenidate. Furthermore, the potential weaknesses of a cross-over study 
design, as discussed in Chapters 4 and 5, meant that there would have been 
difficulties maintaining participant blinding, as well as the possibility of carry-over 
effects through the wash-out period. On this basis, the FaST-MP study was designed 
to increase the evidence base, primarily with the aim of informing the design of 
trials sufficiently large to determine the efficacy of methylphenidate, or alternative 
neurostimulants agents. 
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Several features from the earlier cross-over study were used as the basis for FaST-
MP; the dose range of methylphenidate chosen was equivalent in action to the 
dexmethylphenidate doses used, and the fatigue outcomes used were the same as 
the earlier trial, which would allow direct comparison of changes in scores. The 
inclusion criteria were modified slightly; the requirement to have had a diagnosis of 
sarcoidosis for at least two years was not included, allowing participants with a 
recent diagnosis to be randomised, and participants were also required to have a 
minimum level of fatigue according to the FAS score, in an effort to ensure that 
patients with more severe fatigue were included. The main difference however was 
the decision to design the study as a parallel-arm rather than cross-over trial, as 
well as extending follow-up for a 24-week period. These decisions were made for 
two reasons. Firstly, the parallel-arm design aimed to overcome the challenges of 
maintaining blinding in a cross-over study when using a symptom-targeting 
treatment (which was thought to have potentially obvious effects for patients). The 
increased duration was used to look for persistence of effect beyond 8-12 weeks, 
the duration which trials investigating methylphenidate for a number of indications 
had thus far used for follow-up. It was also unclear how many patients with 
sarcoidosis would be eligible for the study, or wish to participate; the earlier study 
by Lower et al found that 10 out of 44 patients assessed (22.7%) were eligible and 
willing to participate, but it was unclear if this would be replicated in the respiratory 
clinic of a medium-sized tertiary hospital. 
 
Outcomes from the FaST-MP study 
Recruitment to the FaST-MP study was lower than anticipated, with only 55 
patients of the 385 assessed for eligibility (14.3%) meeting the criteria for inclusion 
in the study, and only 22 of those patients (40% of those eligible, 5.7% of the total 
patient cohort assessed) agreeing to participate in the study. This therefore 
represents a small percentage of patients with sarcoidosis who would be eligible for 
participating in future studies if the same inclusion and exclusion criteria were used.  
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However, a number of positive factors were identified. Of the 19 participants 
surveyed at the end of their participation in FaST-MP, all reported the trial as 
having been a useful experience for them, and would recommend participation in 
similar future trials to other patients with the condition. Participant retention 
through the trial, as a result, was excellent. Although one participant had to 
discontinue study medications due to side effects, no participants withdrew from 
the study and all attended the full number of trial visits. The use of activity monitors 
was also a promising outcome, with most participants successfully wearing the 
devices sufficiently to gain valid data for analysis. Another encouraging outcome 
was the well-tolerated nature of the methylphenidate, with no evidence of 
problems with hypertension or sleep abnormalities occurring in the 
methylphenidate group. Despite the small number of eligible patients, the data 
does support feasibility of future studies in this area, although to recruit sufficient 
participants to determine clinical efficacy will require studies to be active across 
multiple sites, preferentially large tertiary centres with large cohorts of patients 
with sarcoidosis under ongoing care. 
The clinical outcomes from the FaST-MP study were unexpected, although these 
were not the primary outcome of interest. The between-group performance 
revealed no persistent significant difference between the placebo and 
methylphenidate arms across most outcomes, with a tendency towards improved 
performance in the placebo group; this was the case in the fatigue score outcomes, 
where the mean values appeared to indicate lower fatigue levels in the placebo 
group. Some outcomes reached a statistically significant difference between arms; 
anxiety (HADS-A) and health utility values (SF-6D and EQ5D) were improved in the 
placebo group, whilst sedentary behaviour time (minutes per day) improved in the 
methylphenidate group. When interpreting the results, it is important to consider 
that the FaST-MP study was never designed or powered to detect evidence of 
clinical benefit for methylphenidate compared with the placebo arm; the primary 
outcome was to determine the feasibility of future work, not to confirm clinical 
efficacy. 
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Lessons the FaST-MP study 
The potential reasons for the unexpected results were discussed in Chapter 4, and 
may relate to a number of factors. These include the small size of the placebo 
group, the large amount of clinical contact with the research team acting as an 
intervention itself, reduced anxiety in the placebo group which may have been 
negated in the methylphenidate group due to common side-effects of the 
medication, an increased level of physical activity seen in the methylphenidate arm 
leading to increased physical exhaustion and fatigue despite achieving more, or 
potential biases in the study population including the presence of demand 
characteristics. The post-hoc analysis of data did not support the inclusion of 
participants with a recent diagnosis of sarcoidosis causing issues due to 
spontaneous resolution in these patients.  
Despite the lack of mean improvement seen in the methylphenidate group relative 
to the placebo group, it is important to consider other results when evaluating 
whether methylphenidate could be a useful treatment for sarcoidosis-associated 
fatigue. Firstly, the proportion of participants in each arm who wished to continue 
taking their allocated intervention at the end of the study was higher in the 
methylphenidate arm than the placebo arm (91.7% vs 71.4%), indicating a high level 
of satisfaction and perceived benefit from methylphenidate. Secondly, in the data 
collected within the focus groups, presented in Chapter 6, a number of participants 
in the methylphenidate group reported significant improvements compared with 
their baseline level of function, without reporting any significant problems 
associated with taking the medication. Finally, concern was also expressed within 
the focus group participants that the outcome measures, including the fatigue 
questionnaires chosen, did not necessarily reflect what they considered to be 
significant changes in levels of fatigue. This may mean that the outcome measures 
being assessed here do not reflect the number of participants who perceived 
significant benefit whilst receiving medications.  
The ability to maintain blinding was also reassuring. During the study there were 
concerns that blinding would be impossible to maintain due to clear positive clinical 
effects or characteristic side effects from the medication. The results from the FaST-
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MP study suggested that participants were reasonably accurate at identifying their 
allocated group (81.8% accuracy across both groups), although they were much 
more accurate at identifying if they had received methylphenidate (93.3% accuracy) 
than if they had received placebo (57.1% accuracy). This is reassuring as it suggests 
that blinding can be maintained to an acceptable extent, but also reinforces the 
importance of any placebo-controlled study being of a parallel-arm design as 
participants would likely be able to identify when they received the active drug in a 
cross-over study, defeating the blinding and potentially altering the results. 
The overall performance of the methylphenidate arm relative to the placebo arm 
should not preclude future trials being performed in this area, although it should 
lead to detailed consideration of the study design. Choosing the ideal outcome 
measures and eligibility criteria are two key issues facing future studies, which are 
discussed in more depth in Section 8.5. 
 
8.4 Difficulties encountered within this thesis 
Although a number of linked projects were undertaken within this thesis, the main 
study, FaST-MP, was the only project that presented a number of problems. Whilst 
some of these issues became apparent with unblinding and analysis of the data, 
relating to the unexpected results in the exploratory clinical outcomes, there were 
difficulties encountered before the trial opened and whilst the trial was being 
undertaken. This has led to important lessons being learnt throughout this PhD 
relating to the undertaking of clinical trials and the importance of proper resourcing 
in terms of staffing and facilities. 
The first difficulty related to the final trial design. The initial design for the FaST-MP 
study planned for participants to meet with the study team fortnightly for the first 
six-weeks to establish a stable medication dose. Following this, participants would 
be seen six-weeks later (at week 12) to check adherence, safety and efficacy, and 
then would not be routinely reviewed until week 24, the final study visit. This 
structure was chosen to attempt to closely replicate usual care, where contact with 
the clinical team would not be more frequent than 6- or 12-weekly once 
Chapter 8 – Discussion 
 265 
established on medication. In order to obtain clearance from the research ethics 
committee to undertake the study, the frequency of participant visits was changed. 
In addition to the planned visits, an additional visit was added at week 18, with 
phone calls added between each visit (see chapter 4 for the final study design), 
which meant that participants were never left more than 2 weeks without contact 
with the study team. These design changes meant that the placebo arm no longer 
reflected “usual care” as there was a significantly higher level of interaction 
between participants and the study team. This may have changed the behaviour of 
the placebo arm, both because the increased contact acted as a form of 
intervention on its own, reducing anxiety in participants, as well as potentially 
introducing bias in the form of demand characteristics. This latter issue may have 
been further affected by limitations in the number of trained staff to perform study 
activities and visits. 
Despite the study being registered on the NIHR clinical research network’s portfolio, 
which meant that funds were made available to provide research nurse support, 
there was great difficulty recruiting and retaining auxillary staff whilst FaST-MP was 
being undertaken. This led to the author running the study on a single-handed basis 
for large periods of time, undertaking research visits with trial participants and 
performing all trial management duties. Whilst running a trial in this manner 
allowed a full understanding of the amount of work a clinical trial of an 
investigational medicinal product is, even a small feasibility study, and provided 
invaluable learning opportunities relating to the management of a clinical trial from 
conception to completion, it also may have had negative consequences on the 
study itself. 
As a result of the lack of additional support, all study visits and most phone calls to 
participants were undertaken by the author. This fostered an excellent relationship 
with the participants but may have provided overly optimistic estimates of 
questionnaire completion rates and retention rates, with participants less likely to 
withdraw from the study despite an onerous visit schedule over a six-month period. 
The level of interaction has also been suggested as a possible reason for the better 
than expected performance of the placebo arm; with frequent interaction with the 
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author, functioning as both a researcher and clinician, this may have led to 
significant reduction in anxiety in participants in the placebo arm through the 
knowledge that they were in close contact with a member of the clinical team, and 
were able to contact them at any time whilst participating in the study. 
Beyond the reassurance of increased contact with the research team and, by 
extension, the clinical team, the possibility of bias from demand characteristics 
influencing the outcomes cannot be excluded. The risk from having one investigator 
performing all study visits, and therefore having contact with each participant at all 
visits, is the development of a relationship that may impact upon the perception of 
participants towards the study and its aims. The risk may have been exacerbated by 
the participants being aware that the research study formed a large section of the 
investigator’s research thesis. Despite the double-blind design of the FaST-MP 
study, it is still possible that the presence of demand characteristics may have 
influenced participant behaviours and outcomes. One indication that demand 
characteristics may have been able to influence outcomes was the discrepancy in 
the number of participants who were able to correctly guess their treatment 
allocation at the end of the study. A higher proportion of participants in the placebo 
group incorrectly identified their allocation, suggesting that they believed they 
were on the active medication, and therefore behaved as if they were receiving 
medication, including attempting to prove the study hypothesis as a “good 
participant” (291). The original work on demand characteristics by Martin Orne 
recommended the use of multiple experimenters as a way of controlling for such 
characteristics (333); due to issues relating to staff trained or available to undertake 
the study visits this was not possible within the study. Whilst the considerations of 
demand characteristics are particularly applied to psychological research, it is 
possible that influence could be exerted on an outcome measure such as fatigue, 
which can only be recorded as it is perceived by the participant. The role of 
participant demand characteristics should therefore not be excluded. 
Additional problems were encountered in securing appropriate facilities to 
undertake one of the clinical outcome measures. The MSWT had been chosen as a 
clinic-based outcome of exercise capacity as it is a maximal-effort test, which was 
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felt to be most likely to yield changes over time with increases in fatigue given that 
reduced fatigue may lead to increased volition, effort and exercise capacity. Whilst 
the test requires a shorter track than a six-minute walk test, another clinic-based 
measure of exercise capacity, participants increase their pace throughout the test, 
ending at a running speed once the later levels of the test have been reached. The 
increased speed of the participants performing the test meant that a larger space 
was required to safely undertake the test. Identifying such a location within the 
hospital proved difficult, with only the clinical research and trials unit having 
sufficient space to undertake the tests. When discussing the outcome measures 
with participants in the focus groups, they considered the location to be 
inappropriate; the location was not considered fully safe with office equipment 
near the area, and other staff members not participating in the research 
occasionally crossing the course unexpectedly. Despite this, the tests were 
completed without injury until the research and trials unit was moved within the 
hospital, leading to a loss of the space for undertaking the MSWT. As a result, only 
participants 1-16 have at least two completed MSWT values; the remaining 
participants were unable to complete a second MSWT. This finding clarified the 
difficulty in identifying sufficient space in hospitals for undertaking tests such as the 
MSWT and, as suggested by participants in the outcomes from the focus groups in 
Chapter 6, maximal exercise tests would be more appropriately performed on a 
static piece of equipment such as an ergometer or treadmill. Performing MSWTs in 
multiple centres, unless they have access to a sports hall or gym, may not be 
feasible; the ability to use static tests such as cardiopulmonary exercise testing is 
likely to be more practical to deliver and standardise across multiple sites, and 
provide more information on participants’ cardio-pulmonary performance and 
exercise capacity. 
 
8.5 Considering a future Phase III study 
This thesis set out to investigate several factors that would determine the feasibility 
of performing a sufficiently large RCT to provide evidence for the clinical efficacy of 
methylphenidate, or an alternative neurostimulants, for the treatment of 
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sarcoidosis-associated fatigue. The outcomes from this thesis provide important 
details on factors that would need to be changed or implemented for a future 
randomised controlled trial investigating symptomatic treatment of sarcoidosis-
associated fatigue. 
DESIGN – Whilst earlier studies have utilised a cross-over design (173, 334), the 
high proportion of participants who were able to determine their allocation based 
on their experience whilst receiving methylphenidate shows that a parallel-arm RCT 
design would be required for any future study. Maintaining blinding effectively in a 
cross-over study would not be possible. Reducing the number of visits and 
telephone contacts with participants may also be beneficial. The amount of contact 
was mandated due to concern that side effects may arise and would not be 
identified or reported without close monitoring and follow-up. During the study any 
adverse events that did occur were reported between visits; participants were able 
to contact the research team in the event of problems and seemed to be able to 
reliably do this. Designing a follow-up study with a reduced number of visits seems 
reasonable given the findings related to the reporting of adverse events. 
INTERVENTION – Methylphenidate was used as the intervention for FaST-MP and 
appeared to be well-tolerated. Future studies should consider an increased 
maximum dose. Within FaST-MP, the maximum daily dose was 20mg twice daily 
(40mg per day), in keeping with the dose regime used in the earlier cross-over 
study (173), and was well tolerated. Studies investigating methylphenidate for 
other conditions, including fatigue related to traumatic brain injury (335), cancer 
(336) and HIV infection (213) have used higher maximum doses (54-60mg per day) 
which were well tolerated. The option to use a higher maximum dose in 
participants who tolerate 40mg per day is within the acceptable dose range for 
methylphenidate, has evidence for earlier work in other interventions, and would 
ensure that an effect for methylphenidate is not missed due to the selected dose 
range being too low. For these reasons, a dose range of up to 60mg/day is 
recommended for future studies. 
One consideration discussed in the conclusions of the FaST-MP study was the use of 
a psychological intervention to manage anxiety in patients where this is a significant 
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driver of their fatigue. Whilst this would require a two-stage design, with 
participants undertaking the psychological intervention prior to being randomised 
to receive methylphenidate or placebo, it would ensure that those included in the 
trial were those who were most likely to benefit from the use of neurostimulant 
medication directly targeting fatigue. 
CONTROL ARM – One of the main lessons learnt from the FaST-MP study 
surrounded the importance of the control arm being a fair reflection of usual care; 
the number of study visits included in FaST-MP was a shortcoming, one which may 
have affected the performance of the placebo group (see previous section). 
Suggestions have been made regarding a control population that is drawn from 
clinic but do not participate in study visits, thereby being more likely to behave as a 
patient receiving “usual care” would. Whilst this would be feasible this would not 
control for a placebo effect, something which would need to be controlled for given 
the performance of the placebo arm seen within the FaST-MP trial. 
SAMPLE SIZE – No difference in fatigue scores, either FAS or FACIT-Fatigue, were 
seen between the study arms; the results seen tended to favour placebo overall. 
However, the FaST-MP study was designed to answer questions surrounding the 
feasibility of a future study, therefore the clinical outcomes observed in either arm 
should not be read into too much. The FAS score appears to be a reasonable 
primary outcome given that it is validated in sarcoidosis and has been used in other 
studies so it allows direct comparison of results; on this basis, powering for the 
MCID of 4 points requires a sample size of 120 patients. Participant retention in the 
FaST-MP study was excellent, possibly relating to the single investigator reducing 
the likelihood of participants withdrawing, so an additional 10% to cover for a 
higher drop-out rate in a larger study would be reasonable to reduce the risk of 
drop-outs leading to an unacceptable reduction in statistical power to detect a 
between-group difference. The total sample required would be 134 patients, based 
on a between-group difference in FAS of 4 points, a mean baseline FAS score of 
33.9 with a standard deviation of 7.8 (taken from the baseline FAS scores across 
both arms), 80% power and a significance level of 0.05, and an anticipated drop-out 
rate of 10%. This number of patients would be feasible from only a few centres 
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around the country if they were large centres with big cohorts, given that it was 
possible to recruit 22 patients from Norwich alone with a cohort of patients with 
sarcoidosis numbering fewer than 400, albeit with an enthusiastic clinical fellow 
which may have increased the recruitment rate. 
ELIGIBILITY CRITERIA – Previous work (173) excluded participants who had been 
diagnosed with sarcoidosis for less than two years prior to study entry, to ensure 
that participants included were more likely to have chronic fatigue that was unlikely 
to spontaneously resolve. A minimum duration of disease was not specified for the 
FaST-MP trial, although sub-analysis of those having the disease for a minimum of 
1, 2 or 3 years did not modify the results of the fatigue data (see Figure 20 in 
Chapter 5). Ensuring the robustness of patient characterisation, through minimising 
the risk of spontaneous resolution of fatigue in patients who have fatigue as part of 
the acute presentation of sarcoidosis, may lend weight to the use of a minimum 
disease duration at study entry. Even with this included as part of the inclusion 
criteria, the projected sample size to investigate clinical efficacy would still appear 
feasible based on the small number of participants required from the sample size 
calculations, therefore a minimum disease duration of 1- or 2-years should be 
specified in addition to the inclusion and exclusion criteria from FaST-MP. 
DURATION – Previous work with methylphenidate has used shorter follow-up; the 
FaST-MP study used a longer duration to investigate whether there was any 
suggestion that the anti-fatigue effect of methylphenidate may drop-off, with the 
results showing no evidence of it. A shorter duration is likely to be all that is needed 
to confirm an effect in a future study.  
QUESTIONNAIRE OUTCOMES – The outcomes from FaST-MP, with the additional 
data collected from individual participants in the focus groups following their trial 
participation, provides much insight relating to the optimal questionnaires to use in 
future trials. Participants in the focus groups were keen to see the number of 
questionnaire outcomes reduced. Within the questionnaire pack used in FaST-MP 
there were several outcome measures that would not be necessary in a future trial. 
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Participant-reported fatigue, measured using questionnaires, would remain a key 
outcome but the data collected suggests that it is not necessary to use two 
questionnaires; both the FAS and FACIT-Fatigue questionnaires showed the same 
pattern of change across the FaST-MP study. Concerns about the negatively marked 
questions in FAS appear unfounded; as long as participants are clearly informed 
about the negatively marked questions in FAS, this questionnaire could be used on 
its own for fatigue outcome.  
Alongside this, to allow cost-utility evaluation, a measure of HRQoL would be 
beneficial. Data from both FaST-MP and the HRQoL comparison study suggest that 
SF36 has benefits but is longer. This questionnaire could be cut down to the SF-12, 
one third of the length, which still includes questions on vitality and can be 
converted to SF-6D health states, from which a utility value can be derived. EQ5D is 
therefore not required.  
Measuring anxiety is clearly important as it was one factor that changed markedly 
over the study duration in the placebo arm; HADS appears reasonable to track this. 
Finally, factors affecting disease-specific health state also differed between arms 
and changed over the course of the study; the KSQ proved its worth in this regard. 
These four questionnaires (FAS, SF-12, HADS and KSQ) would require a significantly 
reduced time to complete.  
The sample size suggested was calculated based on the MCID of the FAS score, but 
concerns were raised during the focus groups that this may not be the ideal 
outcome measure; some participants were concerned that it was not responsive to 
what they considered a significant improvement in their fatigue levels. A simple 
scale may be preferred and could be administered more frequently by participants. 
Fatigue levels could be measured using simple measures, such as a visual analogue 
scale or a five-point likert scale, and could be recorded once or twice a day by 
participants. This could be done via a fatigue diary, with participants recording their 
daily fatigue score at the same time each day within the diary, or through the use of 
electronic devices which could log the score each day. This would provide a much 
greater resolution of fatigue data; if this were to be done via an electronic device 
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for each participant, it could also influence which devices should be used for 
collecting activity data. 
DAILY ACTIVITY OUTCOMES - In the FaST-MP study it appeared feasible to use 
activity monitors at multiple points during the study. However, in the time it has 
taken to complete the work on this thesis, having piloted potential devices and 
settled on the GENEActiv device as the preferred option (which did reliably collect 
data within the context of an RCT), wearable technology has moved on significantly. 
Devices such as the latest version of the Apple Watch (Apple Inc, Cupertino, CA, 
United States) could allow both the recording of activity, potentially even on a daily 
level through the entire study, as well as collection of simple outcome data for 
fatigue levels. These devices have been shown to accurately measure steps, heart 
rate, distance and sleep patterns (337). In addition to these factors, the latest 
versions of these devices can record location and movement via global positioning 
software (GPS), which has been used to monitor activity patterns in trials previously 
(338, 339) and would provide additional benefit on the change in activity 
participants experience during such a trial.  
Using a device fulfilling such criteria would give a much greater resolution of data, 
could provide data on the kinds of activity an individual is undertaking during such a 
trial rather than simple data on levels of activity, and would also overcome some of 
the issues participants had with the GENEActiv devices when wearing it repeatedly 
in the study (notably uncomfortable strap and appearance of the device) which was 
not widely liked by participants according to outcomes from the focus groups. The 
ability to use these devices to record and upload the necessary data is possible, and 
encouraged via developer kits which are specifically targeted at enabling research 
projects to make use of these devices. This allows the custom software to be 
written easily, perform as required though the study, with regular uploading of data 
to a central secure database via data uploads. However, the devices do have the 
downside of requiring charging regularly (daily) and so further work may be 
required to both test the software and confirm that participants can be relied on to 
charge the devices daily. A simple study on participant use of such devices would 
not be particularly difficult to undertake and would enable data to be collected 
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about whether the wear patterns of these devices over time would allow the level 
of data required to be collected. 
Utilising all the data collected within this thesis, it appears that a 12- or 18-week 
study, utilising a blinded, placebo-controlled, parallel arm design, appears both 
feasible and justified based on the lessons learnt from FaST-MP. The dose range for 
methylphenidate available to participants should be increased, with a suggested 
maximum dose of 60mg per day in divided doses. The use of modern wearable 
technology could be utilised, but would need collaboration with appropriate 
expertise to ensure the design and function meets the needs of the study and is 
secure, meeting data protection regulations. The questionnaire outcomes could be 
reduced significantly; the use of FAS, HADS, SF-12 and KSQ is suggested based on 
the data collected, and clinical efficacy could be proven with a sample size of just 
134, a feasible target across multiple sites even if a minimum duration of disease 
cut-off were to be specified as part of the eligibility criteria. 
 
8.6 Concluding remarks 
Taking an RCT from conception through to completion and analysis within a three-
year PhD, even one the size of FasT-MP, has been a great challenge. This was made 
more demanding by issues relating to staffing and facilities encountered through 
the study. Overcoming such problems and delivering the connected studies 
presented within this thesis has been a highly educational experience, both with 
respect to the outcomes that were answered within this thesis, and from the point 
of view of an individual developing skills relating to clinical trial work. The outcomes 
from this work provide useful information relating to the feasibility of a future 
study and it is hoped will influence decisions relating to the design of any trial 
stemming from this work. 
Proceeding to a multi-centre RCT to investigate the clinical efficacy of 
methylphenidate for sarcoidosis-associated fatigue is not planned in the immediate 
future, a decision which is driven by two factors. Firstly, the question of fatigue 
change over time in patients receiving usual care needs to be answered, as well as 
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the consideration of the potential utility of adopting new wearable technology to 
produce an improved outcome measure; these questions were not answered 
within this thesis. Secondly, discussion with other hospitals needs to occur about 
proceeding to a multi-centre study; although the data from this research suggests 
that a full-size study is feasible, it requires other centres to commit to participating 
in this work. In the event that other centres are not keen to support this then a 
future trial cannot take place. 
In conclusion, this thesis and the publications arising from it have demonstrated 
that performing a study to determine the clinical efficacy of methylphenidate for 
sarcoidosis-associated fatigue is feasible, but some further development work, 
coupled with an assessment of organisational capacity, will be required to deliver 
such a trial. Nevertheless, improving the evidence base for potential interventions 
for sarcoidosis-associated fatigue remains an important aim and it is hoped that the 
outcomes from this thesis can help contribute to this. 
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Appendix 3 – PIS forms  
 
 
 
 
 
Prof A M Wilson 
Department of Respiratory Medicine 
Norfolk & Norwich University Hospital 
Colney Lane 
Norwich 
NR47UY 
Website: nnuh.nhs.uk 
Direct Dial: 01603 298639 
Direct Fax: 01603 289640 
 
 
 
Information about Respiratory Research – Participant Information Sheet 
 
Study Title – A comparison of two wrist-worn accelerometer devices for 
the measurement of activity in sarcoidosis patients 
Short title - Comparison of accelerometers for the measurement of 
daily activity 
 
We would like to invite you to take part in our research study. Before you decide we 
would like you to understand why the research is being done and what it would 
involve for you. Please take time to read the following information carefully. Talk to 
others about the study if you wish. Part 1 tells you the purpose of this study and 
what will happen to you if you take part. Part 2 gives you more detailed information 
about the conduct of the study. Please ask us if there is anything that is not clear or 
if you would like more information. Take time to decide whether or not you wish to 
take part. 
 
 
PART 1 
 
What is the purpose of the study? 
This study is comparing two wrist-worn accelerometer devices. The devices 
measure how active a person is over the period of a week. We intend to use 
devices like these in the future in a number of trials. In order to decide which the 
best to use is we need to test them head-to-head with patients. This will allow us to 
see which devices patients think are the best, as well as whether they are able to 
collect the data that we need as researchers. 
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Why have I been invited? 
You have been diagnosed with a condition called sarcoidosis.  
 
Do I have to take part? 
No. The decision to participate is entirely up to you. We will describe the study here, 
and if you have further questions then you are welcome to contact us. If you are 
interested in taking part after reading this information sheet, then please fill in the 
consent form and return it to us. If you are not interested, it will not influence in any 
way your future treatment from us.  
 
 
What will happen to me if I take part? 
If you agree to take part then we will first ask you to sign a consent form to indicate 
your willingness to take part. Once you have signed to indicate that you are willing 
to participate in the trial you will be asked to fill in a short questionnaire (10 
questions) which will tell us about any tiredness or fatigue you may be feeling, then 
one of the research team will show you the two devices (which are each like a small 
wrist-watch) and ask you to wear them on your non-dominant wrist (i.e. your left 
wrist if you are right-handed). You will need to continue wearing the device for 7 
days, and you will need to wear them for 24 hours per day. You will be able to 
shower as the devices are waterproof. However, one of the devices (which has a 
Velcro strap) should be removed if you go swimming or have a bath. The black 
plastic device can remain on your wrist 24 hours a day throughout the 7 day period.  
 
The devices will be active for the 7 day period. Once the device has been worn for 
seven days you can take them off. We will provide you with a pre-paid envelope to 
return them to us by post. We will also give you a questionnaire to answer for each 
of the devices to gain your opinion on how comfortable the device is to wear and 
any problems you may have had with them. These questionnaires should be 
returned in the freepost envelope with the accelerometer devices. 
 
Because the position that you wear the devices may affect the results collected (i.e. 
one device will be closer to the wrist/hand than the other as both devices are worn 
on the same arm), we will ask you to wear the devices in a specific order. You will 
be told which device you will need to wear closest to your wrist over the 7 day 
period. 
 
We will not be testing any drug during this study, nor will you be asked to change 
any of your usual medications. 
 
Expenses and payments 
You will be reimbursed for your travel expenses, including validation of your car 
parking if you park in the main car park. 
What will I have to do? 
We will ask you to fill in one questionnaire when you are first seen. Following this, 
we ask that you wear two wrist-worn accelerometers on your non-dominant wrist for 
7 days (wearing it for 24 hours each day). At the end of the 7 day period you can 
take the devices off, and we ask that you fill in a questionnaire for each of the 
devices (with regards to how acceptable you found the devices and whether you 
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had any problems with them). After this, we would like you to return the devices and 
the questionnaires to us in the pre-paid envelope that we will provide. 
 
What are the possible disadvantages and risks of taking part? 
There are no risks associated with wearing the device, apart from the fact that you 
have to wear it. As you are wearing two devices at the same time on the same wrist 
there is the possibility that they will become uncomfortable. The reason for wearing 
them simultaneously on the same wrist is so we can directly compare the data that 
we get from each device. This will help us decide which device will be best for 
meeting our needs in future studies. 
What are the potential benefits of taking part? 
Wearing the accelerometers and giving us your opinion on the devices will help to 
choose which of them we will use in the future, therefore you will be helping us to 
ensure that we are using the best possible equipment for future studies. 
 
What happens when the research study stops? 
After the motion devices have been returned to us with the questionnaire you will 
not be asked to do anything further. The results will be analysed and help us to 
decide which of the two devices to use in the future.  
What happens if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in Part 2.  
 
Will my taking part in the study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be 
handled in confidence. The details are included in Part 2. 
  
PART 2  
What will happen if I don’t want to carry on with the study? 
You can withdraw your consent at any time. This will not have any effect on your 
care from this department if you do decide not to continue your participation. Once 
your motion device is returned, the results will be entered into our system and 
cannot be removed, so you will be unable to ask for your answers to not be included 
in the final results once this has been done. 
 
What if there is a problem? 
We do not envisage that you will suffer any problems or harms from taking part in 
this study. However, If you have a concern about any aspect of this study, you 
should ask to speak to the researchers who will do their best to answer your 
questions (01603 289876). If you remain unhappy and wish to complain formally, 
you can do this through the NHS Complaints Procedure (or Private Institution). 
Details can be obtained from Patient Advice and Liaison Service (PALS) 01603 
289036. 
 
In the event that something does go wrong and you are harmed during the research 
and this is due to someone’s negligence then you may have grounds for a legal 
action for compensation against University of East Anglia or Norfolk and Norwich 
University Hospitals NHS Foundation Trust but you may have to pay your legal 
costs. The normal National Health Service complaints mechanisms will still be 
available to you (if appropriate). 
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Will my taking part in this study be kept confidential? 
Yes. None of the data from the accelerometer devices or your questionnaires will 
have your name directly linked to them. They will all be identified by a unique 
reference number. A document linking your name with this unique reference number 
will be kept in a on a password protected file on a secure computer server and in a 
secure office. The only people having access to this information will be the 
researchers conducting the study. The researchers will need to link your 
questionnaires back to your clinical records.   
 
Will my GP be involved? 
We will not contact your GP routinely to inform them that you have decided to take 
part in the study, though we will ask your consent to inform your GP of your 
participation should it become necessary. We will only contact your GP if you agree 
to this.  
 
What will happen to the results of the research study? 
The results will be analysed in two parts. The first part will involve analysing the 
results of the questionnaires you provide. This will tell us what the participants in the 
study thought of the devices, and which one was preferred. The second part 
involves analysing the data from the devices. This will tell us how reliable the 
devices are, and whether they collect the data that we need. These results will 
influence the choice of devices for any future trials which will involve the use of 
accelerometers. 
 
Who is organising the research? 
The research is being organised by researchers from Norwich Medical School, 
University of East Anglia and Norfolk and Norwich University Hospitals Foundation 
Trust. None of the researchers will receive any payment or funding for including you 
in the study. The study forms part of a PhD for Dr Atkins which has been funded by 
a doctoral research fellowship from the National Institute of Health Research (grant 
number DRF-190-08-2015) 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity.  
 
Further information 
You can receive general information about participating in research from your doctor 
or from the Public and Patient Involvement in Research (PPIRes) phone 01603 
257292 http://www.nnuh.nhs.uk/Dept.asp?ID=265. Your doctor or the researchers 
will be able to answer any specific questions about this study and whether you 
should participate. If you are unhappy with the study please contact Dr Atkins on 
01603 298876 or on PALS 01603 289036. 
 
Thank you for your consideration of taking part in this study. If you are still 
interested, or have any further questions, then please contact the study team 
using the details below: 
 
Dr Chris Atkins 
Phone 01603 289876 
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Respiratory.research@nnuh.nhs.uk 
Department of Respiratory Medicine, Norfolk and Norwich University Hospital, 
Colney Lane, Norwich, NR4 7UY 
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Information about Respiratory Research – Participant Information Sheet 
 
 
Fatigue in Sarcoidosis – A feasibility study investigating the treatment of 
fatigue in stable sarcoidosis patients using methylphenidate 
 
 
Short title - Fatigue in Sarcoidosis - Treatment with Methylphenidate 
 
 
We would like to invite you to take part in our research study. Before you decide if 
you would like to take part, we would like to explain why the research is being done 
and what it would involve for you. If you are interested, one of our researchers will 
go through this information with you and answer any questions you may have. 
 
Please take time to read the following information carefully. Talk to others about the 
study if you wish. Please ask us if there is anything that is not clear or if you would 
like more information.  
 
This information sheet is divided into three parts: 
 
• Part 1A describes why we are doing the study, what it would involve for you, 
and what the main benefits and risks are. 
• Part 1B describes in more detail the focus groups (discussion groups) which 
will occur after the main study is completed, and is an optional part of the 
overall study. 
• If you are interested in taking part please read part 2 which contains further 
important information.  
 
Thank you for taking the time to read this leaflet. 
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Part 1A 
What is the purpose of this research study? 
Sarcoidosis is a condition, of no known cause, which can cause symptoms involving 
many parts of the body including the lungs, skin and joints. Fatigue or troublesome 
tiredness – which means the feeling of tiredness which is not relieved by rest or 
sleep - is also a common problem in sarcoidosis and is a challenge for doctors 
looking after patients with this condition because it often persists even when the 
other symptoms have been treated. We would like to investigate whether a 
medicine (called methylphenidate), which has been used for many years to help 
people with other conditions, can improve the fatigue associated with sarcoidosis. At 
present we do not have enough information or evidence to recommend that it is 
widely used. We would therefore like to carry out a large clinical trial in the future to 
confirm whether or not methylphenidate improves fatigue in sarcoidosis. However, 
before we can do this we need to do a smaller study involving up to 30 patients to 
see if this would be possible. 
 
The study will compare methylphenidate versus a placebo (a dummy sugar 
capsule). Both of the capsules look identical and neither you, nor the researchers, 
will know which medication you have taken until the end of the study. This is of vital 
importance to ensure that the study remains fair. The results could be spoilt if 
anyone found out which capsule you were taking before the study is over. The 
decision about whether you receive methylphenidate or the placebo is made 
randomly by a computer. You will be asked to take the medication twice a day for up 
to 6 months. You will start on one capsule twice a day, and will increase to two 
capsules twice a day after being reviewed by the research team. 
 
This feasibility study will find out if patients are willing to take a drug like 
methylphenidate every day, how many patients are suitable to receive the drug, and 
how likely it is that patients who enter the trial will complete it. We will monitor you 
throughout the trial, ask you to complete questionnaires about how bad your fatigue 
is, what your quality of life is like, what your mood is like, and ask you to perform 
some tests that measure how well your lungs are working, how much exercise you 
can do, and how active you are. In addition, if you are willing, we would like you to 
ask to come to a meeting after the trial to discuss your experience whilst taking part. 
These will all be explained in more detail later in this information sheet.  
 
 
Why have I been invited? 
You have been invited because you have sarcoidosis and might suffer with 
significant fatigue.  
 
 
Do I have to take part? 
No. The decision to take part is entirely up to you. We will describe the study here 
and go through this information sheet with you.  
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What will happen to me if I take part? 
This study involves up to 8 visits, plus one optional final visit to discuss your 
experience in the trial with a group of other participants in the trial once you’ve 
completed all the visits. These visits will all take place at the Norfolk and Norwich 
Hospital. The visits will all be in addition to the usual care that you receive. In 
addition, you will be called by the research team between visits to see how you are 
getting on with the medication and whether you are having any problems. The study 
will involve taking the trial medication every day in the morning and afternoon for up 
to 24 weeks.  
 
You will be asked to attend the following visits: 
 
Screening Visit: This first visit is our opportunity to explain the study in detail and 
answer any questions you may have. We will ask you to complete a consent form 
and ask a number of questions to make sure that there is nothing that would prevent 
you from taking part in the trial. We will also check your current medications to make 
sure that you are receiving no medications that would interfere with the study drug. 
We will ask you to complete some questionnaires to measure your fatigue before 
starting any medications, and to look for any problems with your sleep that may 
need treatment separately. We will take some blood tests and perform a heart wave 
test called an electrocardiogram (ECG); these tests will ensure that it is safe for you 
to take the medication. We will ask you to perform a walking test and to wear a 
device that looks like a wrist-watch for 7 days so we can measure how active you 
are.  You can post the device back to us or bring it with you at your next visit. 
Finally, we will ask you to perform a breathing test where you will need to forcefully 
blow into a tube (you may have performed this test in clinic). In total this visit will 
take between 60 and 90 minutes. 
 
Baseline visit after 2 weeks: We will check that it is still safe for you to continue with 
the research. We will ask you to fill in eight questionnaires. These will measure your 
quality of life, your mood, your sleep quality, whether there is any evidence of your 
sarcoidosis causing you problems, and measure your fatigue levels. We will also 
ask you to complete a questionnaire about whether your fatigue and your underlying 
condition is costing you money and leaving you out-of-pocket. Finally, if you did not 
perform a walking test when you were seen at the screening visit then it will be 
performed at this visit. Once all this has been completed we will give you a supply of 
medication that will last you until your next visit after 2 weeks. This visit will take 
approximately 60 minutes. 
 
Follow-up visits: We will arrange to see you at the hospital after 2, 4, 6, 12, 18 and 
24 weeks. During these visits we will check to make sure that it is still safe for you to 
take the medication and that you are still willing to be involved. If so, we will ask you 
about potential side effects that you may be noticing from the medication, ask you to 
fill in the same questionnaires as before regarding your fatigue, general well-being, 
quality of life, mood and costs that you may have suffered because of your 
condition. Whilst you are receiving the medication we will take some blood tests and 
perform a heart wave test. At the beginning of the trial (before you start treatment), 
at 12 weeks into the trial and after 24 weeks (at the final visit) we will also ask you to 
perform the breathing tests, walking tests and to wear a device on your wrist to 
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measure your activity levels. At your final visit we will also briefly ask you to answer 
some questions about your thoughts on the trial and the medication you received. 
 
At each visit we will give you a supply of medication to see you through to your next 
visit. The number of questionnaires and tests at each visit varies and so the length 
of each visit will be different but will be between 30 and 90 minutes depending on 
what is being checked at each visit; an estimate of how long each will be is shown 
at the bottom of the table below.  
 
After the study: At your final visit, if you are taking the higher dose of medication 
(two capsules twice daily) then we will give you a two week supply of medication at 
the lower dose of one capsule twice daily to gradually discontinue the drug. We will 
also send you a final pack of questionnaires in the post to complete; this will occur 
approximately six weeks after you attended your last visit, and the questionnaires 
can be returned to us by post. 
 
In addition to these visits in hospital, we will telephone you between visits to see 
how you are and ensure that you are not developing any side effects. We will 
telephone you each week between study visits up until your six week appointment. 
After this, we will phone you every two weeks between visits to see how you are 
getting on with the medications. Each phone call will last between 5 and 10 minutes 
and will be conducted by a member of the trial team. All members of the team who 
will contact you will have been appropriately trained to ask about any potential side 
effects, will be employed by the NHS (not by the university or other external bodies) 
and have a duty of confidentiality to you regarding anything discussed on the phone. 
If any problems are flagged up during these phone calls then you will have the 
opportunity to speak to one of the doctors running this study. 
 
To help you understand the steps involved in the study and the measurements 
taken at each visit, please see the table below showing which measurements are 
taken at which visit: 
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   Visit Time point 
Procedure / Assessment 
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Informed consent taken ü         
Entry criteria checked ü         
Blood tests ü  ü ü ü ü    
Pregnancy Test (females) ü ü        
Heart tracing ü  ü ü ü ü  ü  
Treatment dispensed  ü ü ü ü ü ü   
Questionnaires ü ü ü ü ü ü ü ü ü (post) 
Breathing tests  ü    ü  ü  
Walking test  ü    ü  ü  
Wrist-worn device to 
measure activity (7 days ) ü     ü  ü  
Side effects monitoring   ü ü ü ü ü ü  
Time in minutes for 
each visit 
(approximately) 
60-90 60 30-45 
30-
45 60 
60-
90 30 60-90 n/a 
 
Finally, there is an optional group visit at the end of the study that we will ask your 
consent to invite you to attend. This is to discuss the experience of patients who 
participated in the trial and to see whether there were any problems occurring that 
we hadn’t anticipated. This is an optional extra part of the trial and it is not 
mandatory for you to attend if you wish to take part in this study. We will ask you to 
indicate on the consent form whether you would be happy for us to invite you to 
participate in this after you have completed the medication. This part of the study is 
described in more detail in section 1B of this information sheet. 
 
 
What are my responsibilities? 
 
You will need to bring a list of your current medications that you are currently 
taking to each visit, including the first visit (screening visit). If you are taking 
any medications, either prescribed from your doctor or over the counter, it is 
important that you let the trial team know about them. You will also need to bring all 
trial medication bottles you have been given (whether empty or not) to each visit. 
We will ask you about any potential side-effects at each visit. We need to know if 
you develop any potential side effects – if you develop problems on the drug then 
we would be most grateful if you could let us know using the research contact 
details below. 
 
It is also important that when you are taking the medication you do not take any 
over-the-counter flu remedies or nasal decongestants. These drugs interfere with 
methylphenidate and can cause your blood pressure to become very high. 
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Methylphenidate itself can cause the sensation of a blocked nose or nasal stuffiness 
so it is important to be aware not to take medications like otrivine, night nurse or flu-
relief. Simple paracetamol or ibuprofen is fine. More information about side effects is 
displayed below. 
 
We do not know if methylphenidate is safe during pregnancy or whilst breast 
feeding; for this reason we are unable to include patients who are pregnant or 
breast feeding into the trial. For females in the trial, if you have not gone through the 
menopause and may be able to become pregnant during the trial it is important that 
you use adequate contraception. During the trial, adequate contraception consists 
of using two methods of contraception when having sex – this means a hormonal 
contraception (this would be a contraceptive pill, an injection or an implant), a coil 
(such as the mirena coil), or a barrier method (this would be a condom or 
diaphragm/cap with spermicide). Alternatively, complete abstinence from sexual 
activity whilst participating in the trial is acceptable. If you were to become pregnant 
during the trial you must let the trial team know as soon as possible. 
 
 
What are the potential side-effects of methylphenidate? 
 
In this study there is a 60% chance that you will receive methylphenidate; out of 
every five people enrolled in the trial, three of them will receive methylphenidate. All 
medications have potential side effects. It is important that you are aware of the 
potential side-effects of methylphenidate before you take part in the study. You will 
also have received a copy of the information sheet about methylphenidate (called a 
Summary of Product Characteristics) with this information sheet so you can read 
more about the drug if you wish to. 
 
The side-effects are broken down into the frequency with which they occur: 
Very Common (more than 1 in 10 frequency): Insomnia (difficulty getting to or 
staying asleep), nervousness, headache. 
 
Common (between 1 in 10 and 1 in 100 frequency): Inflammation or irritation of the 
nose (blocked nose), decreased appetite, change in moods, irritability or 
aggression, low mood/depression, dizziness, abnormal movements, restlessness, 
sleepiness, irregular heart beats, fast heart beats, palpitations (awareness of your 
heart beat), high blood pressure, cough, sore throat, stomach pains, diarrhoea, 
nausea, vomiting, dry mouth, hair loss, high temperatures, rashes, weight loss. 
 
Uncommon (between 1 in 100 and 1 in 1000 frequency): Allergic reactions to the 
medication (causing wheals or swelling of the lips, face or ears), other skin 
conditions and rashes, psychosis (bizarre behaviour), hallucinations (seeing, 
hearing or feeling things that aren’t there), anger, suicidal ideation, altered mood 
and mood swings, tearfulness, tics (repetitive movements), tremor, double vision, 
blurred vision, chest pains, shortness of breath, constipation, abnormal liver tests on 
blood results, muscle aches and pains, blood in the urine, tiredness, heart murmurs. 
 
Rare (between 1 in 1000 and 1 in 10,000 frequency): Mania (extremely high mood 
with associated strange or unusual behaviour), disorientation, libido disorder (loss of 
sexual drive or increased sexual drive), difficulties adjusting vision to distance or 
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light, dilated pupils, angina, increased sweating, gynaecomastia (increase in breast 
tissue). 
 
Very Rare (less than 1 in 10,000 frequency): Low blood counts, suicide attempts, 
abnormal thinking, apathy (loss of drive to do anything), repetitive behaviours, 
convulsions and seizures, stroke, dangerously high temperature and muscle 
damage (referred to as Neuroleptic Malignant Syndrome), heart attack, cardiac 
arrest, peripheral coldness and abnormal reaction of the hands and feet to cold 
situations. 
 
We will contact you at least every two weeks during the study so that we can check 
the study medication is not causing you any problems but if you are worried about 
anything in between then please contact us on either 01603 289876 or 01603 
289633 (Monday to Friday, 9am to 5pm). 
 
 
Is methylphenidate addictive? 
 
Methylphenidate is a stimulant medication, and is similar to some other medications 
such as amphetamines. The dose that we are using in this trial is small and there 
should not be a risk of addiction if the medication is taken as directed by the 
research team. It has been used at this dose in other trials and has not caused 
problems with addiction. However, if the medication is taken at a much higher dose 
than directed then it can be addictive and the risk of side effects goes up. It is 
dangerous to take more than the dose prescribed by the research team 
 
Methylphenidate is a controlled drug. This means it is illegal to give your 
medications to anyone else. We will ask you to sign a short form when signing your 
consent to indicate your understanding that you must only take the medication as 
directed by the trial team, and never give away your medication to anyone else. 
 
 
Are there other medications that I am prescribed that could affect the safety of 
the trial medication? 
 
There are a number of medications that should be avoided in combination with 
methylphenidate. This is because they increase the chance of developing side 
effects from methylphenidate. Because we do not know whether you will be 
receiving methylphenidate or not we need to assume you are receiving the drug. 
We will carefully check with you at the first visit and at each follow-up visit to see if 
you are taking any of the medications that could interact with methylphenidate. 
Some medications can be changed for suitable alternatives and would mean you 
can take part in the research. This would only happen if you are willing to receive an 
alternative medication and if your GP or hospital consultant is willing to prescribe 
this. 
 
We will carefully check your list of medications each time we review you as part of 
the study, but if you are prescribed or taking any of the medications from the 
following list then you need to let the researchers know as soon as possible and 
stop taking the trial medication: 
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• Tricyclic anti-depressants (e.g. amitriptyline, clomipramine, dosulepin, 
doxepin, imipramine, lofepramine, nortriptyline, trimipramine, mianserin, 
trazodone) 
• Monoamine oxidase inhibitors (e.g. phenelzine, isocarboxazid, 
tranylcypromine, moclobemide, selegiline) 
• Antipsychotic medications (e.g. Haloperidol, Risperidone, Clozapine, 
Amisulpride, Olanzapine, Paliperidone, Quetiapine) 
• Buprenorphine, Tramadol 
• Levodopa 
• Clonidine 
• Methylene blue 
• Warfarin (there is a risk that control of your blood’s clotting level will be 
unsafe whilst on methylphenidate) 
• Decongestants and cold/flu relief medications (phenylephrine, 
ephedrine, pseudoephedrine and others). Steroid nasal sprays are allowed 
Please check with the trial team before starting any new medications if you are 
unsure. 
 
I’m being asked to wear a device on my wrist at times during the study – what 
do I have to do and what is this for? 
 
At three times during the study (before you start the medication, half way through 
the trial and just before you stop the medication) you will be asked to wear a device 
called an accelerometer on your non-dominant wrist for a seven day period. This is 
the size and shape of a wrist-watch but it measures movement, and from this we 
can estimate how active you are. It can also make some simple measures of the 
quality of your sleep. The device is fully waterproof and can be worn 24 hours a day, 
including in the shower, the bath or when swimming. Some people don’t like to wear 
anything on their wrist when in bed, and if this is the case you can remove the 
device overnight. We would like you to wear the device as much as possible and for 
at least 10 hours a day for each of the 7 days whilst you are asked to wear it. 
 
 
What are the possible benefits of taking part? 
 
There are no direct benefits to taking part.  
 
 
What are the possible disadvantages of taking part? 
 
There are a lot of visits to attend and one disadvantage is the time required for you 
to travel to the hospital and have these follow-up visits. This can incur expenses, 
and so we will reimburse your travel costs; we will reimburse your travel & parking 
expenses at the current accepted rate if travelling by car, or bus/train/taxi fares 
against receipts if using public transport. You may suffer some discomfort from the 
blood tests performed. You may also experience some side effects from the study 
medication (see above). Before participating you should consider whether this will 
affect any insurance you have and seek advice if necessary. 
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What happens when the research study ends? 
 
When you have completed the study medications and completed the questionnaires 
sent to you, this signifies the end of your involvement in this research study. You will 
not receive any further trial medications after you have completed the 24 weeks of 
treatment (plus a further two weeks of a lower dose if you completed the study on 
the higher dose). You will not be able to continue receiving methylphenidate 
once the trial is over. 
 
When the research is finished we will send a summary of the results to anyone who 
was involved in the trial, or who indicated an interest in the trial but was unable to 
participate. At the end of the study, if you would like to know which treatment you 
received (methylphenidate or placebo) then please contact us (see ‘researcher 
contacts’ below). 
 
 
 
 
=============================================================== 
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Part 1B 
What is a “Focus Group”? 
A focus group is a form of research where people are asked about their opinions 
and perceptions. Questions are asked in a group setting where participants are free 
to talk and discuss with other group members. 
 
What is the purpose of these focus groups? 
The main trial that you have been asked to participate in is being performed to find 
out whether it is possible to design a large clinical trial in the future to confirm 
whether or not methylphenidate improves fatigue in sarcoidosis. As part of this it is 
very important that participants in the trial have the opportunity to discuss their 
experiences. This allows the research team to hear what went well and what didn’t 
go well with the trial from your perspective. These discussions may help to improve 
the design of future trials for patients like yourself. 
 
Do I have to take part? 
No. The focus group participation is optional, and the decision to take part is entirely 
up to you. If you decide that you would rather not participate in the focus group 
meeting at the end of your time in the study then you can still take part in the main 
study. If you decide at this point that you would like to take part in the focus groups 
at the end of the study and then later decide that you would rather not then that is 
also fine – you can withdraw your consent at any time for this part of the study 
without withdrawing from the entire trial. If you sign the consent form to indicate that 
you are happy to take part in the focus groups, we will approach you after the end of 
the trial to make sure that you’re still happy to come to one of the group meetings at 
a time that is convenient for you. 
 
What will happen to me if I take part in these focus groups? 
The focus group sessions occur after you have finished the trial. We hope that they 
will occur about 6-8 weeks after you finish taking the study medication but it could 
be a bit sooner or later depending on how many people are finishing the trial at the 
same time as you (everyone will start and finish at different times). 
If you come to one of the focus groups then it will take place at the Norfolk and 
Norwich University Hospital. We will contact you at least 2 weeks in advance of any 
meeting to try and arrange a meeting time which is suitable for everyone. At this 
point we will confirm where the meeting would be and send directions to the 
meeting to you in the post (as well as confirmation of the time and date). You do not 
need to do or prepare anything in advance. 
On the day of the focus group meeting, when you come to the meeting there will be 
at least one member of the research team there to act as a moderator and to help 
facilitate discussion – it is also an opportunity for you to ask any questions of the 
research team that you may have. There will be up to 6 other participants in the 
group. There will be refreshments provided. You are welcome to bring a friend, 
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partner or spouse with you when you come but they will not be able to take 
part in the group discussion.  
When everyone has arrived then the representative of the research team will open 
the discussion, initially welcoming everyone and then discussing the ground rules 
for the session. After this, the discussion will focus around two main aspects: 
1. Experiences of the trial (e.g. Best and worst things about taking part, any 
part of the trial that put you off taking part or that was particularly 
problematic?) 
2. Changes to the trial (e.g. Would you change anything about the trial if you 
could?) 
During the session the conversation is taped. This is to allow all the 
discussion to be recorded without having to take lots of notes at the time. 
There will be a break in the middle of the session. After these topics have been 
discussed, and the member of the research team present has summarised and 
made sure that no significant points have been missed, then you will be free to go. 
You will not be required to attend any further groups or sessions. In total, we expect 
a focus group session to last between 60 and 90 minutes, although it may run on a 
bit longer (but not more than 2 hours). 
 
What happens when the focus group ends? 
When the focus groups have been performed then the study will be over. You will 
not be asked to attend any further groups and there will be no further commitment 
from you. In total we hope to perform three focus groups of 6 people each but you 
will only be asked to attend one of these meetings. To find out what we do with the 
data generated during the focus groups, please see the section, “”What will happen 
to the results of these focus groups” below. 
 
Will the points I raise in discussion be confidential?  
Any comments you make in the focus groups are not attributed to you when they 
are reviewed, so feel free to say what you really think! There will be other patients at 
the focus group contributing to the discussion, so the people attending the meeting 
will be able to hear your points of view, but we ask that everyone’s views are 
respected at the meetings. 
 
I am not taking part in the “Fatigue in Sarcoidosis – Treatment with 
Methylphenidate” study. Can I still take part in these group discussions? 
Unfortunately not. We are interested in the views of participants who have 
undertaken the trial. If you were unable to take part in the main trial then we are 
unable to invite you to participate in the focus groups. 
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=============================================================== 
Part 2 
 
What happens if new information becomes available? 
 
Sometimes we get new information about the study treatment. If this happens then 
we will tell you about the new information that has become available and discuss 
what this means for you. If new information becomes available that affects whether 
or not this study can continue we will inform you, your General Practitioner and your 
respiratory consultant at the earliest opportunity. 
 
If, once you have had time to think about what you have been told, you decide not 
to carry on in the study, your routine care will continue as normal. If you decide to 
continue in the study you may be asked to sign an updated consent form. 
 
 
What will happen if I don’t want to carry on with the study? 
 
You can withdraw your consent to participate at any time without having to give a 
reason. This will not have any effect on the care you receive if you do decide not to 
continue your participation. We will need to use the data collected up until your 
withdrawal. If you do not wish to continue taking the study medication we will invite 
you to continue attending follow-up visits until you would have expected to end the 
trial, including the questionnaires, breathings tests, walking tests and activity 
measurement. If you choose to withdraw from the study we would be very grateful if 
you could complete a short questionnaire on your reasons. It is entirely up to you if 
you choose to complete this questionnaire. The answers are confidential and do not 
influence your clinical care in any way. 
 
 
What happens if there is a problem? 
 
If there is a particular issue that you would like to discuss with the researchers then 
please use the contact details below (see ‘contact for further information’). For any 
complaint about the way you have been dealt with during the study then please 
address this with either the researchers or the Patient Advice and Liaison Service 
(PALS) on 01603 289036. 
 
 
What provisions are in place for compensation if required? 
 
The NHS indemnity scheme applies if you were to come to harm as a result of the 
management, design or conduct of the research where legal liability rests with the 
investigator or sponsor. If you are harmed during the research due to someone’s 
negligence then you may have grounds for legal action for compensation against 
your hospital, but you may have to pay your legal costs. 
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What safeguards are in place? 
 
We will monitor blood tests and the test of your heart’s electrical activity (the ECG) 
closely at regular points during the trial. You will also be in regular contact with the 
trial team who will ask you about any potential side effects that you may be 
experiencing, to try and identify problems at the earliest opportunity. 
 
If you are concerned about a possible side-effect of the treatment or have any 
concerns about the study then you can contact the trial team using the details 
below. Alternatively you may wish to consider getting medical advice via your 
General Practitioner or Accident and Emergency if you have a serious problem. 
 
 
Can I claim travel expenses? 
 
We will reimburse both the transport costs for the return journey from your home to 
the Norfolk and Norwich University Hospital and will validate the ticket for the 
hospital car park (if you come by car) during the clinical trial visits. Please note that 
we are unable to validate car parking tickets if you park in the private car park 
opposite the hospital – this is opposite the helipad and next to the University 
building. 
 
Will my taking part in the study be kept confidential? 
 
Yes. We will follow ethical and legal practice and all information about you will be 
handled with the strictest confidence. All information which is collected about you 
during the research will be held securely in accordance with the Data Protection Act.  
It will be kept for 5 years after which it will be disposed of securely. All of your data 
(your questionnaire information, samples and clinical details) will be labelled by a 
code and will not have your name or any other details about you on it. We refer to 
this as linked anonymised as although your test results are anonymous, it can be 
linked to you by a code. The code will only be known by the members of the 
research team. It will be kept securely. All the members of the research team who 
you will have contact with, either at a visit where you come to the hospital or where 
you are contacted by the team over the phone, will work for the NHS, not the 
university or other external agencies. They will have the same duty of confidentiality 
to you as any other member of your medical team who you would see for treatment 
of your condition. 
Researchers at Norwich are conducting the statistical analysis of the study, and to 
maintain confidentiality, the statistical team will only analyse completely anonymous 
data.  Any reports or publications arising from the study will contain totally 
anonymised data so that it will not be possible to identify you. 
Making clinical trial data available to other investigators is encouraged – it allows 
maximum use to be made of any data generated and it can help with future 
research which may deliver benefits to patients. Other third party researchers may 
wish to access the anonymised data from this study in the future (anonymised data 
do not include names, addresses or dates of birth, and it is not possible to identify 
individual participants from anonymised data). For example, if future work is done 
by another group of researchers investigating treating fatigue in sarcoidosis patients 
Appendices 
 332 
then they may wish to look in detail at the data we collected during this trial or 
analyse it in a different way, which may help with the design and conduct of their 
work. If external researchers wish to access the anonymised data, the Chief 
Investigator will ensure that the other researchers comply with legal, data protection 
and ethical guidelines. 
 
Who will have access to my hospital (medical) notes? 
Your hospital notes will only be seen by members of the trial team that work in the 
Norfolk and Norwich Hospital (this means that they are members of the respiratory 
medicine department and are either involved in looking after your care or work 
closely with the consultant who normally looks after your care, also referred to as 
the “direct care team”). Your notes will not be seen by anyone outside of the 
hospital. 
If you join the study, the data collected for the study and any relevant medical 
records may be looked at by authorised persons from Norwich Medical School, the 
Research and Development Department of the Norfolk and Norwich Hospital and 
the Regulatory Authorities to check that the study is being carried out correctly. If 
your medical notes are reviewed by these bodies then the individuals doing so will 
have a duty of confidentiality to you as a research participant and confidentiality will 
be maintained throughout.  
 
Informing your General Practitioner 
 
With your permission, your GP will be informed of your participation in this study. 
We will also inform your respiratory consultant (the doctor looking after your 
sarcoidosis) if you have one. 
 
 
Withdrawal from the study or early termination of the study. 
 
The study doctor may have to stop your involvement in the study or remove your 
data from the analysis in certain circumstances for example should he/she find out 
that you shouldn’t have been included in the study in the first place. In addition, the 
sponsor may decide to stop the whole study. We will explain the reasons to you if 
you are withdrawn or the whole study is stopped. You can decide to stop taking part 
in the study at any time without this affecting your medical care. If you do decide to 
stop taking part then we would be grateful if you could complete a short 
questionnaire as this will provide important information when designing future 
studies. 
 
 
What will happen to any blood samples that I give? 
 
All of the blood tests will be securely collected, stored and analysed. Your blood 
samples will be tested to see if it is safe for you to continue taking the trial 
medication and to help you answer any research questions. The blood tests taken 
for safety will be processed the day it is taken. If it is not safe for you to continue 
taking the study medication we will let you know as soon as the result is available to 
Appendices 
 333 
us. These blood tests, which are taken for safety, will include your name, age and 
hospital number on the labelling so that the blood can be processed in the usual 
way and will be available to the healthcare professionals directly involved in your 
care. 
 
 
What will happen to the results of the research study? 
 
The study will be written up as a research paper and will be submitted for 
publication in a medical journal. It will be presented by members of the 
research team at medical conferences. The results are important to 
determine whether conducting a future clinical trial of methylphenidate for 
treating fatigue is possible and would inform how best to go about this. 
 
Who is organising the research? 
 
The research is being organised by researchers from University of East Anglia and 
the Norfolk and Norwich University Hospitals Foundation Trust. The research is 
being funded by a research grant from the National Institute for Health Research 
(NIHR) awarded to Dr Atkins as part of a doctoral research fellowship (DRF) 
programme. The NIHR-DRF grant reference is DRF-2015-08-190. None of the 
researchers are being paid for recruiting patients into the study. 
 
 
Who has reviewed the study? 
 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given favourable opinion by one of these 
committees (East of England – Cambridge Central, reference number 16/EE/0087). 
 
In addition, the study has also been reviewed and approved by the Medicine and 
Healthcare Products Regulatory Agency (MHRA). The Research and Development 
department of your local hospital has also reviewed and approved the study. 
 
 
What happens next? 
 
If you are willing to participate then you will be asked to sign a consent form to 
confirm this. If you do not wish to participate at this point then we would like to thank 
you for reading this information and for having considering taking part this project. 
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Contact for further information 
 
Researcher Contact Details: 
Dr Chris Atkins, NIHR Doctoral Research Fellow, Norwich Medical School, 
University of East Anglia, Norwich, NR4 7UQ. 
Email: c.atkins@uea.ac.uk 
 
Chief Investigator Details: 
Professor Andrew Wilson, Professor of Respiratory Medicine, Norwich Medical 
School, University of East Anglia, Norwich, NR4 7UQ.  
Email: a.m.wilson@uea.ac.uk 
 
To contact either member of the research team about this study please call us on 
01603 289876 or 01603 286366 (Norfolk and Norwich University Hospital 
Respiratory Research Group), mentioning the study title. If we are not in the office 
when you call we will get back to you as soon as we can to discuss any queries you 
may have. 
 
 
 
Helpline contacts 
 
To report a trial side-effect or any untoward event related to the trial, phone: 01603 
289876 (Monday to Friday, 9am to 5pm). For out of hours advice call Dr Chris 
Atkins or Professor Andrew Wilson via the hospital switchboard (01603 286286). 
 
 
If you have more general questions about participating in research then please 
speak to your doctor, or contact the Public and Patient Involvement in Research 
(PPIRes) - phone 01603 257292 or visit http://www.nnuh.nhs.uk/Dept.asp?ID=265.  
 
 
 
Thank you for taking the time to read this information leaflet 
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Prof A M Wilson 
Department of Respiratory Medicine 
Norfolk & Norwich University Hospital 
Colney Lane 
Norwich 
NR47UY 
Website: nnuh.nhs.uk 
Direct Dial: 01603 298639 
Direct Fax: 01603 289640 
 
 
Information about Respiratory Research – Participant Information Sheet 
 
The Respiratory Research Team would like to invite you to take part in our research 
study. You do not have to take part if you do not want to. Before you decide we 
would like you to understand why the research is being done and what it would 
involve for you. Please read this information which will help you decide. 
 
Title – A comparison of health status scores in patients with sarcoidosis 
Short title – Measuring health status in sarcoidosis 
 
 
What is the purpose of the study? 
Sarcoidosis is a condition of unclear cause which can lead to symptoms that affect 
any part of the body, including the lungs, skin and joints. It can also cause problems 
such as excessive tiredness, muscle aches and pains, or weakness. Not everyone 
with sarcoidosis develops the same problems. It can affect different people in very 
different ways. Any of these problems can affect your quality of life – by quality of 
life, we mean a measure of how well (or unwell) your health makes you feel. 
 
This study aims to compare some commonly used questionnaires which measure 
how problems with our health affect how well we feel. We would like to see if two of 
the most commonly used questionnaires (one called the Short Form 36 or SF36, 
and one called the EuroQoL-5D) are comparable in patients with sarcoidosis.  
 
We would also like to compare the results from these questionnaires with three 
other questionnaires – one looks at the presence of certain symptoms that may be 
seen in sarcoidosis (the Kings’ Sarcoidosis Questionnaire), one looks at the 
presence of fatigue and the severity of it (the Fatigue Assessment Scale), and a 
final questionnaire looks at symptoms of low mood or anxiety (the Hospital Anxiety 
and Depression Score). We hope to see whether the results of these three 
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questionnaires can predict how you view your quality of life – in other words, 
whether fatigue, low mood or other problems related to sarcoidosis can affect how 
you feel, and if so, by how much?  
 
We hope that the results from this study will allow us to know more about how these 
questionnaires compare with each other, and which ones we should use in the 
future. 
 
 
Why have I been invited? 
You have been diagnosed with a condition called sarcoidosis. 
 
Do I have to take part? 
No. It is entirely up to you to decide. If you do not want to take part that’s OK. Your 
decision will not affect the quality of care you receive.  
 
What will I need to do if I take part? 
If you agree to take part then we will ask that you do the following: 
(1) Fill in some details regarding how long you have had sarcoidosis, how your 
sarcoidosis affects you, what treatment you are receiving for it, and whether 
you have ever smoked  
(2) Complete five questionnaires which are contained within the questionnaire 
pack. You may complete these at home, or in the clinic if you have received 
the questionnaires whilst attending your hospital visit. Completing the 
questionnaires will take up to twenty minutes 
(3) Return the sheet containing details about your sarcoidosis and the five 
questionnaires to us. This can be done using the enclosed pre-paid 
envelope if you have decided to complete the answers at home or 
alternatively return them to the front desk at the respiratory clinic (if you are 
in the hospital).  
 
The questionnaires will be returned to the study team. Following this, you do not 
need to do anything else. 
 
I have already received one set of these questionnaires, do I need to fill in 
another set? 
If you have already completed a set of these questionnaires, either in clinic or 
having received them by post, you do not need to complete them again. You 
should only complete one set of questionnaires. 
 
What are the possible disadvantages and risks of taking part? 
There are no risks associated with undertaking the questionnaires. If, having 
answered the questionnaires, you are worried about anything that you have said (or 
are worried about your health having answered the questions), please contact us 
using the telephone number or e-mail address at the end of this information sheet. 
Alternatively, any concerns about your sarcoidosis can be discussed with your 
consultant in clinic. 
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What are the potential benefits of taking part? 
Whilst it is unlikely that there will be any direct benefit to you as an individual, the 
results will help advance medical knowledge in this area. At present we do not know 
how the questionnaires we are looking at compare with each other. Your 
participation may help us to choose the best questionnaires in future research 
studies when investigating patients with sarcoidosis, as well as identifying which 
problems and symptoms most commonly affect patients with sarcoidosis. 
 
What happens when the research study stops? 
After you have completed the questionnaires you will not be asked to do anything 
further. The results from this study may be used to inform future research, or be 
used as part of future studies. If you would like to get a copy of the results of the 
study, please contact the research team using the details below and we will send 
you a summary of the study findings once it is completed. 
 
What data will be collected and stored and who will have access to personal 
identifiable data? 
The data you enter into the questionnaires will be collected on a database which will 
be stored on secure computers in the Norfolk and Norwich University Hospital. No 
personal data, or data that could be used to identify you, is required in the 
questionnaires – you do not need to put your name or any other identifiable details 
(such as your date of birth or address) anywhere on the questionnaires. This means 
that all the data collected is anonymous; no personal data is returned on the 
questionnaires you complete and no personal data about you is stored. 
 
Who is organising the research? 
The research is being organised by the Respiratory Research team consisting of 
researchers from Norwich Medical School, University of East Anglia and Norfolk and 
Norwich University Hospitals Foundation Trust. None of the researchers will receive 
any payment or funding for including you in the study. The study forms part of a 
PhD for Dr Atkins which has been funded by a doctoral research fellowship from the 
National Institute of Health Research (grant number DRF-190-08-2015) 
 
Thank you for your consideration of taking part in this study. If you are still 
interested, or have any further questions, then please contact the study team 
using the details at the bottom of this page.  
  
You may also obtain more detailed information about this research by contacting us 
using the details below: 
Dr Chris Atkins 
Phone 01603 289876 
c.atkins@uea.ac.uk 
Respiratory Research Department, Hethel Ward Corridor, Level 3 East Block, 
Norfolk and Norwich University Hospital, Colney Lane, Norwich, NR4 7UY 
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Appendix 4 – Topic guide (focus groups – FaST-MP study) 
Focus group objectives 
 
• To establish patient experience of participation in FaST-MP trial 
• To identify shortcomings in the initial trial and generate ideas that might 
influence future trial design (key issues; anything that would influence participant 
enrolling in the trial) 
 
Start Introduction and housekeeping 
 
• Welcome and thanks for coming 
• Introduce moderator  
• Scheduled for a 60 to 90 minute meeting; confirm everyone is OK 
with this 
• Plan to break for refreshments half way through 
• Identify the locations of facilities (toilets) 
• Encourage people to help themselves to coffee, tea, water etc as 
needed 
 
 Presenting the purpose of the meeting 
 
We are here today to talk about your views on your participation in the 
recent “Fatigue and Sarcoidosis – Treatment with Methylphenidate” trial. 
The purpose is to get your thoughts and feelings on how participation in the 
trial was for you – whether you felt participation was a positive or negative 
experience, whether there were any problems that you encountered being 
in the trial, what you didn’t like about it and how you think we might be 
able to improve a future trial. 
 
 Explain ground rules and roles 
 
I was the study co-ordinator and designed the study. However, my role 
today is to guide the discussion and help sharing of your views – I am not 
here to give you my opinions. 
 
 
 Rules of Engagement 
Appendices 
 339 
 
• The focus group is a relaxed discussion, not a Question and Answer 
session 
• There are no right or wrong answers, and you can change your 
mind or opinions 
• The aim is to explore your experiences during the trial and possibly 
generate some ideas that might influence the design of future trials 
in this area 
• We are also interested in whether you felt that your fatigue was 
better whilst you were in the trial. 
• Please respect each other’s contributions – no interruptions or side 
conversations 
• You should feel free to respond to each other’s comments – you 
don’t need to wait for me to invite you 
• The discussion is confidential – comments will not be attributed to 
everyone, so feel free to say what you really think 
• Please do not refer to each other by name to maintain 
confidentiality. You are all wearing badges with initials on – please 
use these when referring to each other 
• There will be no further commitment from you after the session 
 
 Taping the Session 
 
• We would like to record the session today, to make it easier to 
capture everything faithfully which will allow us to make an 
accurate analysis afterwards 
• The notes will help us to establish how effective the treatment was 
for participants within the trial, how you found the trial and 
whether there are any changes we should make for any future trials 
 
 
 Warm up 
 
• Participant introduction – where you have travelled from today, 
how long since you finished the trial 
 
 Discussion topic 1 – Experience of the trial 
 
• What was the best thing about taking part in the trial? 
 
• What was the worst thing about taking part in the trial? 
 
• Was there anything in the trial design that put you off taking part at 
the beginning? 
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• Was there any aspect of the trial that was particularly problematic 
for you? 
Possible prompts if people initially don’t voice any problems about 
taking part in the trial: 
o Number of visits to the hospital 
o Number of tablets to take 
o Difficulty with the size of the tablets 
o Difficulty performing the breathing tests or the walking 
tests 
o The number of questionnaires needing to be filled in 
o Filling in questionnaires that didn’t seem to be relevant 
 
• Did you have any problems wearing the activity monitors for the 7 
day periods during the trial? 
 
• Thinking back on the experience of the trial, would you describe 
your experience as a positive one or a negative one? 
 
• If you had the option to continue the medication, would you want 
to? 
 
• Given the chance again, would you still take part in the trial? 
 
 
 BREAK 
 
 Discussion Topic 2 – Changes to the trial 
 
• Based on what was discussed in the previous in the previous topic, 
is there anything you would change about the trial if you could? 
Possible prompts if people initially don’t voice any suggestions of 
future changes to the trial: 
o Reduced number of visits to the hospital 
o Possibility of a reduced afternoon dose of medication 
o Not wearing the accelerometers for a week at a time 
o Reducing the number of questionnaires needing to be filled 
in 
o Removing questionnaires that didn’t seem to be relevant – if 
so, which ones? 
 
• Was there enough contact with the study team through the study? 
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• Is there anything that would have made you happier to participate 
in the trial? 
Possible prompts: 
o More contact with the study team 
o More safety visits 
o Shorter duration of the trial 
o The possibility of receiving the medication after the trial if 
benefit was shown during the trial 
o The possibility of receiving the active drug 
(methylphenidate) if randomised to the placebo arm initially 
(i.e. open label period where all participants are on the 
active drug) 
 
Finish Closure 
 
• We’ve discussed a lot today and there have been a lot of opinions 
expressed. Some of the key points seem to include (summarise 
some of the points made). 
• Does anybody see the discussion differently, or want to add or 
clarify anything? 
• Is there any information regarding your experience of the trial that 
we haven’t discussed that you think would be useful to share? 
• Thanks for coming 
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Appendix 5 – Non-validated questionnaires 
 
A comparison of two wrist-worn accelerometer devices for the 
measurement of activity in sarcoidosis patients 
Date:    Patient ID: 
For the [device name here] [visual description of the device], please mark a cross on the 
line for each question. 
 
1. How comfortable was the device to wear? 
 
 
2. How aware of it were you? 
 
 
3. Would you have any objection to wearing it again? 
 
 
4. To what extent did it interfere with daily life? 
 
 
5. If you encountered any difficulties, please comment below. If none were 
encountered, please leave blank. Thank-you. 
 
 
 
 
6. Did you have to remove the device at any time? If so, for what reason? If you didn’t 
remove the device, please leave blank 
  
Very 
Comfortable 
Very 
Uncomfortable 
Unaware Very Aware 
No Objection Never Again 
No interference Interfered 
constantly 
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A comparison of two wrist-worn accelerometer devices for the 
measurement of activity in sarcoidosis patients 
Date:    Patient ID: 
 
Which device would you prefer to use if you had the choice of the 
two? 
 
GENEActiv 
 (Black plastic device with blue back) 
 
Actigraph 
(Red device with Velcro strap) 
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Safety Questionnaires 
Please put a cross in the circle that best describes the following: 
In the last fortnight, how frequently have you had any of the following problems? 
 
 
I have difficulty  
getting to sleep 
 
I have difficulty  
staying asleep 
 
I feel jittery 
 
 
I get palpitations 
 
 
I get chest pains 
 
 
Have you noticed any other problems since your last visit or since starting the 
study drug? 
____________________________________________________________________ 
 
____________________________________________________________________ 
 
____________________________________________________________________ 
 
____________________________________________________________________ 
 
____________________________________________________________________ 
 
____________________________________________________________________ 
  
Never Rarely Sometimes Often Always 
Never Rarely Sometimes Often Always 
Never Rarely Sometimes Often Always 
Never Rarely Sometimes Often Always 
Never Rarely Sometimes Often Always 
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FaST-MP study - Exit Questionnaire  
 
If you were given the choice to continue receiving the medication, would you 
want to? 
 
Yes     No 
 
 
 
Did you find participating in the study useful?  
 
Yes     No 
 
 
 
Given the chance again, would you still have taken part in this study?  
 
Yes     No 
 
 
 
Would you recommend taking part in any future study investigating 
methylphenidate for sarcoidosis-associated fatigue to other patients?  
 
Yes     No 
 
 
 
